Annual Report 2010–2011 Copies of this Annual Report are available on QIMR’s website at www.qimr.edu.au/annualreport and at no cost by contacting QIMR on (07) 3362 0222, freecall 1800 993 000 or by emailing [email protected].
Queensland Institute of Medical Research 300 Herston Road, Herston, Queensland Australia 4006 T: +61 7 3362 0222 F: +61 7 3362 0102 W: www.qimr.edu.au
QIMR is committed to providing accessible services to people from culturally and linguistically diverse backgrounds. If you have difficulty in understanding the annual report, you can contact us on (07) 3362 0222 and we will arrange an interpreter to communicate the report to you.
ISSN 1839 – 1877
© 2011 Queensland Institute of Medical Research AnnuAl RepoRt 2010–2011
Contents
Letter of compliance 2 Our governance 22 Student awards 125
Research highlights 3 Our management 27 Patents 127
Awards and achievements 6 Our performance 32 Grants and funding 129
QIMR at a glance 8 Our research 48 QIMR Fellows 131
Message from our Patron 10 Supporting our research 70 Overseas travel 132
Chairman’s report 11 Financial statements 72 Scientific publications 133
Director’s report 12 Awards 111 Compliance checklist 154
Our organisation 14 Invited lectures 112 Acronyms 156
Our people 19 Graduated students 124
Page 1 Letter of compLiance
31 August 2011
The Hon Geoff Wilson MP Minister for Health Parliament House BRISBANE QLD 4000
Dear Minister
I am pleased to present the Annual Report 2010–2011 for the Council of the Queensland Institute of Medical Research. I certify that this Annual Report complies with: • the prescribed requirements of the Financial Accountability Act 2009 and the Financial and Performance Management Standard 2009; and • the detailed requirements set out in the Annual Report Requirements for Queensland Government Agencies.
A checklist outlining annual reporting requirements can be found on the final pages of this Annual Report or accessed at our website:
http://www.qimr.edu.au/annualreport
Yours sincerely
PROFESSOR JOHN HAY AC Chair QIMR Council
300 Herston Road, Herston Q 4006 Australia | QIMR Locked Bag 2000, Royal Brisbane Hospital Q 4029 T (617) 3362 0222 F (617) 3362 0111 W www.qimr.edu.au
Page 2 QIMR Annual Report 2010–2011 2010-11 CANCER ReSeARCH HIGHlIGHtS
Identified small changes in a section of DNA associated with an increased breast cancer risk in women who carry the mutated BRCA1 gene. Found that using sunscreen every day can halve the risk of developing melanoma. Discovered that 75% of oesophageal cancers in Australia can be attributed to Found that for ovarian cancer patients, obesity, acid reflux and smoking. decreasing the time between symptom onset and diagnosis will not improve Identified several new genes that increase survival rates. the risks of melanoma, cancers of the breast, ovary, prostate and endometrium. Began Phase I clinical trials using a monoclonal antibody as a potential Identified a potential new cancer treatment cancer treatment for acute leukaemias, that reduces the size of cancerous tumours melanomas, brain tumours and by blocking the function of microRNA. lung cancers.
Discovered that although Indigenous Influenced a major change in clinical Queenslanders are 21% less likely to practice with the acceptance nationally and be diagnosed with cancer than the total internationally that it is important to remove Queensland population, they are 36% more proximal serrated polyps from the colon. likely to die from cancer.
Image source: National Cancer Institute , Dr Cecil Fox
Page 3 2010-11 INFECTIOUS DISEASES ReSeARCH HIGHlIGHtS
Found that applying clove oil is as effective at killing scabies mites as other Developed a computer system for existing treatments. tracking mosquito-borne disease such as Ross River fever and Barmah Forest Demonstrated the efficacy of novel proteins virus disease. for the treatment of schistosomiasis.
Discovered new regions of the Identified new antimalarial compounds from Epstein-Barr virus that are targeted by plants and fungi. the immune response. Completed preclinical testing of a vaccine Established a system to test antimalarial for cytomegalovirus, which aims to prevent drugs in human volunteers infected with clinical complications in transplant patients malaria parasites. and newborn babies.
Undertook a pilot study, releasing Obtained data to support a Wolbachia infected mosquitoes in Cairns to causal link between scabies and test the effectiveness against the spread of streptococcal infections. dengue fever.
Page 4 QIMR Annual Report 2010–2011 2010-11 MENTAL HEALTH / COMPLEX DISORDERS ReSeARCH HIGHlIGHtS
Published the world’s largest genome-wide association study for major depression which showed the disease is underpinned by many small genetic variants, and Discovered new genes for myopia (long or implicated a protein called galanin. short sightedness), optic nerve hypoplasia Developed a new diagnostic and (one of the leading causes of blindness in monitoring test for major depression children) and glaucoma risk. based on a combination of video and Discovered 30 new genes that control the imaging technology. age of sexual maturation in women and Developed a brain stress test for dementia identified several genetic links between using brain imaging and showed that it early puberty and body fat. could predict the functioning of patients for Located new genetic regions that increase up to two years. endometriosis risk and demonstrated Discovered that eating or drinking full-fat a stronger genetic contribution to more dairy may reduce the risk of cardiovascular- severe cases of the disease. related death. Demonstrated that liver fibrosis identified via Found 59 new DNA regions that influence liver biopsy, predicts the future development levels of LDL and HDL cholesterol and of clinically significant liver disease (portal triglycerides in the blood – key indicators of hypertension) in children with cystic fibrosis heart disease risk. (CF) and should be adopted clinically.
Page 5 AWARDS AND ACHIevementS
QIMR was inducted into the Queensland Business Professor Don McManus (Head of the Molecular Leaders Hall of Fame. Parasitology Laboratory) received an honorary membership of the American Society of Tropical Professor Geoff Hill (Immunology Department Medicine and Hygiene, in recognition of outstanding Coordinator and Head of the Bone Marrow accomplishment by an individual not an American citizen Transplantation Laboratory) was awarded a prestigious who has made eminent contributions to some phase of National Health and Medical Research Council (NHMRC) tropical medicine and hygiene. Australia Fellowship. He also received a Senior Clinical Research Fellowship from the Queensland Government. Dr Patricia Valery (Indigenous Health Program) was awarded a NHMRC Excellence Award, the highest Professor Emma Whitelaw (Cell and Molecular Biology ranking Career Development Award in the category Department Coordinator and Head of the Epigenetics of population health. Laboratory) was elected as an Australian Academy of Science Fellow, and received both the Australia Dr Sarah Medland (Genetic Epidemiology Laboratory) and New Zealand Society for Cell and Developmental was awarded a 2010 Queensland Young Tall Poppy Biology President’s Medal and the International Union of Science Award. Biochemistry and Molecular Biology Jubilee Medal. Professor Michael Breakspear and Dr Susan Professors Kum Kum Khanna (Head of the Signal Woods (Oncogenomics Laboratory) won 2011 Transduction Laboratory) and Georgia Chenevix-Trench Australian Society for Medical Research (ASMR) (Cancer Program Coordinator and Head of the Cancer Queensland Awards. Genetics Laboratory) were awarded a medical research program grant from the NHMRC. The grant worth $5.6 million over five years will be used to support research into the susceptibility and progression of breast cancer.
Professor James McCarthy (Infectious Diseases Program Coordinator and Head of the Clinical Tropical Medicine Laboratory ) and Professor Michael Breakspear (Mental Health/Complex Disorders Program Coordinator and Head of the Systems Neuroscience Group) were awarded Health Research Fellowships from the Queensland Government for their work in malaria and mental health respectively.
Page 6 QIMR Annual Report 2010–2011 Page 7 QImR At A GlAnCe
Business development agreements Patent portfolio 2010-2011 research agreements patent portfolio
Research service Intellectual property agreements agreements Patent portfolio 2010-2011 Vaccine Patents Diagnostic Patents Clinical trial License Business development agreements New Treatment Patents Delivery Platform Patents agreements agreements Commercialisation Others Drug Target Patents agreements
Research service Intellectual property Vaccine Patents Diagnostic Patents agreements agreements New Treatment Patents Delivery Platform Patents Clinical trial License agreements agreements Drug Target Patents Commercialisation Others agreements
nHmrc grants awarded ($ millions)
20
15
10
5
0 2007 2008 2009 2010 2011
Grants Fellowships
Page 8 QIMR Annual Report 2010–2011 Fundraising fundraising revenue ($ millions)
10
8
6
4
2
0 2006-07 2007-08 2008/09 2009/10 2010/11
Donations & Gifts Event Revenue Sponsorships Bequests / Gifts in Kind
Scientific publications
600
500
400
300
200
100
0 2007 2008 2009 2010 2011
Articles High Impacts (publications in journals with impact factors of 10 or more)
Staff numbers
600
500
400
300
200
100
0 2007 2008 2009 2010 2011
Staff Students
Page 9 meSSage from our patron
QIMR Annual Report 2010-11 Patron’s Message
2010-11 was a challenging year for QIMR, in some ways, but one which nevertheless delivered many gains and advances, for the Institute itself and for the individual researchers and research teams working across its diverse research program, consolidating its reputation as one of Australia’s most highly regarded and most successful medical research institutes. The decision by Professor Michael Good AO to relinquish his position as Director and CEO, after ten years of committed and energetic leadership, to concentrate on his own research, posed a significant challenge for the Council, needing to find a worthy successor and assure a smooth transition during a period of significant expansion and ongoing growth. The appointment of distinguished molecular biologist, Professor Frank Gannon of Ireland - after an extensive national and international search - however, met this challenge admirably, assisted by the contribution of Professor Adèle Green, who stepped into the Director role for several months. I congratulate Professor Gannon on his appointment and welcome him most warmly to Queensland, as I thank Professor Green, equally warmly, for her steady leadership at a demanding time for the Institute and its 600 scientists, staff and students. Many of those demands, of course, related to the major expansion of QIMR’s research facilities ongoing through the year and now approaching completion. Professor Gannon has joined the Institute at a significant point in its development. Following a decade of impressive achievements under Professor Good, QIMR is now approaching what is arguably the most exciting period in its history, with the imminent completion of the state-of-the-art Smart State Medical Research Centre at Herston in 2012. The capacity and capability that this Centre will add is immense, creating new opportunities for many more hundreds of scientists to pursue the Institute’s mission of preventing and curing disease through research, and it is they who will further cement the reputation of QIMR – and of Queensland – as a centre of excellence in this field. It is no exaggeration to say that their explorations could affect the health and hopes of millions, as they work to unravel the secrets of the diseases and conditions that confront contemporary society, to find answers to those still unsolved medical riddles and puzzles and to realise the scientific break-throughs we all want to see in our lifetime. I congratulate and thank the Council, staff and supporters of the Institute for all they have done throughout the year to build and strengthen QIMR. I was particularly delighted to see the Institute inducted into the Queensland Business Leaders Hall of Fame in September, 2010 and to have the honour, as Governor, of presenting this highly prestigious award to Council Chairman, Professor John Hay AC, accepting it on behalf of all QIMR scientists and staff. It was just recognition of QIMR’s significant contribution to Queensland - a contribution I have every confidence will be sustained and enhanced during the year ahead.
Penelope Wensley AC Governor of Queensland
Page 10 QIMR Annual Report 2010–2011 cHairman’S report
In January 2011, we welcomed Professor Frank Gannon We have also embarked on our largest signature fundraising as QIMR’s seventh Director and CEO. Professor Gannon, event – the Rio Tinto Ride to Conquer Cancer. The event an internationally renowned expert in the field of molecular promises to both raise the profile of QIMR as well as raise biology has significant experience in managing science, much needed funds for our Cancer Program. Thank you to widespread ties with the international scientific community Rio Tinto and Sunsuper for sponsoring this event. I would and a passion for scientific excellence. also like to acknowledge the ongoing support of Suncorp, who continue to support our skin cancer research. I would like to pay tribute to Professor Adèle Green, who stepped into the Director role until Professor A change to the Queensland Institute of Medical Research Gannon commenced. Act 1945 saw the abolition of the QIMR Trust. The role of Trust has been absorbed by the QIMR Council and I would Professor Gannon’s appointment comes at a particularly like to take the opportunity of thanking the members of Trust important juncture in QIMR’s history. The Institute is poised for their commitment and guidance over the past 31 years. for a period of exponential growth and research achievements when our new 15 floor research facility is completed in early I would like to acknowledge the significant contribution of Mr 2012. The capital expansion was made possible by a most Clive Berghofer, who has been a major supporter of QIMR generous gift from The Atlantic Philanthropies, and funding for the past 10 years, Mr Chuck Feeney whose vision and from the State and Federal Governments. support was instrumental for the construction of our new facility and former Director, Professor Michael Good, whose A highlight of the new building will be a piece of art leadership enabled QIMR to achieve its vision of better health commissioned by acclaimed Indigenous artist Ms Judy through medical research. Watson. This three-storey piece will be featured in the foyer of the new facility, greeting visitors and encapsulating the history of both QIMR and the local Herston area. QIMR Council Chairman QIMR continues to be recognised as one of Australia’s largest Professor John Hay AC and most successful medical research institutes. This year I had the honour of representing QIMR when we were inducted into the Queensland Business Leaders Hall of Fame.
“QIMR continues to be recognised as one of Australia’s largest and most successful medical research institutes.”
Her Excellency, the Governor of Queensland Ms Penelope Wensley AC presents the Queensland Business Leaders Hall of Fame award to Professor John Hay AC, Chairman of QIMR Council.
Page 11 Director’S report
It is with great pleasure that I write my first annual report as “i am excited about the Director and CEO of the Queensland Institute of Medical Research. Taking over from Michael Good is both a challenge, new direction for the because of what has been achieved in the past ten years, institute as we move into and a benefit because much of what is needed for QIMR is already in place. a period of growth.”
Since its inception in 1945, QIMR has become a world recognised centre of excellence for medical research. Our research continues to make an enormous impact on the health of society and it has been another productive year for the Institute. who not only won ASMR’s Senior Researcher Award but was also awarded a joint Cancer Australian and Cure Cancer In response to a review of the current strengths of QIMR Foundation Research Grant for her work on the regulation of and the opportunities and future needs, I have prepared melanoma growth. a roadmap. This will allow us to concentrate our research effort on areas that are of high importance to Queensland QIMR continues to provide excellent research facilities for including regionally relevant diseases and those that are major over 400 researchers. On 29 March 2011, we celebrated causes of mortality and morbidity to the community. Our the topping out of our new 15 floor research facility made research will focus on cancer; infectious diseases; and mental possible by generous support from the Commonwealth and health/ complex disorders. These scientific activities will be Queensland Governments and The Atlantic Philanthropies. supported by cross program departments in Immunology, The building, due for completion in early 2012, will include Genetics, Population Health, Computational Biology, Biology, 20 purpose built laboratories and increase QIMR’s current Cell and Molecular Biology to increase collaboration across research capacity in areas such as tropical diseases, vaccine the Institute. development, cancer and genetics. It will allow the expansion of our mental health research, as well as QIMR’s highly I am excited about the new direction for the Institute as we successful Education Program. move into a period of growth. We will be recruiting to further strengthen QIMR in priority areas such as computational Located in the heart of the Herston medical campus, biology, imaging, mental and infectious diseases, as well QIMR is well placed to bridge the gap between scientists as increasing the number of students supported at the and clinicians. As it expands, QIMR will place a particular Institute. We will also be working to further support our emphasis on increasing the frequency of these interactions current researchers by providing world-class facilities, the and incorporating researchers with a clinical background into best equipment and training, as well as providing clear career our laboratories. To achieve this we will expand our bioseurity paths and financial security. capability, and maintain our good manufacturing practice (GMP) facilities. In order to make a real benefit to society, I believe our research has to go beyond the laboratory and be effectively In addition to the Herston based activities, we will work translated into the clinical setting. This has been achieved to strengthen current collaborations and continue to in many disease areas (highlighted elsewhere) including build our relationships with universities and other medical the development of an online based system to help track research institutes. mosquito-borne diseases such as Ross River fever; clinical trials that have began for a new antibody that has been I want to thank our team of dedicated researchers for their effective as a treatment against acute leukaemia; and we hard work and determination. Thanks also to all the corporate have embarked on the largest ever purpose built study of staff for providing the services and support needed to make skin cancer in order to develop an effective predictive tool for our Institute what it is today. I look forward to working with general practitioners. Council and staff to continue to build on our world-class reputation and take QIMR into the future. QIMR continues to employ and support excellent researchers. Special congratulations must go to Professor Geoff Hill who was awarded a NHMRC Australia Fellowship, which will be used to continue to improve the outcome for bone marrow Professor Frank Gannon transplant patients; Professor Emma Whitelaw who has Director and CEO been recognised as one of the world’s leading epigeneticists having been elected as an Australian Academy of Science Fellow and receiving the International Union of Biochemistry and Molecular Biology Jubilee Medal; and Dr Susan Woods
Page 12 QIMR Annual Report 2010–2011 Page 13 Page 14 QIMR Annual Report 2010–2011 ouR oRGAnISAtIon
Page 15 our organiSation
role and main function
QIMR was established under the Queensland Institute of Working in close collaboration with clinicians and other Medical Research Act 1945 for the purpose of research into research institutes, our aim is to improve health by developing any branch or branches of medical science. prevention strategies, new diagnostics and better treatments.
QIMR is a world leading medical research institute. Our research focuses on three areas: cancer; infectious diseases; and mental health and a range of complex disorders.
our vision
to be a world renowned medical research institution
our mission
Better health through medical research
our philosophy
Qimr supports scientists who perform world-class medical research aimed at improving the health and well-being of all people
Page 16 QIMR Annual Report 2010–2011 government objectives operating environment for the community rapid growth QIMR conducts medical research that supports the Queensland Government’s Smart State Strategy 2005–2015 QIMR is preparing for a period of accelerated growth with and Towards Q2: Tomorrow’s Queensland ambitions of the construction of a 15 floor research facility scheduled for Healthy – Making Queenslanders Australia’s healthiest people completion in early 2012. QIMR will be actively recruiting and Strong – Creating a diverse economy powered by bright researchers in specific areas in order to increase its capacity ideas. This is evidenced by research undertaken by QIMR by 50% to approximately 1,000 staff and students. across the three research programs that focuses on areas of high importance to Queensland including those that are major causes of ill health and death. competition for funding
In particular, QIMR supports the Queensland Government’s QIMR operates in a competitive environment with much of commitment to making Queenslanders Australia’s healthiest its research funded by competitive grants obtained by our people and, through the Toward Q2 strategy, targets to researchers. For the 2010–2011 year, QIMR researchers reduce tobacco smoking, overweight and obesity, risky secured more than $21 million in funding from NHMRC. alcohol consumption, and unsafe sun exposure by one-third by 2020. Funds were provided from 1 January 2011 for a total of 17 new research projects ranging from the genetics of brain In 2010, QIMR embarked on the largest skin cancer research structure and function, to understanding the causes and risks study every conducted in Australia. More than 200,000 men of breast and ovarian cancers, to improving the health of and women will be invited to participate in the QSkin study, Indigenous populations. which aims to help us better understand the factors that underlie skin cancer risk. QIMR researchers found that using sunscreen every day can halve the risk of melanoma and economic climate discovered that 75% of oesophageal cancers in Australia can be attributed to obesity, acid reflux and smoking. The global financial crisis has impacted philanthropic giving for both individuals and the corporate sector. In this environment, with a large number of charities competing for the fundraising dollar and especially after the devastating Queensland machinery of floods, securing funding to support our operating costs has been even more challenging. However, QIMR continues to government changes secure ongoing funding support from the community and valued donors. The Queensland Institute of Medical Research Act 1945 was amended by legislation, entitled the Water and Other Legislation Amendment Act 2010. This was enacted and Decline of students completing assented to by the Queensland Parliament on 25 November 2010. As per section 137 of the Amendment Act, the Trust science degrees was abolished on 1 February 2011. Responsibilities of the Over the next few years, QIMR will recruit up to an additional Trust have been transferred to the QIMR Council. 500 scientists. Regrettably, the number of students completing science degrees is declining, with less than 10% The QIMR Final Trust Annual Report can be found at of undergraduates enrolling in science related degrees. As www.qimr.edu.au/trustreport or a copy can be obtained by a society that relies on medical research to improve our calling (07) 3362 0222 or freecall 1800 993 000. health, we must ensure a continual supply of researchers into the future. QIMR is committed to inspiring the scientists of tomorrow through its Education Program which saw over 1,000 senior school students tour QIMR and hear first-hand from researchers about medical research and potential career options.
Page 17 objectives progress
QIMR is committed to better health through medical research Changes have already been implemented in line with the by achieving the following objectives: new direction for QIMR. QIMR’s activities are now organised into three programs with disease related themes: Cancer, 1. To transfer outstanding fundamental knowledge and Infectious Diseases and Mental Health/Complex understanding from the laboratory to the clinic in Disorders. These will be underpinned by the following the form of improved diagnostics, prevention and departments: Immunology, Genetics, Population Health, treatment strategies; Computational Biology, Biology and Cell and Molecular 2. To perform excellent world class research; Biology. Each research group will align itself with at least one program and one department. 3. To seek and utliise commercial opportunities and to diversify income sources; The individual laboratories remain the core entities of QIMR 4. To perform research with consequence and have a and the programs and departments are established to provide positive impact on society; and functioning support for the laboratories. Coordinators of each program and department will collectively provide a strong 5. To continue to build QIMR’s world leading reputation. input from all scientists into the decision making processes of Our performance against the outputs translation, scientific QIMR through the Management Advisory Group (MAG). This quality, commercial consequence, societal impact and has replaced the previous Interim Management Executive international reputation is detailed in our performance section Committee (IMEC). on page 32.
future outlook
Excellence in research and researchers will continue to characterise QIMR under the leadership of Professor Frank Gannon and the QIMR Council. The future goals for the Institute are to: 1. Become a world leader in medically relevant research and the transfer of this knowledge and understanding to the clinic; 2. Focus on areas that are of high importance to Queensland including regionally relevant diseases and those that are major causes of mortality and morbidity to the community; and 3. Undertake outstanding fundamental research of direct relevance to the research that is closer to translation.
Our vision to be a world renowned medical research institution will be achieved by focusing QIMR’s research on cancer, infectious diseases and mental health/complex disorders. Research activities, particularly in systems biology and computational biology, will be strengthened to further support excellent translational research.
QIMR will build on existing inter-institutional collaborations and continue to strengthen collaborations on the Herston campus, including the RBWH, in order to increase the health outcomes of our research. Opportunities to diversify sources of income for QIMR will be sought with a particular emphasis on identifying and leveraging commercial opportunities that arise naturally from excellent research.
QIMR will support and develop staff and provide funding stability for outstanding early stage and senior research scientists.
Page 18 QIMR Annual Report 2010–2011 our peopLe
QIMR has 567 employees. Due to the reliance on short-term grant funding, 83.72% of employees are employed on ethics and code of conduct fixed-term contracts. In 2010–2011, 91.52% of permanent FTE staff who were employed with QIMR as at 1 July 2010 QIMR has in place a Code of Conduct which sets out the were retained (i.e. still employed as at 30 June 2011) by expected standards of the official conduct, relationships and the organisation. behaviour for staff.
Taking into account the number of permanent FTE employees as at 1 July 2010, a slight increase in recruitment for new permanent positions over the reporting period, and the carers act 2008 number of employees who voluntarily ceased (e.g. resigned) from the organisation, QIMR experienced a separation rate QIMR’s Human Resource policies were reviewed to ensure (or turnover) of 13.26% over the reporting period. These that they comply with obligations set out for public authorities figures continue to reflect a stable and permanent workforce under the Carers Act 2008. QIMR provides access to flexible consistent with previous years. working arrangements, flexible leave options, a child care assistance policy, and definitions of a carer compliant with the 63.81% of QIMR’s workforce and 60.58% of the current Act. Employees have access to information regarding benefits student population are women. Women hold 33% of QIMR’s and policy on the QIMR intranet. scientific leadership positions. This compares to 15% in 2003.
Workforce planning, attraction and retention
Workforce planning initiatives at QIMR include an Education and Higher Degrees program to attract students to medical research and a career at QIMR, the ongoing support for a culture of work and life balance to attract and retain employees, and maximising salary benefits for employees. Resource planning is limited by short term funding cycles for research employees; however within the Corporate Division QIMR has planned resourcing requirements to ensure growth is supported when the new building is completed in 2012.
The strategic plan for QIMR has identified priority recruitment in the areas of bioinformatics, systems biology, basic immunology, and imaging in cell biology and scientific recruitment will be focussed on these areas over the next 12 months. Initial attraction efforts have focused on increasing exposure, and strengthening QIMR’s reputation both nationally and internationally.
A key attraction strategy at QIMR is the promotion of work/life balance. Initiatives include access to variable working hours, flexible working arrangements, flexible leave options (including taking leave at half pay), and the implementation of a child care policy to support parents returning to work after the birth of a child.
QIMR is covered by the QIMR Enterprise Agreement 2010, which expires on 31 August 2011 and is to be replaced by a new agreement. QIMR has in place a range of workforce policies that support the operation of the agreement and the achievement of strategic objectives, addressing workplace conduct and performance, professional and career development, leave provisions and remuneration.
Page 19 organiSationaL Structure QIMR Council
Director
Deputy Director
Administrative Support
Management Advisory Group
Corporate Division Cancer Program Infectious Diseases Mental Health/Complex Program Disorders Program
Antigen Presentation & Gynaecological Cancer Malaria Drug Resistance Administrative Support Human Resources Bacterial Pathogenesis Cancer Genetics Membrane Transport Immunoregulation Group & Chemotherapy
Building Services Information Services Bone Marrow Transplantation Indigenous Health Bioinformatics Molecular Parasitology CCQ Transgenics Molecular Epidemiology
Business Development Procurement Cancer & Population Studies Leukaemia Foundation Cellular Immunology Molecular Vaccinology Epigenetics Neurogenetics of Queensland
External Relations Regulatory Affairs Cancer Control Group Membrane Transport Clinical Tropical Medicine Mosquito Control Genetic Epidemiology Psychiatric Genetics
Molecular Cancer Finance Safety CCQ Transgenics EBV Biology Parasite Cell Biology Hepatic Fibrosis Qld Statistical Genetics Epidemiology
Grants Scientific Services Cancer Genetics Oncogenomics HIV Molecular Virology Protein Discovery Centre Indigenous Health Radiation Biology & Oncology
Cancer Immunotherapy Radiation Biology & Oncology Immunity & Vaccinology Scabies Inflammatory Bowel Disease Systems Neuroscience
RBWH Foundation Clinical Immunohaematology Immunology & Infection Tropical Parisitology Iron Metabolism Conjoint Gastroenterology
Dendritic Cells & Cancer Signal Transduction Immunovirology Tumour Immunology
Drug Discovery Group Skin Cancer Carcinogenesis Malaria Biology Key
Epigenetics Tumour Immunology Laboratory is also represented in another program
Familial Cancer
Page 20 QIMR Annual Report 2010–2011 QIMR Council
Director
Deputy Director
Administrative Support
Management Advisory Group
Corporate Division Cancer Program Infectious Diseases Mental Health/Complex Program Disorders Program
Antigen Presentation & Gynaecological Cancer Malaria Drug Resistance Administrative Support Human Resources Bacterial Pathogenesis Cancer Genetics Membrane Transport Immunoregulation Group & Chemotherapy
Building Services Information Services Bone Marrow Transplantation Indigenous Health Bioinformatics Molecular Parasitology CCQ Transgenics Molecular Epidemiology
Business Development Procurement Cancer & Population Studies Leukaemia Foundation Cellular Immunology Molecular Vaccinology Epigenetics Neurogenetics of Queensland
External Relations Regulatory Affairs Cancer Control Group Membrane Transport Clinical Tropical Medicine Mosquito Control Genetic Epidemiology Psychiatric Genetics
Molecular Cancer Finance Safety CCQ Transgenics EBV Biology Parasite Cell Biology Hepatic Fibrosis Qld Statistical Genetics Epidemiology
Grants Scientific Services Cancer Genetics Oncogenomics HIV Molecular Virology Protein Discovery Centre Indigenous Health Radiation Biology & Oncology
Cancer Immunotherapy Radiation Biology & Oncology Immunity & Vaccinology Scabies Inflammatory Bowel Disease Systems Neuroscience
RBWH Foundation Clinical Immunohaematology Immunology & Infection Tropical Parisitology Iron Metabolism Conjoint Gastroenterology
Dendritic Cells & Cancer Signal Transduction Immunovirology Tumour Immunology
Drug Discovery Group Skin Cancer Carcinogenesis Malaria Biology Key
Epigenetics Tumour Immunology Laboratory is also represented in another program
Familial Cancer
Page 21 our goVernance
council purpose and membership
In accordance with Part 2, Section 4A of the Queensland Institute of Medical Research Act 1945, QIMR is controlled and governed by The Council of the Queensland Institute of Medical Research (“The Council”). Under the Statutory Bodies Financial Arrangements Act 1982, the QIMR Council is a statutory body.
functions of the council membership of the council
The functions of the QIMR Council are to: The Council consists of the following members appointed by the Governor in Council: (a) control and manage the Institute; 1. The Chief Health Officer (an official member) – (b) raise and accept moneys for the purposes of Dr Jeannette Young the Institute; 2. The chairperson of the Trust (Trust abolished 01/02/11) (c) invest moneys raised or accepted by the Council for the purposes of the Institute; and 3. Two nominees of the National Health and Medical Research Council, at least one of whom has expertise (d) invest moneys derived from any property or other in health research – Professor Judith Clements + invested moneys of the Council for the purposes of one vacancy the Institute. 4. One nominee of the senate of The University of Queensland – Vacant number of meetings 5. One person with expertise in health research – Attendance by Members of Council who held office during the Professor Lyn Griffiths 2010–2011 financial year are as follows: 6. One medical practitioner with expertise in health research – Associate Professor Paula Marlton Appointed Members Meetings Attended 7. One person with expertise in health research ethics – John Hay 7 Professor Bryan Campbell Bryan Campbell 7 8. One lawyer – Mr Christopher Coyne Judith Clements 5 9. Two persons with expertise in financial management, business or public administration – Mr Paul Fennelly/ Chris Coyne 4 Professor John Hay (Chair) Paul Fennelly 2 All members of the QIMR Council are appointed for a Lyn Griffiths 4 three year term. If at the expiration of the term of office the Paula Marlton 5 member’s successor has not been duly appointed, the member shall hold office as a member of the Council until the Jeannette Young 7 member’s successor takes up office. Secretary: Donna Hancock 6
remuneration of council
The aggregate remuneration for the QIMR Council for the 2010–2011 financial year was $51,837.
Page 22 QIMR Annual Report 2010–2011 members of council
professor John Hay ac professor Judith
BA (Hons) (Western Australia and clements Cambridge), MA (Cambridge), PhD BAppSc MAppSc PhD (Western Australia), Hon LittD (Deakin), Hon DLitt. (UWA); Hon DU (QUT), Hon LLD (Queensland), FAHA, FACE, Professor Clements has over FAIM, FQA 20 years’ experience as a basic researcher in biomedical Professor Hay is Chair of research, primarily in the general QIMR Council. field of molecular endocrinology. Professor Hay was Vice- Her current research seeks Chancellor of The University understanding of the molecular of Queensland from 1996–2007. In that time, he led the basis of hormone dependent development of many major new research institutes including cancers such as prostate and ovarian cancer. the Institute for Molecular Bioscience and the Queensland She is currently Scientific Director of the Australian Prostate Brain Institute. He was also instrumental in securing funding Cancer Research Centre-Queensland and Program Leader for the Translational Research Institute to be built at the of the Cancer Program within the Institute of Health and Princess Alexandra Hospital. Biomedical Innovation at the Queensland University of Under his leadership, both Deakin University and The Technology. She coordinates the Australian Prostate Cancer University of Queensland were named Australian Universities BioResource, a national tissue bank for prostate cancer of the Year by the Good Universities Guide. research. She is also an NHMRC Principal Research Fellow and an NHMRC Academy member since 2009. In 2007 Professor Hay was appointed as Chair of QIMR by the Professor Clements was awarded the prestigious international Queensland Government in September 2009. Frey-Werle Foundation Gold Medal for her significant contributions to the kallikrein protease field. professor Bryan Professor Clements is Chair of the QIMR Appointment and campbell Promotions Committee. AM MD BS FRACP FRACMA
Professor Campbell was mr christopher coyne formerly Chief Health Officer Christopher Coyne is a of Queensland and Head of solicitor of the Supreme The University of Queensland Court of Queensland, an Medical School. accredited specialist in the field of Commercial He has been a Councillor of Litigation, specialising in the Royal Australasian College insurance law, health law, of Physicians, the Royal Australian College of Medical corporate governance and risk Administrators and a member of the National Health and management. Following his Medical Research Council (NHMRC). He was Deputy Chair admission as a solicitor in 1979 of the Australian Health Ethics Committee and a member of he practised law in Brisbane and was a partner in the national the NHMRC Embryo Research Licensing Committee until law firm Clayton Utz from 1984 to 2004. June 2006. Mr Coyne now practices on his own account. He was Professor Campbell is the Chair of the QIMR Finance and appointed an Adjunct Professor of The University of Audit Committee. Queensland School of Law in 2002. Chris is Board Chairman of Lexon Insurance Pte Ltd (Queensland Law Society, Singapore Captive Insurer), a Director of the Incorporated Council of Law Reporting for the State of Queensland, past president Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee. Christopher is a sessional member of the Queensland Civil and Administrative Tribunal and also a member of the QIMR Personnel Administration Committee.
Page 23 members of council | continued
mr paul fennelly associate professor
BA LLB paula marlton
Paul Fennelly has wide MB BS (Hons I) FRACP FRCPA experience in financial Paula Marlton is the Head of management, business and Leukaemia and Lymphoma public administration. He is Services at the Princess an executive with Hastings Alexandra Hospital where Funds Management, which she is also Deputy Director of is a member of the Westpac Haematology. Her previous Group. His focus is on major appointments include three equity investments, primarily years at the MD Anderson in social and economic infrastructure. From 2002–2006, Mr Cancer Centre in Houston, Texas. She has extensive Fennelly was Director-General of the then Department of experience in clinical research including the role of principal State Development; concurrently he served as Queensland’s investigator for national multi-centre trials and supervisor of Coordinator-General. Prior to joining the Queensland molecular translational research associated with trials. She Government he was Victorian Director of the Australian was the founding Chair of the Australasian Leukaemia and Industry Group, which is the nation’s largest industry Lymphoma Group (ALLG) Laboratory Science Committee association. Mr Fennelly chaired the QIMR Finance and and has established and continues to direct the ALLG Tissue Audit Committee. Bank. Her other professional roles include Medical Advisor and Board member of the Leukaemia Foundation, member of professor Lyn griffiths several Drug Advisory Boards and Government and College Advisory Committees as well as a wide range of academic BSc (Hons) PhD and clinical service roles. Professor Griffiths is Director of the Griffith Health Institute and Dr Jeannette Young the Genomics Research Centre at Griffith University. She has MB BS FRACMA AFACHSE expertise in human molecular Dr Jeannette Young is the Chief genetics, undertaking research Health Officer for Queensland, a to map and identify genes role she has filled since August involved in common complex 2005. Prior to this, she held the human disorders, including position of Executive Director studies on migraine, cardiovascular disease risk, multiple of Medical Services at the sclerosis and certain types of cancer. Her research has been Princess Alexandra Hospital in well funded by national competitive grants and industry and Brisbane and has previously she has authored more than 200 peer-reviewed publications worked in a range of positions to date in molecular genetics international journals as well as in Queensland and Sydney. She has specialist qualifications supervising 28 PhD students to completion. She is a current as a Fellow of the Royal Australasian College of Medical Queensland President Human Genetics Society Australasia, Administrators and as a Fellow by Distinction of the Faculty past ASMR Director, current Member and past Chair of the of Public Health of the Royal Colleges of Physicians of the Scientific Program Committee for the International Congress United Kingdom. She is an Adjunct Professor at Queensland of Human Genetics and has been awarded the Centenary University of Technology and at Griffith University. Medal for Distinguished Service to Education and Medical Research. Professor Griffiths is a member of the QIMR Today she is responsible for such matters as health disaster Appointments and Promotions Committee. planning and response, aero-medical retrieval services, licensing of private pospitals, organ and tissue donation services, provision of health services to prisoners, cancer screening services, communicable diseases, environmental health and other population health services and mental health, alcohol and other drugs policy and legislation.
Along with sitting on the QIMR Council, Dr Young is a member of numerous State and National committees and Boards, some of which include the Queensland Board of the Medical Board of Australia, NHMRC, the Australian Health Protection Committee, the Clinical Technical Ethical Principal Committee of Australian Health Ministers’ Advisory Council, the Australian Population Health Development Principal Committee and the newly created Australian National Preventive Health Agency Advisory Council.
Page 24 QIMR Annual Report 2010–2011 committees to council • Mr John Stead • Associate Professor Katharine Trenholme finance and audit committee • Dr Tom Sculley • Ms Donna Hancock The primary objective of the Finance and Audit Committee is to assist QIMR Council in fulfilling its responsibilities relating to • Dr Agnieszka Mitchell (ex officio) financial planning, policy and performance of QIMR. • Ms Nicola Yu – Secretary (From 01/07/10)
The Finance and Audit Committee has observed the terms of animal ethics committee its charter and has due regard to Queensland Treasury’s Audit Committee Guidelines. The QIMR Animal Ethics Committee (AEC) on behalf of • Mr Paul Fennelly (Chair to 23/02/11) Council ensures the maintenance of ethical standards in • Professor Bryan Campbell (Chair from 23/02/11) research and compliance with regulatory guidelines. • Mr Rodney Wylie the Smart State medical research Steering • Professor John Hay committee (to 22/09/10) appointments and promotions committee The Smart State Medical Research Steering Committee (SSMRSC) on behalf of Council oversees the development of The Appointments and Promotions Committee (APC) assists the Smart State Medical Research Centre Project. Council with the maintenance of academic standards at QIMR • Professor John Hay (Chair) by reviewing all proposals for the appointment and promotion of Faculty staff. • Mr Rodney Wylie • Professor Judith Clements (Chair) • Mr John Parnell • Professor Graham Brown • Mr Alan Stockman • Professor Julie Campbell (Chair for the Senior Research • Ms Rosemary Hood Officer APC, a subset of the APC) • Dr Rick Andrew • Professor Lyn Griffiths • Ms Karen Thompson • Professor James McCluskey • Ms Donna Hancock • Dr Jurgen Michaelis • Ms Beatrix Wanrooy – Secretary • Professor Joe Trapani • Professor Adèle Green (ex officio) the Smart State medical research committee (From 01/07/10 to 04/01/11) (from february 2011) • Professor Frank Gannon (ex officio) (From 04/01/11) • Professor Frank Gannon (Chair) • Professor Adèle Green investment committee • Mr Alan Stockman The Investment Committee is responsible for overseeing the • Mr John Parnell investment of QIMR Council funds. • Ms Donna Hancock • Mr Rodney Wylie (Chair) • Dr Joseph Pereira • Mr Bruce Phillips • Ms Beatrix Wanrooy – Secretary • Mr Michael Sargent (From 08/08/10) Human research ethics committee risk management The Human Research Ethics Committee (HREC) on behalf of Council ensures the maintenance of ethical standards in The review and management of risk at QIMR is undertaken research and compliance with regulatory guidelines. by QIMR Council through the Finance and Audit Committee. Through the Finance and Audit Committee, QIMR • Dr Ian Wilkey (Chair) management have developed a register of potential risks • Dr Roger Allison applicable to functions of the Institute. A schedule of quarterly • Ms Madeline Brennan reviews incorporates the actions required to improve any • Mrs Gwen Eardley identified gaps in controls. • Mr Angus Edmonds The review process will record all incidents reported to • Mr Colin Forrest (To 01/02/11) Committees, Management or Council and allocate those incidents to risk categories. If a risk has not previously been • Mrs Mary Mackenzie described in the register, it will be added in the appropriate • Mr David Russell category and controls developed. • Dr Christopher Schmidt (To 14/06/11)
Page 25 audit committee the period 1 July 2010 – 30 June 2011: 27 August 2010, 26 November 2010, 25 February 2011 and 10 June 2011. The primary objective of the Finance and Audit Committee is The approach taken to identifying areas of significant risk to assist QIMR Council in fulfilling its responsibilities relating to combines a focus on both cyclical reviews of core business financial planning, policy and performance of QIMR with the processes as well as reviews of key risk areas. KPMG’s following prime objectives: integrated Governance, Risk and Controls (GRC) Framework • Sound financial planning and management processes; builds on a traditional internal audit model to take a holistic • Low level financial and business risk; view of QIMR’s key objectives, risks, controls and supporting • Establish guidelines for the financial budgeting process; structure across the organisation.
• Processes to manage variations to budget; In formulating an internal audit plan for presentation to the • Measure financial performance against budget, including Finance and Audit Committee for approval, consideration is the establishment of provisions and write-offs; given to past internal audit findings, recent and forthcoming • Internal controls to establish exposure to business risk changes in systems and processes, key business risks and and fraud; the period since the last internal audit of each core business • Effective and adequate accounting, administrative, process. Annual internal audit plans are prepared and operating and delegation policies; presented to the Finance and Audit Committee prior to the commencement of each financial year. • Responsive management actions to accounting reports produced by external and internal auditors; The internal audit function has observed the terms of its • Policies to avoid conflicts of interest for past, present and charter and has due regard to Queensland Treasury’s Audit future transactions between QIMR and staff; Committee Guidelines. • Policies and procedures to ensure QIMR complies with Federal, State and local government legislation; external Scrutiny • Ethical approaches to QIMR’s policies and practices. QIMR was not subject to any reports of any parliamentary The Committee meets quarterly to review business and committees, the Crime and Misconduct committee or the financial risk, financial operating performance and audit Queensland Ombudsman. performance. The Committee reviews all issues and recommendations arising from internal audit and Queensland Audit Office, along with agreed management action implemented to address any issues found. Whistleblowers protection act 1994
The Finance and Audit Committee has observed the terms No public interest disclosures were received during the of its charter and has due regard to Queensland Treasury’s 2010–2011 reporting year. Audit Committee Guidelines. The Finance and Audit Committee comprises: information systems and • Mr Paul Fennelly (Chair until 23/02/11) • Professor Bryan Campbell (Chair from 23/02/11) recordkeeping
• Mr Rodney Wylie QIMR maintains full and accurate records of its activities in • Professor John Hay accordance with the Public Records Act 2002, Information Standard 40 and Information Standard 31. The QIMR Committee members are paid $167 (Chair) or $141 (member) Recordkeeping Policy 2008 was established and adopted to per meeting, up to four hours per meeting. provide an organisation-wide policy on the management of documents and records, both hardcopy and electronic.
internal audit QIMR has implemented a single, official records and electronic document management system called Total Records and The role of Internal Audit is to provide the Finance and Information Management (TRIM) Context. The implementation Audit Committee and QIMR Council with independent, of TRIM Context has enabled QIMR to maximise the value of objective assurance and advice designed to add value and records with consistent and timely capture. It also improves assist QIMR in accomplishing its objectives by bringing a accessibility, reduces duplication and promotes information- systematic, disciplined approach to evaluating and improving sharing across the organisation. the appropriateness and effectiveness of risk management and internal control. Internal audit is a fundamental part of Records are not disposed of, or archived, unless their disposal corporate governance that ensures that the organisation is authorised under the Public Records Act 2002 or by operates effectively, efficiently and economically. The Finance reference to the Retention and Disposal Schedule approved and Audit Committee acts as a forum to oversee the planning, by the Queensland Studies Authority (QSA). All QIMR records performance and reporting of the Internal Auditor. are registered into TRIM Context before transfer to the off-site storage provider or QSA. All QIMR hardcopy records stored The internal audit contractor (KPMG) met with the Finance off-site are managed under legislatively appropriate risk and Audit Committee on the following occasions during management standards and guidelines.
Page 26 QIMR Annual Report 2010–2011 our management executive management
Director and CEO, Professor Frank Gannon
Professor Frank Gannon is QIMR’s seventh Director and CEO. In that role he is responsible for the research work undertaken by the Institute and management of our employees, under the overall control of the Council. Professor Frank Gannon joined QIMR as Director and CEO in January 2011.
Previously, Professor Gannon was the Director General at Science Foundation Ireland (SFI) from 2007.
From 1994–2007, Professor Gannon was the Executive Director of the European Molecular Biology Organisation (EMBO) and Senior Scientist at the European Molecular Biology Laboratory (EMBL), based in Germany; and Director of the National Diagnostic Centre and Associate Professor in the Department of Microbiology at University College Galway, Ireland (1981–1994).
He obtained a Bachelor of Science from the National University of Ireland, Galway in 1970, a PhD from the University of Leicester, England in 1973, was a post-doctoral fellow at the University of Madison Wisconsin, USA from 1973 to 1975, and Chargé de Recherche in INSERM at the University of Strasbourg, France from 1975 to 1981, when he returned to Galway.
His major research interest is the expression and functional regulation of the oestrogen receptor, which plays a major role in breast cancer and osteoporosis. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers.
Professor Gannon has authored over 200 research articles published in international journals. In addition, from 2000–2008, he contributed to a monthly editorial to EMBO Reports of which he was founding Senior Editor and also writes extensively on diverse topics related to science policy. Professor Gannon has seven patent applications, four of which are active and was the founder of both Bimini Ltd (1990) and Elara Pharmaceuticals (2006). He was a member of the interim Board of Science Foundation Ireland from 2002 to 2004 and was elected as a Member of the Royal Irish Academy in May 2008.
He has been awarded honorary Doctorates by the University of Jozsef Attila Szeged (Hungary), The University of Queensland and Queens University Belfast (Northern Ireland).
He has served on a range of high-level scientific advisory boards at institutes throughout the world and was co-founder of the European Life Sciences Forum (ELSF) and the Initiative for Science Europe (ISE) that played significant roles in the establishment of the European Research Council (ERC).
He was Vice President of the European Heads of Research Council and an advisor to the European Union Commissioner for Research and Innovation prior to his move to Brisbane.
Page 27 management advisory group (mag) membership
Program/Department Director: Professor Frank Gannon Deputy Director: Professor Adèle Green Chief Operating Officer: Ms Donna Hancock Program Coordinators: Professor Georgia Chenevix-Trench Cancer Professor James McCarthy Infectious Diseases Professor Michael Breakspear Mental Health/Complex Disorders Department Coordinators: Professor Geoff Hill Immunology Professor Emma Whitelaw Cell and Molecular Biology Professor Grant Montgomery Genetics Computational Biology Professor David Whiteman Population Health Professor Denise Doolan Biology Secretary: Ms Nerida Fox
Standing left to right: Professor Emma Whitelaw, Professor Geoff Hill, Professor Grant Montgomery, Professor James McCarthy, Professor Michael Breakspear, Professor Denise Doolan, and Professor David Whiteman Sitting left to right: Professor Adèle Green, Professor Frank Gannon, Ms Donna Hancock Absent: Professor Georgia Chenevix-Trench
Page 28 QIMR Annual Report 2010–2011 Adèle Green Grant Montgomery AC MBBS MSc PhD BAgSc (Hons) PhD Deputy Director, QIMR Coordinator, Genetics Head, Cancer and Population Department, QIMR Studies Group, QIMR Coordinator, Computational Biology Department, QIMR Adèle Green is the Deputy Head, Molecular Epidemiology Director of QIMR and Head Laboratory, QIMR of QIMR’s Cancer and Population Studies Group. Professor Montgomery She has served on national graduated with a PhD from and international health Massey University, Palmerston and research committees including the NHMRC, and the North in 1977 and spent the first 20 years of his career Scientific Council of the International Agency for Research working in animal reproduction and genetics in New Zealand. on Cancer. She is currently a member of the International He trained in endocrinology, including two years as a post- Commission on Non-Ionising Radiation Protection and its doctoral fellow at the Institute National de la Researches Epidemiology Standing Committee. In 2004, Professor Green Agronomique, Tours, France. After returning to New Zealand, was awarded a Companion of the Order of Australia (AC) he set up a genomics laboratory located in the Biochemistry for “Service to medical research to public health including Department at the University of Otago and helped build the improved Indigenous health, and for leadership in the wider first sheep genetic map and mapped and cloned genes scientific community”. affecting twinning frequency.
Georgia Chenevix-Trench He moved to QIMR in 1999 and is currently an NHMRC BA (Hons) BSc PhD Principal Research Fellow, Head of the Molecular NHMRC Senior Principal Epidemiology Laboratory, Coordinator of the Genetics Division Research Fellow at QIMR, and a co-leader of the International ENDOGENE Coordinator, Cancer Consortium. The goal of Professor Montgomery’s research is Program, QIMR to determine critical genes and pathways increasing risk for Head, Cancer Genetics common diseases, with specific interests in the genetics of Laboratory, QIMR endometriosis, melanoma and inflammatory bowel disease.
Georgia Chenevix-Trench is Emma Whitelaw a NHMRC Senior Principal BSc (Hons) PhD Research Fellow and Head of NHMRC Australia Fellow the Cancer Genetics Laboratory at QIMR. She is also the Coordinator, Cell and Molecular conjoint Professor in the Division of Health Sciences at The Biology Department, QIMR University of Queensland. She holds a BA (Hons) from the Head, Epigenetics Department of Genetics at Trinity College in Ireland, and was Laboratory, QIMR awarded a PhD in 1985 from the Department of Human Genetics at the Medical College of Virginia, USA. Emma Whitelaw is an NHMRC Australia Fellow at QIMR. After Her current research focuses mainly on the study of genes completing her undergraduate that predispose stomach, breast and ovarian cancers, and degree at the Australian genes involved in response to chemotherapy in ovarian cancer National University, she obtained a Doctor of Philosophy at patients. She has played a leading role in national efforts to the University of Oxford and remained working in London establish resources for this kind of research, and is involved in and Oxford for the next 15 years, moving back to Australia in many international consortia aimed at coordinating these gene 1991. She was offered a Senior Lectureship at the University finding efforts. of Sydney and carried out both teaching and research. She has focused her research on eukaryotic transcription using She possesses an impressive national and international profile, the mouse as a model organism. Her most notable research with invitations to speak at many high profile conferences. achievements are in the area of epigenetics. In particular, her studies on the transgenerational inheritance of epigenetic She was the Sutherland Lecturer at the International Congress marks have stimulated a great deal of interest from the wider of Human Genetics in 2006. scientific community. In 2008, she was awarded an Australia She has received funding from many national and international Fellowship, the most prestigious fellowship in medical grant funding bodies, and published more than 200 papers in research in Australia. peer reviewed journals. In 2011 Professor Whitelaw, was elected as an Australian Academy of Science Fellow, and received both the Australia and New Zealand Society for Cell and Developmental Biology President’s Medal and the International Union of Biochemistry and Molecular Biology Jubilee Medal.
Page 29 management advisory group (mag) membership | continued
James McCarthy Michael Breakspear MBBS MD FRACP DHTM BSc (Med Hons) BA (Hons) MBBS PhD Coordinator, Infectious Diseases FRANZCP Program, QIMR Coordinator, Mental Head, Clinical Tropical Medicine Health/Complex Disorders Laboratory QIMR Program, QIMR Senior Consultant Infectious Head, Systems Neuroscience Diseases Physician, RBWH Laboratory, QIMR Professor of Medicine, The Michael Breakspear undertook University of Queensland undergraduate studies at After graduating in Medicine the University of Sydney, from the University of Melbourne in 1984, James McCarthy graduating in 1994 with Honours in Arts, Science and undertook postgraduate training in Internal Medicine and Medicine. Following three years of basic medical residency, Infectious Diseases in Australia, the UK and the USA. He he commenced training in clinical psychiatry at St Vincent’s then undertook research training in molecular parasitology Hospital, Sydney, and a concurrent PhD at the University of at the Laboratory of Parasitic Diseases, NIH (1991–1996), Sydney. After completing post-doctoral fellowships in Physics graduating as a Doctor of Medicine in 1997. He returned at the University of Sydney and the Black Dog Institute, he to Australia in 1996 to take a post in the Department of became an Associate Professor in Psychiatry at the University Medicine at the University of Western Australia, before of New South Wales in 2006. He accepted the position of moving to QIMR in 2002. At QIMR his research focuses on Head of a new Division of Mental Health Research at QIMR translational aspects of vaccines, drugs and diagnostics in in 2008. This division aims to add the latest advances in tropical diseases. James is an NHMRC Practitioner Fellow neuroscience to the Institute’s internationally renowned and Queensland Health Research Fellow. He serves on the expertise in genetics, cell biology and population health. He Editorial Board of the American Journal of Tropical Medicine, has also completed his clinical training and is a Fellow of the the International Journal of Parasitology and as Associate Royal Australian and New Zealand College of Psychiatrists. Editor of PLoS Neglected Tropical Diseases. His laboratory Michael’s expertise lies in both computational and includes a multidisciplinary team of scientists undertaking experimental neurosciences. He has made theoretical, bench research, a regulatory affairs specialist in clinical methodological and empirical contributions in a “system’s trial management, and staff and students undertaking neuroscience” framework that sees the brain as a complex, epidemiologic studies and clinical research. Sources of dynamical network. His interests are in the application of this research funding include competitive grants from NHMRC, framework to underpin a novel generation of diagnostic brain Medicines for Malaria, and Queensland Health, and the World imaging tests in clinical psychiatry. He is a chief investigator on Health Organization. a number of major national and international grants totalling Geoff Hill approximately $8 million and leads an independently funded MBChB MD BHB FRCPA FRACP research team of 10 young students and scientists. He is NHMRC Australia Fellow a Section Editor at NeuroImage, a major international brain Coordinator, Immunology imaging journal. Department, QIMR Head, Bone Marrow Donna Hancock Transplantation BCom MBA MAICD Laboratory, QIMR Secretary and Chief Operating Officer, QIMR Geoff Hill is a medical graduate of the University of Auckland Donna Hancock is the Chief and haematologist, training in Operating Officer, Secretary New Zealand, The Dana Farber Cancer Institute, and Harvard to QIMR Council and heads Medical School in Boston. He is a NHMRC Australia Fellow the Corporate Division. She and his immunology laboratory focuses on the interactions holds a Bachelor of Commerce between cytokines, antigen presenting cells and regulatory from Newcastle University cells during transplantation. Professor Hill was 2005 and a Masters in Business Queenslander of the Year and recipient of the Transplantation Administration from the University of Melbourne. She has Society of Australia and New Zealand 2009 Ian McKenzie an extensive background in finance, business planning, Award for excellence within basic and clinical research in the business development, systems development and commercial transplant field. He was also awarded a Queensland Health management. Prior to joining QIMR, Donna worked for over Senior Clinical Research Fellowship in 2010 to translate 20 years as a senior executive with BHP Billiton. new therapies into clinic practice; and in 2011 received a prestigious NHMRC Australia Fellowship worth $800,000 Donna is a director of Q-Pharm Pty Ltd, a member of the annually for five years. Medical Board of Australia (Qld Registrations Committee) and a former member of the Pharmacists Board of Queensland.
Page 30 QIMR Annual Report 2010–2011 David Whiteman Denise Doolan BMedSc MBBS (Hons) PhD FAFPHM BSc (Hons) MPh PhD Australian Research Council Pfizer Australia Research Fellow, Future Fellow 2007–2011 Coordinator, Population Health Coordinator, Biology Department, QIMR Department, QIMR Head, Cancer Control Head, Molecular Vaccinology Laboratory, QIMR Laboratory, QIMR
David Whiteman is a medical Denise Doolan graduated from epidemiologist with a special The University of Queensland interest in the causes, diagnosis, with a Bachelor of Science prevention and treatment of cancer. He received his medical (Honours) (Biochemistry major) in 1985. She began her degree from The University of Queensland in 1991. With a research career at the CSIRO and was subsequently awarded PhD in cancer epidemiology at QIMR (1997) and specialist an MPhil in 1991. In 1993, she completed her PhD in the training in Public Health Medicine, David was invited to the laboratory of Professor Michael Good at QIMR and went on University of Oxford as a Nuffield Medical Research Fellow to complete a postdoctoral fellowship at the Naval Medical to work in several areas of cancer research. He returned Research Institute in the USA where she worked with Dr to Queensland in 2000, where he is currently studying the Stephen Hoffman to develop malaria vaccines. She was later causes of melanoma and diseases of the oesophagus, ovary appointed as Head of Basic Research, and later Head of and skin. Preclinical Research and Development, and finally as Scientific Director of the Naval Medical Research Center Malaria In addition to his research activities, he is currently a member Program, a major biomedical research facility of the United of the Academy of the NHMRC, the National Research States Department of Defence. Professor Doolan returned to Advisory Committee for Cancer Australia, the Research Australia in 2006 and was awarded a Pfizer Australia Senior Committees of Cure Cancer Australia Foundation and Research Fellowship, establishing the Molecular Vaccinology Wesley Research Institute, and the Fellowships Committee Laboratory at QIMR in 2007. Subsequently, she was of the International Agency for Research on Cancer. He has appointed as Professor, Griffith Medical Research College, previously served as a Member of Council of NHMRC, and Griffith University, and as Professor, School of Medicine, served on the NHMRC National Asbestos Research Working The University of Queensland. Her laboratory investigates Group and the NHMRC Strategic Research Development the molecular basis of immunity to disease and vaccine Committee. In 2006, he was awarded a Fulbright Scholarship development, with a focus on malaria. to visit cancer researchers in the USA.
Page 31 Page 32 QIMR Annual Report 2010–2011 ouR peRFoRmAnCe
Translation
Scientific quality
Commercial consequence
Societal impacts
International reputation
Page 33 Translation
In order to improve the health of all, scientific discoveries need to be translated from the laboratory into the clinic. QIMR was the prototype of what is, today, referred to as a translational medical research institute. It is one of Australia’s only fully integrated biomedical research and development centres.
Translational research undertaken at QIMR has lead to the development of a T cell therapy for EBV-associated nasopharyngeal carcinoma; influenced a major change in clinical practice with the acceptance that it is important to remove proximal serrated polyps; and human clinical trials are underway using a monoclonal antibody developed at QIMR for the teatment of acute leukaemias, melanomas, brain tumours and lung cancers.
translation facilities Q-gen
QIMR is one of Australia’s only fully integrated biomedical Q-Gen is licensed by the Therapeutic Goods Administration research and development centres. Within the Institute, there (TGA) for the maintenance and storage of working cell banks, is the capability to translate fundamental basic research from the storage on site of cellular products. The TGA license the discovery phase through development, scale-up and makes Q-Gen one of a very small number of organisations in manufacture, to Phase I and II clinical trials. Australia able to store human samples under GMP conditions.
QIMR also has facilities for the manufacture of cell-based Q-Gen is one of the largest facilities of its type in Australia, and molecular therapies. Co-located within the Institute is an with 13 ISO Class 7 clean rooms. Each clean room is fully associated commercial Phase I/II clinical trials facility, Q-Pharm equipped for the manufacture of clinical therapies. Pty Ltd, providing QIMR scientists and external clients the Q-Gen provides QIMR with a unique facility to conduct its capability to take research findings from bench to the bedside. translational research and processes for clinical therapies and is currently utilised in the manufacture of a number of QIMR sponsored developmental immunotherapies. Under a joint funding agreement with Therapeutic Innovation Australia (formerly Research Infrastructure Support Services) and the Australian Red Cross Blood Service, Q-Gen is able to manufacture clinical trial products for eligible external researchers.
Page 34 QIMR Annual Report 2010–2011 Q-pharm In 2010–2011, QIMR’s clinical collaborations have produced a range of significant outcomes: Q-Pharm is a specialist contract research organisation that conducts early phase clinical trials of pharmaceutical and • Helped better identify patients at high risk of developing biotechnology products spanning the areas of therapeutic, primary melanoma; diagnostic and disease prevention agents. • Identified a novel oncogene in asbestos-related In order to facilitate the translation of QIMR’s research into lung cancers; clinical practice, QIMR holds a 24.5% share in Q-Pharm. • Identified a microRNA that appears to suppress lung The company offers the best appointed early phase clinical cancer development; trials facilities in Australasia, which include recruitment and • Discovered that major depression consists of multiple outpatient clinics, a specialised 18-bed clinic for the conduct partly overlapping subtypes and bipolar depression, of the most medically demanding trials and an open plan 24 in comparison to unipolar depression, has a distinct bed facility for larger healthy volunteer trials. clinical profile; • Discovered that working memory-related cortical activity clinical collaborations predicts functional decline in people with mild cognitive impairment; and Because of its close proximity to major teaching hospitals and The University of Queensland Medical School, QIMR • Showing that patients with haemochromatosis are at is ideally placed for clinical research collaborations. It has a increased risk of colon and breast cancer. proud history of working closely with hospitals, in particular the RBWH. Clinicians have research groups in QIMR and medical researchers in QIMR have clinical sessions at the Drug discovery RBWH. QIMR’s researchers also have significant relationships The discovery of small molecules or related agents, reveal with clinicians nationally and internationally. Last year, 64% new insights and new biological pathways, which may of QIMR researchers collaborated with clinicians in over 100 ultimately lead to the development of therapeutics for a range projects, in hospitals worldwide. of human diseases. Some of QIMR’s current clinical collaborations include: Examples of drug discovery projects currently underway at • Collection of samples from cystic fibrosis, glioma, ataxia- QIMR include screening for: telangiectasia, melanoma and oesophageal cancer • Small molecules that might inhibit or enhance membrane patients for genetic, tissue and cell culture studies (Prince iron transport, or that interfere with the action of iron Charles Hospital, BrizBrain and Spine, Wesley Hospital, regulatory molecules such as hepcidin (implications for RBWH, Greenslopes Hospital, St Vincent’s Hospital, disorders of iron metabolism); Murdoch Children’s Research Institute, Royal Brisbane Children’s Hospital, Princess Alexandra Hospital); • Drugs that convert hepatic stellate cells to myofibroblasts or reverse the conversion (implications for therapeutic • Recruitment of patients into national tissue and data bank intervention in chronic liver disease); (Flinders University, University of New South Wales); • Modifiers of p53 regulation, in cell lines where novel • Looking at the effect of advanced paternal age on risk proteins involved in the regulation of p53 have been of autism or schizophrenia (Queensland Centre for deleted (implications for cancer treatment); Schizophrenia Research, Wolston Park Hospital, Brain Research Institute); • Antimalarial (antigametocyte) drugs; • Assessing disease risk in patients with haemochromatosis • Novel compounds to improve the efficacy of malaria (Royal Children’s Hospital Melbourne, University of vaccines, especially compounds that stimulate a robust Western Australia, RBWH); cell mediated immune responses to malaria in vivo; • Investigating the role of Epstein-Barr virus in multiple • Compounds that affect the immune system sclerosis (RBWH); (immunomodulators); • Ongoing collection of samples of diffuse large • Protease inhibitors in malaria; B cell lymphoma (Westmead Hospital, Princess • Antibacterials, especially against group A streptococcus; Alexandra Hospital); • Activators or inhibitors of ATM kinase to target DNA • Developing a model for scabies to study the interaction damage pathways in cancer; between scabies mite and bacterial infection (RBWH, • Synergistic modulators of pathways in breast Royal Darwin Hospital); and cancer cells; • Identifying serum and tissue biomarkers to predict • Inhibitors of MIC-1 transcription in reporter cancer outcome in biliary atresia and cystic fibrosis liver cells; and disease (St Louis Children’s Hospital, St Louis and • Inhibitors of HIV-1 Tat medicated transactivation using Washington University). a dual luciferase cell based assay in order to develop a treatment for HIV.
Page 35 Vaccine development • Establishment of collaborative links with international biotechnology companies on the development The Australian Centre for Vaccine Development (ACVD) and testing of a vaccine to prevent birth defects in at QIMR is one of the largest vaccine research centres in newborn babies; Australia. It provides opportunities for its members to develop • Initiation of project aiming to conduct gene signature collaborative links with national and international academic analysis of potential immune adjuvants identified using institutions and the biotechnology industry and also provides natural product library; a platform for young Australian and international scientists to • Development of strategies to revert the dysfunctional develop new techniques in the field of vaccine research. cellular and humoral anti-viral response (e.g. targeting ACVD is collaborating with internationally renowned Emory of PD-1); and Vaccine Centre (EVC) Atlanta, USA under the Queensland • Establishment of collaborative studies with RBWH and Government funded National and International Smart State BrizBrain and Spine (Wesley Hospital) to test novel killer Research Program (Queensland-US Vaccine Technology T cell therapy for stem cell transplant and brain cancer Alliance) to explore new technologies that can be used to patients respectively; develop and improve vaccines. Both organisations have strong links with the biotechnology current clinical trials industry and health institutions that are being leveraged to translate the outcomes of research from bench to bedside, Fundamental research at QIMR in 2010–2011 underpinned a which will have significant implications for improving health number of clinical trials that may ultimately lead to improved outcomes for Australians. This collaborative program is also treatment options for patients. Some highlights include: aiming to bring new technologies to Queensland and create • Began Phase I clinical trials using a monoclonal antibody training and employment opportunities for Queenslanders. as a potential cancer treatment for acute leukaemias, ACVD has unique expertise and resources in antigen melanomas, brain tumours and lung cancers; discovery with a strong focus on immunomics, bioinformatics • Completed a human malaria infection study to develop a and high throughput re-sequencing. This approach allows sensitive protocol for testing new antimalarial drugs; rapid whole genome scanning of infectious pathogens and • Completed an EBV immunotherapy trial; cancer antigens to map novel vaccine determinants. • Developed a killer T cell therapy for EBV-associated The major achievements for the ACVD include: nasopharyngeal carcinoma; • Completion of in vitro screen of natural products library as • Completed the preclinical testing of a prophylactic immune adjuvants capable of activating innate immunity; vaccine for cytomegalovirus. A Phase I clinical trial is planned for this vaccine, which aims to prevent clinical • Completion of Phase I of clinical testing of novel complications in transplant patients and newborn babies; immunotherapy for nasopharyngeal carcinoma patients; • Continued trialling a novel immunotherapy for • In vivo immune analysis of natural products identified brain cancer; and through in vitro screen with primary objective to identify the most promising candidates for further research; • Started a clinical trial of a novel immune-based diagnostic tool for cytomegalovirus.
QIMR’s fundamental research has led to the development of a potential cancer therapy
QIMR’s fundamental research has lead to the neck cancers and other solid tumours where injection development of a potential cancer therapy. can be guided by imaging.
EBC-46 is a novel and highly potent compound in Although only in late pre-clinical development for development for local treatment of solid tumours. humans, QIMR and QBiotics have conducted studies Research by QIMR’s Professor Peter Parsons from in laboratory cell culture and in mice. They have also the Drug Discovery Laboratory has assisted in this successfully treated dogs, cats and horses with compound being further developed by QBiotics. advanced spontaneous tumours that were considered untreatable with current standards of care. EBC-46 has potential applications for skin cancers including melanomas, squamous cell carcinomas QIMR researchers continue to uncover the mode of (SCC) and basal cell carcinomas (BCC); head and action of this compound to develop analogues and other potential anti-cancer therapies.
Page 36 QIMR Annual Report 2010–2011 Scientific quality
QIMR’s philosophy is to support scientists who perform world-class medical research aimed at improving the health and well being of all people.
QIMR has demonstrated scientific quality in a number of ways in 2010-2011 including producing 567 peer reviewed publications, securing more than $21 million of competitive NHMRC funding, as well as producing a range of world-class research outcomes across its 50 laboratories.
QIMR will continue to strive for the highest standard of scientific quality by attracting outstanding researchers; producing and contributing to publications and high-impact publications; and gaining ongoing support from funding bodies to continue our medical research.
publications Scientific publications
Publications and citations are a key indicator of achievement 600 and excellence in academic research and are a core output of QIMR. Confirming our ongoing pursuit of excellence in 500 science, researchers at QIMR contributed to 567 scientific publications; a significant increase on 390 publications in 400 2009–2010 and 419 in the 2008–2009 financial year. 300 Not only have the number of publications increased but at 200 the same time the quality of the research has improved. Of these 567 publications, 61 were published in very high impact 100 journals (those with an impact factor over 10); compared to 55 in 2009–2010, and 42 in 2008–2009. 0 2007 2008 2009 2010 2011 For a full list of publications, see page 133. Articles High Impacts (publications in journals with impact factors of 10 or more)
Page 37 This year, QIMR researchers been published in a range of high invited lectures impact scientific journals such as Science, Nature and Nature Genetics. These include articles on: QIMR researchers are well respected throughout Australia and • the genetics of breast and ovarian cancer, migraine, the world and were invited to speak about their work at over myopia (short or long sightedness), open angle 340 lectures in 2010–2011, including: glaucoma, endometriosis, ulcerative colitis, height, and • Associate Professor Don Gardiner presenting at the personality traits (Nature Genetics); Medicines for Malaria Venture ESCA Meeting in Geneva • DNA damage and repair mechanisms in Science; in October 2010; • the genetics of human height and new genes • Professor Denise Doolan presenting at the International associated with blood lipids, a key indicator of heart Congress of Parasitology in Melbourne in August 2010; disease (Nature); • Professor Grant Montgomery discussed the genetics • training T cells to fight malaria (Nature Medicine); of endometriosis at the Society for Gynaecological Investigation in Miami in March 2011; and • diagnosing and treating schistosomiasis, a parasitic disease that affects 207 million people worldwide • Professor Jeff Gorman spoke at the Australian (British Medical Journal (BMJ) and Lancet Infectious Proteomics Society in Lorne in February 2011. Diseases); and For a full list of invited lectures, see page 112. • papillomaviruses and the number of cases of non-melanoma skin cancer (BMJ). awards funding Institute staff members also received over 90 local and international awards in the last financial year, including: QIMR was recognised and gained support for our innovative • Professor Emma Whitelaw, Head of the Epigenetics work, with researchers securing more than $21 million in Laboratory, was elected as an Australian Academy funding from the National Health and Medical Research of Science Fellow, and received both the Australia Council (NHMRC). and New Zealand Society for Cell and Developmental Funds were provided from 1 January 2011 for a total of Biology President’s Medal and The International Union of 17 new research projects ranging from the genetics of brain Biochemistry and Molecular Biology Jubilee Medal; structure and function, to understanding the causes of breast • Professor Geoff Hill receiving an Australian Fellowship. and ovarian cancer and risks, to improving the health of Australian Fellowships are the most prestigious of the Indigenous populations. NHMRC fellowships and awards, with only six awarded this year. They are designed to support the most nHmrc grants awarded ($ millions) outstanding and creative health and medical researchers across the range of disciplines in biomedical, clinical, 20 health services and public health research and are highly competitive among leading researchers both in Australia and around the world. 15 • Professor Don McManus, Professor Rajiv Khanna and Dr David Duffy received Senior Principal Research
10 Fellowships from the NHMRC; • Dr Darren Gray was awarded Publication of the Year by Griffith University; 5 • Dr Susan Woods received the Queensland Senior Researcher Award from the Australian Society for 0 Medical Research; 2007 2008 2009 2010 2011 • Dr Patricia Valery, from the Indigenous Health Program, Grants Fellowships was awarded a NHMRC Excellence Award, the highest ranking Career Development Award in the category of population health; and employment • Dr Sarah Medland from the Genetic Epidemiology Laboratory was awarded a 2010 Queensland Young Tall Ensuring the ongoing quality of research, QIMR employed Poppy Science Award. 17 NHMRC Fellows in 2010–2011. For a full list of awards, see page 111.
Page 38 QIMR Annual Report 2010–2011 postgraduate students QIMR’s postgraduate students have continued to make an impressive impact on the wider scientific community this year Today’s students are the scientists of the future, so in order with many receiving external awards during their candidature. to ensure the continuation of the Institute’s scientific quality, Highlights include: postgraduate students are an important part of the research • Renee Robb, a third year PhD student, was awarded effort at QIMR. The excellent research facilities, support a Young Investigator Award and the President’s Prize services, extensive network of international and national from the Transplantation Society of Australia and research collaborations, and the internationally-ranked quality New Zealand; of QIMR scientists, combine to provide an outstanding environment for advanced training in health and biomedical • Karin Verweij received a Research Excellence Award research. Mentoring of the students remains a high priority. from the School of Psychology at The University of Queensland; and 2010–2011 was again a productive year for students at QIMR • Vijayendra Dasari was awarded a Training Fellowship with a total of nine PhD students, five Research Masters from the ACVD-Emory Vaccine Centre. and 10 Honours students successfully graduating from their degree programs. During the year, the Institute admitted In total, more than 20 travel awards were received from 17 new PhD, two Research Masters, two coursework Masters organisations including the Australian Twin Registry, the and 20 Honours students. Janine Whitney joined the Institute Cancer Council Queensland and the Australian Society for under the Australian Government’s Indigenous Cadetship Parasitology. These awards allow students to attend and Program. QIMR also hosted 43 visiting students during the present at conferences within Australia and overseas. PhD year, many from overseas. students Franziska Bieri, Yi Lu and Maggy Sikulu were also awarded prizes for their conference presentations.
Top recognition for QIMR researchers
australia fellowship australian academy of
The Australia Fellowships, awarded by the NHMRC, Science fellows recognise outstanding health and medical researchers Election to the Australian Academy of Science (AAS) across all disciplines. The recipients have international Fellowship recognises a research career that has status in their fields and are now conducting research significantly advanced the world’s store of scientific programs of major impact and benefit to Australia. knowledge. QIMR currently has five AAS Fellows: Only 39 Australia Fellowships were ever awarded and • Professor Brian Kay; two of QIMR researchers, Professors Emma Whitelaw • Professor David Kemp; and Geoff Hill are among them. • Professor Nick Martin; • Professor Peter Visscher; and • Professor Emma Whitelaw. Queensland government fellowships
Professor James McCarthy and Professor Michael Breakspear were awarded Health Research Fellowships from the Office of Health and Medical Research for their work in malaria and mental health respectively. Professor Geoff Hill also received a Senior Clinical Research Fellowship for his work in bone marrow transplantation for leukaemia.
Page 39 Commercial consequence
QIMR has achieved significant health outcomes and secondary economic benefits through its connections with industry. These include the development of cancer therapeutics, diagnostic targets, cancer vaccines and infectious disease vaccines. Its reputation for excellence is further enhanced through its collaborative projects with companies and its involvement in projects of commercial significance.
QIMR undertakes industry sponsored collaborative research with a large number of local, national and international companies. Currently, QIMR has contracts with over 20 national and international biotechnology and pharmaceutical companies. In 2010-2011, 15 new projects were established with companies attracting approximately $2 million in external revenue. QIMR is a strong research partner of Queensland companies CBio and Ecobiotics.
Contract research carried out in QIMR has resulted in the discovery and development of cancer therapeutic agents and other commercial products.
related commercial entities trust for the cooperative research centre (crc) for Vaccine technology (crcVt trust ii) QIMR has assisted in the economic development of the State through its involvement in the establishment of start-up QIMR is the Trustee of the CRC for Vaccine Technology companies based in Queensland. QIMR has also been (CRC –VT) Trust (CRCT Trust II), a trust responsible for a key research provider to Queensland based company managing patent families and licensing agreements on behalf Ecobiotics Ltd since 2004. of those participating in the CRC for Vaccine Technology, which was abolished in June 2006. Vactx Vaccine Solutions QIMR is a shareholder in VacTx Pty Ltd, a Melbourne based company established to develop vaccine technology arising QIMR is a shareholder in Vaccines Solutions Pty Ltd, a out of the CRC for Vaccine Technology. company established to commercialise intellectual property resulting from the CRC for Vaccine Technology. The company trust for cooperative research centre (crc) for has key licence agreements with Pfizer Inc. Vaccine technology (crcVt trust i) Q-pharm QIMR is the Trustee of the CRC for Vaccine Technology Q-Pharm Pty Limited is a specialised contract research Trust, a trust managing shares in VacTx Ltd on behalf of the organisation that undertakes a broad range of early phase participants of the CRC. (Phase I and Phase II) clinical trials for clients in the global pharmaceutical and biotechnology industries. QIMR holds a 24.5% share and Q-Pharm pays a licence fee per annum to QIMR to lease office, laboratory and clinical trial ward facilities in the Clive Berghofer Cancer Research Centre, and for information technology services and stores services. For details, see page 99.
Page 40 QIMR Annual Report 2010–2011 Business development
Through commercial grant proposals and the negotiation industries, and also include collaborative research with large of commercial agreements with industry partners, QIMR is international companies. working to build and strengthen the Institute’s reputation. QIMR’s patent portfolio supports a strong presence in tropical The majority of agreements this financial year have and infectious diseases, with a significant proportion in vaccine been providing research services to Queensland-based technologies. For a full list of patents, see page 127. Business development agreements Patent portfolio 2010-2011 research agreements patent portfolio
Research service Intellectual property agreements agreements Vaccine Patents Diagnostic Patents Clinical trial License Patent portfolio 2010-2011 New Treatment Patents Delivery Platform Patents Business development agreements agreements agreements Commercialisation Others Drug Target Patents agreements
Research service Intellectual property Vaccine Patents Diagnostic Patents agreements agreements New Treatment Patents Delivery Platform Patents Clinical trial License agreements agreements Drug Target Patents Commercialisation Others agreements
Life work culminates in testing of cancer therapy in humans
Phase I clinical trials have commenced using the The initiation of a Phase I clinical trial in patients monoclonal antibody KB004 to determine if it might with acute leukaemia by KaloBios is an important be efficacious in humans. It is the culmination landmark and will hopefully lead to further testing and of 25 years of research for QIMR researcher the ultimate use of this antibody as a treatment. Professor Andrew Boyd, Head of the Leukaemia The development of this antibody as an anti-cancer Foundation Laboratory. therapeutic was the result of a collaboration between KB004 has been shown to kill certain types of QIMR’s Professor Andrew Boyd, Professor Andrew cancerous tumours in a laboratory using human Scott from the Ludwig Institute and Associate samples. It is targeted towards EphA3 expressing Professor Martin Lackmann from Monash University, haematologic malignancies, which are believed to who initiated and lead the translational aspects of account for about 50% of acute leukaemias as well this venture. It would not have been possible without as a number of other human cancers including a ongoing financial support for Professor Boyd from the significant proportion of malignant melanomas, brain Leukaemia Foundation. tumours and lung cancers. KB004 is a first-in-class engineered IgG1κ antibody KaloBios Pharmaceuticals, a San Francisco targeting the EphA3 receptor tyrosine kinase. biotechnology company took the original mouse Developed using KaloBios’ proprietary antibody antibody and through a process known as Humaneering™ technology, KB004 has variable Humaneering™ technology, developed an antibody regions that are very similar to human germ-line that could be used in humans as it would be more sequences, providing the potential for low likely to be tolerated by the human immune system. immunogenicity in patients. In addition, KB004 is engineered to enhance antibody-dependent cytotoxic (ADCC) activity.
Page 41 Societal impacts
QIMR’s mission is better health through medical research. Gaining support from funding bodies, the government and the community, QIMR is committed to performing research which addresses the health needs of our society.
The Institute’s research provides valuable information to assist policy makers enhance the health of the wider community and help individuals make well informed decisions about their own health. QIMR researchers also rely on members of the community to support their research by sitting on advisory groups and volunteering to participate in a range of research projects.
QIMR ensures the public is informed about our research and is committed to inspiring the students of tomorrow through its education program.
addressing society’s health needs cancer • Finding that in combination smoking, obesity (BMI ≥30 kg/m2) and acid reflux together accounted for 76% of 1 in 2 Australian’s will be affected by cancer before the age oesophageal adenocarcinoma cases. When considered of 85. For that reason cancer research continues to be a separately, smoking, obesity and frequent reflux major focus for QIMR. In 2010-2011, QIMR made a number (≥weekly) accounted for 29%, 23% and 36% of these of important cancer discoveries that can help the community cancers respectively. This study suggests that these in making informed decisions about their health and cancers may be largely prevented by maintaining healthy lifestyle, including: BMI, avoiding smoking and controlling symptomatic • Showing that people with many moles, or with a family gastroesophageal reflux in the population; history of melanoma are significantly more like than • Discovering that high intakes of folates from food sources others to develop a second melanoma. This result will are associated with lower risks of oesophageal cancers; help identify people who are at higher at risk and require more regular surveillance; • Demonstrating that regular walking for women undergoing chemotherapy for ovarian cancer is safe, • Showing scientifically that the regular use of sunscreen feasible and acceptable to women; prevents melanoma. The effectiveness of sunscreen to prevent melanomas has been a point of conjecture • Finding that diets with a high glycaemic load may among researchers and clinicians for many years. This increase the risk of ovarian cancer, particularly among evidence supports the importance of regular sunscreen overweight/obese women, and a high intake of fibre may application, which provides valuable strength to the long provide modest protection; and running slip slop slap health campaigns; • Discovering an increased risk of both pancreatic and • Finding evidence that long chain fatty acids found in oily colorectal cancer in the relatives of patients with serrated fish such as salmon, anchovies and sardines, may be polyposis, which help identify people at higher risk and able to precent skin tumour formation, reinforcing the require regular checkups. importance of oily fish in a well balanced diet;
Page 42 QIMR Annual Report 2010–2011 infectious Diseases • Identifying two genetic variants that increase the risk of developing endometriosis, giving hope to patients, by Infectious disease is the cornerstone of QIMR, having been validating he condition which has often been dismissed established in 1945 to combat tropical diseases affecting by clinicians. Endometriosis is a painful, gynaecological Queensland. Researchers at the Institute are world leaders disease that is estimated to affect six to ten per cent of in a range of infectious diseases that affect communities all women in their reproductive years. thoughout the world including malaria, HIV, schistosomiasis and scabies. Many of the diseases under study are simultaneously the cause of very significant morbidity and partnership with the community mortality, but are also often understudied by other research groups elsewhere in the world. The infectious agent may Much of QIMR’s research could not be completed without be parasitic (e.g. malaria), viral (e.g. HIV/AIDS), or bacterial contribution from the community. QIMR has teamed up with (e.g. streptococcus A). In 2010–2011, QIMR carried out a individuals, patient groups and community groups to conduct number of studies to reduce the spread of infectious diseases a range of research projects including: through the community, including: • QIMR researchers have embarked on the world’s largest • Developing a new system for public health officials to skin cancer survey. 200,000 people will be invited monitor for outbreaks of Ross River virus disease and to participate. The survey was developed in close Barmah Forest virus disease. The VEDS (vector-borne consultation with Melanoma Patients Australia. Data disease early detection and surveillance) system collected will support the development of a scientifically is a joint venture between QIMR and Queensland based risk assessment tool to be used by all general Health to provide timely data about the prevalence of practicians. This will enable doctors to accurately identify mosquito-borne diseases within Local Government those at greater risk of developing skin cancers and Areas in Queensland; melanomas and to work with the patient to implement risk minimising strategies; • Conducting surveys on domestic mosquito breeding in and around Brisbane, using GPS and portable • QIMR is heading the largest Australian study of asthma tablets to integrate this data into VEDS. Information genetics. Over 5,000 people have participated, enabling collected will help advise local council and residents researchers to search for genes that increase the risk of on strategies to remove potential breeding grounds developing asthma; for mosquitoes and reduce the overall incidence of • Researchers in the Clinical Medicine Laboratory are mospquito-borne diseases; conducting a human clinical trial on healthy volunteers to • Commencing a field trial in Cairns to test how well develop a sensitive scientific protocol that will enable the Wolbachia can spread into mosquito populations in the testing of potential new antimalarial drugs in a controlled wild and prevent the spread of Dengue Fever; and clinical setting; • Contributing to the World Health Organization Malaria • Depression is the leading cause of disability worldwide Rapid Diagnostic Tests Product Testing Program (Round (WHO, 1990). In response to this growing health crisis, 3) to provide invaluable guidance for governments and QIMR’s Mental Health Division, which officially opened non-profit organisations that purchase these products. on 11 February 2010, continues to be an area of much growth within the Institute. The aim is to work with the mental Health/complex Disorders community to reduce the stigma of mental illness and improve treatment and access so it is on parity with Disorders such as cardiovascular disease, endometriosis, physical illnesses. An area of focus is the development asthma and mental illness are complex to treat and are of a diagnostic tool for depression and other major often poorly understood, despite affecting large numbers psychiatric diseases. The techniques will also be of people in Australia and throughout the world. Complex applied to identifying depression or early dementia in conditions can impact greatly on an individual’s lifestyle and our ageing population and will rely on volunteers from make daily life difficult. QIMR has a dedicated Mental Health/ the healthy population as well as patients suffering from Complex Disorders Program to investigate these disorders. In mental illness; and 2010–2011, the Program made several discoveries that may offer solutions to individuals to improve their behaviours, and • Over 6,000 identical and non-identical twins have in turn their health, including: volunteered to assist researchers from the Genetic Epidemiology and Molecular Epidemiology Laboratories • Discovering that eating or drinking full fat dairy may disentangle the impact of genes versus environmental reduce the risk of cardiovascular related death; on the risk of developing a range of diseases. By • Finding 30 new genes that control the age of sexual studying twin data, QIMR researchers have found maturation in women and identified several genetic links genes responsible for: schizophrenia, bipolar disorder, between early puberty and body fat; glaucoma, dyslexia, endometriosis, addiction, migraine, • Developing a Supportive Care Needs Survey for and melanoma. Indigenous People (SCNS-IP) with cancer. The SCNS-IP tool provides a standardised assessment of the supportive care needs of Indigenous adults with cancer in a culturally appropriate manner; and
Page 43 community engagement education program
QIMR strongly values the support of the community and To address the decline in the number of students completing is committed to keeping the public informed about its science based degrees and to ensure a supply of quality research outcomes. researchers into the future, QIMR’s Education Program aims to inspire the scientists of tomorrow. Over 1,000 senior school The External Relations Department’s Community Engagement students and their teachers from all around Australia have Program aims to increase community awareness, support toured QIMR this year and heard first hand from researchers and involvement in QIMR’s research. During the past year about science and potential career options. This included 600 4,000 people from 116 different community groups toured students and 55 teachers attending the High School Lecture QIMR or booked a speaking engagement. QIMR also kept the Series and more than 40 students placed in QIMR laboratories community informed through a series of research roadshows as part of the school work experience program. located at Kedron; Toowoomba; Gold Coast and Nambour. Other outreach educational activities included a Science and QIMR’s public seminar program continues to provide DNA day at Albany Creek primary school; Professor Emma opportunities for members of the public, community groups, Whitelaw participating in the Scientist-in-Schools program; and health specialists to hear from our researchers. This year, and QIMR joining Operation Archimedes to support Milpera a Mental Health Forum was held on 26 October 2010 and a State High School badly affected by the Queensland floods. Women’s Health Forum on 16 March 2011.
As part of the National Science Week activities, QIMR participated in the annual Exhibition (Ekka) at the Brisbane Showgrounds from 5 – 14 August 2010. Children and adults participated in hands-on science activities including pipetting, diluting, running a DNA gel, as well as examining a range of cells and parasites under microscopes.
QIMR improving health in China
PhD student Franziska Bieri from the Molecular The aim of the project was to improve Parasitology Laboratory travelled to the remote personal hygiene habits and reduce reinfection. Chinese province of Hunan to teach local children An entertaining cartoon DVD was developed to how to avoid contracting intestinal worms, such as educate the schoolchildren about the importance of whipworm, hookworm and roundworm. Infection with wearing shoes, washing their hands, boiling water for these worms in children leads to malnutrition, stunted drinking and using lavatories instead of the local river. growth and development. Over 2,000 children between 9 and 11 years old participated in the study.
Page 44 QIMR Annual Report 2010–2011 International reputation
QIMR is an internationally recognised centre for medical research, attracting outstanding researchers, funding and collaborators from around the world. Its research community consists of researchers and students from all corners of the globe.
QIMR researchers are highly regarded on the world stage and are regularly invited to participate in international conferences, meetings, committees and lectures.
Making their mark on a world-wide scale, QIMR researchers have also won numerous international awards and contribute to various collaborations.
international lectures international awards
Researchers from QIMR attended and presented at over 145 QIMR researchers were also recognised internationally with a lectures throughout the world, reflecting its strong international number of awards: reputation. Specific examples for 2010–2011 include: • Professor Emma Whitelaw received the International • Professor Adèle Green was the Plenary Speaker for Union of Biochemists and Molecular Biologists Jubilee the British Society for Investigative Dermatology Annual Medal for her contribution to the understanding of Conference in Manchester; transcription and epigenetic inheritance; • Associate Professor Grant Ramm was a session chair at • Professor Don Mc Manus received an honorary the World Congress on Iron Metabolism in Vancouver; membership of the American Society of Tropical Medicine and Hygiene, in recognition of outstanding • Professor David Whiteman presented at the 1st accomplishment by an individual not an American citizen International Conference on UV and Skin Cancer who has made eminent contributions to some phase of Prevention in Copenhagen; and tropical medicine and hygiene; • Professor Frank Gannon was invited to deliver the • Dr Sarah Medland received the Fulker Awards by the Redfern Lecture at the 50th Anniversary of the Behavior Genetics Association for the best paper Department of Biochemistry at the University of Leicester. published in Behavior Genetics in 2010; and For a full list of international lectures please see our invited • QIMR students Karin Verweij and Miriam Mosing received lectures table on page 112. Early Career Investigator Program Travel Awards from the World Congress on Psychiatric Genetics.
Page 45 international conferences/meetings overseas travel
In 2010–2011, QIMR supported a number of international Travel by researchers and corporate staff is critical to facilitate conferences and meetings including: collaborations and ensure the Institute keeps pace with new technologies and techniques. • 7th Indo-Australian Biotechnology Conference in Brisbane, October 2010; Attendance of these meetings often give rise to new • Boden Research Conference in Canberra, November– international contacts that are reflected in the many consortia December 2010 covering Metals in biological systems: that QIMR is involved in (see table page 47), in addition to structure, catalysis and metabolism; and individual international collaborations. • International Skin Cancer Research Workshop in For a full list of overseas travel refer to page 132. Brisbane showcasing the ongoing research into skin cancer in Queensland and Arizona, March 2011.
international panels/committees
Internationally, QIMR researchers are recognised for their expertise and are sought after to hold positions on international boards, societies and publication editorial groups, including: • Professor Frank Gannon Chair of the Selection Panel for the European Research and Innovation Area Board; • Professor Greg Anderson was awarded President Elect of the Society for the International BioIron Society; • Professor David Whiteman is a member of the Fellowships committee for the International Agency for Research on Cancer; and • Professor Don McManus was invited to become an editorial board member on the international Veterinarni Medicina journal.
Nasopharyngeal carcinoma (NPC) trials
In Hong Kong, nasopharyngeal carcinoma (NPC) is QIMR researchers have used similar immunotherapy one of the major cancers of males. This cancer is techniques to successfully treat heart and lung associated with a virus known as Epstein-Barr virus transplant patients who had developed EBV- (EBV). In NPC patients, tumour cells contain EBV associated lymphomas after transplantation. proteins while normal cells do not. The first stage of the funded trial is to determine if the Researchers at QIMR have used this point of treatment is safe. differentiation to develop a new experimental treatment for NPC. Unlike many other cancers, the NPC patients are recruited in Hong Kong where blood presence of the EBV virus gives the body’s immune is taken. The blood is flown to QIMR where the white system a definite target. blood cells (lymphocytes) are grown and trained to selectively kill EBV infected cells. The cells are then By enhancing the patient’s own immune cells to more returned to Hong Kong where they are infused into effectively target the EBV infected cells, while leaving the patient. the non-tumour cells alone, the treatment is non- invasive and nontoxic. The Princess Alexandra Hospital in Brisbane has joined the study, allowing NPC patients in Queensland to participate.
Page 46 QIMR Annual Report 2010–2011 major international collaborations
Collaborations are important for sharing resource and expertise, facilitating joint research and publications and building networks and relationships, all of which are essential for scientific excellence.
QIMR has a diverse research program as demonstrated by our extensive range of international collaborations including the following:
Program Project Research Collaborator locations
Cancer Ovarian Cancer Association Studying genetic and environmental Germany, Belgium, USA, Finland, Japan, Consortium risk factors to inform preventive efforts, Denmark, Netherlands, Canada, Poland, UK screening, future drug development and treatment
Breast Cancer Association Analysing genetic and epidemiological data Ireland, France, Denmark, Spain, Finland Consortium from breast cancer studies from around Japan, Russia, Sweden, Belgium, Cyprus, Italy, the world Australia, Mexico, Malaysia, Norway, Nigeria, Finland, Canada, Netherlands, Singapore, Sweden, Korea, Germany, Poland, Thailand, Taiwan, USA, UK
International Melanoma Genetics Identifying new melanoma risk genes UK, France, Germany, Israel, Italy, Latvia, Consortium and assessing genetic and environmental Netherlands, Poland, Scotland, Slovenia, interactions Spain, Sweden, USA, Argentina, Brazil, Chile, Colombia, Mexico, Uruguay
kConfab Understanding the genetics of familial UK, New Zealand breast cancer
Colon Cancer Family Registry Increasing our understanding of multiple New Zealand, Canada and USA factors affecting familial colorectal cancer
Nasopharyngeal Cancer Developing novels treatments for Hong Kong nasopharyngeal cancer (cancer of the nose and throat)
Transplant Research Understanding the causes of graft-versus- North Carolina, USA host disease
Nanotechnology Developing novel nanoparticle-based Beijing, China iron supplements and metal-based nanoparticles in order to develop novel diagnostic and therapeutic agents
Infectious Diseases Eliminate Dengue Project Developing a biological control to eliminate Vietnam and UK, USA dengue fever
International Research Alliance for Developing strategies for eliminating US, Switzerland, Mexico, UK and China Schistosomiasis Elimination schistosomiasis from developing countries worldwide
Malaria Assessing the quality of commercially UK, Switzerland and USA available rapid diagnostic tests and antimalarial drug development
Mental Health/ International Schizophrenia Identifying the genetic causes of UK and USA Complex Disorders Consortium schizophrenia
Psychiatric Genome Wide Analysing the genetic causes of ADHD, USA and Sweden Association Studies Consortium autism, bipolar disorder, major depressive disorder, and schizophrenia
Indigenous Health Comparative study: Patterns of care, New Zealand comorbidities and quality of life of Indigenous and non-Indigenous people with lung, head and neck, breast or gynaecological cancers
Alcohol and Nicotine Dependency Generation of a large biobank of adult twin St Louis, USA families to identify novel genes for nicotine and alcohol dependence
Page 47 Page 48 QIMR Annual Report 2010–2011 ouR ReSeARCH
Page 49 Cancer Program
professor georgia chenevix-trench, The highlights for the Cancer Research Program in the last coordinator year have included: • Recruitment of 22,000 people to QSkin, which upon The Cancer Program consists of 23 laboratories located completion will be the world’s largest study of melanoma in QIMR’s Bancroft Centre and the Clive Berghofer Cancer and skin cancer; Research Centre. Research carried out in the Cancer Program covers a variety of topics, including: • Development of a unique mouse model that spontaneously develops melanoma; • Identification of the genetic, epigenetic and environmental risk factors that underlie an individual’s risk • Finding that deregulation of the HER3 receptor and its of cancer; downstream pathway is involved in brain metastases; • Studying the molecular changes that occur in precursor • Delineation of the interleukin-17 pathway in chronic lesions that can subsequently give rise to cancer and graft-versus-host disease following bone marrow those that occur during the formation of a tumour and its transplantation for treatment of leukaemia, and of subsequent metastasis; and interleukin-6 in acute graft-versus-host disease; • Development and testing of novel therapies for cancer in • Development of a new compound from the rain forest the laboratory and in clinical trials. that has anti-cancer activity; • Completion of the first stage of a clinical study in Hong The Program has a strong focus on skin cancers, including Kong to test a killer T cell-based therapy in patients with melanoma; hormone-related cancers, such as those of the advanced nasopharyngeal cancer; and breast, prostate, ovary and endometrium; leukaemia and lymphoma, including exploring the complications that can • Acceptance in clinical practise both nationally and arise after stem cell transplantation, which is used for the internationally that it is important to remove proximal treatment of leukaemia; brain tumours; and tumours of the serrated polyps from the colon. gastrointestinal tract.
Members of the Cancer Program have productive local and national collaborations with clinical oncologists, pathologists and biobanks, and many are also leading, or are involved in, large international consortia that have made great advances into our understanding of the genes that predispose individuals to many types of cancer.
Page 50 QIMR Annual Report 2010–2011 antigen presentation and Highlights: immunoregulation • Used a novel CSF-1R blocking antibody (M279) to demonstrate that macrophages protect against the early Laboratory Head: Dr Kelli MacDonald stages of graft-versus-host disease (GVHD). • Published a study that explains why stem cell transplant The Antigen Presentation and Immunoregulation Laboratory recipients of mobilised stem cell grafts develop more investigates how donor and host antigen presenting cells chronic GVHD than recipients of bone marrow grafts, contribute to immune responses after haematopoietic stem and identified the IL-17 pathway and macrophages as cell transplantation. This laboratory conducts research on therapeutic targets for the prevention and treatment of antigen presenting cell (APC) development, mechanisms of chronic GVHD. antigen presentation and APC induced T cell responses and their regulation. • Identified SOCS3 as a molecule involved in dampening T cell activity during GVHD.
Bone marrow transplantation Highlights: • Delineated the IL-17 pathway as controlling factor Laboratory Head: Professor Geoff Hill in chronic graft-versus-host disease, the major late The Bone Marrow Transplantation Laboratory works towards complication of bone marrow transplantation. understanding the mechanisms by which transplant recipients • Identified IL-6 as a critical pathogenic molecule in acute eradicate leukaemia but also develop life-threatening graft-versus-host disease. complications, particularly graft-versus-host disease. • Demonstrated that the SOCS3 molecule regulates immune responses and poor outcome after bone marrow transplantation. • Demonstrated that natural killer cells limit the ability of the immune system to generate killer T cells to control infection. cancer and population Studies Highlights: • Provided the first evidence from a randomised controlled Laboratory Head: Professor Adèle Green trial that regular use of sunscreen prevents melanoma. The Cancer and Population Studies Group aims to understand • Conducted a 16-year longitudinal population-based the causes of cancer and how to better prevent and manage study, and showed no association between tobacco cancer. The group investigates the roles of environmental smoking and cutaneous squamous cell carcinoma and personal factors in the causation of cancer and its (SCC), suggesting that cutaneous SCC should be taken precursors, and in cancer prognosis. The group collaborates off the list of tobacco–related cancers. with clinicians, statisticians and behavioural scientists and also with laboratory scientists to better understand the underlying • Found evidence that that long-chain fatty acids found in mechanisms of carcinogenesis. Particular focuses are cancers oily fish such as salmon, anchovies and sardines, may be of the skin and of the pancreas. able to modify and prevent skin tumour formation. cancer control group Highlights: • Recruited more than 22,000 people in the world’s largest Laboratory Head: Professor David Whiteman study of melanoma and skin cancer, QSkin. The Cancer Control Group performs research into a • Showed that people with many moles, or with a family number of different cancers, with a view to gaining practical history of melanoma, are significantly more likely than knowledge for preventing these diseases, or limiting their others to develop a second melanoma. adverse impacts. The need for such research is clear, given that almost one in three deaths in Australia is due to cancer. • Showed that obesity, acid reflux and smoking together account for more than 75% of all cases of oesophageal adenocarcinomas in Australia. • Found that high intakes of folates from food sources are associated with lower risks of oesophageal cancers.
Page 51 cancer program | continued
cancer council Queensland Highlights: (ccQ) transgenics • Used genome-wide analysis of epigenetic modifications to identify autosomal genes whose expression is Laboratory Head: Associate Professor Graham Kay modulated by Smchd1. • Developed a unique mouse model that spontaneously The CCQ Transgenics Laboratory studies the epigenetic develops melanoma. mechanisms that modulate gene expression and the role of tumour suppressor genes in preventing cancer during normal development.
cancer genetics Highlights: • Identified many genetic variants that increase the risk of Laboratory Head: Professor Georgia Chenevix-Trench breast and/or ovarian cancer, in the general population The Cancer Genetics Laboratory investigates why some and in women who are already at high risk because they people get cancer, and how these cancers, particularly those inherit a mutation in the BRCA1 or BRCA2 genes. of the breast, ovary and stomach, develop from a normal • Discovered that genetic variants in the gene that cell. The laboratory also looks at why these cancers are encodes telomerase can also alter a woman’s risk of often found together in the same families and share many ovarian cancer. similar characteristics. • Found that deregulation of the HER3 receptor and its downstream pathway is involved in the colonisation of brain metastasis, which suggests that anti-HER inhibitors may provide effective therapies.
cancer immunotherapy Highlights: • Optimised a novel technology for examining antigen- Laboratory Head: Dr Chris Schmidt specific immune responses. The focus of the Cancer Immunotherapy Laboratory is on • Finalised a bank of matched normal and cancer cell understanding how the immune system succeeds in its lines from melanoma patients. This resource is generally fight against malignancies which is central to the future available to researchers through an Enabling Grant from development of cancer immunotherapies. the NHMRC to the Australasian Biospecimen Network. • Developed lentivirus vectors encoding cancer antigens, and found they could stimulate both helper and killer T lymphocytes efficiently.
Page 52 QIMR Annual Report 2010–2011 clinical immunohaemotology Highlights: • Entered the second year of Phase I clinical trial of Laboratory Head: Associate Professor Maher Gandhi adoptive immunotherapy in EBV-positive lymphomas. The major research area in the Clinical Immunohaemotology • Performed an in-depth profile of viral microRNAs in a Laboratory is the immunobiology of lymphoma. Interests range of primary samples from histologically diverse include biomarkers, immuno-evasion, microRNA expression EBV-positive lymphomas. and cellular immunotherapies for virus associated lymphomas. • Completed the second year of a multi-centre Phase II The research aims to understand the basis of lymphoma to lymphoma trial, in which the laboratory will perform a devise new treatments that are less toxic and more effective; correlative study in collaboration with Griffith University. to establish new biomarkers that will help determine the most • Established the genetic susceptibility to immune effective treatment strategies and to monitor response and thrombocytopenic purpura. relapse and understand the development of lymphomas. • Characterised the clinical and immunobiological characteristics of a new and highly aggressive EBV-positive lymphoma. • Characterised a subtype of monocyte that has profound immunosuppressive properties in aggressive lymphoma.
Dendritic cells and cancer Highlights: • Generated data supporting a mathematical model for the Laboratory Head: Associate Professor Alejandro Lopez initiation of cancer. The Dendritic Cells and Cancer Laboratory explores the • Identified two molecules that are highly expressed function of dendritic cells in patients with breast cancer in breast cancer stem cells that could be targets and investigates the role of breast cancer stem cells in the for immunotherapy. generation of tumours. Resulting findings will yield novel dendritic cell-based immunotherapies. • Identified characteristics of the breast cancer cells cultured in vivo that resemble primary tumours. • Characterised a dendritic cell-like line to be used in an animal model of cancer immunotherapy.
Drug Discovery group Highlights: • Developed a new compound from the rainforest with Laboratory Head: Professor Peter Parsons anti-cancer activity. Studies of the mechanism of action The Drug Discovery Group combines expertise in have so far revealed the primary target of the compound, cancer biology with genomics and drug discovery. Cell and given important clues about the cell signalling communication networks in serious cancers reveal responses pathways that might be relevant to its action. that provide opportunities for prevention and treatment. • Identified key regulators of melanoma invasiveness (in conjunction with the Oncogenomics Laboratory). • Profiled cutaneous squamous cell carcinoma of the head and neck tumours with perineural invasion. • Identified other plants from the rainforest that possess a range of potentially useful bioactivities including anti- inflammatory properties.
Page 53 cancer program | continued
familial cancer Highlights: • Discovered an increased risk of both pancreatic and Laboratory Head: Dr Joanne Young colorectal cancer in the relatives of patients with The Familial Cancer Laboratory examines the genetic changes serrated polyposis. that make some families more susceptible to colorectal • Demonstrated that cryptic mutations in non-coding areas and other cancers. This work is augmented by tumour of genes can cause Lynch syndrome. pathology studies in families, and epidemiology studies in a multi-ethnic population. • Confirmed that Lynch syndrome can arise when neither parent is affected, but this is very rare. • Described a model for serrated polyposis involving hypermaturity of the normal bowel wall producing a variety of polyp types. • Found further evidence that genetic background can influence the expression of polyposis through studies of PTEN germline mutation.
gynaecological cancers group Highlights: • Showed that once a woman with ovarian cancer Laboratory Head: Associate Professor Penny Webb experiences symptoms, shortening the time taken to The Gynaecological Cancers Group investigates all aspects of diagnose her cancer is unlikely to lead to better survival. gynaecological cancer from aetiology to diagnosis, patterns • Found that approximately half of caregivers of women of care, quality of life and survival. A particular focus is on the with ovarian cancer do not meet Australian guidelines role of environmental (non-genetic) factors and the interaction for diet and physical activity and more than half report between genetic and environmental factors in the causation negative behaviour changes after becoming a caregiver. and prognosis of gynaecological cancer. • Showed that a walking intervention for women undergoing chemotherapy for ovarian cancer is safe, feasible and acceptable to women. • Found that diets with a high glycaemic load may increase the risk of ovarian cancer, particularly among overweight/ obese women, and a high intake of fibre may provide modest protection. • Contributed to international studies that identified new genes for ovarian cancer. • Found that women with polycystic ovarian syndrome are at increased risk of endometrial cancer.
Leukaemia foundation of Highlights: Queensland Laboratory • Started a clinical trial of anti-EphA3 antibody against leukaemias. Laboratory Head: Professor Andrew Boyd • Identified genes that may prove to be key therapy targets in glioma. The Leukaemia Foundation of Queensland Laboratory is exploring the biology of leukaemia and other cancers through studies of leukaemia-associated proteins. A major project is to understand the function of Eph and ephrin membrane proteins in cancer. Members of these protein families are highly expressed in many human cancers where, by actively promoting de-adhesion of cells, they contribute to tumour spread and invasion. The laboratory explores how these proteins function in a number of cancers through work in animal models and through in vitro studies.
Page 54 QIMR Annual Report 2010–2011 molecular cancer epidemiology Highlights: • Identified a genetic link between prostate and Laboratory Head: Associate Professor Amanda Spurdle endometrial cancer. The Molecular Cancer Epidemiology Laboratory studies • Confirmed that a prostate cancer locus identified in breast and ovarian cancer, endometrial cancer, colon cancer Japanese patients is also associated with disease in and prostate cancer, with a focus on identifying molecular Caucasian individuals. signatures of normal and tumour tissue that can point to the genetic and environmental causes of these cancers. The • Developed a qualitative scheme and a quantitative laboratory covers a range of projects with the themes of statistical model to interpret the significance of variants cancer epidemiology and molecular pathology. in mismatch repair genes, which predispose to familial endometrial and colorectal cancer. • Continued work to assess the role of splicing aberrations as the underlying mechanism for mutation of breast and ovarian cancer predisposition genes BRCA1 and BRCA2, by leading a quality control project within the ENIGMA consortium Splicing Working Group. oncogenomics Highlights: • Completed a genome-wide association study for Laboratory Head: Professor Nick Hayward melanoma and identified two new genes (PARP1 The Oncogenomics Laboratory identifies novel cancer genes and SETDB1) that confer risk of melanoma in the and studies the way in which defects in these genes are general population. associated with cancer predisposition or development. In • Carried out sequencing of selected cases from large particular, the laboratory focuses on melanoma, oesophageal melanoma-prone families and identified a variant in the cancer, and endocrine tumours. MITF gene that is associated will melanoma susceptibility in some families, as well as the population at large. The laboratory is interested in investigating the process of cancer development at the level of individual cancer • Shown that gene expression changes associated with predisposition genes, and by looking at the whole genome the ability to combat the adverse effects of acid reflux scale. This work will lead to a better understanding of the may influence oesophageal cancer risk. genetic events that cause cancer and hopefully better ways of • Proven that individuals with Barrett’s oesophagus, a diagnosing or treating cancers in the future. pre-cancerous tissue associated with oesophageal adenocarcinoma, often have chromosomal changes similar to those seen in oesophageal cancer. • Found that expression of GATA4, a general transcription factor, is dysregulated in pancreatic tumours and may contribute to the development of multiple endocrine neoplasia. radiation Biology and oncology Highlights: • Revealed a new mechanism for activation of the Laboratory Head: Professor Martin Lavin protein defective in ataxia-telangiectasia (A-T) by The focus of the Radiation Biology and Oncology Laboratory oxidative stress. is DNA damage response and its role in maintaining • Identified additional sites of autophosphorylation for the integrity of DNA to minimise the risk of cancer ATM activation. and neurodegeneration. • Used ATM mouse models to investigate DNA damage signalling and DNA repair. • Developed a new mouse model for the autosomal recessive ataxia with oculomotor apraxia type 2(AOA2). • Contributed to the establishment of a clinic for A-T patients on the Herston campus at UQCCR.
Page 55 cancer program | continued
rBWH foundation conjoint Highlights: gastroenterology • Influenced a major change in clinical practice with the acceptance nationally and internationally that it is Laboratory Head: Professor Barbara Leggett important to remove proximal serrated polyps. • Completed expression and methylation arrays on The RBWH Foundation Conjoint Gastroenterology Laboratory representative series of serrated polyps and cancers. identifies genetic changes which define distinct subtypes of colon cancers and premalignant polyps with the aim of • Developed a mouse model of mutant BRAF expression predicting the clinical behaviour of these tumours. In this in the adult intestine that leads to hyperplasia, which laboratory, scientists collaborate with gastroenterologists, likely equates to early serrated polyp development. pathologists, surgeons and oncologists on research that • Found that villous change in polyps is associated with is only possible due to the large tissue bank comprised of increased malignant potential even if it makes up less samples kindly donated by patients. than 25% of the polyp. • Demonstrated that the bacteria in the bowel are different in the proximal bowel of female subjects where serrated polyps are most likely to occur.
Signal transduction Highlights: • Discovered that the loss of a new DNA damage repair Laboratory Head: Professor Kum Kum Khanna gene SSB1 is linked with susceptibility to lymphoma. The Signal Transduction Laboratory researches signal • Identified a new regulator of cell division (FBX031) that is transduction pathways involved in the detection, signalling lost in breast cancer. or repair of DNA damage and seeks other genes in these • Developed a novel combination treatment to prevent pathways, which might have similar involvement in cancer recurrence and relapse of breast cancer. susceptibility by preventing the generation of mutations in DNA. • Identified a specific target necessary to improve treatment outcomes for patients with triple negative breast cancers.
Skin carcinogenesis Highlights: • Found that melanoma localisation in the skin is controlled Laboratory Head: Dr Graeme Walker by stem cell factor released by other skin cells. The Skin Carcinogenesis Laboratory studies the mechanisms • Discovered that the Cdk4 gene drives the development by which sun exposure modulates melanoma development. of naevi (moles). • Revealed that p53 gene loss in melanocytes resulted in the complete bypass of the precursor stage of melanoma progression. • Completed studying 40 animal model strains, and found one carrying genes that greatly exacerbate melanoma development, and another with genes that dramatically slow it. • Found that stem cells only divide in response to ultraviolet light in the presence of surrounding normal melanocytes. • Constructing a model for the regulation of the activation of follicular melanocyte precursors, leading to better understanding of vitiligo, a condition characterised by white areas of skin due to a complete loss of melanocytes.
Page 56 QIMR Annual Report 2010–2011 Infectious Diseases Program professor James mccarthy, coordinator Highlights for the Infectious Diseases Program in the last year have included: The 19 laboratories that contribute to QIMR’s Infectious • Development of molecular methods for rapid and Diseases Program study how a range of important pathogenic accurate identification of the three human pathogenic organisms cause illness, search for better ways to diagnose streptococci species; and treat them, as well as developing vaccines to prevent infections. A major emphasis of work is on infections that • Demonstration that the current diagnostic methods for disproportionately affect people living in the developing world assessing intravascular catheter related infection are and the tropics. inadequate for the care of critically ill patients;
Pathogens studied include viruses such as HIV, • Successful establishment of the Bioinformatics cytomegalovirus, Epstein Barr virus and mosquito-borne Laboratory; viruses; bacteria such as streptococci; and parasites such • Discovery of new regions of Epstein-Barr virus that are as malaria, intestinal protozoa, worms and scabies. One targeted by the immune response; laboratory in the program focuses on the application of proteomic technology to biomedical science. • Identification of a series of aminopeptidase inhibitors with potential as new antimalarial drugs, which are currently in QIMR’s ability to analyse large quantities of data has been the medicinal chemistry phase of development; enhanced with the establishment of the Bioinformatics • The world’s first high throughput screening against Laboratory. This facilitates researchers’ ability to utilise malaria parasite gametocytes to identify compounds that advances in computational science and information are potential antimalarial therapies; technologies to understand biological systems and ultimately provide valuable insights into the causes of diseases. • The first gene atlas of multiple schistosome tissues. This dataset is a major resource to the research community A focus continues to be strong collaborations with clinicians, in enhancing functional knowledge of key parasite researchers from within QIMR and other institutes, as well as proteins, particularly those used by the helminths in their working with pharmaceutical companies to develop patented feeding biology; therapeutic technologies that improve the health of many. • Substantial data supporting a causal link between QIMR is a founding member of the Queensland Tropical the biology of scabies and associated streptococcal Health Alliance (QTHA), which is designed to enhance infections; and collaborations and networking in tropical health issues. • Establishment of a system to test antimalarial drugs QIMR’s Professor Brian Kay is currently Deputy Director. in human volunteers experimentally infected with malaria parasites.
Page 57 infectiouS DiSeaSeS program | continued
Bacterial pathogenesis Highlights: • Optimised and improved one of the current group A Laboratory Head: Professor Kadaba Sriprakash streptococcus (GAS) vaccine candidate molecules so The Bacterial Pathogenesis Laboratory undertakes research that it remains immunogenic. into Streptococcus and Staphylococcus and other medically • Developed molecular methods for rapid and important bacteria that cause a wide range of potentially fatal accurate identification of the three human pathogenic diseases in humans. streptococci species. • Demonstrated that the current diagnostic methods for assessing intravascular catheter related infection are inadequate for the care of critically ill patients. • Established a multi-locus sequence typing scheme for group G streptococcus (GGS) with collaborators in Portugal and the USA. • Collaborated on a project that will sequence 108 GGS genomes at the Wellcome Trust Sanger Centre, Cambridge, UK.
Bioinformatics Highlights: • Developed a computing infrastructure for mining, Laboratory Head: Dr Lutz Krause visualising and interpreting complex molecular biological The Bioinformatics Laboratory develops and applies datasets, which has already been applied in various computational science and information technologies to medical research projects. biological systems. It specialises in data-mining, machine • Found that epigenetics – modifications of DNA that learning, phylogenetics, computational ecology, efficient regulate the activity of genes – could play a role in algorithms for next-generation sequencing, epigenetics, mental disorders. The research findings could lead to the biomarker-discovery, whole-genome-association studies, and development of novel biomarkers or treatments. genetics of complex disorders. • Demonstrated that used blood catheters are colonised by various different bacteria. These findings are important for preventing and maintaining blood infections, particular in intensive care units.
cellular immunology Highlights: • Discovered new regions of EBV that are targeted by the Laboratory Head: Associate Professor Scott Burrows immune response. The Cellular Immunology Laboratory researches Epstein-Barr • Discovered that inherited deletions in the genes that virus (EBV) as a way to observe the human immune encode T cell receptors influence the immune response system. The main focus is the cytotoxic T lymphocyte and to viral infection. factors controlling its primary function in recognising and killing virus-infected cells, which affects vaccine development.
By investigating the interaction of the immune system with EBV (a virus that remains in the body for life) it provides insights into how to combat glandular fever and EBV- related cancers such as nasopharyngeal carcinoma and Hodgkin’s lymphoma.
Page 58 QIMR Annual Report 2010–2011 clinical tropical medicine Highlights: • Discovered that the main ingredient of clove oil is as Laboratory Head: Professor James McCarthy effective against scabies mites as existing therapies. The Clinical Tropical Medicine Laboratory undertakes • Developed and tested a system for experimental translational research in tropical infectious diseases. A malaria infection of human volunteers to test the activity particular focus is the identification and testing of new drugs, of antimalarial drugs in collaboration with the Malaria study of drug resistance, and the development of novel Biology Laboratory. diagnostic techniques. • Used its recently developed porcine scabies model to: - demonstrate that Th17 associated cytokines contribute to the severe immune pathology of crusted scabies, a life-threatening and poorly understood complication of scabies; - profile the humoral immune response to Sarcoptes scabiei over the course of infection, thereby informing the development of serodiagnostic tests for scabies; and - completed an exploratory clinical trial to define activity of a licensed veterinary tick treatment against S. scabiei infection. • Completed a study investigating whether hookworm infection improves gluten tolerance in celiac disease and showed no obvious benefit for symptoms. • Developed a motility-based assay to test the efficacy of antihelmintic drugs. • Began a project to investigate the benefits of community- based de-worming programs in a remote northern Australian Indigenous community. epstein-Barr Virus Biology Highlights: • Completed an immunotherapy trial in collaboration with Laboratory Head: Professor Denis Moss the Head and Neck Department, Princess Alexandra The Epstein-Barr Virus Biology Laboratory is committed to Hospital, Brisbane. understanding the biology and immunology of two clinically • Screened 1,000 extracts from EcoBiotics’ plant extract important human pathogens, namely Epstein-Barr virus (EBV) library and identified 240 extracts which may have and vaccinia virus. The EBV Laboratory findings are captured adjuvant or immunosuppresive activity and will be for use in human clinical trials. further studied.
EBV causes glandular fever and is associated with a number of cancers, including lymphomas in transplant patients and a relatively common form of cancer in the back of the nose called nasopharyngeal carcinoma. The EBV Biology Laboratory has a broad interest in all aspects of the biology of the virus and is closely linked with other EBV laboratories within the Immunology Department.
Page 59 infectiouS DiSeaSeS program | continued
HiV molecular Virology Highlights: • Revealed a non-canonical role for translation factors in Laboratory Head: Dr David Harrich early steps of HIV replication. The HIV Molecular Virology Laboratory analyses human • Disrupted HIV-1 Rev trafficking by mutating a HIV immunodeficiency virus (HIV) replication. This includes the Tat protein. process by which HIV is able to convert its genetic material composed of RNA into a form compatible with human • Defined critical parameters of Tat and PRMT6 interaction. DNA. The laboratory’s focus is the discovery of key viral or • Created a potent HIV-1 inhibitor called Nullbasic that cellular molecules required for HIV to grow, and then to target can target the virus replication complex, acting even their action so that HIV growth can be effectively blocked. before a cell becomes infected. Further research will define precisely how the inhibitor functions with a goal to advance this as a new HIV therapy. • Found that human cells treated in the laboratory with gene therapy vectors are strongly resistant to HIV-1 infection.
immunity and Vaccinology Highlights: • Designed a multifunctional vaccine delivery platform that Laboratory Head: Associate Professor Colleen Olive can be tailored to generate specific types of immune The Immunity and Vaccinology Laboratory investigates responses against various pathogens through the the immunological mechanisms of pathogen recognition combination of different Toll-like receptor (TLR) agonists, and intracellular signalling pathways that culminate in host peptides, and targeting moieties. immunity, with the objective of developing new vaccines for • Designed a novel group A streptococcal vaccine infectious diseases. based on polyfunctional liposomes that is designed to optimally activate key immune cells called dendritic cells (DCs) and provide protection against mucosal bacterial colonisation. • Demonstrated functionality of the vaccine in terms of ability to bind to DCs, stimulate TLRs and induce the production of cytokines required for an effective immune response. • Identified TLR signalling pathways in DCs that may be altered for modulation of immune responses.
immunology and infection Highlights: • Identified the lymphotoxin beta receptor found on Laboratory Head: Dr Christian Engwerda immune cells as an important therapeutic target to treat The Immunology and Infection Laboratory studies the host visceral leishmaniasis. immune response during malaria and leishmaniasis, and • Discovered that type I interferons potently suppress anti- aims to distinguish anti-parasitic host immune responses that parasitic T cell responses directed against blood stage control disease from those that cause disease. malaria parasites. • Showed an interdependent relationship between parasite burden in tissues and the activation status of immune cells in these sites during malaria. This has implications for understanding how disease develops and can be treated.
Page 60 QIMR Annual Report 2010–2011 immunovirology Highlights: • Tested chikungunya virus vaccines. Laboratory Head: Professor Andreas Suhrbier • Investigated the activity of ingenol mebutate, a The Immunovirology Laboratory is developing and exploiting new topical treatment for actinic keratoses and knowledge about interactions between viruses and the non-melanoma skin cancer. immune system to develop new anti-cancer, antiviral and anti- inflammation strategies. • Investigating further the mechanism of action of chaperonin 10, a new drug being trialled in rheumatoid The search for the role of SerpinB2 in inflammatory disease has arthritis and psoriasis patients. been a major theme of the laboratory for several years.
Work on mosquito-borne viruses has been a long standing research field for the laboratory with work on Ross River fever and chikungunya virus, illustrating the importance of immune cells, called macrophages, in the development of arthritis. The research aims to understand how the disease is caused and develop new strategies for treatment. malaria Biology Highlights: • Completed two US National Institutes of Health (NIH) Laboratory Head: Associate Professor Don Gardiner funded high throughput screens and identified a series The Malaria Biology Laboratory researches the molecular and of novel aminopeptidase inhibitors with the potential to cellular processes involved in critical phases of the malaria undergo development as antimalarial drugs. parasite life cycle in order to identify novel drug targets • Completed a human malaria infection study for testing and to translate fundamental biological research into new new antimalarial drugs in collaboration with the Clinical interventions for the control of malaria. The laboratory has Tropical Medicine Laboratory. a fully integrated research program that uses established research methods in conjunction with recent advances in • Identified an aminopeptidase inhibitor with potent in vivo malaria transgenics, molecular modelling and in vivo and antimalarial activity. in vitro testing. • Developed a high throughput screening assay for drugs that inhibit the growth and development of malaria parasite gametocytes. • Performing the first high throughput screen against Plasmodium falciparum gametocytes to identify compounds with anti-gametocyte activity.
Page 61 infectiouS DiSeaSeS program | continued
malaria Drug resistance and Highlights: chemotherapy • Demonstrated a variety of phenotypic changes in vitro that occur when Plasmodium falciparum parasites Laboratory Head: Dr Michelle Gatton become resistant to artemisinin. • Established that the amount of HRP2 antigen produced This Malaria Drug Resistance and Chemotherapy Laboratory by a parasite varies between different parasite studies malaria and selected other mosquito-borne diseases lines and this affects the sensitivity of malaria rapid using theoretical and laboratory techniques for the purpose diagnostic tests. of improving surveillance, diagnosis, treatment and control of those diseases. • Identified that pre-existing antibodies against HRP2 in patient blood can block the detection of malaria parasites by some malaria rapid diagnostic tests. • Contributed to the World Health Organization Malaria Rapid Diagnostic Tests Product Testing Program (Round 3) to provide invaluable guidance for governments and non-profit organisations that purchase these products. • Developed statistical methodology to increase the utility of data and results produced by the Schizont Maturation Test when used on Plasmodium vivax parasites. • Estimated the duration of each asexual life stage in Plasmodium vivax, a parasite that can not readily be cultured in the laboratory. • Developed an interactive web-interface for scientists to estimate the age of a mosquito population. • Produced the Vector-borne disease early detection and surveillance (VEDS) system. The VEDS system currently monitors Ross River virus and Barmah Forest virus in real-time in Queensland.
molecular parasitology Highlights: • Determined that the dominant antigen in hydatid Laboratory Head: Professor Don McManus cyst fluid, Antigen B (EgAgB), is encoded by a The Molecular Parasitology Laboratory researches the biology gene family comprising 10 unique genes and that and epidemiology of parasitic worms of humans and works on these are expressed at different life cycle stages of developing new interventions and diagnostic procedures that Echinococcus granulosus. will lead to their elimination. • Showed that inconsistent protective efficacy and marked polymorphism limits the value of Schistosoma japonicum The laboratory researches parasitic worms of humans, tetraspanin-2 as a vaccine target. particularly schistosome blood flukes, which are responsible for the potentially debilitating disease schistosomiasis • Determined aspartate aminotransferase, hyaluronic acid (Bilharzia), and dog tapeworms (Echinococcus), which are the and matrix metalloproteinase were reliable and sensitive cause of hydatid disease. markers for the diagnosis of fibrosis and cirrhosis in advanced schistosomiasis patients. • Identified cellular and transcriptional features that correlate to the outcome of hepatic pathology using contrasting mouse models.
Page 62 QIMR Annual Report 2010–2011 molecular Vaccinology Highlights: • Established that T cell responses and antibody Laboratory Head: Professor Denise Doolan responses to the Plasmodium parasite are broadly Research in the Molecular Vaccinology Laboratory investigates distributed throughout the genome, suggesting that the molecular basis of immunity to disease, with a focus vaccine efforts restricted to only one or a few parasite on malaria and model systems that can inform the basic proteins are not likely to be highly effective. immunology, mechanisms and antigenic targets of immunity, • Established that antigens that are highly reactive for and evaluation of candidate vaccines. T cells are not highly reactive for antibody responses. Different approaches are required to identify the This laboratory works with humans using samples from areas most effective targets of T cell responses and such as Africa and Papua New Guinea. antibody responses. • Identified a putative signature of sterile protective immunity against malaria comprising 19 proteins, 17 of which are novel. These proteins are excellent candidates for the development of a malaria vaccine or a diagnostic tool. • Identified novel proteins targeted by T cell responses of individuals with immunity to malaria that are much better targets than current vaccine candidates. These proteins are excellent candidates for a vaccine designed to prevent both the clinical symptoms and transmission of malaria. • Developed an assay for the rapid and reliable analysis of multiple parameters of parasite infection and host response from very small quantities of blood. This assay allows the progression of infection and immune responses to be closely monitored in the laboratory or field. mosquito control Highlights: • Evaluated the safety of infecting mosquito with strains of Laboratory Head: Professor Brian Kay the endosymbiont bacteria, Wolbachia. Research in the Mosquito Control Laboratory focuses on • Commenced a field trial in Cairns to now test how well the biology and control of mosquito-borne viruses such as Wolbachia can spread into mosquito populations in dengue, Ross River virus and Barmah Forest virus. This the wild. laboratory is designated by the World Health Organization (WHO) as an official global Collaborating Centre for • In collaboration with the Malaria Drug Resistance and Environmental Management for Vector Control. Chemotherapy Laboratory, created a decision support tool called VEDS (vector-borne diseases early detection The laboratory specialises in designing new mosquito system) to include Barmah Forest, and Ross River virus surveillance and control strategies and has strong data and supporting entomological surveillance data. collaborative linkages with dengue prevention research This system is designed to take raw incidence data and groups in Vietnam and Australia and work directly with local transform it into a risk analysis framework to prompt government in Queensland regarding mosquito control and all early response. mosquito-transmitted arboviruses. • Conducted surveys on domestic mosquito breeding in The Mosquito Control Laboratory has the largest quarantine and around Brisbane, using GPS and portable tablets to approved insectary in Australia. integrate this data into VEDS. • Developed a proteomic assay to determine the age of Aedes aegypti mosquitoes. These assays will be essential to evaluating mosquito control strategies that are designed to modify or shorten life expectancy. • Identified proteins in Anopheles mosquitoes that will be used to evaluate their age.
Page 63 infectiouS DiSeaSeS program | continued
parasite cell Biology Highlights: • Completed a gene atlas of human schistosomes, Laboratory Head: Associate Professor Malcolm Jones providing essential functional data on many schistosome The Parasite Cell Biology Laboratory researches three specific molecules for future vaccine development. parasites: schistosomes (human blood flukes), the hydatid • Described the native structure of two helminth tapeworm Echinococcus granulosus and the malaria parasite SAPLIPs+C11 molecules proposed to have major roles Plasmodium. A range of molecular, protein and advanced in red blood cell lysis. microstructural characterisation technologies are employed to study the cell biology of these parasites, particularly in relation • Demonstrated efficacy of novel peptide as to their host interactions – an aspect which can be exploited antihelminthics for treatment of schistosomiasis. in control strategies.
protein Discovery centre Highlights: • Uncovered a mechanism by which respiratory syncytial Laboratory Head: Professor Jeff Gorman virus dampens the oxidative stress response of The Protein Discovery Centre is a state-of-the-art facility infected cells. in the mass spectrometry and proteomics field. It is one • Discovered that proteins of viruses from the same family of the most advanced and best equipped of its kind in as respiratory syncytial virus are modified extensively by Australia. The centre collaborates broadly on both national phosphorylation and by ubiquitination. and international projects. • Uncovered evidence for association between proteins The centre aims to discover the identities of proteins involved of the infected cell and viruses from the same family as in and/or affected by physiological and disease processes respiratory syncytial virus that modulate budding of new and the ways in which these proteins function and interact viruses from the infected cell. and to develop techniques to observe stimulated cells and the • Identified a cohort of novel cartilage proteins reaction within cell proteins. and biological processes associated with cartilage development. • Characterised protein expression differences that appear to correlate with a breast cancer stem cell phenotype. • Invested in two new state-of-the-art LTQ-Velos- Orbitrap mass spectrometers to complement other high performance MALDI-TOF/TOF mass spectrometers.
Scabies Highlights: • Biochemically characterised two scabies mite Laboratory Head: Dr Katja Fischer Serpins and provided a detailed analysis of their Work in the Scabies Laboratory concentrates on the control anti-complement activities. of diseases caused by the scabies mites, Sarcoptes scabiei • Identified and characterised a novel scabies that burrow under the skin to cause the condition commonly mite’s peritrophin. known as scabies. • Provided substantial data supporting a causal link between the biology of scabies and associated streptococcal infections. • Constructed a library of expressed Sarcoptes scabiei sequences from mites obtained from skin shed into the bedding of patients with the severe form of the disease, crusted scabies. A multi-gene family was identified during this sequencing in which the amino acids necessary for catalysis are mutated and therefore cannot function as active proteases. • Established material and preliminary data to commence a S. scabiei genome project.
Page 64 QIMR Annual Report 2010–2011 tropical parasitology Highlights: • Conducted genome wide microarray analysis that Laboratory Head: Dr Kathy Andrews provided new insights into how histone deacetylase The Tropical Parasitology Laboratory is using different inhibitors (a promising new antimalarial drug class) kill approaches to investigate new antimalarial compounds malaria parasites. and potential new drug targets. In a piggy back approach, • Identified new antimalarial compounds from plants and anti-cancer and anti-HIV drugs (and related compounds) are fungi in collaboration with Griffith University researchers. being investigated for their ability to kill malaria parasites. To complement this work, the laboratory is using molecular, biochemical and synthetic chemistry approaches to identify and validate the targets of antimalarial compounds and to better understand essential processes, such as transcriptional regulation, in malaria parasites. tumour immunology Highlights: • Developed a killer T cell therapy for EBV-associated Laboratory Head: Professor Rajiv Khanna nasopharyngeal carcinoma. The main goal of the Tumour Immunology Laboratory is • Completed the preclinical testing of a prophylactic to obtain a deeper understanding of the mechanisms by vaccine for cytomegalovirus. A Phase I clinical trial is which an immune response to tumours may be generated, planned for this vaccine, which aims to prevent clinical augmented and applied to the inhibition of tumour growth. complications in transplant patients and newborn babies.
The members of this laboratory share the expectation that • Continued trialling a novel immunotherapy for such insight will be applicable to the treatment and prevention brain cancer. of cancer. • Started a clinical trial of a novel immune-based diagnostic tool for cytomegalovirus.
Page 65 Mental Health/Complex Disorders Program
associate professor michael Breakspear, clear that the two arms of the program (Mental Health/ coordinator Complex Disorders) overlap. Technology plays a crucial role in the study of these disorders. Recent structural change at QIMR brought teams from a QIMR is home to a growing number of imaging technologies variety of disciplines together into the new Mental Health/ that enable unprecedented insight into the biology of cells, Complex Disorders Program. The new structure recognises animals and humans. Cutting edge animal imaging facilities that QIMR must continue on the road to building a were recently installed and plans for a major new human major research capacity in mental health whilst fostering imaging facility on the Herston campus are well advanced. outstanding biomedical research of major clinical relevance. The growth of sequencing technologies that underpin genetic Whilst the disease focus is broad and multi-system, the research also continue. The enormous volume of biological program is united by a number of common conceptual and data generated by these technologies demands a new methodological themes. The diseases studied within the approach to data analysis. Scientists across the program program, ranging from schizophrenia and depression to are actively engaged in QIMR’s expansion in Information haemochromatosis and migraine, all arise from an interaction Technologies and Bioinformatics. of genetic and multi-factorial environmental influences. Highlights for the Mental Health/Complex Disorders Program The last twelve months have been a watershed year in the last year include: for Mental Health with a series of high profile national developments, new funding opportunities and, most • Development of a new brain stress test to predict importantly, growing awareness in the community. QIMR outcome in older Australians at risk of dementia, a major scientists continue to make important breakthroughs in mental national public health priority. health research from genetics and epidemiology to brain • Advancing our understanding of healthy brain activity, imaging and computational modelling. Research capabilities, including the nature of brain rhythms and the disturbance technology opportunities and public awareness into mental of these rhythms in schizophrenia. health continue to grow - creating a unique opportunity for research at QIMR to improve recovery and outcome for those • Through participation in large international consortia, in the community with mental health disorders. QIMR researchers also made important discoveries in the genetic basis of major mental illnesses, including Important discoveries have also occurred in the Complex depression, schizophrenia and migraine. Disorders of other key systems that we study, including • Providing new insights into the genetic contributions to diseases of iron metabolism, those involving fibrosis of the a myriad of healthy human behaviours including visual liver, those arising from abnormal membrane transport and a perception and personality style. constellation of disorders with a strong genetic underpinning. Advances in basic clinical science include the development of • The use of a liver biopsy to provide vital clinical new laboratory techniques to study foetal alcohol syndrome, information to predict the future development liver insights into the role of inflammation in haemochromatosis and disease in children with cystic fibrosis, the nature of genetic factors in endometriosis and inflammatory • Improving our understanding of the role of malabsorption bowel disease. Insights into the genetic determinants of a of iron in anaemia. range of healthy variants of human intelligence, emotion and • Confirming a genetic contribution to endometriosis risk, appearance have also been achieved. Here it again becomes with stronger genetic effects for more severe disease.
Page 66 QIMR Annual Report 2010–2011 epigenetics Highlights: • Developed a mouse model of fetal alcohol syndrome to Laboratory Head: Professor Emma Whitelaw increase understanding of the condition in humans. The Epigenetics Laboratory aims to understand the basic • Investigated the effects of epigenetic reprogramming on mechanisms of disease at a molecular level. The laboratory telomere length. focuses on chemical changes to DNA and chromatin, the • Developed a new model to study tissue regeneration in proteins that package DNA. mammals. • Discovered that the Dnmt3L gene is involved in regulating expression of a large number of genes within cells, including gametes. • Found that a particular missense mutation Foxo3a gene may be involved in ovarian cancer. genetic epidemiology Highlights: • Identified two new loci predisposing for asthma risk. Laboratory Head: Professor Nick Martin • Discovered a new gene, ITGA4, identified as a major The Genetic Epidemiology Laboratory investigates the pattern regulator of peripheral blood monocyte counts. of disease in families to assess the relative importance of • Demonstrated that many genes contribute to variation in genes and environment in a variety of important health alcohol use and alcohol dependence. problems and to locate the genes responsible using genome- • Discovered gene variants that affect the carbohydrate wide association analysis. component of transferrin, the main iron transport protein in plasma. • Combined personality data with 10 other samples from around the world, leading to the identification of a gene influencing conscientiousness and region associated with a person’s openness to experience. • Showed that genetic factors influencing the personality trait of neuroticism, a measure of emotional stability, also contribute to symptoms of anxiety and depression and to perceived somatic symptoms.
Hepatic fibrosis Highlights: • Demonstrated that liver fibrosis identified via liver biopsy, Laboratory Head: Associate Professor Grant Ramm predicts the future development of clinically significant liver disease (portal hypertension), in children with CF. The Hepatic Fibrosis Laboratory investigates the cellular and molecular mechanisms of scar tissue formation in the liver, • Proved the poor performance of non-biopsy tests such as the iron overload disease haemochromatosis, that currently employed to detect or predict the development leads to fibrosis and cirrhosis in adults, and cystic fibrosis (CF) of clinically significant CF liver disease. and biliary atresia in children. • Proposed biopsy as the “gold standard” to detect liver scarring and thus this approach should be adopted clinically to better manage patient care and assist in developing more targeted medical interventions in children with CF. indigenous Health Highlights: • Developed a Supportive Care Needs Survey for Laboratory Head: Associate Professor Gail Garvey Indigenous People (SCNS-IP) with cancer. The SCNS- IP tool provides a standardised assessment of the The Indigenous Health Program aims to promote improved supportive care needs of Indigenous adults with cancer health and wellbeing for Aboriginal and Torres Strait Islander in a culturally appropriate manner. peoples through medical research and education; develop culturally appropriate research projects in partnership with • Sponsored the National Roundtable on Priorities for Aboriginal and Torres Strait Islander peoples; cooperate with Aboriginal and Torres Strait Islander Cancer Research and assist the work of other agencies to improve the health conference in partnership with the Lowitja Institute. and wellbeing of Aboriginal and Torres Strait Islander peoples and act as a health advocate.
Page 67 mentaL HeaLtH/compLeX DiSorDerS program | continued
iron metabolism Highlights: • Examined mechanisms of intestinal iron absorption Laboratory Head: Professor Greg Anderson during suckling. The Iron Metabolism Laboratory focuses on understanding • Defined disease progression and penetrance in the homeostasis of iron in the body and the natural history hereditary haemochromatosis. of disorders of iron metabolism such as the iron loading • Showed a critical role for hephaestin and related disease haemochromatosis. oxidases in iron absorption. • Identified factors responsible for regulating iron homeostasis in thalassaemia and other haemolytic anaemias. • Examined links between iron and gut and lung microbiota is cystic fibrosis.
membrane transport Highlights: • Showed that in the absence of HFE and TfR2 (genes Laboratory Head: Associate Professor mutated in hereditary haemochromatosis) the response Nathan Subramaniam to inflammation is reduced. The Membrane Transport Laboratory studies how iron • Demonstrated increased liver iron levels in a metabolism is regulated by the liver and has an interest in both mouse model of the cancer-related disorder basic and applied studies of membrane biology. Identification ataxia-telangiectasia. of the molecules involved in iron metabolism and defining the way they work, has major implications for the treatment of • Demonstrated that iron loading leads to increased iron-related disorders such as hereditary haemochromatosis oxidative stress in livers of ataxia-telangiectasia null mice. and anaemia. • Identified the first case of ferroportin disease in Australia in an Australian family of Vietnamese origin. The majority of projects in the laboratory focus on defining how the liver and a number of liver-expressed molecules • Demonstrated that the trafficking protein Syntaxin 5 plays regulate the absorption, recycling and distribution of iron in an important role in regulating copper levels suggesting the body. that it may be involved in copper-related disorders.
molecular epidemiology Highlights: • Published the world’s largest genome-wide association Laboratory Head: Professor Grant Montgomery study for endometriosis identifying new risk loci and The Molecular Epidemiology Laboratory seeks to applied novel methods to confirm a genetic contribution identify genes and gene pathways contributing to risk to endometriosis risk and identified a stronger genetic for common human diseases. The laboratory is a world effect in the more severe cases of the disease. leader in the genetics of endometriosis and works on • Identified some of the first genetic variants (on melanoma, inflammatory bowel disease and a range of chromosomes 1 and 7) that increase endometriosis risk. other diseases including asthma, migraine, depression, Follow up from these discoveries will lead to greater alcohol, nicotine and drug dependence. This laboratory understanding of mechanisms increasing disease risk holds a large biobank supporting projects for QIMR’s and help improve treatments. Genetic Epidemiology, Queensland Statistical Genetics and Neurogenetics Laboratories. • Discovered new genes for a range of diseases including Crohn’s disease, ulcerative colitis, endometrial cancer, and glaucoma. Completed a genome-wide search for new genes contributing to melanoma risk, identifying several new leads to follow up.
Page 68 QIMR Annual Report 2010–2011 neurogenetics Highlights: • Completed the first Australian genome-wide Laboratory Head: Dr Dale Nyholt association study (GWAS) of the more common forms The Neurogenetics Laboratory studies the role of genetics of migraine (migraine with and migraine without aura). in the development and mechanism of the nervous system This has produced some exciting results that are with the specific goal of identifying genes responsible for currently undergoing replication and meta-analysis by neurological disorders, with a primary focus on migraine. international collaborators. • Published the first GWAS for endometriosis in Caucasian The work includes monitoring the inheritability of relevant patients that identified two novel susceptibility loci. genes, establishing DNA markers to find inheritability in family blood samples and identifying common genetic links with • Published the second GWAS for migraine. other disorders. psychiatric genetics Highlights: • Published the largest genome-wide association study for Laboratory Head: Dr Naomi Wray major depression showing the disease is underpinned The Psychiatric Genetics Laboratory specialises in the by many variants of small effect size, and implicating the development and application of statistical methods and theory neuropeptide galanin. to psychiatric disorders and related quantitative traits. The • Furthered understanding of the genetic architecture of underlying aim is to further our understanding of the causes of schizophrenia and major depression, shedding light on these common, complex genetic disorders and in particular, future research strategies. to understand the genetic basis of differences in risk of disease between individuals. • Challenged the role of synthetic associations in complex genetic disease.
Queensland Statistical Highlights: genetics Laboratory • Shone light on the ‘missing heritability’ problem in complex trait genetics. Laboratory Head: Professor Peter Visscher • Demonstrated that complex traits, including common diseases and traits such as height and body-mass- The Queensland Statistical Genetics Laboratory (QSTAG) index, are caused by the cumulative effect of hundreds specialises in quantitative and statistical genetics, population of genes. genetics, human genetics and bioinformatics, with the ultimate aim of trying to understand the genetic basis of differences in • Discovered, in conjunction with Australian risk to disease and other phenotypes between individuals. ophthalmologists, two new genes linked to open angle glaucoma. This discovery will help to identify patients at the highest risk of severe glaucoma.
Systems neuroscience group Highlights: • Developed a new diagnostic and monitoring test for Laboratory Head: Professor Michael Breakspear major depression based on a combination of video and The Systems Neuroscience Group studies brain sciences by imaging technology. utilising principles across three broad domains – empirical, • Developed a brain stress test for dementia using brain computational and clinical neuroscience. The overarching aim imaging and showed that it could predict the functioning of this work is to contribute towards unifying mathematical of patients for up to two years. models of brain architecture, dynamics and cognitive function and dysfunction. These models then inform the design of • Discovered changes in brain activity in healthy young brain imaging experiments to improve our understanding of people who were related to patients with bipolar disorder. major mental illnesses.
Page 69 SuppoRtInG ouR ReSeARCH
modernised and work continues on implementing a large corporate Division scale, research data storage solution. A new ethics approval and occupational health and safety system is under Dedicated corporate staff are committed to providing the development, as is a new grants management system, high level of support required to keep QIMR researchers at scheduled for completion late 2011. the forefront of medical research. Consisting of Scientific Services, Finance, Procurement, Grant Management, QIMR strived to provide the best equipment and scientific Human Resources, Regulatory Affairs, Safety, Information and laboratory services for its researchers including media Services, Building Services, External Relations and Business preparation, glassware services, peptide synthesis, DNA Development, the Corporate Division ensures researchers sequencing, flow cytometry, histology, microscopy, as well have the services and equipment to undertake world as regulatory and safety services. QIMR committed more class research. than 9% of its 2010–2011 budget to purchasing new and improved equipment, making certain that our researchers A focus for the Corporate Division this year has been are using the most up-to-date tools to ensure efficient and preparing for the new research facility, which continues to quality outcomes. These included a new PET/CT scanner, meet budget and timing estimates. In preparation for the Nanodispenser, iScan, Flow Cytometer (Fortessa), BioTek opening in 2010, the Bancroft Centre building management Synergy H4 and ViiA 7 quantitative PCR machine. system has been upgraded to ensure compatibility with the new facility’s system. In December 2010, QIMR received NHMRC certification for the review process of multi-centre human research thus Following the comprehensive IT review in early 2010, reducing the administrative burden borne by researchers the entire network infrastructure has been replaced and collaborating with other institutes.
fundraising
Much of QIMR’s research would not be possible without the support of community groups, individuals and corporate sponsors. 2010–2011 marked the tenth year QIMR also welcomed many new QIMR would also like to recognise the that Mr Clive Berghofer AM provided supporters through the inaugural Rio contributions from our monthly donors; substantial support to QIMR. Tinto Ride to Conquer Cancer event, planned givers who kindly made Above: Chair of QIMR Council Professor John Hay which is raising vital funds for cancer provision for the Institute in their Wills; (left) and QIMR Director and CEO Professor Frank research at QIMR. In particular, the and long-term supporters Mrs Marno Gannon (right) present a commemorative plaque to Institute would like to thank the event’s Mr Clive Berghofer (centre) in recognition of his ten Parsons AM and Mr Royce Blackburne. years of outstanding support of the Clive Berghofer major sponsors: Rio Tinto, Sunsuper Cancer Research Centre at QIMR. and the Ausenco Foundation.
Above: Rio Tinto’s Jason Gallagher, John Becker, Tim Lane and Neil Cox with QIMR’s Professor David Whiteman celebrate the announcement of Rio Tinto’s major sponsorship of the inaugural Rio Tinto Ride to Conquer Cancer.
Page 70 QIMR Annual Report 2010–2011 a special thank you to the following major donors:
• Mr Clive Berghofer AM – • The Estate of Cathryn • Mrs Ailsa Zinns • Mrs Lorraine Duckwitz Jeteld Pty Ltd Janet Christensen • Walking on Sunshine event • Clipsal Australia Pty Ltd • John Thomas Wilson Foundation • Riverside Centre Charity Golf Day (organised by Mrs Anne Stanton) • Miss Valmai Pidgeon AM (managed by Perpetual) (organised by Riverside Centre • Mrs Helen Gow • Selwyn Thomas Fassifern • The Estate of Kevin Joseph Hill Management) • Henderson Foundation Ozanne and Doreen Elaine • William and Hilde Chenhall • Mrs Marno Parsons AM • The Estate of Heather Ozanne Trust Research Trust • Data #3 Limited Maldwyn Stoney • Mr Ron Statham • Rio Tinto Coal Australia Pty Ltd • The Estate of Evelyn • J J Richards and Sons Pty Ltd • Brisbane Girls Grammar School • The Estate of Melvin Monica Dutton • Campbell Brothers Ltd • The Estate of Elsie Rutter James Anderson • Mr Barry and Mrs Maureen • Mrs L B Burgess • Rotary Club of Blackwater • Sunsuper Pty Ltd Stevenson • Mr Gerry and Mrs Geeske • Reuben Pelerman • Suncorp Metway • The Pamela Joan Dinning Perpetual Charitable Trust Gerrard (in memory of Benevolent Foundation • The Estate of Brian Musgrove Peggy Stephens) • Shop Distributive and Allied O’Connor • The Estate of Esme Joy Shipham • Mr Robert Gerrard (in memory of Employees Association • The Estate of Lila Marian Kenny • Sherrin Investments Pty Ltd Peggy Stephens) • Mr Lindsay Evans • BT Investment • Queensland Community • Kenneth Trice Peters • Mr Douglas and Mrs Helen Management Pty Ltd Foundation Discretionary Will Trust Cowlishaw • The Estate of John • Fitton Insurance Brokers • Barbara Rhoda Phyllis Dalton • Mr Kevin and Mrs Elsie Hayes Francis Pickering • Witchery Perpetual Charitable Trust Qld • Mr Dan Holzapfel • The Estate of Thelma • Tattersall’s Club • Mr Peter R Rowland Josephine Bingham • Mrs Margaret J Gibson • The Henry Cyril Robjohns • The Estate of Camrin • Mr Ivan and Mrs Sandra Mitchell and Stella May Robjohns Anthony Reeve • Mrs Heather Jordan • Mr Royce Blackburne – Memorial Trust • Mr Ronald E Hancock • Ms Barbara McKay Roycorp Pty Ltd • In Vitro Technologies Life Science • Sidney Richard and Beryl Lillian • The Estate of Ronald • Dr E Glen Truscott • Biniris Pty Ltd Early Perpetual Trust Graeme Douglas • Mr Leo Weninger • Happy Face Cent Auctions • Moran Cup Charity Golf Day • Endometriosis Association (Qld) Inc. • E M Squires Charitable Trust (organised by Mrs Sunny (organised by Scott Moran) (managed by Perpetual) Drescher) • Mr Tim and Mrs Kym Reid • Mrs Jacqueline Pascual
Another important source of support Each year QIMR also acknowledges QIMR’s mental health research received was generated by individuals and community members for their vital funding from Trusts managed by businesses that allocate resources and outstanding support of medical Perpetual. organise fundraising events benefiting research. In 2010, recipients of the Above: Mr Andrew Thomas, General Manager of QIMR. Suncorp has supported QIMR’s QIMR Ambassador Awards included: Perpetual Philanthropy (far left) discusses mental research for many years and continues Ms Denise Schellbach, Mr Mark health research with Professor Michael Breakspear and Professor Emma Whitelaw. The establishment to work closely with the Institute on a Newman, Ms Carol Ramsay (Suncorp), of this research area was funded by the John number of skin cancer related projects. and Mrs Lorraine Duckwitz. Thomas Wilson Endowment and the EM Squires Charitable Trust.
Page 71 FInAnCIAl StAtementS
Page 72 QIMR Annual Report 2010–2011 operating result consultancies
The operating result for the 2010–2011 financial year Category Summary $ was a surplus of $137,867k (2009–2010: $19,978k) Business Services Global Philanthropic engaged to $16,800 after providing for depreciation of $5,412k. This surplus provide fundraising services to assist includes recognition of capital grants from Commonwealth QIMR in managing donor relations with supporters of its Hong Kong Government, Queensland State Government, and The research program. Atlantic Philanthropies towards the construction of the Smart State Medical Research Centre ($71,840k), and a gain on the transfer of net assets of the former QIMR Trust that was abolished 1 February 2011 ($54,985k). financial documentation
QIMR’s financial structure is based on the management The financial reports should include the following of core and grant funds. Funding for competitive research documentation: grants for the 2010-11 financial year was $40,218k (2009-10: $44,209k), representing 53% of total comprehensive income, • Final Financial Statements as audited by QAO, in line excluding capital grants and gain from abolition of QIMR Trust with Treasury’s Financial Reporting Requirements for (2009-10: 60%). A majority of the Institute’s core funding is Govt Agencies; provided through a grant from Queensland Health $13,969k • Certification of Final Financial Statements, in line with (2009-10: $6,169k). the Financial Accountability Act (s62) and FPMS 2009 (s42,43 + 50); QIMR’s total funding resources, including amounts under management at 30 June 2011 totalled $172,269k (2009-10: • Independent Auditors Report, in line with the Financial $94,633k), of which $66,550k was represented by capital Accountability Act (s62) and FPMS 2009 (s50); and grants (2009-10: $57,511k). The increase in funds held during • Remuneration Disclosures, in line with Financial the year is mainly due to transfer of cash and investments Reporting Requirements for Qld Government Agencies. from the abolished QIMR Trust, and capital grants received in relation to the Smart State Medical Research Centre.
Construction of the Smart State Medical Research Centre is fully funded with total contributions from Commonwealth Government ($110M), Queensland State Government ($35M), and The Atlantic Philanthropies ($27.5M). Occupation of the new building is scheduled for early 2012. abolition of Qimr trust
The Queensland Institute of Medical Research Act 1945 was amended by legislation, entitled the Water and Other Legislation Amendment Act 2010, enacted and assented to by the Queensland Parliament on 25 November 2010. As per section 137 of the Amendment Act, the Trust was abolished with effect on 1 February 2011, with the responsibilities of the Trust transferred to the Council of the Queensland Institute of Medical Research as of the abolition date. To support this transfer, total assets valued at $55.116 million and total liabilities valued at $0.131 million were transferred to the Council at 31 January 2011.
Page 73 tHe counciL of tHe QueenSLanD inStitute of meDicaL reSearcH financiaL StatementS 2010-11
contents general information
• Statement of Comprehensive Income These financial statements cover the Queensland Institute of Medical Research and its jointly controlled entities.
• Statement of Financial Position The Queensland Institute of Medical Research is a Queensland statutory body established under the Queensland • Statement of Changes in Equity Institute of Medical Research Act 1945.
• Statement of Cash Flows The statutory body is controlled by the State of Queensland which is the ultimate parent. • Notes To and Forming Part of the The head office and principal place of business of the Financial Statements statutory body is:
• Management Certificate 300 Herston Rd, Herston QLD 4006
A description of the nature of the Council’s operations and its principal activities is included in the notes to the financial statements.
For information in relation to the statutory body’s financial statements please call +61 7 3362 0222, email [email protected] or visit the statutory bodies’s website www.qimr.edu.au
Amounts shown in these financial statements may not add to the exact sub-totals or totals due to rounding.
Page 74 QIMR Annual Report 2010–2011 The Council of The Queensland Institute of Medical Research Sttheate cmeouncilnt of C ofom tphereh Queenslandensive Income institute of medical research Statement of comprehensive income for the year ended 30 June 2011
Notes 2011 2010 $'000 $'000 Income from Continuing Operations Grants and other contributions 2 137,835 75,623 User charges 3 4,386 5,204 Other revenue 4 9,950 10,776 Total Revenue 152,171 91,603
Gains 5 53,932 990 Total Income from Continuing Operations 206,103 92,593
Expenses from Continuing Operations Employee expenses 6 39,892 39,920 Supplies and services 7 18,106 23,359 Depreciation and amortisation 8 5,412 5,272 Other expenses 9 4,496 3,879 Finance Costs 141 56 Share of loss of equity accounted investees 24 189 130 Total Expenses from Continuing Operations 68,236 72,616
Operating Result from Continuing Operations 137,867 19,977
Other Comprehensive Income
Increase (decrease) in asset revaluation surplus 19 (1,480) ( 5,290)
Total Other Comprehensive Income (1,480) ( 5,290)
Total Comprehensive Income 136,387 14,687
The accompanying notes form part of these statements.
Page 75 The Council of The Queensland Institute of Medical Research tShetate cmouncilent of Fin ofa tncheial QueenslandPosition institute of medical research Statement of financial position as at 30 June 2011
Notes 2011 2010 $'000 $'000
Current Assets Cash and cash equivalents 10 112,453 80,648 Receivables 11 10,488 8,346 Inventories 12 277 269 Prepayments 398 752
Total Current Assets 123,616 90,015
Non Current Assets Other financial assets 13 59,863 14,031 Intangible assets 14 722 786 Property, plant and equipment 15 206,287 132,822 Investments accounted for using the equity method 24 301 490 Total Non Current Assets 267,173 148,129
Total Assets 390,789 238,144
Current Liabilities Payables 16 10,804 7,381 Accrued employee benefits 17 3,104 3,213 Unearned revenue 18 87,243 74,406
Total Current Liabilities 101,151 85,000
Non Current Liabilities Accrued employee benefits 17 870 763
Total Non Current Liabilities 8 70 763
Total Liabilities 102,021 85,763
Net Assets 288,768 152,381
Equity Accumulated surplus 249,641 111,774 Asset revaluation surplus 19 39,127 40,607
Total Equity 288,768 152,381
The accompanying notes form part of these statements.
Page 76 QIMR Annual Report 2010–2011 The Council of The Queensland Institute of Medical Research tShetate cmouncilent of C ofha tnghees Queenslandin Equity institute of medical research Statement of changes in equity for the year ended 30 June 2011
Accumulated Asset TOTAL Surplus Revaluation Surplus (Note 19)
$'000 $'000 $'000
Balance as at 1 July 2009 91,797 45,897 137,694 Operating Result from Continuing Operations 19,977 - 19,977
Total Other Comprehensive Income Increase/(decrease) in Asset Revaluation Surplus - (5,290) (5,290)
Balance as at 30 June 2010 1 11,774 40,607 152,381
Balance as at 1 July 2010 111,774 40,607 152,381 Operating result from Continuing Operations 137,867 - 137,867
Total Other Comprehensive Income Increase/(decrease) in Asset Revaluation Surplus - (1,480) (1,480)
Balance as at 30 June 2011 2 49,641 39,127 288,768
The accompanying notes form part of these statements.
Page 77 The Council of The Queensland Institute of Medical Research the council of the Queensland institute of medical research Statement of Cash Flows Statement of cash flows for the year ended 30 June 2011
Notes 2011 2010 $'000 $'000
Cash flows from operating activities Inflows: Grants and other contributions 150,889 66,462 User charges 4,152 6,392 Other income 6,328 10,229 GST collected (640) (178) Outflows: Employee expenses (39,644) (39,592) Supplies and services (18,489) (23,801) Finance costs (141) (56) GST paid (71) (223) Other (4,438) (3,879)
Net cash provided by (used in) operating activities 20 9 7,946 1 5,354
Cash flows from investing activities Inflows: Sales of property, plant and equipment 1,049 4 Proceeds from sales of other financial assets 9,671 18,919 Outflows: Payments for property, plant and equipment (77,512) (19,236)
Net cash provided by (used in) in investing activities (66,792) (313)
Net increase (decrease) in cash and cash equivalents 31,154 15,041
Cash and cash equivalents at beginning of financial year 80,648 65,607
Cash and cash equivalent transferred from QIMR Trust 651
Cash and cash equivalents at end of financial year 10 112,453 8 0,648
The accompanying notes form part of these statements.
Page 78 QIMR Annual Report 2010–2011 Ththee cCouncilouncil of o ft Thhee Queensland Queenslan idnstitute Institu ofte mofedical Med icraesearchl Research Nonotestes to a tond fandormin gforming part of the fpartinanc iaofl s ttheatem efinancialnts 2010-11 statements 2010–11
Objectives and Principal Activities of the Council Note 1: Summary of Significant Accounting Policies Note 2: Grants and other contributions Note 3: User charges Note 4: Other revenue Note 5: Gains Note 6: Employee expenses Note 7: Supplies and services Note 8: Depreciation and amortisation Note 9: Other expenses Note 10: Cash and cash equivalents Note 11: Receivables Note 12: Inventories Note 13: Other financial assets Note 14: Intangible assets ` Note 15 Property, plant and equipment Note 16: Payables Note 17: Accrued employee benefits Note 18: Unearned revenue Note 19: Asset revaluation surplus by class Note 20: Reconciliation of operating surplus to net cash from operating activities Note 21: Non-cash financing and investing activities Note 22: Commitments for expenditure Note 23: Contingencies Note 24: Jointly controlled entities Note 25: Trust transactions and balances Note 26: Key executive management personnel and remuneration Note 27: Transfer of the assets and liabilities of the abolished QIMR Trust to the Council of the Queensland Institute of Medical Research Note 28: Financial instruments Note 29: Events Occurring After Balance Date Note 30: Changes in Accounting Estimates and Correction of Errors
Page 79 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
Objective and Principal Activities of the Council
The objective of the Council is to control and manage the Queensland Institute of Medical Research (the Institute). The Institute has been established to conduct research into all branches of medical science. The Institute operates predominantly in one geographical area, being Queensland, Australia, although it has research collaborations in Australia and overseas.
The Smart State Medical Research Centre project has been funded with total contributions from Federal Government $110m, Queensland State Government $35m and Atlantic Philanthropies $27.5m.
The Council receives an operational grant from Queensland Health on an annual basis. The majority of the Institute's funding is generated from competitive, peer reviewed research grants, commercial and other earned revenue. Funds are also received from donation, fundraising and investment activities performed by the Institute under the guidance of the Council.
1. Summary of Significant Accounting Policies
(a) Statement of Compliance
The Council has prepared this financial report in compliance with section 43 of the Financial and Performance Management Standard 2009 .
These financial statements are general purpose financial statements, and have been prepared on an accrual basis in accordance with Australian Accounting Standards and Interpretations. In addition, the financial statements have regard to Treasury's Minimum Reporting Requirements for the year ending 30 June 2011, and other authoritative pronouncements.
With respect to compliance with Australian Accounting Standards and Interpretations, the Council has applied those requirements applicable to not-for-profit entities, as the Council is a not-for-profit statutory body. Except where stated, the historical cost convention is used.
(b) The Reporting Entity
The financial statements include the value of all revenues, expenses, assets, liabilities and equity of the Council. The Council has no material controlled entities as at 30 June 2011.
(c) Investment in Joint Ventures Jointly controlled entities are those where the Council has joint control, established by contractual agreement. As at 30 June 2011, the Council has entered into two material joint ventures — Vaccine Solutions Pty Ltd and Q-Pharm Pty Ltd. The interest of the Council in its joint ventures is brought to account by using the equity method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the Council's share of net assets of the joint venture. In addition, the Council's share of the profit or loss of the joint venture is included in the Council's operating result. Vaccine Solutions Pty Ltd is not equity accounted as QIMR has no claim over of joint venture. Further details of the Council's interest in jointly controlled operations are contained in note 24.
(d) Trust Transactions and Balances
The Council undertakes certain trustee transactions on behalf of CRC Vaccine Technology and QIMR employee research activities.
As the Council acts only in a custodial role in respect of these transactions and balances, they are not recognised in the financial statements, but are disclosed in Note 25.
(e) Grants and other contributions
Grants, contributions, donations, bequests, gifts and fundraising that are non-reciprocal in nature are recognised as revenue in the year in which the Council obtains control over them. Where grants are received that are reciprocal in nature, revenue is recognised over the term of the funding arrangements.
Contributed assets are recognised at their fair value. Contributions of services are recognised only when a fair value can be determined reliably and the services would be purchased if they had not been donated.
Page 80 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
(f) User Charges and recoveries
User charges and fees from commercial services and recoveries of expenditure incurred by associated bodies which use QIMR laboratory consumables and services, controlled by the Council, are recognised as revenues when the revenue has been earned and can be measured reliably with a sufficient degree of certainty. This involves either invoicing for related goods/services and/or the recognition of accrued revenue. User charges and fees are controlled by the Council where they can be deployed for the achievement of departmental objectives.
(g) Interest, Dividends and Distributions
Revenue for interest is recognised and allocated over the reporting period by employment of the effective interest method. Revenue for dividends and distributions from managed funds classified as financial instruments held at fair value through profit or loss are recognised when the Council's right to receive payment is established.
(h) Imputation credits
As an endorsed income tax exempt charity, imputation credits attached to franked dividends received by the Council are refundable and may be claimed retrospectively after the end of the financial year. Imputation credits are brought to account when the right to receive the credits is established.
(i) Cash and cash equivalents
For the purposes of the Statement of Financial Position and the Statement of Cash Flows, cash assets include all cash and cheques receipted but not banked at 30 June as well as deposits at call with financial institutions.
(j) Receivables
Trade debtors are recognised at the amounts due at the time of sale or service delivery i.e. the agreed purchase/contract price. Settlement of these amounts is required within 30 days from invoice date.
The collectability of receivables is assessed periodically with provision being made for impairment. All known bad debts were written-off as at 30 June.
Other debtors generally arise from transactions outside the usual operating activities of the Council and are recognised at their assessed values. Terms are a maximum of one month, no interest is charged and no security is obtained.
(k) Inventories
Inventories are represented by consumable laboratory supplies valued at the lower of cost and net realisable value.
Cost is assigned on a weighted average basis and includes expenditure incurred in acquiring the inventories and bringing them to their existing condition, except for training costs which are expensed as incurred.
Net realisable value is determined by estimating the selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
No inventory assets have been classified as inventories held for distribution.
(l) Acquisitions of Assets
Actual cost is used for the initial recording of all non-current physical and intangible asset acquisitions. Cost is determined as the value given as consideration plus costs incidental to the acquisition, including all other costs incurred in getting the assets ready for use, including architects' fees and engineering design fees. However, any training costs are expensed as incurred.
Where assets are received free of charge from another Queensland Government entity, the acquisition cost is recognised as the gross carrying amount in the books of the transferor immediately prior to the transfer together with any accumulated depreciation.
Assets acquired at no cost or for nominal consideration, other than from an involuntary transfer from another Queensland Government entity, are recognised at their fair value at date of acquisition in accordance with AASB 116 Property, Plant and Equipment.
Page 81 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
(m) Property, Plant and Equipment
Items of property, plant and equipment with a cost or other value equal to or in excess of the following thresholds are recognised for financial reporting purposes in the year of acquisition:
Buildings $10,000 Plant and Equipment $5,000 Other (including heritage & cultural) $5,000
Items with a lesser value are expensed in the year of acquisition.
(n) Revaluations of Non-Current Physical and Intangible Assets
Buildings and heritage and cultural assets are measured at fair value in accordance with AASB 116 Property, Plant and Equipment and Queensland Treasury’s Non-Current Asset Policies for the Queensland Public Sector . In respect of these asset classes, the cost of items acquired during the financial year has been judged by management of the Council to materially represent their fair value at the end of the reporting period.
Where intangible assets have an active market, they are measured at fair value, otherwise they are measured at cost.
Plant and equipment is measured at cost in accordance with Treasury's Non-Current Asset Policies .
Non-current physical assets measured at fair value are independently re-valued by an external registered valuer at least once every five years with interim valuations, using appropriate indices, being otherwise performed on an annual basis where there has been a material variation in the index. Refer to note 15 for details.
Any revaluation increment arising on the revaluation of an asset is credited to the asset revaluation surplus of the appropriate class, except to the extent it reverses a revaluation decrement for the class previously recognised as an expense. A decrease in the carrying amount on revaluation is charged as an expense, to the extent it exceeds the balance, if any, in the revaluation surplus relating to that asset class.
On revaluation, accumulated depreciation is restated proportionately with the change in the carrying amount of the asset and any change in the estimate of remaining useful life.
Materiality concepts under AASB 1031 Materiality are considered in determining whether the difference between the carrying amount and the fair value of an asset is material.
Separately identified components of assets are measured on the same basis as the assets to which they relate.
(o) Intangibles
Intangible assets with a cost or other value equal to or greater than $100,000 are recognised in the balance sheet, items with a lesser value being expensed. Each intangible asset, less any anticipated residual value, is amortised over its estimated useful life to the council. The residual value is zero for all the council's intangible assets.
It has been determined that there is not an active market for any of the Council's intangible assets. As such, the assets are recognised and carried at cost less accumulated amortisation and accumulated impairment losses.
No intangible assets have been classified as held for sale or form part of a disposal group held for sale.
Purchased Software
The purchase cost of this software has been capitalised and is being amortised on a straight-line basis over the period of the expected benefit to the council, namely 10 years.
Internally Generated Software
Expenditure on research activities relating to internally-generated intangible assets is recognised as an expense in the period in which it is incurred.
Costs associated with the development of computer software have been capitalised and are amortised on a straight line basis over the period of expected benefit to the council, namely 10 years.
Page 82 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
(p) Amortisation and Depreciation of Intangibles and Property, Plant and Equipment
All intangible assets of the council have finite useful lives and are amortised on a straight line basis.
Property, plant and equipment is depreciated on a straight-line basis so as to allocate the net cost or re-valued amount of each asset, less its estimated residual value, progressively over its estimated useful life to the council.
Assets under construction (work-in-progress) are not depreciated until they reach service delivery capacity. Service delivery capacity relates to when construction is complete and the asset is first put to use or is installed ready for use in accordance with its intended application. These assets are then reclassified to the relevant classes within property, plant and equipment.
Where assets have separately identifiable components that are subject to regular replacement, these components are assigned useful lives distinct from the asset to which they relate and are depreciated accordingly.
Any expenditure that increases the originally assessed capacity or service potential of an asset is capitalised and the new depreciable amount is depreciated over the remaining useful life of the asset to the Council.
The depreciable amount of improvements to or on leasehold land is allocated progressively over the estimated useful lives of the improvements or the unexpired period of the lease, whichever is the shorter. The unexpired period of a lease includes any option period where exercise of the option is probable.
Common use items of the Institute's research library are expensed on acquisition. Heritage and cultural assets include research library monographs, Australiana and scarce items. The service potential of these assets is not expected to diminish with time or use and therefore, they are not depreciated.
For each class of depreciable asset the following depreciation and amortisation rates are used:
Class Rate %
Buildings 2 Plant and equipment: Motor Vehicles 20 Scientific equipment 5 - 33.3 Leasehold improvements 4 Other equipment 5 - 33.3 Intangible Assets: Software Purchased 10 Software Internally Generated 10
(q) Impairment of Non-Current Assets
All non-current physical and intangible assets are assessed for indicators of impairment on an annual basis. If an indicator of possible impairment exists, the Council determines the asset's recoverable amount. Any amount by which the asset's carrying amount exceeds the recoverable amount is recorded as an impairment loss.
The asset's recoverable amount is determined as the higher of the asset's fair value less costs to sell and depreciated replacement cost.
An impairment loss is recognised immediately in the Statement of Comprehensive Income, unless the asset is carried at a re-valued amount. When the asset is measured at a re-valued amount, the impairment loss is offset against the asset revaluation surplus of the relevant class to the extent available. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised as income, unless the asset is carried at a re-valued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. Refer also note 1(n).
Page 83 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
(r) Leasehold Improvements
The Queensland Institute of Medical Research occupies two buildings situated on Crown land reserved and set apart for hospital purposes and under the control of Queensland Health on behalf of the State of Queensland.
A lease for the land and building known as the Bancroft Centre exists between the Institute and The State of Queensland (represented by the Department of Health), at a nominal rental, terminating on 27 June 2066. The Bancroft Centre was constructed by the Council using grants from the Federal and Queensland State Government. A lease for the land and building known as The Clive Berghoffer Cancer Research Centre exists between the Institute and The State of Queensland (represented by the Department of Health), at a nominal rental, terminating on 27 June 2066. The building was constructed by the Council using grants from the Federal and Queensland State Governments, and private donors.
The costs of leasehold improvements relating to these properties will be amortised over the remaining period of the lease, or the estimated useful life to the Institute, whichever is shorter.
The Council currently erected a new building. Costs are in work in progress.
(s) Leases
A distinction is made in the financial statements between finance leases that effectively transfer from the lessor to the lessee substantially all risks and benefits incidental to ownership, and operating leases, under which the lessor retains substantially all risks and benefits.
Where a non-current physical asset is acquired by means of a finance lease, the asset is recognised at the lower of the fair value of the leased property and the present value of the minimum lease payments. The lease liability is recognised at the same amount.
Lease payments are allocated between the principal component of the lease liability and the interest expense.
Operating lease payments are representative of the pattern of benefits derived from the leased assets and are expensed in the periods in which they are incurred.
Incentives received on entering into operating leases are recognised as liabilities. Lease payments are allocated between rental expense and reduction of the liability.
(t) Other Financial Assets
Other financial assets held at fair value through profit or loss represent investments in managed funds and shares in listed and unlisted companies. The investments are stated at current market value at the reporting date. Changes in the market value of these instruments, whether realised or unrealised, are recognised in the Statement of Comprehensive Income. These investments were originally classified as at fair value through profit or loss upon initial recognition and the Council manages these investments and makes purchases and sales decisions based on their fair value in accordance with the Council's documented investment strategy.
(u) Payables
Trade creditors are recognised upon receipt of the goods or services ordered and are measured at the nominal amount i.e. agreed purchase/contract price, gross of applicable trade and other discounts. Amounts owing are unsecured and are generally settled on 30 day terms.
(v) Financial Instruments
Recognition Financial assets and financial liabilities are recognised in the Statement of Financial Position when the Council becomes party to the contractual provisions of the financial instrument.
Classification Financial instruments are classified and measured as follows: i) Cash and cash equivalents - held at fair value through profit or loss ii) Receivables - held at amortised cost iii) Other financial assets - held at fair value through profit or loss iv) Payables - held at amortised cost
Page 84 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
The Council does not enter into transactions for hedging purposes.
All other disclosures relating to the measurement and financial risk management of financial instruments held by the Council are included in Note 28.
(w) Employee Benefits Employer superannuation contributions, annual leave and long service leave levies are regarded as employee benefits.
Payroll tax and workers' compensation insurance are a consequence of employing employees, but are not counted in an employee's total remuneration package. They are not employee benefits and are recognised separately as employee related expenses.
Wages, Salaries and Annual Leave and Sick Leave
Wages, salaries and annual leave due but unpaid at reporting date are recognised in the Statement of Financial Position at the current salary rates.
For unpaid entitlements expected to be paid within 12 months, the liabilities are recognised at their undiscounted values. Entitlements not expected to be paid within 12 months are classified as non-current liabilities and recognised at their present value, calculated using yields on Fixed Rate Commonwealth Government bonds of similar maturity, after projecting the remuneration rates expected to apply at the time of likely settlement.
Prior history indicates that on average, sick leave taken each reporting period is less than the entitlement accrued. This is expected to continue in future periods. Accordingly, it is unlikely that existing accumulated entitlements will be used by employees and no liability for unused sick leave entitlements is recognised.
As sick leave is non-vesting, an expense is recognised for this leave as it is taken.
Long Service Leave
Under the Queensland Government’s long service leave scheme, a levy is made on the statutory body to cover the cost of employees' long service leave. The levies are expensed in the period in which they are payable. Amounts paid to employees for long service leave are claimed from the scheme quarterly in arrears.
No provision for long service leave is recognised in the Council's financial statements, the liability being held on a whole-of-government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting .
Superannuation Employer superannuation contributions are paid to QSuper, the superannuation scheme for Queensland Government employees, at rates determined by the Treasurer on the advice of the State Actuary. Contributions are expensed in the period in which they are paid or payable. The council's obligation is limited to its contribution to QSuper.
The QSuper scheme has defined benefit and defined contribution categories. The liability for defined benefits is held on a whole-of-government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting .
Key executive management personnel and remuneration
Key executive management personnel and remuneration disclosures are made in accordance with the section 5 Addendum (issued in May 2011) to the Financial Reporting Requirements for Queensland Government Agencies issued by Queensland Treasury. Refer to note 26 for the disclosures on key executive management personnel and remuneration.
Page 85 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
(x) Provisions Provisions are recorded when Council has a present obligation, either legal or constructive as a result of a past event. They are recognised at the amount expected at reporting date for which the obligation will be settled in a future period. Where the settlement of the obligation is expected after 12 or more months, the obligation is discounted to the present value using an appropriate discount rate. However, no present obligations have been identified by Council requiring the recognition of provision as at 30 June 2011.
(y) Insurance
The Council's non-current physical assets and other risks are insured through the Queensland Government Insurance Fund, premiums being paid on a risk assessment basis. In addition, the Council pays premiums to WorkCover Queensland in respect of its obligations for employee compensation.
(z) Services Received Free of Charge or for Nominal Value
Contributions of services are recognised only if the services would have been purchased if they had not been donated and their fair value can be measured reliably. Where this is the case, an equal amount is recognised as revenue and an expense.
(aa) Taxation
The Council is a State body as defined under the Income Tax Assessment Act 1936 and is exempt from Commonwealth taxation with the exception of Fringe Benefits Tax (FBT) and Goods and Services Tax (GST). FBT and GST are the only taxes accounted for by the Council. GST credits receivable from, and GST payable to the ATO, are recognised (refer to note 11).
(ab) Issuance of Financial Statements
The financial statements are authorised for issue by the Chairman of Council, Director and Secretary at the date of signing the Management Certificate.
(ac) Judgements The preparation of financial statements necessarily requires the determination and use of certain critical accounting estimates, assumptions, and management judgements that have that potential to cause a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Such estimates, judgements and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in future periods as relevant.
Estimates and assumptions that have a potential significant effect are outlined in the following financial statement notes:
Valuation of Property, Plant and Equipment - notes 1(n) and 15 Contingencies - note 23
(ad) Rounding and Comparatives
Amounts included in the financial statements are in Australian dollars and have been rounded to the nearest $1,000 or, where that amount is $500 or less, to zero, unless disclosure of the full amount is specifically required.
Comparative information has been restated where necessary to be consistent with disclosures in the current reporting period.
(ae) New and Revised Accounting Standards The Council did not voluntarily change any of its accounting policies during 2010-11. No amendments to the Australian accounting standards applicable for the first time for 2010-11 were relevant to the Council's financial statements.
The Council is not permitted to early adopt a new or amended accounting standard ahead of the specified commencement date unless approval is obtained from the Treasury Department. Consequently, the Council has not applied any Australian accounting standards and interpretations that have been issued but are not yet effective. The Council applies standards and interpretations in accordance with their respective commencement dates.
At the date of authorisation of the financial report, significant impacts of new or amended Australian accounting standards with future commencement dates are as set out below.
Page 86 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
AASB 2010-4 Further Amendments to Australian Accounting Standards arising from the Annual Improvements Project [AASB 1, AASB 7, AASB 101 & AASB 134 and Interpretation 13] becomes effective from reporting periods beginning on or after 1 January 2011. The Council will then need to make changes to its disclosures about credit risk on financial instruments in note 28(c). No longer will the Council need to disclose amounts that best represent an entity’s maximum exposure to credit risk where the carrying amount of the instruments reflects this. If the Council holds collateral or other credit enhancements in respect of any financial instrument, it will need to disclose - by class of instrument - the financial extent to which those arrangements mitigate the credit risk. There will be no need to disclose the carrying amount of financial assets for which the terms have been renegotiated, which would otherwise be past due or impaired.
Also, for those financial assets that are either past due but not impaired, or have been individually impaired, there will be no need to separately disclose details about any associated collateral or other credit enhancements held by the Council.
AASB 9 Financial Instruments (December 2010) and AASB 2010-7 Amendments to Australian Accounting Standards arising from AASB 9 (December 2010) [AASB 1, 3, 4, 5, 7, 101, 102, 108, 112, 118, 120, 121, 127, 128, 131, 132, 136, 137, 139, 1023 & 1038 and Interpretations 2, 5, 10, 12, 19 & 127] become effective from reporting periods beginning on or after 1 January 2013. The main impacts of these standards on the Council are that they will change the requirements for the classification, measurement and disclosures associated with financial assets. Under the new requirements, financial assets will be more simply classified according to whether they are measured at either amortised cost or fair value. Pursuant to AASB 9, financial assets can only be measured at amortised cost if two conditions are met. One of these conditions is that the asset must be held within a business model whose objective is to hold assets in order to collect contractual cash flows. The other condition is that the contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
On initial application of AASB 9, the Council will need to re-assess the measurement of its financial assets against the new classification and measurement requirements, based on the facts and circumstances that exist at that date. Assuming no change in the types of transactions the Council enters into, it is not expected that any of the Council's financial assets will meet the criteria in AASB 9 to be measured at amortised cost. Therefore, as from the 2013-14 financial statements, all of the Council's financial assets will be required to be classified as "financial assets required to be measured at fair value through profit or loss" (instead of the measurement classifications presently used in notes 1(v) and 31). The same classification will be used for net gains/losses recognised in the Statement of Comprehensive Income in respect of those financial assets. In the case of the Council's receivables, the carrying amount is considered to be a reasonable approximation of fair value.
AASB 1053 Application of Tiers of Australian Accounting Standards and AASB 2010-2 Amendments to Australian Accounting Standards arising from Reduced Disclosure Requirements [AASB 1, 2, 3, 5, 7, 8, 101, 102, 107, 108, 110, 111, 112, 116, 117, 119, 121, 123, 124, 127, 128, 131, 133, 134, 136, 137, 138, 140, 141, 1050 & 1052 and Interpretations 2, 4, 5, 15, 17, 127, 129, & 1052] apply to reporting periods beginning on or after 1 July 2013. AASB 1053 establishes a differential reporting framework for those entities that prepare general purpose financial statements, consisting of two tiers of reporting requirements – Australian Accounting Standards (commonly referred to as “tier 1”), and Australian Accounting Standards – Reduced Disclosure Requirements (commonly referred to as “tier 2”). Tier 1 requirements comprise the full range of AASB recognition, measurement, presentation and disclosure requirements that are currently applicable to reporting entities in Australia. The only difference between the tier 1 and tier 2 requirements is that tier 2 requires fewer disclosures than tier 1. AASB 2010-2 sets out the details of which disclosures in standards and interpretations are not required under tier 2 reporting. Pursuant to AASB 1053, public sector entities like the Council of the Queensland Institute of Medical Research may adopt tier 2 requirements for their general purpose financial statements. However, AASB 1053 acknowledges the power of a regulator to require application of the tier 1 requirements. In the case of the Council, the Treasury Department is the regulator. Treasury Department has advised that its policy decision is that statutory bodies captured within the whole-of-government financial statements require all to adopt tier 1 reporting requirements. In compliance with Treasury's policy which prohibits the early adoption of new or revised accounting standards unless Treasury approval is granted, the Council has not early adopted AASB 1053.
All other Australian accounting standards and interpretations with future commencement dates are either not applicable to the council's activities, or have no material impact on the council.
Page 87 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
2011 2010 $'000 $'000 2. Grants and other contributions
Grants Grants- Queensland Health* 13,969 6,169 Grants- QIMR Trust- Research support 1,164 4,417 Grants - Other 40,219 44,209 Grants - RBWH - 953 Grants - Smart State Medical Research Centre* * 71,840 14,849 Grants - NHMRC Infrastructure Funding ^ 4,765 5,011 Donations and fundraising 5,586 15 Bequests 292 - Total 137,835 75,623
* Included in revenue from grants for 2011 is a grant of $13.969 million from Queensland Health. The terms of the grant are that it must be used to fund the administrative operations and maintenance of the Institute throughout the reporting period. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, all of the grant had been spent.
** Included in revenue from grants for 2011 are milestone grant payments of $10 million from the Queensland Department of Employment, Economic Development and Innovation, $55.5 million from the Commonwealth Department of Education, Employment and Workplace Relations' Education Investment Fund, and $5.5 million from the Atlantic Philanthropies Group. The terms of these grants are that these moneys must be used to fund the construction and fit out of the QIMR Smart State Research Centre building on the Herston site. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, $66.550 million of the grant remained unspent.
^ Included in revenue from grants for 2011 is a grant of $4.765 million from the National Health and Medical Research Council. The terms of the grant are that it must be used to fund capital scientific equipment acquisitions and maintenance of the Institute. The recognition of revenue has been deferred upon receipt with revenue recognised over the term of the funding arrangement. At 30 June 2011, all of the grant had been spent.
3. User charges
Commercial and contract research 1,912 1,966 Sundry tenants recoveries 1,869 2,551 Other 605 687 Total 4,386 5 ,204
4. Other revenue
Interest 2,115 1,185 Interest-Smart State Medical Research Centre 3,242 4,288 Investment distributions 3,416 781 Reimbursements 1,028 4,488 Other 149 34 Total 9,950 10,776
Page 88 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
2011 2010 $'000 $'000 5. Gains
Net gain on market value of other financial asset (1,053) 683 Net gain on sale of property, plant and equipment - 4 Net gain on foreign exchange transactions - 303 Net gain on transfer of QIMR Trust net assets to Council (note 27) 54,985 - Total 53,932 990
6. Employee expenses
Employee benefits Wages and salaries 32,051 32,162 Employer superannuation contributions * 3,744 3,740 Long service leave levy * 632 512 Annual leave expense * 3,040 3,104 Other employee benefits 241 272
Employee related expenses Workers' compensation premium * 73 9 Fringe benefits tax expense 36 31 Other employee related expenses 75 90 Total 39,892 3 9,920
* Refer to note 1(w)
The number of employees including both full-time employees and part-time employees measured on a full- time equivalent basis is:
Number of Employees: 448 453
7. Supplies and services
Consultants and contractors 3,221 7,655 Supplies and consumables 12,127 13,038 Travel 1,793 1,755 Minor equipment and software purchases 782 700 Rent 183 211 Total 18,106 2 3,359
Page 89 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
2011 2010 $'000 $'000 8. Depreciation and amortisation
Depreciation and amortisation were incurred in respect of: Buildings 2,373 2,561 Plant and equipment 2,954 2,667 Software purchased 68 42 Software internally generated 17 2 Total 5,412 5 ,272
Heritage assets include research library monographs, Australiana and scarce items that were independently valued at $0.28 million. The service potential of these assets are not expected to diminish with time or use and therefore, they are not depreciated.
9. Other expenses
Scientific collaboration distributions 3,714 3,285 Audit fee* 182 107 Insurance 380 335 Legal expenses 112 103 Net loss on sale of property, plant and equipment 59 - Net loss on foreign exchange transactions 33 - Impairment of bad debts 16 - Other - 49 Total 4,496 3 ,879
* Total external audit fees relating to the 2010-11 financial year are estimated to be $60,000 (2010: $52,000). There are no non audit services included in this amount.
10. Cash and cash equivalents
Imprest accounts 1 1 Cash at bank 7,140 2,615 Term deposits 105,312 78,032 Total 112,453 80,648
11. Receivables
Trade Debtors 4,220 3,634 4,220 3,634
GST receivable 1,226 586 GST payable (159) (230) 1,067 356
Long service leave reimbursements 91 210 NHMRC Infrastructure Funding 2,274 2,491 Other 2,836 1,655 Total 10,488 8 ,346
Page 90 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
2011 2010 $'000 $'000 12. Inventories
Supplies and consumables - at cost 277 269 Total 2 77 269
During the 2011 reporting period, $1.065 million of inventories (2010: $1.219 million) were expensed.
All inventories on hand at 30 June are expected to be realised before 12 months.
13. Other financial assets
Other financial assets at fair value through profit or loss: Managed fund investments 59,816 13,985 Shares - US listed entities 47 46 Total 59,863 1 4,031
QIMR holds shares in Sequenom Inc. which were acquired as a result of the takeover of Gemini pic, in which the shares owned by QIMR were originally held. These shares are quoted on the NASDAQ exchange in the United States of America and are recorded at their market value at reporting date.
14. Intangible assets
Software purchased: At cost 679 590 Less: Accumulated amortisation (110) (42) 569 548
Software internally generated: At cost 172 133 Less: Accumulated amortisation (19) (2) 153 131
Software WIP At cost - 107 - 107
Total 7 22 786
Page 91 Page 92 The Council of The Queensland Institute of Medical Research Notes to and forming part of the financial statements 2010-11 notes toandformingpartofthefinancialstatements2010–11 the councilofQueenslandinstitutemedicalresearch QIMR Annual Report2010–2011
14. Intangible assets (cont'd)
Software Internally Intangibles Reconciliation Generated Software Purchased Software WIP Total 2011 2010 2011 2010 2011 2010 2011 2010 $'000 $'000 $'000 $'000 $'000 $'000 $'000 $'000
Carrying amount at 1 July 131 - 548 - 107 193 786 193
Acquisitions - - - - 21 636 21 637
Transfers between classes 40 133 89 590 (128) (722) 1 -
Amortisation (17) (2) (68) (42) - - (85) (44)
Carrying amount at 30 June 1 54 1 31 5 69 5 48 - 107 7 22 7 86
Amortisation of intangibles is included in the line item Depreciation and Amortisation in the Statement of Comprehensive Income. the council of the Queensland institute of medical research nThotese Co utonc iland of Th forminge Queen spartland Inofs ttheitute financialof Medical Rstatementsesearch 2010–11 Notes to and forming part of the financial statements 2010-11 2011 2010 $'000 $'000
15. Property, plant and equipment
Buildings: At fair value 118,641 120,900 Less: Accumulated depreciation (40,856) (39,262) 77,785 8 1,638 Heritage and cultural assets: At fair value 283 283 283 283 Plant and equipment: At cost 52,401 47,353 Less: Accumulated depreciation (28,441) (25,837) 23,960 2 1,516 Work in progress: At cost 104,259 29,385 104,259 29,385
Total 206,287 132,822
Buildings were last revalued as at 30 June 2008 by independent valuer Davis Langdon Australia Pty Ltd. Such valuations were based on calculation of the depreciable replacement cost as at 30 June 2008. The values for these asset classes have since been indexed annually to ensure the value materially reflect fair value as at each reporting date.
An interim revaluation of buildings was performed as at 30 June 2011 by indexation using the implicit price deflator. The external registered valuer believed this was the most appropriate index given the number of laboratories contained within these buildings. A revaluation index of -1.9% was applied as at 30 June 2011 (2010: -5.6%).The building revaluation for 2010-11 resulted in a decrement of $1.480 million (2010:$5.290 million).
Heritage and cultural assets consisting of research library monographs, Australiana and scarce items have been included at current replacement cost as assessed by an Approved Commonwealth Valuer (Books) Christine M. Tilley, MA QU, MA Adel, Dip ContEd UNE, GradDipLibSc QIT as at 5 September 2006. Management believe this valuation of periodicals to be applicable at 30 June 2011 as there is minimal market movement in the value of these rare documents.
Page 93 Page 94 The Council of The Queensland Institute of Medical Research
Notes to and forming part of the financial statements 2010-11 notes toandformingpartofthefinancialstatements2010–11 the councilofQueenslandinstitutemedicalresearch QIMR Annual Report2010–2011 15. Property, plant and equipment (cont'd)
Property, plant and equipment reconciliation Buildings Heritage and Cultural Plant and Equipment Work In Progress Total 2010 2010 2010 2010 2010 $'000 $'000 $'000 $'000 $'000 Carrying amount at 1 July 2009 89,491 283 21,903 9,619 121,296
Acquisitions - - 1,940 20,139 22,079
Disposals - - (35) - (35)
Transfers between classes - - 373 (373) -
Revaluation decrements (7,816) - - - (7,816)
Accum Depn Revaluation adjustment 2,526 - - - 2,526
Depreciation/amortisation (2,561) - (2,667) - (5,228)
Carrying amount at 30 June 2010 81,640 283 21,514 29,385 132,822
Buildings Heritage and Cultural Plant and Equipment Work In Progress Total 2011 2011 2011 2011 2011 $'000 $'000 $'000 $'000 $'000 Carrying amount at 1 July 2010 81,640 283 21,515 29,385 132,822
Acquisitions - - 4,954 76,096 81,049
Disposals - - (777) - (777)
Transfers between classes - - 1,222 (1,222) -
Revaluation decrements (2,259) - - - (2,259)
Accum Depn Revaluation adjustment 779 - - - 779
Depreciation/amortisation (2,373) - (2,954) - (5,327)
Carrying amount at 30 June 2011 77,787 283 23,960 104,259 206,287
The Council has plant and equipment with an original cost of $15.939 million (2010: $14.854 million) and a written down value of zero still being used in the provision of services. The Institute intends to retire these assets over the following five years. the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
2011 2010 $'000 $'000 16. Payables
Trade creditors 10,792 7,358 Others 12 23 Total 10,804 7,381
17. Accrued employee benefits
Current Wages outstanding ^ - 302 Long service leave levy payable 176 139 Annual leave entitlements payable 2,488 2,339 Other 440 433 Total 3 ,104 3,213
^ Wages outstanding in 2009-10 financial year relates to Enterprise Bargaining Agreement relating to accrued back pay.
Non-Current Annual leave entitlements payable 870 763 Total 8 70 763
18. Unearned revenue Unearned revenue 87,243 74,406 87,243 74,406
As at 30 June 2011 ($'000) Grants Grants Grant Grant Brought Received to Expenditure Carried Forward date Forward to 1 July 2010 next period
Smart State Medical Research Centre 57,511 84,132 75,093 66,550 National Health & Medical Research Council 7,959 25,313 23,126 10,146 Queensland Health - 13,969 13,969 - QIMR Trust - 1,160 1,160 - Cancer Australia 1,222 819 749 1,292 Cancer Council Qld 415 1,447 1,616 246 National Institute of Health 647 2,310 2,879 78 Other granting bodies 6,089 13,894 11,895 8,088 Other Commercial Funding Bodies 563 830 550 843 7 4,406 143,874 131,037 87,243
Page 95 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
18. Unearned Revenue (cont'd)
2011
As at 30 June 2010 ($'000) Grants Grants Grant Grant Brought Received to Expenditure Carried Forward date Forward to 1 July 2009 next period Smart State Medical Research Centre 62,471 14,177 19,137 57,511 National Health & Medical Research Council 5,779 26,462 24,282 7,959 Queensland Health - 6,169 6,169 - QIMR Trust - 4,417 4,417 - Cancer Australia 1,586 73 437 1,222 Cancer Council Qld 177 1,894 1,656 415 National Institutes of Health 1,460 4,772 5,585 647 University of Queensland 1,251 (335) (17) 933 Other Granting Bodies 6,042 10,570 11,456 5,156 Other Commercial Funding Bodies 1,101 836 1,374 563 7 9,867 69,035 74,496 74,406
19. Asset revaluation surplus by class
Heritage & Buildings cultural assets Total $'000 $'000 $'000 Balance 1 July 2009 45,714 183 45,897 Revaluation increments/decrements (5,290) - (5,290) Balance 30 June 2010 40,424 183 40,607
Heritage & Buildings cultural assets Total $'000 $'000 $'000 Balance 1 July 2010 40,424 183 40,607 Revaluation increments/decrements (1,480) - (1,480) Balance 30 June 2011 38,944 1 83 39,127
Page 96 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
20. Reconciliation of operating surplus to net cash from operating activities
2011 2010 $'000 $'000 Operating surplus/(deficit) 137,867 19,977
Depreciation and amortisation expense 5,412 5,272 Loss on sale of property, plant and equipment 59 - Gain on sale of property, plant and equipment - (4) Net increase in other financial asset (2,363) (1,464) Transfer of gain and financial assets from QIMR Trust (54,766) -
Change in assets and liabilities: (Increase)/decrease in trade receivables (585) 1,188 (Increase)/decrease in GST input tax credits receivable (640) (178) (Increase)/decrease in long service leave reimbursement receivables 119 (170) (Increase)/decrease in NHMRC Infrastructure Funding 217 (3,700) (Increase)/decrease in other receivables (206) (69) (Increase)/decrease in inventories (8) 21 (Increase)/decrease in prepayments 353 206 Increase/(decrease) in accounts payable (465) (496) Increase/(decrease) in accrued employee benefits (3) 325 Increase/(decrease) in unearned revenue 12,837 (5,461) Increase/(decrease) in GST payable (71) (223) (Increase) / decrease in investments accounted for using equity method 189 130
Net cash from operating activities 97,946 15,354
21. Non-cash financing and investing activities Assets and liabilities received or donated/transferred by the council and recognised as revenues and expenses are included in balances contained in Notes 4 and 15 respectively.
22. Commitments for expenditure (a) Non-Cancellable Operating Lease Commitments under operating leases at reporting date are inclusive of anticipated GST and are payable as follows: Payable: Not later than one year 48 46 Later than one year and not later than five years 36 84 Later than five years - - Total 84 130
Page 97 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
22. Commitments for expenditure (cont'd)
Operating lease have renewal options however, no leases have escalation clauses other than in the event of payment default.
No lease arrangements create restrictions on other financing transactions.
No other material expenditure items were committed by the Council as at the end of the reporting period.
(b) Capital Expenditure Commitments
Material classes of capital expenditure commitments inclusive of anticipated GST, contracted for at reporting date but not recognised in the accounts are payable as follows:
2011 2010 $'000 $'000
Payable: Not later than one year 1,255 1,589 Later than one year and not later than five years - - Later than five years - - Total 1 ,255 1,589
Other expenditure committed at the end of the period but not recognised in the accounts are as follows:
Payable: Not later than one year 1,253 1,074 Later than one year and not later than five years - - Later than five years - - Total 1 ,253 1,074
23. Contingencies
Contingent assets
Contributions to Queensland Community Foundation The abolished QIMR Trust established a fund with the Queensland Community Foundation (QCF) for the purpose of creating a specific fund to generate future income and donations. This fund was transferred to Council upon abolition of the Trust on the 1 February 2011. All contributions made to this named fund within QCF are held in trust and invested in perpetuity with net income distributed to the Council at the discretion of the Trustee in accordance with the Queensland Community Fund Declaration of Trust. The available balance of this fund was $ 0.358 million at 30 June 2011 (2010: $0.354 million) of which $10,000 was contributed by the former QIMR Trust. The Council expects that earnings from the 2010/11 financial year will be brought to account during the financial year ending 30 June 2012.
Contingent liabilities
There were no known contingent liabilities at 30 June 2011.
Page 98 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
24. Jointly controlled entities a) Q-Pharm Pty Ltd
Q-Pharm Pty Limited is a Phase 1 Clinical Trial company. The company is a joint venture between Professors Hooper and Dickinson, QIMR and The University of Queensland. QIMR holds 24.5% of the shares of Q-Pharm Pty Limited [2009/10: 24.5%]. QIMR accounts for its 24.5% interest in Q-Pharm Pty Limited on an equity accounted basis. . A summary of the financial transactions and balances for Q-Pharm Pty Limited is as follows:
Q-Pharm Pty Ltd 2011 2010 $'000 $'000
Income 5,129 5,538 Expenses (5,900) (6,067) Net Surplus/(Deficit) (771) (529)
Current Assets 1,994 2,380 Non Current Assets 369 359 Current Liabilities (1,132) (739) Non Current Liabilities - - Net Assets 1,231 2,000
Q-Pharm did not have any material contingent liabilities or commitments as at 30 June 2011. Council has not individually or jointly incurred any contingent liabilities in Q-Pharm. Council is not contingently liable for the liabilities of the other ventures of Q-Pharm. b) Vaccine Solutions Pty Ltd
QIMR and CSL Limited are equal shareholders in Vaccine Solutions Pty Ltd, a company established in 1998 to provide Clinical Trial Sponsorship, intellectual property management and commercialisation services to the CRC for Vaccine Technology (CTC-VT). Upon the winding up of the CRC-VT the company manages a number of licensing arrangements for the benefit of the members of CRC-VT Trust II. Vaccine Solutions does not own any physical or intellectual property assets of its own and is required to return 97% of all commercial income received from licensing activities to the CRC- VT Trust II for distribution to members of that trust.
25. Trust transactions and balances a) Trust for the CRC for Vaccine Technology (CRCVT Trust I)
QIMR is the Trustee of the CRC for Vaccine Technology Trust [CRCVT Trust I], a trust managing shares in VacTx Pty Ltd on behalf of the participants of the CRC-VT. VacTx Pty Ltd is a company focused on the development of vaccines through intellectual property created by the CRC-VT. The CRC-VT wound up operations in June 2006. Income received from the sale of the shares is to be distributed to the members in the trust according to their participating share in the CRC-VT as of June 2006. The members of this trust are: The Queensland Institute of Medical Research, CSIRO, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University. b) Trust for the CRC for Vaccine Technology (CRCVT Trust II)
QIMR is the Trustee of the CRC for Vaccine Technology (CRC-VT) Trust [CRCVT Trust II], a trust responsible for managing patent families and licensing arrangements on behalf of the participants in the CRC for Vaccine Technology since winding up in June 2006, Income received from licensing arrangements is distributed to the members in the trust according to their participating share in the CRC-VT as of June 2006. The members of the trust are: The Queensland Institute of Medical Research, CSIRO, CSL Limited, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University.
As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in these notes for the information of users.
Page 99 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
25. Trust transactions and balances (cont'd)
Trust for the CRC for Vaccine Technology (CRCVT Trust II) 2011 2010 $'000 $'000 Trust Revenues and Expenses Income 272 584 Expenses (275) (576) Net Surplus/(Deficit) (3) 8
Trust Assets and Liabilities Current Assets Cash 45 133 Receivables 572 411 Total Assets 617 544
Current Liabilities Payables 4 14 Provision for income tax 66 Beneficiaries entitlements payable 602 517 Total Liabilities 612 537
Total Trust Net Assets 5 7
c) Employee Research Services
The Institute undertakes a custodial role in respect of transactions and balances relating to employee research services and they are therefore not recognised in the financial statements. As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in these notes for the information of users.
Employee Research Services
Trust Revenues and Expenses Income 925 882 Expenses (931) (475) Increase / (Decrease) in net employee research services (6) 407
Trust Assets Current Assets Cash held in short term deposits 2,332 2,338 Total Trust Assets 2,332 2,338
26. Key executive management personnel and remuneration
a) Key Executive Management Personnel
The following details for key executive management personnel include those positions that had authority and responsibility for planning, directing and controlling the activities of the agency during 2010-11. Further information on these positions can be found in the body of the Annual Report under the section relating to Executive Management.
Page 100 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
26. Key executive management personnel and remuneration (cont'd)
Current Incumbent Position Responsibilities Contract classification and appointment Date appointed authority to position Director Director is responsible for Appointed by Governor in Council, s10 QIMR 4 January 2011 efficient and effective Act 1945 administration of the Institute b) Remuneration
Remuneration policy for the agency’s key executive management personnel is set by Council as provided for under the Queensland Institute of Medical Research Act 1945 . The remuneration and other terms of employment for the key executive management personnel are specified in employment contracts. The contracts provide for the provision of other benefits including motor vehicles.
Remuneration packages for key executive management personnel comprise the following components:- i) Short term employee benefits which include: o Base - consisting of base salary, allowances and leave entitlements paid and provided for the entire year or for that part of the year during which the employee occupied the specified position. Amounts disclosed equal the amount expensed in the Statement of Comprehensive Income. o Non-monetary benefits – consisting of provision of vehicle together with fringe benefits tax applicable to the benefit. ii) Long term employee benefits include long service leave accrued. iii) Post employment benefits include superannuation contributions. iv) Redundancy payments are not provided for within individual contracts of employment. Contracts of employment provide only for notice periods or payment in lieu of notice on termination, regardless of the reason for termination. v) There are no performance bonuses payable to key executive management.
Total fixed remuneration is calculated on a ‘total cost’ basis and includes the base and non-monetary benefits, long term employee benefits and post employment benefits:
1 July 2010 - 30 June 2011 Long Term Post Short Term Employee Termination Total Employee Employment Benefits Benefits Remuneration Benefits benefits Position Non- Base monetary $'000 $'000 $'000 $'000 $'000 Benefits $'000 Director / Acting Directors 410 27 8 25 - 470
1 July 2009 - 30 June 2010 Long Term Post Short Term Employee Termination Total Employee Employment Benefits Benefits Remuneration Benefits benefits Position Non- Base monetary $'000 $'000 $'000 $'000 $'000 Benefits $'000 Director 293 25 6 37 - 361
Page 101 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
27. Transfer of the assets and liabilities of the abolished QIMR Trust to the Council of the Queensland Institute of Medical Research
The Queensland Institute of Medical Research Trust was abolished with effect on the 1 February 2011. On the Trust abolition day the net assets of the Trust immediately before the Trust abolition day became the assets and liabilities of the Council, as prescribed by the Water and Other Legislation Amendment Act 2010 . The 2010 balances have been reported below for comparative purposes only. The book values of the assets and liabilities transferred to the Council, as at 31 January 2011, were recorded in the abolished Trust as follows: 2011 2010 $'000 $'000 Current Assets Cash and cash equivalents 651 1,067 Trade and other receivables 314 608 Other current assets 36 -
Total Current Assets 1 ,001 1,675
Non Current Assets Other financial assets 54,115 50,029
Total Non Current Assets 54,115 50,029
Total Assets 55,116 51,704
Current Liabilities Payables 131 246
Total Current Liabilities 1 31 246
Total Liabilities 1 31 246
Net Assets 54,985 51,458
28. Financial Instruments
(a) Categorisation of Financial Instruments
The Council has the following categories of financial assets and financial liabilities:
Category Note
Financial Assets Cash and cash equivalents 10 112,453 80,648 Receivables 11 10,488 8,346 Other financial assets 13 59,863 14,031 182,804 103,025
Financial Liabilities Financial liabilities measured at amortised cost: Payables 16 (10,804) (7,381) Total ( 10,804) (7,381)
Page 102 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
28. Financial Instruments (cont'd)
(b) Financial Risk Management
The Council's activities expose it to a variety of financial risks - interest rate risk, credit risk, liquidity risk and market risk.
Financial risk management is implemented pursuant to Government and Council policy. These policies focus on the unpredictability of financial markets and seek to minimise potential adverse effects on the financial performance of the Council.
All financial risk is managed by the Queensland Institute of Medical Research Corporate Services Division under policies approved by the Council. The Council provides written principles for overall risk management, as well as policies covering specific areas.
The Council measures risk exposure using a variety of methods as follows -
Risk Exposure Measurement method Credit risk Ageing analysis, earnings at risk Liquidity risk Sensitivity analysis Market risk interest rate sensitivity analysis
(c) Credit Risk Exposure
Credit risk exposure refers to the situation where the Council may incur financial loss as a result of another party to a financial instrument failing to discharge their obligation.
The maximum exposure to credit risk at balance date in relation to each class of recognised financial assets is the gross carrying amount of those assets inclusive of any provisions for impairment.
The following table represents the Council's maximum exposure to credit risk based on contractual amounts net of any allowances:
2011 2010 Note $'000 $'000 Financial Assets Cash and cash equivalents 10 112,453 80,648 Receivables 11 10,488 8,346 Other financial assets 13 59,863 14,031 Total 182,804 103,025
No collateral is held as security and no credit enhancements relate to financial assets held by the Council.
The Council manages credit risk through the use of a credit management strategy. This strategy aims to reduce the exposure to credit default by ensuring that the Council invests in secure assets and monitors all funds owed on a timely basis. Exposure to credit risk is monitored on an ongoing basis.
No financial assets and financial liabilities have been offset and presented net in the Statement of Financial Position.
The method for calculating any provision for impairment is based on past experience, current and expected changes in economic conditions and changes in client credit ratings. These economic and geographic changes form part of the council's documented risk analysis assessment in conjunction with historic experience and associated industry data. This analysis has identified that that none of the Trust's financial assets are impaired and subsequently provisions for impairment have not been raised.
No financial assets have had their terms renegotiated so as to prevent them from being past due or impaired, and are stated at the carrying amounts as indicated.
Ageing of past due but not impaired financial assets are disclosed in the following tables. No financial assets were assessed as being impaired as at 30 June 2011:
Page 103 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
28. Financial Instruments (cont'd)
2011 Financial Assets Past Due But Not Impaired Overdue Less than 30 30- 60 More than 90 Note Days Days 61-90 Days Days Total $'000 $'000 $'000 $'000 $'000 Receivables 11 9,448 657 7 376 10,488 Total 9 ,448 6 57 7 3 76 10,488
2010 Financial Assets Past Due But Not Impaired
Overdue Less than 30 30- 60 More than 90 Note Days Days 61-90 Days Days Total $'000 $'000 $'000 $'000 $'000 Receivables 11 6,272 749 279 1,046 8,346 Total 6 ,272 7 49 279 1 ,046 8,346
(d) Liquidity Risk
Liquidity risk refers to the situation where the Council may encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset.
The Council is exposed to liquidity risk in respect of its payables.
The Council manages liquidity risk through the use of a liquidity management strategy. This strategy aims to reduce the exposure to liquidity risk by ensuring the Council has sufficient funds available to meet employee and supplier obligations as they fall due. This is achieved by ensuring that minimum levels of cash are held within the various bank accounts so as to match the expected duration of the various employee and supplier liabilities.
The following table sets out the liquidity risk of financial liabilities held by the Council. It represents the contractual maturity of financial liabilities, calculated based on undiscounted cash flows relating to the liabilities at reporting date. The undiscounted cash flows in these tables may differ from the amounts included in the Statement of Financial Position that are based on discounted cash flows.
2011 Payable in Total Note <1 year 1-5 years >5 year $'000 $'000 $'000 $'000 Financial Liabilities Payables 16 (10,804) - - (10,804) Total (10,804) - - (10,804)
2010 Payable in Total Note <1 year 1-5 years >5 year $'000 $'000 $'000 $'000 Financial Liabilities Payables 16 (7,381) - - (7,381) Total (7,381) - - (7,381)
Page 104 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
28. Financial Instruments (cont'd)
(e) Market Risk
The Council does not trade in foreign currency and is not materially exposed to movements in foreign currency exchange rates, although it does hold some residual funds in Hong Kong. The Council does not undertake any hedging in relation to interest risk and manages its risk as per the Council's liquidity risk management strategy articulated in the Council's policies. The Council is exposed to movements in interest rate risk through its investment in externally
(f) Interest Rate Sensitivity Analysis
The following interest rate sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on net income if interest rates would change by +/- 1% from the year-end rates applicable to the Council's financial assets and liabilities. With all other variables held constant, the Council would have a surplus and equity increase/(decrease) of $1,125million (2010: $806k). This is mainly attributable to the Council's exposure to interest rate movements in its holdings in cash and cash equivalents.
2011 Interest Rate Risk Financial Instruments Carrying Amount -1% +1% $'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Cash & cash equivalents 112,453 (1,125) (1,125) 1,125 1,125 Potential Impact (1,125) (1,125) 1,125 1,125
2010 Interest Rate Risk Financial Instruments Carrying Amount -1% +1% $'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Cash & cash equivalents 80,648 (806) (806) 806 806 Potential Impact (806) (806) 806 806
Other Price Risk Sensitivity Analysis The following other price risk sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on profit or loss if unit/share price would change by +/-1% from the year-end price applicable to the Council's other financial asset investments. With all other variables held constant, the Council would have a surplus and equity increase/(decrease) of $599k (2010: $140k). This is mainly attributable to exposure to unit price movements in its investments managed funds and movements in market value of US listed shares.
2011 Other Price Rate Risk Financial Instruments Carrying Amount -1% +1% $'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Managed Funds & 59,863 (599) (599) 599 599 Listed Shares Potential Impact (599) (599) 599 599
2010 Other Price Rate Risk Financial Instruments Carrying Amount -1% +1% $'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Managed Funds & 14,031 (140) (140) 140 140 Listed Shares Potential Impact (140) (140) 140 140
Page 105 the council of the Queensland institute of medical research notes to and forming part of the financial statements 2010–11
28. Financial Instruments (cont'd)
(g) Fair Value The recognised fair values of financial assets and liabilities are classified according to the following fair value hierarchy that reflects the significance of the inputs used in making these measurements:
Level 1 - fair values that reflect unadjusted quoted prices in active markets for identical assets/liabilities; Level 2 - fair values that are based on inputs that are directly or indirectly observable for the asset/liability (other than unadjusted quoted prices); and Level 3 - fair values that are derived from data not observable in a market.
According to the above hierarchy, the fair values of each class of asset/liabilities recognised at fair value are as follows:
2011 Classification according to fair value hierarchy Carrying Amount Level 1 Level 2 Level 3 Class $'000 $'000 $'000 $'000 Financial Assets Managed fund investments 59,816 - - 59,816 US listed entities 47 - - 47 Total 59,863 - - 59,863
2010 Classification according to fair value hierarchy Carrying Amount Level 1 Level 2 Level 3 Class $'000 $'000 $'000 $'000 Financial Assets Managed fund 13,985 - - 13,985 investments US listed entities 46 - - 46 Total 14,031 - - 14,031
The fair value of trade receivables and payables is assumed to approximate the value of the original transaction, less any provision for impairment.
29. Events Occurring After Balance Date
There are no events occurring after balance date having a material impact on the figures reported in the above statements.
30. Changes in Accounting Estimates and Correction of Errors
Financial Statement comparative figures have been restated to correct inaccurate revenue estimates in the financial years 2004-05 to 2009-10 related to estimates of funding receivable through the NHMRC Infrastructure Support (IRIIS). The cumulative effect of the error resulted in an overstatement of Receivables, and an overstatement of Accumulated Surplus at June 2010 of $1,209k. The error has been corrected by restating each affected financial statement line items for the prior year.
Funding for the Smart State Medical Research Centre (SSMRC) is recognised as revenue in the financial statements in the period in which the Institute gains control of the funds. Since the commencement of the SSMRC project, revenue has been recognised in the financial statements as Capital Grants. Revenue recognised as Capital Grants includes amounts earned on investment of grant funds received. Financial Statement comparative figures have been restated to reflect the amount of interest earned on Capital Grant funds in the 2009-10 financial year. A reclassification of the revenue in the Statement of Comprehensive Income has resulted in a decrease to the line item Grants and other contributions and an increase to Other Revenue by $4,288k.
Page 106 QIMR Annual Report 2010–2011 the council of the Queensland institute of medical research certificate of the council of the Queensland institute of medical research
These general purpose financial statements have been prepared pursuant to section 62(1) of the Financial Accountability Act 2009 (the Act), relevant sections of the Financial and Performance Management Standard 2009 and other prescribed requirements. In accordance with section 62(1)(b) of the Act we certify that in our opinion: a) the prescribed requirements for establishing and keeping the accounts have been complied with in all material respects; and b) the statements have been drawn up to present a true and fair view, in accordance with prescribed accounting standards, of the transactions of the Council of the Queensland Institute of Medical Research for the financial year ended 30 June 2011 and of the financial position of the Council at the end of that year.
Dated at Brisbane this 2nd day of September 2011
Professor John Hay AC Professor Frank Gannon Donna Hancock Chairman of Council Director & Chief Executive Officer Secretary
Page 107 the council of the Queensland institute of medical research independent auditor’s report
Page 108 QIMR Annual Report 2010–2011 Page 109 SuppoRtInG InFoRmAtIon
Page 110 QIMR Annual Report 2010–2011 aWarDS
Bestower of Recipient Date Award Reason award Kylie Alexander ASMR May-11 ASMR Premier's Award 1st place - oral presentation. Best research by postgraduate researcher Prof Greg Anderson International May-11 President Elect of the Society Voted by the membership to be the next President BioIron Society of IBIS Dr Simon Apte ASI Aug-10 Travel award (international) Conference attendance Dr Simon Apte ASI Jan-11 Appointment ASI Newsletter Editor Assoc Prof Michael ASMR Jun-11 Clinical Researcher Award Breakspear Enda Byrne Australasian Young Investigator Travel Award Conference attendance Society of Psychiatric Research Fernanda Cardoso ASI Aug-10 Travel award (international) Conference attendance Prof Denise Doolan Australia - Europe Feb-10 Appointment Scientific Advisory Board Malaria Research Cooperation Prof Denise Doolan Australian Society Aug-10 Appointment President-Elect for Parasitology Blake Ferguson Nov-10 1st prize poster competition, 7th Annual International Melanoma Congress Dr Katja Fischer QIMR May-11 QIMR Postgraduate Travel Award Conference attendance 2011 Dr Darren Gray GU Dec-10 Publication of the Year Best paper in Public Health at GU Prof Geoff Hill NHMRC Mar-11 Australia Fellowship Prof Geoff Hill OHMR Jun-11 Senior Clinical Research Fellowship Prof Geoff Hill NHMRC Mar-11 Practitioner Fellowship (level 2) Assoc Prof Malcolm Australian Society Aug-10 Fellow of the Australian Society for Contributions to Australian Parasitology Jones for Parasitology Parasitology Dr Motoko Koyama TSANZ Jun-11 Young Investigator Award Quality of research by young investigator Dr Motoko Koyama ASI Dec-10 Travel award Conference attendance Dr Felicity Lose PCFA Aug-10 Travel award Dr Felicity Lose Contributing Apr-11 Travel award to Australian Scholarship and Science Foundation Dr Felicity Lose CCQ May-11 Travel award Dr Kelli MacDonald CCQ Jan-11 Senior Research Fellowship Dr Cameron McDonald ALF Jan-11 ALF Hospitality Industry Career Development Research Fellowship Prof Don McManus NHMRC Dec-10 Senior Principal Research NHMRC RF Scheme Fellowship Prof Don McManus Veterinarni Jan-11 Invited Editorial Board Member Medicina Prof Don McManus American Society Nov-10 Honorary membership of the In recognition of outstanding accomplishment by an of Tropical American Society of Tropical individual not an American citizen who has made Medicine and Medicine and Hygiene eminent contributions to some phase of tropical Hygiene medicine and hygiene. Dr Sarah Medland Australian Institute Nov-10 Young Tall Poppy Science Award Early career researcher award for scientific of Policy and milestones and demonstrative ability to engage Science people in science Dr Sarah Medland Behavior Genetics Jun-11 Fuller and Scott Award Outstanding young investigator who has Association made substantial contributions to the field of Behavior Genetics Dr Sarah Medland Behavior Genetics Jun-11 Fulker Award Best paper published in the journal Behavior Association Genetics in 2010 Dr Sarah Medland QIMR Jun-11 QIMR Travel Award Conference attendance Dr Catherine Olsen QIMR Nov-10 QIMR Overseas Conference 1st International Conference on UV and Skin Support Cancer Prevention Renee Robb TSANZ Jun-11 President’s prize Best research at annual meeting Dr David Reid OHMR Feb-11 Clinical Fellowship
Page 111 Bestower of Recipient Date Award Reason award Haran Sivakumaran MSD Schering- Jun-11 Top Post-Doc Award (HIV) Outstanding scientific presentation Plough Pty Ltd Dr Patricia Valery NHMRC Dec-10 Excellence award Highest ranked Career Development Award application Prof Emma Whitelaw ANZSCDB Sep-10 President's Medal Outstanding contribution to cell and developmental biology Prof Emma Whitelaw International Union Feb-11 IUBMB Jubilee Lecture and Medal Contribution to the understanding of transcription of Biochemists and epigenetic inheritance and Molecular Biologists Dr Susan Woods ASMR Jun-11 2011 Queensland Senior Researcher Award Dr Daniel Worthley NHMRC Jun-10 RG Menzies Fellowship Most outstanding recipient of CJ Martin Postdoctoral Fellowship Dr Neil Youngson Lalor Foundation Apr-11 Travel Award Conference attendance
Legend
ANZSCDB Australia and New Zealand Society for Cell and Developmental Biology ASI Australasian Society of Immunology ASMR Australian Society of Medical Research CCQ Cancer Council Queensland GU Griffith University NHMRC National Health and Medical Research Council OHMR Office of Health and Medical Research PCRFA Prostate Cancer Research Foundation Australia TSANZ The Transplantation Society of Australia and New Zealand
inViteD LectureS
Speaker Title of lecture Date Audience or event City, Country Prof Greg Anderson Iron absorption and its regulation in the Jul-10 Biometals 2010. Seventh International Tucson, USA perinatal period Biometals Symposium Prof Greg Anderson Iron metabolism. Nov-10 Metabolism and Cancer Symposium. Brisbane, Australia School of Biomedical Sciences, The University of Queensland Prof Greg Anderson Iron metabolism and testing Mar-11 RCPA: Pathology Update 2011 Melbourne, Australia Prof Greg Anderson Essential but toxic: Controlling the flux of Apr-11 Third Australia-China Biomedical Melbourne, Australia iron in the body Research Conference Prof Greg Anderson Invited Session Chair - Iron signalling May-11 Bioiron 2011. World Congress on Vancouver, Canada pathways Iron Metabolism. Kylie Alexander Speaker May-11 The ASMR Medical Research Week Brisbane, Australia Student Conference Dr Ann Apolloni A New, Potent Transdominant Negative Tat Jun-11 Australian Centre for HIV and Hepatitis Sunshine Coast, Blocks HIV-1 Replication Research 7th Annual Workshop Australia Dr Simon Apte The role of PD-1 in malaria Nov-10 Emory Vaccine Research Centre Atlanta, USA Dr Kathy Andrews Transcriptional profiling the effects of Aug-10 International Congress of Melbourne, Australia hydroxamate-based HDAC inhibitors in P. Parasitology XII falciparum Dr Kathy Andrews Transcriptional profiling the effects of Nov-10 Australian Health and Medical Melbourne, Australia hydroxamate-based HDAC inhibitors in Research Congress P. falciparum Dr Barrie Anthony Schistosoma mansoni egg-induced Oct-10 Australian Gastroenterology Week Gold Coast, Australia downregulation of hepatic stellate cell 2010 meetIng activation and fibrogenesis Dr Annika Antonsson Viruses in breast cancer May-11 National Breast Cancer Foundation Sydney, Australia Dr Vanessa Beesley Current and planned cancer survivorship Nov-10 Clinical Oncology Society of Australia Melbourne, Australia research at QIMR Annual Scientific Meeting - Cancer Survivorship Workshop
Page 112 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Dr Vanessa Beesley Pancreatic cancer patients’ supportive Nov-10 Psycho-Oncology Co-operative Melbourne, Australia care needs and corresponding use of allied Research Group (PoCoG) health services Professional Day Gabriëlla Blokland Genetic influences on white matter tract May-11 2011 Australian Society for Brisbane, Australia density within the working memory network Medical Research Postgraduate Student Conference Prof Andrew Boyd Recent advances in brain tumour research: May-11 Cancer Council Queensland Brain Brisbane, Australia Prospects for therapy Tumour Symposium Dr Glen Boyle Local cure of melanoma in mice and dogs Nov-10 Society for Melanoma Research Sydney, Australia by intratumoral injection of EBC46 2010 Congress Assoc Prof Michael Predictive coding Nov-10 Monash University Melbourne, Australia Breakspear neuroscience workshop Assoc Prof Michael Brain modelling Jan-11 University of Queensland Brisbane, Australia Breakspear Summer School Assoc Prof Michael Neonatal burst suppresion Jun-11 Brain Connectivity Workshop Montreal, Canada Breakspear Assoc Prof Michael Multistable brain rhythms Jun-11 Yale Seminar Series New Haven, USA Breakspear Assoc Prof Michael Multistable brain rhythms Jun-11 Human Brain Mapping Quebec, Canada Breakspear Assoc Prof Michael Brain Modelling Jun-11 Human Brain Mapping Quebec, Canada Breakspear Assoc Prof Michael Scale-free brain dynamics Nov-10 Computational neuroscience Brisbane, Australia Breakspear summer school Assoc Prof Michael Brain connectivity: A primer Dec-10 Australian Society for Sydney, Australia Breakspear Psychiatric Research Assoc Prof Scott Allelic polymorphism in the T cell receptor – Jul-10 Structural Immunology Meeting, Melbourne, Australia Burrows assessing its overall importance Monash University Assoc Prof Scott The sensitivity of peptide-MHC-TCR Nov-10 Emory Vaccine Centre Atlanta, USA Burrows binding Assoc Prof Scott T cell immune response to Nov-10 Australian Society for Microbiology WA Perth, Australia Burrows Epstein-Barr virus branch dinner Assoc Prof Scott The T cell immune response to Epstein- Nov-10 Institute for Immunology and Infectious Perth, Australia Burrows Barr virus Diseases, Murdoch University Assoc Prof Scott New insights into alloreactivity Nov-10 Australian Society for Immunology (WA Perth, Australia Burrows Branch) monthly meeting Assoc Prof Scott The T cell immune response to Epstein- May-11 Centenary Institute Sydney, Australia Burrows Barr virus Dr Fernanda Cardoso Development of a high throughput Aug-10 International Congress of Immunology Kobe, Japan approach to identify the targets of cellular immunity on a proteome-wide scale Dr Fernanda Cardoso Proteome-wide screening of complex Aug-10 International Congress of Parasitology Melbourne, Australia pathogen to identify antigens targets by T cell mediated immune responses Prof Georgia Chenevix- Genome wide association studies: are we Jun-10 Children’s Medical Research Institute Sydney, Australia Trench there yet? Prof Georgia Chenevix- Genome wide association studies: are we Nov-10 Human Genetics Society of Australasia Melbourne, Australia Trench there yet? Annual Scientific Conference Prof Georgia Chenevix- A guide for PhD students Apr-11 Student Retreat, UQ Brisbane Australia Trench Diamantina Institute Prof Georgia Chenevix- Genome wide association studies: the role Dec-11 8th Annual Australasian Biospecimen Brisbane Australia Trench of biobanks Network Meeting Prof Georgia Chenevix- Towards personalised therapy for Feb-11 The Charles Rodolphe Zurich, Switzerland Trench ovarian cancer Brupbacher Foundation Dr Qin Cheng A large proportion of asymptomatic malaria Nov-10 The 59th ASTMH annual meeting Atlanta, USA infections with low parasite densities in Temotu province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Dr Qin Cheng Genotying P. vivax May-11 APMEN vivax Working Group Kota Kinabalu, Malaysia Genotyping Workshop Dr Qin Cheng Facts and challenges: knowledge gaps in May-11 APMEN vivax Working Group Kota Kinabalu, Malaysia malaria diagnosis for elimination Genotyping Workshop Dr Suyinn Chong Maternal ethanol consumption alters May-10 Queensland Brain Institute Symposium: Brisbane, Australia the epigenotype and the phenotype of Epigenomics, Behaviour & Disease offspring in a mouse model Dr Suyinn Chong Epigenetics and a mouse model of foetal Oct-10 Annual inservice for Queensland Brisbane, Australia alcohol syndrome geneticists and genetic counsellors, Royal Brisbane and Women’s Hospital
Page 113 invited lectures | continued
Speaker Title of lecture Date Audience or event City, Country Dr Suyinn Chong The role of epigenetics in phenotypic Mar-11 Children's Medical Research Institute Sydney, Australia variation and disease risk Seminar Series Dr Suyinn Chong The role of epigenetics in gestational Sep-10 Endocrine Society of Australia & Sydney, Australia programming of progeny phenotype by Society of Reproductive Biology Annual maternal ethanol consumption Scientific Meeting Dr Suyinn Chong Maternal ethanol consumption alters Oct-10 7th India-Australia Biotechnology Brisbane, Australia the epigenotype and the phenotype of Conference offspring in a mouse model Dr Jon Darbro Assessment of Beauveria bassiana for Sep-10 Australian Mosqutio Control Caloundra, Australia control of Aedes aegypti: Effects on blood- Association feeding behaviour, fecundity and virulence in semi-field conditions Lucia Daxinger Rif1, a novel modifier of epigenetic Dec-10 Max-Planck Freiburg Epigenetics Freiburg, Germany reprogramming in the mouse Meeting Prof Denise Doolan Mining genomic, proteomic and Aug-10 International Congress of Parasitology Melbourne, Australia transcriptomic datasets for next generation malaria vaccine development Prof Denise Doolan Molecular immunology in the genomics era: Dec-10 Australasian Society of Immunology Perth, Australia novel advances for vaccine development. Postgraduate Student Workshop Prof Denise Doolan Proteome-wide screening of P. falciparum Dec-10 Australasian Society of Immunology Perth, Australia CD4 and CD8 T cell epitopes Symposium Prof Denise Doolan Genomes to vaccines: a 21st century Oct-10 Pfizer Australia Melbourne, Australia solution for complex pathogens Prof Denise Doolan Malaria – 21st century approaches to Apr-11 Papua New Guinea Biomedical and Papua New Guinea combating an ancient enemy Social Sciences Society Symposium. Prof Denise Doolan Molecular vaccinology Nov-10 Emory Vaccine Research Centre Atlanta, USA Dr David Duffy Estimating extremely small Monte-Carlo Apr-11 8th GeneMappers Conference Hobart, Australia P-values cheaply Ken Dutton-Regester A high throughput mutation screening Oct-10 TRX10- Translational Research Brisbane, Australia panel for the identification of clinically Excellence 2010 relevant profiles in melanoma Dr Christian Engwerda Immune regulation during parasitic Jul-10 Biology of Parasitism Course Woods Hole, USA diseases. Dr Christian Engwerda Immune regulation during parasitic Aug-10 The XIIth International Congress of Melbourne, Australia diseases. Parasitology (ICOPA) Dr Christian Engwerda Immune regulation during parasitic Nov-10 Department of Biochemistry, Indian Kolkata, India diseases. Institute of Chemical Biology Dr Christian Engwerda Immune regulation during parasitic Nov-10 Rajendra Memorial Research Institute Patna, India diseases. of Medical Sciences Dr Christian Engwerda Immune regulation during parasitic Nov-10 Institute of Medical Sciences, Banaras Varabasi, India diseases. Hindu University Dr Christian Engwerda Immune regulation during parasitic Dec-10 Department of Pathogen Molecular London, UK diseases. Biology, London School of Hygiene and Tropical Medicine Dr Christian Engwerda Immune regulation during parasitic Dec-10 Use of animal models in malaria Cambridge, UK diseases. research (Wellcome Trust) Dr Christian Engwerda Immune regulation during parasitic Dec-10 Australian Society for Immunology Perth, Australia diseases. Dr Christan Engwerda Immune regulation during parasitic Apr-11 Local regulation of infection, Hamburg, Germany diseases. inflammation and autoimmunity. SFB 841 Symposium. Bernhard Nocht Institute for Tropical Medicine Dr Manuel Ferreira Invited Faculty Mar-11 2011 International Workshop on Boulder, Colorado Statistical Methodology for Human Genomic Studies Dr Manuel Ferreira Mapping common and rare risk variants Apr-11 8th GeneMappers Conference Hobart, Australia for asthma Dr Manuel Ferreira Australian Asthma Genetics Consortium Apr-11 2011 TSANZ ASM Perth, Australia Dr Katja Fischer Scabies mite inactivated protease paralogs Aug-10 XIIth International Congress of Melbourne, Australia inhibit the human complement system Parasitology (ICOPA) Dr Katja Fischer Scabies mite complement inhibitors Mar-11 Heart Foundation Conference 2011 Melbourne, Australia promote streptococcal skin infections, rheumatic fever and heart disease Assoc Prof Maher 'It started with a kiss: I never thought it Apr-11 World Immunology Day Brisbane, Australia Gandhi would end like this' Assoc Prof Maher ITP Mar-11 Grand Rounds, Princess Alexandra Brisbane, Australia Gandhi Hospital Assoc Prof Maher World Lymphoma Day Sep-11 Leukaemia Foundation Brisbane, Australia Gandhi
Page 114 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Assoc Prof Maher EBV-related post-transplantation Jun-11 Transplantation Society of Australasian Canberra, Australia Gandhi lymphoproliferative disorders: a and New Zealand haematologists perspective Assoc Prof Maher A new and highly aggressive lymphoma Aug-11 World Congress of Virology and Busan, South Korea Gandhi Immunology Assoc Prof Maher EBV+ DLBCL Sep-11 International Association for Research Birmingham, UK Gandhi on Epstein-Barr virus and Associated Diseases Assoc Prof Don High throughput screening for new anti Oct-10 Medicines for Malaria Venture ESCA Geneva , Switzerland Gardiner gametocidal agents Meeting Assoc Prof Gail Garvey Understanding dementia in urban, rural and Aug-10 Statewide Dementia Clinical Network Brisbane, Australia remote Aboriginal and Torres Strait Islander Forum communities in Queensland Assoc Prof Gail Garvey Knowledge of dementia in an Indigenous Sept-10 Dementia Collaborative Research Surfers Paradise population Centre Forum Queensland Dr Michelle Gatton Quantifying the sensitivity of malaria Aug-10 XIIth International Congress of Melbourne, Australia transmission to temperature and Parasitology seasonality: implications for malaria control programs Dr Michelle Gatton Directions for infectious diseases modelling Jan-11 Research and Policy for Infectious Washington, USA Disease Dynamics (RAPIDD) Annual Convocation Dr Michelle Gatton Modelling mosquito adaptation to control May-11 RAPIDD-sponsored workshop of London, UK international scientists Dr Michelle Gatton Analysis of WHO Malaria RDT Product May-11 WHO Product Testing Steering London, UK Testing (Round 3) Committee Dr Michelle Gatton Disasters and Diseases Jun-11 ASMR Science in the Pub Brisbane, Australia Imogen Gillions Development and validation of a murine Dec-10 ASI Tumour Immunology Workshop. Perth, Australia model for dendritic cell (DC)-based ASI Annual Scientific Meeting immunotherapy Priscilla Goh The role of peritrophins in scabies mite Aug-10 XIIth International Congress of Melbourne, Australia innate immunity (poster presentation) Parasitology (ICOPA) Dr Geoffrey Gobert Schistosome cell and molecular biology Nov-10 Department of Medicine, UNAM Mexico City, Mexico Dr Geoffrey Gobert Schistosome comparative genomics Nov-10 ASTMH Annual Meeting Atlanta, USA Prof Jeff Gorman Regulation of Type I Interferon-Dependent Sep-10 HUPO2010 Sydney, Australia and -Independent Antiviral Responses by Respiratory Syncytial Virus Non-Structural Protein 1 Prof Jeff Gorman Global Proteomic Views of Interferon Feb-11 Australian Proteomics Society Lorne, Australia Responses in Respiratory Syncytial Virus Infected A549 Type II Alvelor Epithelial Cells Prof Jeff Gorman Global Proteomic Views of Interferon Feb-11 Lorne Infection and Immunity Lorne, Australia Responses in Respiratory Syncytial Virus Conference Infected A549 Type II Alevelolar Epithelial Cells Dr Darren Gray Schistosomiasis Sep-10 MPH Students, School of Population Brisbane, Australia Health, The University of Queensland Prof Adèle Green The role of sunscreen in melanoma Feb-11 Qld Mining Health Improvement and Brisbane, Australia prevention Awareness Committee Prof Adèle Green Current evidence on skin cancer prevention Apr-11 British Society for Investigative Manchester Dermatology Annual Conference Prof Adèle Green Childhood exposure to ultra-violet radiation May-11 International Joint Conference on Ljubljana, Slovenia and harmful skin effects: epidemiological Non-Ionizing Radiation and Children's evidence Health Prof Adèle Green Effectiveness of sunscreens in skin cancer May-11 22nd World Congress of Dermatology Seoul, Korea prevention Prof Adèle Green Melanomas in the Sunshine State- what's Jun-11 Capacity Building Grant Public Health Melbourne, Australia new? Leadership Forum Dr Sarah Harten Epigenetic control of reprogramming May-11 Mater Medical Research Institute Stem Brisbane Cell Symposium Prof Nick Hayward A multi-faceted approach to discover new Sept-10 Queenstown Molecular Biology Queenstown, New familial melanoma genes Meeting Zealand Prof Nick Hayward Update on the Aussie melanoma GWAS May-11 International Melanoma Genetics Tel Aviv, Israel Consortium meeting Prof Nick Hayward Approaches to discover new melanoma Nov-10 Scott Kirkbride Melanoma Research Perth, Australia Centre ‘Advances in melanoma’ predisposition genes satellite symposium Prof Nick Hayward An Australian genome-wide association Nov-10 7th International Melanoma Research Sydney, Australia study to identify melanoma predisposition genes Prof Geoff Hill Antigen presentation after transplantation: Feb-11 American Society of Bone Marrow Hawaii, USA where and when? Transplantation
Page 115 invited lectures | continued
Speaker Title of lecture Date Audience or event City, Country Prof Geoff Hill IL-17 responses in transplantation Sep-10 Society for Hematology and Stem Cells Melbourne, Australia Prof Geoff Hill The great debate: doctors make poor Dec-10 Australasian Society of Immunology Perth, Australia scientists Prof Geoff Hill Antigen presentation in transplantation Jun-11 Centenary Institute Sydney, Australia Prof Geoff Hill Transplantation, from bench to bedside May-11 Amgen Haematology and Oncology Sydney, Australia scientific meeting Dr Leon Hugo Survival characteristics of a wild population Sep-10 Australian Mosqutio Control Caloundra, Australia of Aedes aegypti in central Vietnam as Association determined by transcriptional age grading Dr Tim Hurst Disasters and diseases Jun -11 Australian Society of Medical Research Brisbane, Australia ASMR lecture Dr Tim Hurst Tanks, buckets and drums…oh my Sep-10 Australian Mosqutio Control Caloundra, Australia Association Dr Masego Johnstone Sars 1c, an active cysteine protease from Aug-10 XII International Congress of Melbourne, Australia Sarcoptes scabiei inhibits complement by Parasitology (ICOPA) degrading complement factors C3 and C5 (oral) Assoc Prof Malcolm Correlative microscopy methods to Jul-10 Australian Conference of Microscopy Brisbane, Australia Jones investigate egg structure and development and Microanalysis in schistosomes Assoc Prof Malcolm Tissue-specific transcriptomics of the Aug-10 International Congress of Parasitology Melbourne, Australia Jones human helminth parasite Associations Schistosoma mansoni Assoc Prof Malcolm Advanced structural investigations of Mar-11 The International Congress of Liver Khon, Kaen Thailand Jones helminths Flukes, 96 Years of Opisthorchiasis: Past, Present and Future Assoc Prof Malcolm Functional genomics approaches for Apr-11 Royal Golden Jubilee Postrgraduate Pattaya, Thailand Jones investigations into human schistosomiasis Students Congress Prof Brian Kay Update on Wolbachia and other mosquito Apr-11 MARC Inc. Brisbane, Australia research Colm Keane LMO2 and BCL6 in DLBCL Jun-11 International Congress in Malignant Lugano, Switzerland Lymphoma Dr Douglas Kerlin Modelling of P. vivax Feb-11 Collaborator meeting Darwin, Australia Prof Kum Kum Khanna New single-stranded DNA binding proteins Nov-10 Indian Institute of Science Bengalore, India involved in DNA damage repair Prof Kum Kum Khanna Cellular responses to DNA damage and Oct-10 Indo-Australia Biotechnology Brisbane, Australia their link with tumor suppression Conference Prof Kum Kum Khanna Defective DNA damage response and Nov-10 International Conference of Radiation Chennai, India cancer susceptibility Biology: Nanotechnology, Imaging and Stem Cell Research in Radiation Oncology Prof Kum Kum Khanna DNA damage repair and genome Jul-10 Murdoch Childrens Research Institute Melbourne, Australia maintenance: discovery of new players Prof Kum Kum Khanna Genome maintenance and role of single- Nov-10 Symposium entitled Current Trends Delhi, India stranded DNA binding proteins in Radiation Biology and Radiation Countermeasures Prof Kum Kum Khanna Novel players involved in cell division cycle Jan-11 Cancer Genomics and Development Utretch, Netherlands regulation Biology School, Utretch University Prof Rajiv Khanna Invited to chair (session on EBV immune- Sep-10 14th Biennial Conference of the Birmingham, UK regulation) and participate as member of International Association for Research the International Scientific Committee on Epstein-Barr Virus and Associated Diseases Prof Rajiv Khanna Using polyepitope vaccine technology for Mar-11 World Vaccine Summit New Delhi, India chronic viral infections. Prof Rajiv Khanna Clinical assessment of cytotoxic T cell- Apr-11 3rd Australia-China Biomedical Melbourne, Victoria based adoptive immunotherapy for the Research Conference treatment of late stage nasopharyngeal carcinoma Prof Rajiv Khanna EBV polyepitiope-based adoptive T cell Jun-11 5th International Symposium on Penang, Malaysia therapy for nasopharngeal carcinoma. Nasopharngeal Carcinoma Prof Rajiv Khanna Profiling of HCMV-specific T cell responses May-11 13th International CMV/ Nuremberg, Germany in patients with Glioblastoma Multiforme BetaHerpesvirus Workshop. Dr Lutz Krause Studying the Intestinal Microbiota by Mar-11 Workshop: Application of Genomics Brisbane, Australia pyrosequencing of the 16S RNA Gene and Bioinformatics to Clinical Samples, Australian Infectious Disease Research Centre Dr Lutz Krause Studying the human gut microbiota by Oct-10 7th Indo Australia Biotechnology Brisbane, Australia high-throughput sequencing of the 16S Conference ribosomal gene
Page 116 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Dr Lutz Krause Human microbiota, diabetes and high- Mar-11 Brisbane Lung Research Group Brisbane, Australia throughput sequencing of the 16S RNA Seminar Series gene Petra Lahmann Adult weight change is associated with risk Oct-10 International Association for the Study Valencia, Spain of aggressive prostate cancer: the Malmö of Obesity Diet and Cancer Study, Sweden. Min-Hsuan Lin An HIV-1 Tat mutant interfers with Rev Jun-11 Australian Centre for HIV and Hepatitis Sunshine Coast, Trafficking Research 7th Annual Workshop Queensland Dr Felicity Lose Association of common variation in Aug-10 Prostate Cancer Foundation of Gold Coast, Australia Kallikrein genes KLK5, KLK6, KLK12 and Australia International Conference KLK13 with risk of prostate cancer and tumour aggressiveness Guangjin Lu The effect of endosymbiont Wolbachia on Sep-10 Australian Mosqutio Control Caloundra, Australia vector competence of Aedes aegypti Association Kelly Loffler Developmental roles of the tumour Oct-10 Brisbane Cell and Developmental Brisbane, Australia suppressor menin Biology Meeting Prof Barbara Leggett Serrated lesions: how they arise and what Nov-10 Adelaide Gut Club Adelaide, Australia they mean in practice Prof Barbara Leggett The serrated pathway in colonic May-11 Digestive Diseases Week Chicago, USA tumorigenesis Dr Kelli MacDonald Antigen presentation in graft-versus-host Aug-11 ISEH International conference Melbourne, Australia disease Dr Kelli MacDonald Stem cell mobilization with G-CSF Mar-11 European Society of Bone Marrow Paris, France promotes type-17 generation and Transplantation scleroderma. Dr Kelli MacDonald Evolving tolerance strategies II BMT and June/July TSANZ Postgraduate course Canberra, Australia chimerism 2011 Prof Don McManus Comparative genomics of schistosomes Aug-10 ICOPA XII Melbourne, Australia Prof Don McManus Large animal vaccines: Schistosoma Aug-10 ICOPA XII Melbourne, Australia japonicum zoonotic vaccines Prof Don McManus The interface of human and animal health: Oct-10 The Gairdner International Vaccine Saskatoon, Canada vaccine for Asian schistosomiasis Symposium Prof Don McManus Integrated control of schistosomiasis in Nov-10 Tenth Regional Network Meeting for Wuxi, China Asia Asian Schistosomiasis and Other Helminth Zoonoses Prof Don McManus Schistosome vaccines Nov-10 Ningxia Medical University Yinchuan, Ningxia, China Prof Don McManus Development of a Transmission Blocking Dec-10 Gold Coast Health and Medical Gold Coast, Australia Vaccine for Asian Schistosomiasis. Research Conference 2010 Prof Don McManus Integrated Control of Schistosomiasis in Apr-11 British Society of Parasitology Spring Nottingham, UK China Meeting Dr Kate Markey Speaker Aug-10 The Transplantation Society Congress Vancouver, Canada Dr Kate Markey Speaker Jun-11 The Transplantation Society of Australia Canberra and New Zealand Dr Kate Markey GVHD induces immune suppression via Aug-10 The World Transplant Congress Vancouver, Canada a selective defect in MHC class II antigen processing Prof Nick Martin Longitudinal twin studies of anxiety and Oct-10 CELSE 2010 5th Conference of Paphos, Cyprus depression in adult and adolescent twins Epidemiological Longitudinal Studies in Europe Prof Nick Martin Translational medicine approaches to Nov-10 1st International Conference on Canberra, Australia diseases of global impact - The genetic Translational Medicine : the 13th Frank susceptibility to substance abuse and Bobbie Fenner Conference Prof Nick Martin VisiGen Consortium Meeting Nov-10 VisiGen Consortium Meeting Amsterdam, Holland Prof Nick Martin Connecting biobanks: the benefits for the Nov-10 BBMRI-NL AMC Conference Amsterdam, Holland researchers? Connecting Biobanks Prof Nick Martin Binocular rivalry and bipolar disorder Dec-10 Golden Helix® Symposium Genetic Athens, Greece (Poster) Analysis in Translational Medicine Prof Nick Martin Invited Faculty Mar-11 2011 International Workshop on Boulder, Colorado Statistical Methodology for Human Genomic Studies Prof Nick Martin Genome-wide association study of sleep Mar-11 Australasia Sleep Trials Network (ASTN) Sydney, Australia disorders Biobanking Prof Nick Martin Genetics of environmental exposure : a Apr-11 8th GeneMappers Conference Hobart, Australia GWAS for sun-related skin damage Prof Nick Martin The genetics of complex traits: the GWAS Apr-11 JCSMR School Seminars 2011 Canberra, Australia revolution and beoynd Prof Nick Martin Personality, sex, and finger length: Jun-11 41st Behaviour Genetics Association Newport, USA intersecting interests Meeting Prof Nick Martin The Queensland Twin Imaging Project: Jun-11 Imaging and Cognition Genetics Os, Norway Genetics of brain structure and function Meeting
Page 117 invited lectures | continued
Speaker Title of lecture Date Audience or event City, Country Nico Martin Educational attainment: a genome Nov-10 The 60th American Society of Human Washington DC, USA wide association study in over 10,000 Genetics 2011 Australians Nico Martin Educational attainment : A meta-analysis of May-11 2011 Australian Society for Medical Brisbane, Australia genome wide association studies Research Postgraduate Student Conference Dr Sarah Medland Overcoming heterogeneity to identify genes Oct-10 18th World Congress on Psychiatric Athens, Greece influencing handedness: results from the Genetics International Handedness Consortium Dr Sarah Medland Invited to participate in forum Feb-11 Explore a Social Science Genetic Boston, USA Association Consortium Dr Sarah Medland Invited Faculty Mar-11 2011 International Workshop on Boulder, USA Statistical Methodology for Human Genomic Studies Dr Sarah Medland ENIGMA : Enhancing Neuro Imaging Apr-11 8th GeneMappers Conference Hobart, Australia Genetics Through Meta-Analysis Dr Sarah Medland Invited Teaching Position - Unravelling the May-11 Croucher Advanced Study Institute Hong Kong genome in health and dusease Unravelling the genome in health and disease Dr Sarah Medland ENIGMA : Enabling Neuroimaging Genetics Jun-11 41st Behaviour Genetics Association Newport, USA Through Meta-Analysis : progress six Meeting months in. Dr Sarah Medland Invited to instruct course Jun-11 Summer School IOP Kings College London, UK Angela Mika Scabies Mite Serpins inhibit all three Aug-10 XIIth International Congress of Melbourne, Australia pathways of the human complement Parasitology (ICOPA) system and enhance Group A streptococcal growth (oral) Prof Grant Montgomery Genome-wide association study identifies Aug-11 Society for Reproductive Biology Sydney, Australia a locus at 7p15.2 associated with Conference the development of moderate-severe endometriosis Prof Grant Montgomery Genetics of endometriosis Oct-10 Fertility Society of Australia Adelaide, Australia Prof Grant Montgomery Genetics of endometriosis Mar-11 Society for Gynecological Investigation Miami, USA Miriam Mosing Genetics of left-right asymmetry in the May-11 2011 Australian Society for Medical Brisbane, Australia brain: a twin study focusing on the Research Postgraduate Student hippocampus Conference Miriam Mosing Genetic influences on the relationship Oct-10 18th World Congress on Psychiatric Athens, Greece between personality and mortality Genetics Miriam Mosing Genetic influences on mortality and its May-11 2011 Australian Society for Medical Brisbane, Australia relationship to personality : a 16 year Research Postgraduate Student prospective study of aged twins Conference Miriam Mosing Genetic influences on mortality and its Jun-11 41st Behaviour Genetics Association Newport, USA relationship to personality : a 16 year Meeting prospective study of aged twins Dr Christina Nagle Time to diagnosis does not influence stage Nov-10 Clinical Oncology Society of Australia Melbourne, Australia of disease or survival among women with Annual Scientific Meeting symptomatic ovarian cancer. Dr Christina Nagle Alcohol and tobacco use predict survival Sep-10 Australasian Epidemiological Sydney, Australia in patients with esophageal squamous cell Association, Annual Scientific Meeting carcinoma. Dr Christina Nagle Dietary glycaemic load, glycaemic index, Sep-10 Australasian Epidemiological Sydney, Australia carbohydrates and risk of ovarian cancer Association, Annual Scientific Meeting Sujeevi Nawaratna Tissue-specific transcriptomics of the Jul-10 Australian Conference of Microscopy Brisbane, Australia human helminth parasite, Schistosoma and Microanalysis mansoni Dr Jamie Nourse EBV-microRNA May-11 Diamantina Institute Lecture Series Brisbane, Australia Dr Dale Nyholt The indirect estimation of risk using Jun-10 PRIVATE Gen Nuremberg, Germany genomic data Dr Dale Nyholt Examining the genetics of migraine and its Oct-10 Colloquium organised by the William Amsterdam, The symptoms James Graduate School, VU Netherlands Tracy O'Mara A genome-wide association study to May-11 ASMR Postgraduate Student Brisbane, Australia identify genetic markers associated with Conference, Health and Medical endometrial cancer grade Research Awards Finalist Dr Colleen Olive Understanding Toll-like receptor signaling Sep-10 Bioengineering Department Seminar California, USA in dendritic cells with a view to immune Series, Berkeley modulation Dr Catherine Olsen Towards melanoma risk prediction Jul-10 Queensland Public Health Forum Brisbane, Australia
Page 118 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Assoc Prof Grant Stellate cells and liver fibrosis Aug-10 World Congress of the International Pasadena, USA Ramm Society for Hepatic Sinusoidal Research Assoc Prof Grant Session Chair: Mechanisms of iron- May-11 World Congress on Iron Metabolism Vancouver, Canada Ramm mediated tissue injury, ER stress Dr Jodie Painter Application of GWA data to address issues Jul-11 Genetics Society of Australasia annual Canberra, Australia of genetic loading in complex human meeting diseases Dr Jodie Painter Genome-wide linkage scan for familial Sept-11 Endocrine Society of Australia and Sydney, Australia dizygotic twinning Society for Reproductive Biology Annual Scientific Meeting Dr Jodie Painter Genetics of complex diseases: Nov-11 University of Connecticut Genetics Storrs, USA endometriosis Department Dr Jodie Painter Genome-wide association study identifies Apr-11 Australasian Human Gene Mapping Hobart, Australia two candidate loci for endometriosis (Genemappers) Conference Dr Jodie Painter Genetics of endometriosis Mar-11 Queensland Endometriosis Support Brisbane, Australia Association (QENDO) information night David Pattinson A novel DNA vaccine delivery strategy Aug-10 International Congress of Parasitology Melbourne, Australia using bi-specific antibodies to target dendritic cells with bacterial minicells encapsulating plasmid DNA and recombinant protein Darren Pickering Testing scabies mite complement Inhibitors Aug-11 XIIth International Congress of Melbourne, Australia under physiological conditions (poster Parasitology (ICOPA) presentation) Dr Joseph Powell Statistical programming Dec-10 ICTE UQ – International postgraduate Brisbane, Australia course at The University of Queensland Prof Lawrie Powell Iron overload - a global perspective Feb-11 Asian Pacific Association for the Study Bangkok, Thailand of the Liver Andrew Redmond Parenteral immunization with cholera toxin Aug-10 International Congress of Parasitology Melbourne, Australia induces cellular immune responses Dr David Reid Novel antimicrobials against Pseudomonas Nov-10 Boden Research Conference: Metals in Canberra, Australia aeruginosa Biological Systems Dr David Reid Is it asthma or COPD or both? May-11 Australian Lung Foundation Education Brisbane, Australia Day Dr David Reid Iron and Pseudomonas aeruginosa Nov-10 Brisbane Lung Group Brisbane, Australia Dr David Reid Neutrophil function in cystic fibrosis Nov-11 Brisbane Lung Group Brisbane, Australia Dr David Reid Transition to adult care in cystic fibrosis Jul-10 Queensland Cystic Fibrosis Education Brisbane, Australia (CF) Day Miguel Renteria Multivariate Genome-wide association Apr-11 8th GeneMappers Conference Hobart, Tasmania, study of height, occipito-frontal Australia circumference and total brain volume Renee Robb Speaker Feb-11 European Bone Marrow Transplant Paris, France Society Renee Robb Speaker Jun/Jul-11 President’s Prize Session, TSANZ Canberra, Australia Dr Peter Ryan Development of on-line decision support Sep-10 Australian Mosquito Control Caloundra, Australia tools for surveillance and control of Association mosquitoes and vector-borne diseases in Queensland Dr Chris Schmidt Characteristics of immunotherapeutic Sep-11 Reliable Cancer Therapies Roundtable Brussels, Belgium dendritic cells (Keynote) Dr Chris Schmidt MCM matured mo-DC with autologous Sep-11 Reliable Cancer Therapies Roundtable Brussels, Belgium tumour as antigen source Dr Chris Schmidt Characteristics of successful immune Oct-11 Perth Tumour Immunology Group Perth, Australia responses to melanoma Annual Scientific Meeting Dr Chris Schmidt How does cancer immunotherapy work? Oct-11 National Centre for Asbestos Related Perth, Australia Diseases Annual Scientific Meeting, Perth Dr Chris Schmidt Successful anti-tumour immune responses Dec-11 Australasian Society for Immunology Perth, Australia are broadly targeted Annual Meeting, Dr Chris Schmidt Burnet oration: Subverting paradigms Dec-11 Tumour Immunology Workshop, Perth, Australia Australasian Society for Immunology Annual Meeting Dr Chris Schmidt Dendritic cell immunotherapy of advanced Feb-11 University of Otago Wellington Cancer Wellington, New metastatic melanoma – how does it really Symposium Zealand work? Maggy Sikulu Age grading tools for Anopheles Sep-10 Australian Mosquito Control Sunshine Coast, mosquitoes Association Australia Haran Sivakumaran Arginine methylation increases the stability Jun-11 Australian Centre for HIV and Hepatitits Sunshine Coast, of Tat Research 7th Annual Workshop Australia
Page 119 invited lectures | continued
Speaker Title of lecture Date Audience or event City, Country Dr Tina Skinner-Adams The Plasmodium falciparum neutral Aug-10 International Congress of Parasitology Melbourne. Australia aminopeptidases: valid targets for novel anti-malarial drugs Dr Amanda Spurdle Understanding unclassified variants in Nov-10 Human Variome Project and HGSA Melbourne, Australia molecular diagnosis. ASM joint meeting – understanding Human Variation Dr Amanda Spurdle Translational research capabilities of Feb-10 Australian & New Zealand Noosa, Australia ANECS Gynaecological Oncology Group Annual Meeting Dr Amanda Spurdle Mismatch repair gene unclassified variants May-10 InSIGHT / Human Variome Project Paris, France – research in progress and suggestions for meeting collaborative opportunities. Dr Amanda Spurdle Update on the moderate-risk study, May-10 Evidence-based Network for the London, UK assessing risk associated with the BRCA1 Interpretation of Germline Mutant R1699Q variant Alleles (ENIGMA) Meeting Dr Amanda Spurdle Pathology markers as predictors of Sep-10 Evidence-based Network for the Milan, Italy BRCA1/2 mutation status; Results from Interpretation of Germline Mutant segregation studies of the BRCA1 R1699Q Alleles (ENIGMA) Meeting variant; Activities of the ENIGMA Splicing Working Group. Dr Amanda Spurdle ENIGMA Splicing Working Group Jun-11 Evidence-based Network for the Stockholm, Sweden presentations: Clinical interpretation of Interpretation of Germline Mutant splicing aberrations; ENIGMA variants to Alleles (ENIGMA) Meeting consider for splicing analysis Dr Brett Stringer Targeting EphA3 in AML and other cancers Oct-10 19th Annual RBWH Health Care Brisbane, Australia Symposium Assoc Prof Nathan Non-HFE haemochromatosis Nov-10 Boden Research Conference on Metals Canberra, Australia Subramaniam in Biological Systems: Structure, Catalysis and Metabolism Prof Andreas Suhrbier Chikungunya virus disease: Pathogenesis, Jun-11 Australasian Society for Microbiology Hobart, Australia animal models and interventions. Prof Andreas Suhrbier Ingenol mebutate: a new topical treatment May-11 Australasian Society for Dermatology Perth, Australia for actinic keratoses and non-melanoma Research skin cancer with a novel mechanism of action Prof Andreas Suhrbier Chikungunya virus, mice, monkeys, Aug-10 SMBS Seminar Series Adelaide, Australia macrophages and money Prof Andreas Suhrbier The development of ingenol mebutate Oct-10 Peter MacCallum Cancer Centre Melbourne, Australia (PEP005) as a new chemotherapeutic agent Prof Andreas Suhrbier Chikungunya virus disease: models and Oct-10 7th Indo-Australia Biotechnology Brisbane, Australia interventions Conference Prof Andreas Suhrbier Viral arthritis and chikungunya virus disease Sep-10 Griffith Medical Research College Brisbane, Australia Retreat Prof Andreas Suhrbier Chikungunya virus arthritis in adult wild- Aug-10 Brisbane Immunology Group Brisbane, Australia type mice Prof Andreas Suhrbier Biological agents in war, terror and the Aug-10 Sydney Nursing School, University Sydney, Australia everyday Sydney Prof Andreas Suhrbier Chikungunya virus, mice, monkeys, Aug-10 University of Adelaide School of Adelaide, Australia macrophages and money Molecular and Biomedical Sciences Seminar series Prof Andreas Suhrbier Ingenol mebutate: a new topical treatment Jun-11 LEO Pharma Copenhagen, Denmark for actinic keratoses and non-melanoma skin cancer with a novel mechanism of action Prof Andreas Suhrbier Chikungunya virus; expression profile of a Nov-10 Joint QIMR, ACVD, Emory Vaccine Atlanta, USA viral arthritis. Center Meeting Prof Andreas Suhrbier The development of ingenol mebutate: a Nov-10 Leiden University Medical Center: Leiden, The new topical skin cancer treatment with a Molecular tumor genetics seminar Netherlands novel mode of action series Dr Clara Tang Invited Faculty - Tutorial on copy number Mar-11 2011 International Workshop on Boulder, Colorado analysis Statistical Methodology for Human Genomic Studies Dr Clara Tang A tool to test for functional enrichment of Apr-11 8th GeneMappers Conference Hobart, Australia GWAS hits Bryony Thompson Clinical evaluation of mismatch repair Aug-10 kConFab familial aspects of cancer Kingscliff, Australia gene sequence variants using qualitative, conference, 2010 analytical and molecular methods Assoc Prof Katharine Identification of lead gametocidal agents by Oct-10 Medicines for Malaria Venture ESCA Geneva , Switzerland Trenholme high throughput screening Meeting
Page 120 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Dr Patricia Valery Discussing strategies for successful Nov-10 Tonkin’s Indigenous Health Care Brisbane, Australia community engagement Delivery Conference Dr Patricia Valery The developmental origins of childhood Oct-10 Royal Brisbane and Women’s Hospital Brisbane, Australia obesity: a snapshot from the Torres Strait Health 19th Annual Health Care Symposium Dr Patricia Valery Adapting an existing Supportive Care Mar-10 Cancer Care Coordination Conference, Gold Coast, Australia Needs tool to be used with Indigenous Clinical Oncological Society of Australia cancer patients. Dr Antiopi Varelias Recipient HO-1 prevents GVHD. May-11 American Association of Immunology San Francisco, USA Karin Verweij Meta-analysis of genome-wide association Oct-10 18th World Congress on Psychiatric Athens, Greece studies on cannabis use initiation and Genetics quantity of use Karin Verweij Genetics of personality Apr-11 8th GeneMappers Conference Hobart, Tasmania, Australia Karin Verweij The genetic etiology of cannabis use May-11 2011 Australian Society for Medical Brisbane, Australia Research Postgraduate Student Conference Karin Verweij The genetic etiology of cannabis use Jun-11 41st Behaviour Genetics Association Newport, USA Meeting Prof Peter Visscher Genetics of complex traits Jul-10 Western Australian Institute of Medical Perth, Australia Research seminar Prof Peter Visscher Genetics of complex traits in human Aug-10 World Congress of Genetics Applied to Leipzig, Germany populations Livestock Production (plenary) Prof Peter Visscher Genetic analysis of complex traits Aug-10 Max Planck Institute seminar Leipzig, Germany Prof Peter Visscher Novel analyses of GWAS data Aug-10 Illumina workshop Brisbane, Australia Prof Peter Visscher Missing heritability Sept-10 Peter MacCallum Institute seminar Melbourne, Australia Prof Peter Visscher Genetic architecture of complex traits Sept-10 Belgium Academy of Science thinktank Rome, Italy workshop Prof Peter Visscher Genetic architecture of complex traits Oct-10 Indo-Australia Biotechnology Brisbane, Australia Conference Prof Peter Visscher Genetic architecture of complex traits Nov-10 Institute of Psychiatry seminar London, UK Prof Peter Visscher Genome partitioning of genetic variation Feb-11 Erasmus University seminar Rottterdam, The Netherlands Prof Peter Visscher Genome partitioning of genetic variation Feb-11 University of Alabama seminar Birmingham, USA Prof Peter Visscher Genome partitioning of genetic variation Feb-11 Emory University seminar Atlanta, USA Prof Peter Visscher Genome partitioning of genetic variation Mar-11 Broad Institute seminar Boston, USA Prof Peter Visscher Genome partitioning of genetic variation Mar-11 Harvard Medical School seminar Boston, USA Prof Peter Visscher New analyses of GWAS data Mar-11 Genetics of ankylosing spondylitis Shanghai, China conference presentation Prof Peter Visscher Genome partitioning of genetic variation May-11 Biology of Genomes session chair and Cold Spring Harbor, presentation USA Dr Graeme Walker Differential roles of the pRb and p53 Nov-10 7th Annual International Melanoma Sydney, Australia pathways in naevo and melanoma genesis Congress Dr Graeme Walker Transgenic mice as models for naevi and May-11 International Skin Cancer Research Brisbane, Australia melanoma Workshop Dr Graeme Walker Genetically modified mice as UVR-induced Nov-10 Australian Health and Medical Melbourne, Australia melanoma Research Conference Logan Walker The role of germ-line DNA copy number Aug-10 KConFab annual meeting: Familial Kingscliff, Australia variation in familial breast cancer risk. Cancer and Research and Practice Logan Walker The role of germ-line DNA copy number Sep-10 Australasian Microarray and Associated Hobart, Australia variation in familial breast cancer risk Technologies Association (AMATA) Meeting Logan Walker Germ-line DNA copy number variation and May-11 New Zealand Society of Oncology Auckland, New Zealand familial breast cancer development Logan Walker Copy number variants as modifiers of Jun-11 Consortium of Investigators of Stockholm, Sweden BRCA1 associated breast cancer risk and Modifiers of BRCA1/2 (CIMBA) Meeting progression Logan Walker ENIGMA Splicing Working Group Project 1: Jun-11 Evidence-based Network for the Stockholm, Sweden Quality control and protocol comparison Interpretation of Germline Mutant Alleles (ENIGMA) Meeting Dr Daniel Wallace Investigating the role of Ataxia Sept-10 Griffith Medical Research College Brisbane, Australia Telangiectasia Mutated (ATM) in iron Retreat homeostasis Dr Daniel Wallace Blunted hepcidin response to inflammation Nov-10 Boden Research Conference on Metals Canberra, Australia in the absence of Hfe and Tfr2 in Biological Systems: Structure, Catalysis and Metabolism Dr Daniel Wallace Blunted hepcidin response to inflammation Jun-11 London Iron Metabolism Group London, UK in the absence of Hfe and Tfr2 Meeting: Iron and immune responses
Page 121 invited lectures | continued
Speaker Title of lecture Date Audience or event City, Country Dr Penny Webb Ovarian Cancer Patterns of Care Study: Feb-11 Australian and New Zealand Gold Coast, Australia management of women with invasive Gynaecological Oncology Group ovarian cancer in Australia in 2005 Dr Penny Webb Epidemiology in real life: case-control Aug-10 Master of Public Health Program, The Brisbane, Australia studies University of Queensland Dr Penny Webb Epidemiology in real life: dealing with error Apr-11 Master of Public Health Program, The Brisbane, Australia University of Queensland Ting Wei Cell factors and HIV-1 reverse transcripiton Jun-11 Australian Centre for HIV and Hepatitits Sunshine Coast, Qld Research 7th Annual Workshop Phillip Whiley Identification of clinically significant splicing Aug-10 kConFab Familial Aspects of Cancer Kingscliff, Australia aberrations for intronic BRCA1 and BRCA2 Conference 2010 variants and the association of alternative splice isoform regulation with pathogenicity Prof Emma Whitelaw The genetics of epigenetics Jul-10 Mater Medical Research Institute Brisbane, Australia Annual Symposium Prof Emma Whitelaw Epigenetics and the determination of Jul-10 School of Medical Sciences, UNSW Sydney, Australia phenotype Prof Emma Whitelaw Epigenetics and the determination of Jul-10 Children's Medical Research Institute, Sydney, Australia phenotype Westmead Prof Emma Whitelaw Epigenetics in mammals Jul-10 2nd Nutrigenomics Symposium Adelaide, Australia Prof Emma Whitelaw Transgenerational epigenetic inheritance Aug-10 Telethon Institute for Child Health Perth, Australia Research Prof Emma Whitelaw Epigenetics and the determination of Sep-10 Asia Millipore Bioforum on Epigenetics Singapore, Australia phenotype and Stem cells Prof Emma Whitelaw Epigenetics and the determination of Sep-10 Asia Millipore Bioforum on Epigenetics Beijing, China phenotype and Stem cells Prof Emma Whitelaw Transgenerational epigenetic inheritance Sep-10 Asia Millipore Bioforum on Epigenetics Taipei, Taiwan and Stem cells Prof Emma Whitelaw Epigenetics in mammals Sep-10 Cold Spring Harbour Asia Conference Suzhou, China on Molecular Switches and Genome Function in Stem Cells and Development Prof Emma Whitelaw Transgenerational epigenetic inheritance Sep-10 ANZSCDB President's Medal and Melbourne, Australia Lecture, OzBio2010 Prof Emma Whitelaw Epigenetics and the determination of Oct-10 7th Nestle International Nutrition Lausanne, Switzerland phenotype Symposium Prof Emma Whitelaw Transgenerational epigenetic inheritance Dec-10 Howard Hughes Medical Institute, Bethesda, USA Symposium on the Epigenome Prof Emma Whitelaw Epigenetics and the determination of Feb-11 IUBMB Jubilee Lecture and Medal, Miami, USA phenotype Miami 2011 Winter Symposium Prof Emma Whitelaw Epigenetics and the determination of Mar-11 Center for Developmental Biology Kobe, Japan phenotype Symposium Epigenetic Landscape in Development and Disease Prof Emma Whitelaw Transgenerational epigenetic inheritance Apr-11 Plenary Lecture, Noncoding London, UK RNA, Epigenetic Memory and the Environment Prof Emma Whitelaw Epigenetics in mammals Mar-11 Keystone Environmental Epigenomics North Carolina, USA Prof Emma Whitelaw Transgenerational epigenetic inheritance May-11 Workshop on Epigenetics, Garvan Sydney, Australia Institute Prof Emma Whitelaw Transgenerational epigenetic inheritance May-11 Fellows Lecture, Australian Academy of Canberra, Australia Science, Shine Dome Prof Emma Whitelaw Epigenetics and the determination of May-11 Plenary Lecture, Advanced Studies Hong Kong phenotype Institute, Hong Kong University Prof Emma Whitelaw Epigenetics and the determination of May-11 Workshop Lecture, Advanced Studies Hong Kong phenotype Institute, Hong Kong University Prof David Whiteman Obesity and cancer May-11 Queen Elizabeth II Hospital Grand Brisbane, Australia Rounds Prof David Whiteman Careers in medical research May-11 Australian Society for Medical Research Brisbane, Australia Student Conference Prof David Whiteman QSkin - sun and health study May-11 1st International Conference on UV and Copenhagen, Denmark Skin Cancer Prevention Prof David Whiteman The causes of melanoma Jun-11 8th International Skin Cancer Gold Coast, Australia Conference Prof David Whiteman The epidemiology and genetics of Jun-11 15th Annual Gastroenterology Update, Coolum, Australia oesophageal cancer Gastroenterological Society of Queensland Prof David Whiteman Oesophageal Cancer Research Progress Nov-10 PROBE-NET annual meeting Melbourne, Australia Prof David Whiteman Blue Sky Epidemiology Feb-11 Queensland Epidemiology Group Brisbane, Australia
Page 122 QIMR Annual Report 2010–2011 Speaker Title of lecture Date Audience or event City, Country Prof David Whiteman Skin cancer research in Queensland - an Oct-10 Pan-Pacific Skin Cancer Consortium Tucson, USA overview Meeting Dr John Whitfield Common variants of large effect : do they Apr-11 8th GeneMappers Conference Hobart, Australia exist, do they matter? Dr Susan Woods The pigment cell specific microRNA, miR- Nov-11 7th International Melanoma Research Sydney, Australia 211, as a novel tumour suppressor for melanoma Dr Susan Woods miR-380-5p represses p53 to control May-11 ASMR Awards presentation Brisbane, Australia cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma Dr Naomi Wray Recent advances in our understanding of Aug-10 Plenary,Youth Mental Health Brisbane, Australia the genetics of pscyhiatric disorders Symposium Dr Naomi Wray Genetics of psychiatric Sept-10 University of Queensland, Dept Brisbane, Australia disorders:assimilating genome-wide Psychiatry association and genetic epidemiology studies Dr Naomi Wray Prospects for genetic testing in psychiatry Oct-10 Plenary, World Congress Psychiatric Athens, Greece Genetics Dr Naomi Wray Whole-genome analysis of GWAS data for Oct-10 Symposium, World Congress Athens, Greece complex traits Psychiatric Genetics Dr Naomi Wray Insights into genetic architecture from Oct-10 Symposium, World Congress Athens, Greece genetic epidemiology and GWAS Psychiatric Genetics Dr Naomi Wray Use of GWAS for prediction of genetic risk Oct-10 Plenary, GWAS mega-analysis for Edinburgh, Scotland to disease complex diseases: Satellite workshop of the International Conference of Systems Biology Dr Naomi Wray Insights into genetic architecture from Dec-10 Bioinformatics Summer School Melbourne, Australia GWAS: Looking for the "missing heritability" Dr Naomi Wray Putting synthetic associations into Apr-11 Australian GeneMappers Meeting Hobart, Australia perspective Dr Margie Wright Neuroimaging genetics, finding genes for Sep-10 Queensland Brain Institute, The Brisbane, Australia brain function and dysfunction University of Queensland Seminar Series Dr Margie Wright Unravelling the genetic mechanisms Dec-10 The Australasian Society for Psychiatric Sydney, Australia influencing the human brain in health, Research 2010 Conference: Glial- illness, youth and old age Neuronal Networks in Neuropsychiatry Assoc Prof Joanne Serrated neoplasia update Jul-10 Norris Comprehensive Cancer Centre Los Angeles, USA Young Seminar Assoc Prof Joanne Serrated polyposis risk factors Nov-10 NZ Gastroenterology Society Meeting Auckland, New Zealand Young Assoc Prof Joanne Epigenetics update Oct-10 Australian Gastroenterology Week Gold Coast, Australia Young Assoc Prof Joanne Molecular pathology of colorectal cancer Oct-10 Australian Gastroenterology Week Gold Coast, Australia Young Assoc Prof Joanne Origin of cancers in serrated polyposis Oct-10 Consensus Meeting on Serrated Cleveland, USA Young Neoplasia Assoc Prof Joanne The mucosa in serrated polyposis Oct-10 Consensus Meeting on Serrated Cleveland, USA Young Neoplasia
Page 123 graDuateD StuDentS
Student University Supervisor Thesis title BSC (HONS)
Ainslie QUT David McMillan Identification of the virulence gene, sicG, in Australian clinical isolates of CAMERON Streptococcus dysgalactiae subspecies equisimilis Carly PERRY QUT Geoffrey Gobert, Comparison of hepatic gene expression in mouse strains with contrasting Melissa Burke, Don pathology during infection with Schistosoma japonicum McManus Cornel MIRCIOV Bond Greg Anderson Characterisation of iron-related gene expression in the mouse lung University Ai Hwee KHO University of Leon Hugo Combined effects of nutritional stress and Wolbachia infection on the vector Tunku Abdul competence of Aedes aegypti for dengue Rahman, Malaysia Timothy REEKS QUT Keyur Dave, Jeff Identification of cellular pathways perturbed by the human respiratory syncytial Gorman virus attachment protein Yadveer QUT Marcus Hastie, Jeff Quantitative proteomics: using iTRAQ to examine changes involved in breast GREWAL Gorman cancer mammosphere formation Annaliese WOODS GU Kathy Andrews Antimalarial action of HDAC inhibitors Priscilla GOH UQ Katja Fischer, Angela The role of peritrophins in scabies mite Immunity Mika Emma UQ Amanda Spurdle, Assessing the clinical relevance of rare sequence variants in BRCA1 and BRCA2 SEDLACEK Phillip Whiley genes Nurul OSMAN UQ Kelli MacDonald, Characterisation of molecular mediators of murine chronic graft-versus-host Geoff Hill disease
PHD
Suzanne MOORE UQ Adèle Green, Gail A comparative study of cancer incidence, diagnosis, treatment and survival Garvey between Indigenous and non-indigenous people in Queensland Simin UQ Adèle Green, Jolieke Longitudinal change in anthropometric characteristics & diet quality in Australian ARABSHAHI van der Pols adults Jennifer QUT Andrew Boyd The role of the Eph and ephrin proteins in prostate cancer MCCARRON Hau Phuc TRAN UQ Brian Kay Relationships between dengue vector abundance, household water storage practices and new water supply Infrastructure in Southern Vietnam Amber UQ Malcolm Jones Iron biology of schistosomes: molecular characterisation and vaccine potential of GLANFIELD iron homeostasis proteins David HEWETT UQ Barbara Leggett Communication between doctors and the quality of patient care: An intergroup perspective Mikail RUBINOV UNSW Michael Breakspear Brain networks Meru SHEEL QUT Michael Batzloff Immunogenicity and protective efficacy of an anti-Streptococcus pyogenes vaccine candidate in multiple animal species Kate MARKEY UQ Kelli MacDonald, Antigen presentation and inflammation in allogeneic bone marrow transplantation Geoff Hill
MASTERS
Andrew LALOO UQ David Harrich Analysis of RNA binding and heat shock proteins in the regulation of HIV-1 reverse transcripiton Lisa WHOP ANU Patricia Valery, Gail Cadetship Garvey Audra DE'WITT UQ Patricia Valery, Gail Health behaviours in Indigenous and non-Indigenous people and their Garvey associations with asthma Hosam GU David McMillan Development and evaluation of a rapid real-time PCR based diagnostic tool to ZOWAWI detect pathogenic bacteria colonising catheters. Elizabeth LEDDY UQ Nathan Subramaniam The role on hemojuvelin and matriptase-2 in iron metabolism Legend
ANU Australian National University GU Griffith University QUT Queensland University of Technology UNSW University of New South Wales UQ The University of Queensland
Page 124 QIMR Annual Report 2010–2011 StuDent aWarDS
Recipient Bestower of award Date Award Reason Franziska Bieri Queensland Tropical Jun-11 Travel Award Conference attendance Health Alliance Franziska Bieri ASMR May-11 Postgraduate Student Conference The People’s Choice prize for the best poster presentation: The Magic Glasses. Franziska Bieri QIMR 2011 QIMR PhD Award Gabriëlla Blokland QIMR Jul-10 QIMR PhD Top-up Award Scholarship Top-up Gabriëlla Blokland QIMR 2010 ANZ Trustees PhD scholarship in PhD scholarship Medical Research Gabriëlla Blokland ANZ Trustees Jan-11 Travel award PhD scholarship Gabriëlla Blokland ATR Mar-11 Travel award Conference attendance Gabriëlla Blokland UQ School of Psychology May-11 Honours scholarship Conference attendance Catherine Bond QIMR 2011 PhD Award Zara Bruce QIMR Jan-11 Honours scholarship Ainslee Cameron QIMR 2011 Honours scholarship Melody Cheong QIMR 2011 Honours scholarship Ken Dutton-Regester QIMR 2010 QIMR PhD Award Ken Dutton-Regester Australian Academy for 2011 ATSE Young Science Ambassador Technological Sciences Award and Engineering Ken Dutton-Regester QIMR 2011 QIMR PhD Top-up Award Ken Dutton-Regester QIMR 2011 QIMR Postgraduate Student Travel Award Ken Dutton-Regester CCQ 2011 Cancer Council Queensland Travel Grant Imogen Gillions QIMR Aug-10 Travel award Conference attendance Catherine Gordon QIMR 2011 QIMR PhD Award Kimberley Jones Boehringer Ingelheim Dec-10 Travel award Fonds Kimberely Jones QIMR 2011 QIMR PhD Award Yee Leow ACVD Feb-11 ACVD Edward Jenner PhD Scholarship Yi Chieh Lim QIMR 2010 QIMR PhD Award Yi Lu QIMR 2010 QIMR PhD Award Rachael McGeorge Australian Society for Jul-10 Travel award Travel to USA Parasitology Rachael McGeorge QIMR Jun-11 QIMR PhD Award Kate Markey ASI Aug-10 Travel award Conference attendance Kate Markey The Transplant Society Aug-10 Astellas Pharma Educational Grant A grant received for submission of one of the top 10 scored abstracts by a Young Investigator for The Transplantation Society annual meeting, to be held in Vancouver Canada Kate Markey TSANZ Jun-11 Amgen Young Investigator Award Awarded for the Best Presentation in the Field of Laboratory Research, TSANZ meeting Kate Markey School of Medicine Jun-10 Selected to attend the 60th After a competitive selection process, awarded Meeting of Nobel Laureates in a place as a “Young Researcher” delegate at Lindau, Germany this meeting. Part of the award includes full travel support to attend. Kate Markey TSANZ Jun-11 Young Investigator award Quality of research by young investigator Kate Markey NHMRC Jan-11 Clinical Training Fellowship Nico Martin QIMR Aug-10 Postgraduate Student Travel Award Conference attendance Nico Martin ATR Oct-10 Travel award Conference attendance Nico Martin ANZ Trustees Jan-11 ANZ Trustees PhD scholarship in PhD scholarship Medical Research Nico Martin UQ School of May-11 Travel award Conference attendance Psychology Cornel Mirciov QIMR 2010 QIMR Honours Award Marcela Montes de Oca QIMR 2011 QIMR Honours Award Brian Morrison CCQ Sep-10 Travel award Conference attendance Brian Morrison QIMR Sep-10 Travel award Conference attendance Miriam Mosing World Congress on Aug-10 Early Career Investigator Program Conference attendance Psychiatric Genetics Travel Award
Page 125 Student awards | continued
Recipient Bestower of award Date Award Reason Miriam Mosing ANZ Trustees Jan-11 ANZ Trustees PhD scholarship in PhD scholarship Medical Research Miriam Mosing ATR Mar-11 Travel award Conference attendance Miriam Mosing UQ School of Psychology May-11 Travel award Conference attendance Miriam Mosing Behavior Genetics Jun-11 Travel award Conference attendance Association Sujeevi Nawaratna QIMR 2010 QIMR PhD Award Tracy O'Mara ASMR May-11 ASMR Postgraduate Student Conference, Health and Medical Research Awards Finalist Thomas Partridge QIMR 2011 Honours scholarship David Pattinson Australian Society for Aug-10 Travel award Conference attendance Parasitology David Pattinson QIMR 2011 QIMR PhD Award Chris Peatey Australian Society for Sep-10 Travel award Travel to Melbourne/Researcher exchange Parasitology Melinda Protani QIMR 2011 QIMR PhD Award Melanie Rampton QIMR 2011 Honours scholarship Andrew Redmond Australian Society for Aug-10 Travel award Conference attendance Parasitology Simone Reynolds Australian Society for Mar-11 ASP and ARC/NHMRC Network for Conference attendance Parasitology & ARC/ Parasitology Travel Award 2011 NHMRC Network for Parasitology Simone Reynolds Australian Society for Feb-11 Australian Society for Parasitology International Summer School (Germany) and Parasitology JD Smyth Postgraduate Travel Researcher Exchange (Sweden) ($8000) Award 2010 Simone Reynolds QIMR 2010 QIMR Postgraduate Travel Award 2010 Conference attendance Sophie Schussek Australian Society for Aug-10 Travel award Conference attendance Parasitology Maggy Sikulu Aust Mosqutio Control Sept-10 Best Student Presentation Association Maggy Sikulu QIMR 2011 QIMR PhD Award Daniel Smith Prince Charles Hospital Feb-11 PhD scholarship Research Foundation Dulangi Sumanadasa Australian Society for Jul-11 ASP Travel Award Parasitology Aaron Thrift QIMR 2011 QIMR PhD Award Karin Verweij QIMR Jul-10 QIMR PhD Top-up Award Karin Verweij QIMR Jul-10 Postgraduate Student Travel Award Conference attendance Karin Verweij World Congress on Aug-10 Early Career Investigator Program Conference attendance Psychiatric Genetics Travel Award Karin Verweij ANZ Trustees Jan-11 ANZ Trustees PhD scholarship in PhD scholarship Medical Research Karin Verweij ATR Apr-11 Travel award Conference attendance Karin Verweij UQ School of Apr-11 Travel award Conference attendance Psychology Karin Verweij Behavior Genetics Jun-11 Travel award Conference attendance Association Karin Verweij UQ School of Sep-10 2010 Psychology Student Psychology Research Excellence Award Annaliese Woods Australian Society for Jul-11 ASP Travel Award Parasitology Legend
ACVD Australian Centre for Vaccine Development ARC Australian Research Council ASI Australasian Society of Immunology ASMR Australian Society of Medical Research ATR Australian Twin Registry CCQ Cancer Council Queensland NHMRC National Health and Medical Research Council OHMR Office of Health and Medical Research PCRFA Prostate Cancer Research Foundation Australia TSANZ The Transplantation Society of Australia and New Zealand
Page 126 QIMR Annual Report 2010–2011 patentS patent families managed by Qimr
Title Inventor(s) Application Number Novel molecules Toni Antalis; John Hooper PCT/AU1998/000085
Immunogenic agent and pharmaceutical composition for use against Michael Good; Mary Stevenson PCT/AU2004/000870 homologous and heterologous pathogens
Polytope vaccines Andreas Suhrbier; Scott Thomson; Rajiv PCT/AU1995/000461 Khanna; Scott Burrows; Barbara Coupar; Denis Moss
Synthetic peptides and vaccines comprising the same Juan Cooper; Wendy Relf; Michael Good; PCT/AU1995/000681 Allan Saul
Cytotoxic T-cell epitopes Denis Moss; Scott Burrows; Rajiv Khanna; PCT/AU1995/000140 Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier
EBV CTL epitopes Rajiv Khanna; Beverley Kerr; Ihor Misko; Denis PCT/AU1997/000328 Moss; Scott Burrows
CTL epitopes from EBV Martina Sherritt; Scott Burrows; Rajiv Khanna PCT/AU1998/000531
EBV peptide epitopes, polyepitopes and delivery system therefor Rajiv Khanna; Jaikumar Duraiswamy PCT/AU2003/001451
Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising Rajiv Khanna; Rebecca Elkington; Susan PCT/AU2002/000829 same and diagnostic and prophylactic and therapeutics uses therefor Walker
Human cytomegalovirus immunotherapy Rajiv Khanna PCT/AU2005/001798
Peptide compounds Istvan Toth; William Gibbons PCT/GB1993/001558
Novel human ssDNA binding proteins and methods of cancer diagnosis Kum Kum Khanna; Derek Richard; Malcolm PCT/AU2008/000181 White
Cancer drug targets and methods of diagnosis Andrew Boyd; Bryan Day; Brett Stringer PCT/AU2009/000672
Human cytomegalovirus immunotherapy Rajiv Khanna 61/347,352
Qimr patent families managed outside Qimr
Title Inventor(s) Application Number Receptor ligand system and assay Andrew Boyd US 1998/104340
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis Andrew Boyd PCT/AU2004/000142
A method of treatment Andrew Boyd PCT/AU1999/000931
Differentiation modulating agents and uses therefor Johannes Prins PCT/AU2005/000008
Melanoma-associated MHC Class 1 Associated oligopeptide and its use Chris Schmidt PCT/EP2006/008533
Method for screening for anticancer agents Kum Kum Khanna PCT/GB2008/003390
A novel growth factor and a genetic sequence encoding same Nicholas Hayward PCT/AU1996/000094
Page 127 patent families resulting from industry Sponsored contract research performed at Qimr
Title Inventor(s) Application Number Treatment of virally induced lesions Andreas Suhrbier PCT/AU2008/000596
Use of angeloyl-substituted ingenones in combination with other agents to treat cancer Andreas Suhrbier; PCT/AU2006/001700 Peter Parsons
Treatment of solid tumours Andreas Suhrbier PCT/AU2005/001827
Chaperonin 10 modulators of toll-like receptors inducible cytokine and cytokine secretion Andreas Suhrbier PCT/AU2005/000041
Treatment of prostate cancer Peter Parsons PCT/AU2001/000966
Therapeutic agents I Andreas Suhrbier; PCT/AU2001/000679 Peter Parsons
Therapeutic agents II Andreas Suhrbier; PCT/AU2001/000680 Peter Parsons
Therapeutic agents III Andreas Suhrbier; PCT/AU2001/000678 Peter Parsons
patents families managed by Qimr as trustee for the crc-Vaccine technology
Title Inventor(s) Application Number T helper epitopes David Jackson PCT/AU2000/000070
Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte David Jackson PCT/AU2003/001019 (CTL) epitope
Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes David Jackson PCT/AU2003/001018
Truncated LHRH formulations David Jackson PCT/AU2005/001383
Immunogenic molecules David Jackson PCT/AU2006/000162
trade marks managed by Qimr
Mark Status Australian Trade Mark Number Queensland Institute of Medical Research Registered / Protected 1233303
QIMR Registered / Protected 1233307
Hexagons device Registered / Protected 1233317
Page 128 QIMR Annual Report 2010–2011 grantS anD funDing
(over $100,000)
Total Source Chief Investigators and Project Title Term Period Funding NHMRC Antonsson, A – Squamous cell carcinomas of the head and neck: 2yrs 2011 – 2012 $212,015 Exploring the role of human papillomavirus infection ALF McDonald, Cameron – Hospitality Industry Career Development Research 3yrs 2011 – 2013 $270,000 Fellows ARC Chong, Suyinn – Epigenetic neurobehavioral changes in new mouse 4yrs 2011 – 2014 $701,842 models of foetal alcohol spectrum disorders ARC Valery, Patricia – Developing an evidence base to improve the health 4yrs 2011 – 2014 $568,352 Aboriginal and Torres Strait Islander people ARC Lopez, Alejandro et al – Characterisation of the anti-inflammatory pathway 4yrs 2010 – 2013 $530,000 targeted by chaperonin 10 (Administered by Griffith University) ARC Martin, Nick – From genotype to phenotype: Molecular photo fitting for 3yrs 2011 – 2013 $245,358 criminal investigations (Administered by University of Canberra) ARC Kay, Graham and Hayward, Nick – Molecular characterization of the role 3yrs 2011 – 2013 $345,000 of menin in embryonic development (Administered by The University of Queensland) BUSHEL Subramaniam, Nathan – Hereditary haemochromatosis: Characterisation 4yrs 2010 – 2013 $288,400 of the HepcidiAxia. CA/NBCF MacGregor, Stuart – Identifying markers of risk and outcome in ovarian and 4yrs 2011 – 2014 $521,490 breast cancer via efficient evaluation of DNA methylation CANCERAU Spurdle, Amanda – Development of a model to classify mismatch repair 3yrs 2011 – 2013 $600,000 CCQ Boyd, Andrew – Suppression of high-grade glioma by Nfib over expression 2yrs 2011 – 2012 $146,500 CCQ Hayward, Nick – Identification of novel methylated tumour suppressor 2yrs 2011 – 2012 $199,472 genes in melanoma CCQ Hill, Geoff – Therapeutic targeting of adhesion and costimulatory pathways 2yrs 2011 – 2012 $200,000 after transplantation CCQ Khanna, Kum Kum – Understanding the contribution of DNA repair genes 2yrs 2011 – 2012 $199,472 in breast metastasis CCQ Khanna, Rajiv – Novel immunotherapy for herpes virus infection in stem cell 2yrs 2011 – 2012 $195,016 transplant patients. CCQ MacDonald, Kelli – Requirements for class II antigen presentation to 5yrs 2011 – 2015 $594,970 generate curative anti-leukaemic responses CCQ Walker, Graeme – Pilot study to assess the role of classical and oxidative 2yrs 2011 – 2012 $200,000 UVR-induced DNA adducts in melanoma induction CCQ Young, Joanne – Excome capture, miRNA and next generation sequencing 2 yrs 2011 – 2012 $200,000 inprobands with hyperplastic polyposis CSIRO Hurst, Tim – Urbanism, Climate Adaptation and Health Cluster (Flagship 4yrs 2010 – 2013 $200,000 Cluster) DEEDI Boyle, Glen – Smart Futures Commercialisation Program 3yrs 2010 – 2012 $107,048 ECO Boyle, Glen – Smart Futures Commercialisation Program 3yrs 2010 – 2012 $107,048 GARNETT Antonsson, Annika – Exploring the role of human papillomavirus infection in 3yrs 2011 – 2013 $150,016 mucosal squamous cell carcinomas of the head and neck. HEARTF McMillan, David – Grant in Aid Research Program 2yrs 2011 – 2012 $127,456 NHMRC Hill, Geoff – NHMRC Australia Fellowship (Jan 2011-Dec 2015) 5yrs 2011 – 2015 $4,000,000 NHMRC Parsons, Peter – Taking a cancer drug towards a clinical trial 3yrs 2011 – 2013 $254,584 NHMRC Jones, Malcom – Roles of annexins in schistosome surface homeostasis 3yrs 2011 – 2013 $295,866 and host parasite interaction NHMRC Beesley, Jonathan – The TERT locus as a susceptibility gene for ovarian 3yrs 2011 – 2013 $382,524 and breast cancer: genetic and functional evaluation NHMRC Burrows, Scott – The impact of micropolymorphism within the T cell 3yrs 2011 – 2013 $352,524 receptor genes and their target antigenic peptides NHMRC Chong, Suyinn – Epigenetic and neuribehavioural changes in a new mouse 3yrs 2011 – 2013 $701,732 model of foetal alcohol spectrum disorder NHMRC Harrich, David – An RNA element negatively regulates HIV-1 reverse 3yrs 2011 – 2013 $561,453 transcription and inhibits proviral intergration NHMRC Harrich, David – How does a host cell stimulatory factor stabilize the HIV-1 3yrs 2011 – 2013 $610,074 reverse transcription complex? NHMRC Khanna, Rajiv – Prophylactic vaccine to prevent cytomegalovirus disease. 3yrs 2011 – 2013 $421,299 NHMRC MacDonald Kelli – The role of alloantigen presentation in transplantation 3yrs 2011 – 2013 $490,470 NHMRC McRea, Allan – Inheritance of DNA methylation state in humans 3yrs 2011 – 2013 $579,766 NHMRC Medland, Sarah – Genetic influences on the comorbidity between Attention 2yrs 2011 – 2012 $238,978 Deficit Hyperactivity Disorder and substance use
Page 129 grants and funding | continued
Total Source Chief Investigators and Project Title Term Period Funding NHMRC Ramm, Grant – Role of tissue ferritin as a proinflammatory mediator of 3yrs 2011 – 2013 $555,048 hepatic stellate cell activation in heptic iron overload NHMRC Spurdle, Amanda – Prediction, verification and clinical significance of 3yrs 2011 – 2013 $553,390 splicing aberrations associated with BRAC1 and BRAC2 variants NHMRC Tellam, Judith – Enhanced expression of Epstein-Barr virus nuclear 3yrs 2011 – 2013 $344,208 antigen, EBNA1, as a target for T cell based immunotherapy for prevention of viral-associated diseases NHMRC Valery, Patricia – A comparative study: Patterns of care, comorbidities and 3yrs 2011 – 2013 $610,731 quality of life of Indigenous and non-Indigenous people with lung, head and neck, breast or gynaecological cancers NHMRC Wray, Naomi – Better methods for individual risk prediction of complex 3yrs 2011 – 2013 $578,416 traits in human populations NHMRC Wright, Margaret – Genetics of brain structure and function 3yrs 2011 – 2013 $560,218 NHMRC Yang, Yurong – Does environmental change drive the spatiotemporal 3yrs 2011 – 2013 $632,128 transmission dynamics of Echinococcus spp. in Ningxia, China? NHMRC Duffy, David – Genetic epidemiology of complex disease 5yrs 2011 – 2015 $630,505 NHMRC Khanna, Rajiv – Immunobiology of herpes virus infections 5yrs 2011 – 2015 $780,805 NHMRC McManus, Don – Elimination of zoonotic schistosomiasis 5yrs 2011 – 2015 $855,805 NHMRC Harten, Sarah – A piggy-back screen for genes involved involved in cancer 4yrs 2011 – 2014 $290,032 NHMRC Markey, Kate – The immune system in graft-versus-host disease 4yrs 2011 – 2014 $145,016 NHMRC Wei, Ting – A Novel RNA repressor element regulates HIV-1 4yrs 2011 – 2014 $290,032 NHMRC Willis, Charlene – Haemolysines and haemoglobinases as anti-hookworm 2yrs 2011 – 2012 $122,875 vaccines (Transferred from Griffith University) NHMRC Webb, Penny – CARE Kidney Study (Administered by The University of 3yrs 2011 – 2013 $245,275 Queensland) NHMRC Hayward, Nick – Molecular determinants of risk, progression and treatment 5yrs 2011 – 2015 $1,608,665 response in melanoma (Administered by University of Sydney) NIH Martin, Nick – Genetic and environmental pathways to drug use, abuse 4yrs 2010 – 2013 $389,251 and dependence (Administered by Virginia Commonwealth University – USA) OHMR Hill, Geoff – Senior Clinical Research Fellowship 5yrs 2011 – 2015 $4,250,000 PCFA Boyd, Andrew – Express and Function of Eph and ephrin proteins in 2yrs 2011 – 2012 $250,000 prostate cancer RBWH Breakspear, Michael – Health Research Fellowship – Mental Health 5yrs 2011 – 2015 $375,000 Research Division (Administered by RBWH) ROTRF Gandhi, Maher – Post transplant lymph proliferative disorders: A lab based 2yrs 2011 – 2012 $206,653 study within LS CT ROTRF Khanna, Rajiv – MHC Class II all recognition by virus-specific CD*+ T cell 2yrs 2011 – 2012 $206,653 SMART Wykes, Michelle – A novel treatment to generate long-term protection 4yrs 2010 – 2013 $300,000 against malaria Legend
ALF Australian Liver Foundation ARC Australian Research Council BUSHEL Bushel Foundation CA/NBCF Cancer Australia/National Breast Cancer Foundation CANCERAU Cancer Australia CCQ Cancer Council Queensland CSIRO Commonwealth Scientific and Industrial Research Organisation DEEDI Dept of Employment, Economic Development and Innovation ECO Ecobiotics GARNETT Garnett Passe and Rodney Williams Memorial Foundation HEARTF Heart Foundation NHMRC National Health and Medical Research Council NIH National Institutes of Health OHMR Office of Health and Medical Research PCFA Prostate Cancer Foundation Australia RBWH Royal Brisbane and Women’s Hospital ROTRF Roche Organ Transplantation Research Foundation SMART Smart State Futures Fellowship
Page 130 QIMR Annual Report 2010–2011 Qimr feLLoWS
Sir Macfarlane Burnet Dr Natth Bhamarapravati Dr Michael O’Rourke
Prof Ralph Doherty Dr Louis Miller Mr Michael Barry
Prof Frank Fenner Sir Eric Saint Prof Kay Ellem
Dr Eric French Dr Robert Shope Dr Ian Taylor
Sir Abraham Fryberg Sir Bruce Watson Prof Lawrie Powell
Dr Douglas Lee The Hon Mike Ahern Mr Tom Veivers
Ms Margaret Macgregor Dr Neville McCarthy Mr Phillip Desbrow (Deceased)
Dr Aubrey Pye Sir Gustav Nossal Prof William O’Sullivan
Mr William Reeves Dr E D O’Callaghan Dr Diana Cavaye (Deceased)
Mr John Sprent Prof Frank Schofield Sr Regis Mary Dunne
Mr Harry Standfast Sir Edward Stewart Mr Clive Berghofer
Mr George Taylor Prof Tao Yixun Prof Bryan Campbell
Mr John Tonge Dr Chamlong Harinasuta Mr Sam Coco
Dr Carleton Gajdusek Prof Chev Kidson Dr Peter Wills
Dr David Henderson Dr Peter Livingstone Prof John Kerr
Prof Owen Powell Dr Michael Alpers Mr Paul Wright
Prof Julie Saroso Mr Rod Wylie Mr David Lyons
Prof Edwin Westaway Prof Graham Mitchell Mr Ian Goddard
Prof Vincent Zigas Prof Mervyn Eadie Ms Helen Luckoff
Sir Anthony Epstein Prof Bryan Emmerson Mr John Garnsey (Deceased)
Dr Douglas Gordon Dr Ian Wilkey Prof Graham Brown
Dr Elizabeth Marks Prof Ted Brown Prof Robert MacLennan
Dr Neville Davis Prof Peter Doherty Prof Peter Brooks
Dr Robert Porter Prof Paul Korner Dr Peter Roeser
Prof Brian Wilson Dr Stephen Lynch
Page 131 oVerSeaS traVeL
Travel by researchers and corporate staff is critical to facilitate collaborations and ensure the Institute keeps pace with new technologies and techniques. The following overseas travel was taken during the 2010–2011 financial year.
Contribution from Name of Officer & Position Destination Reason for Travel Agency Cost ($) other agencies or sources Prof Frank Gannon Europe EMBO/EMBC Conference 9,679 (Director)
Prof Frank Gannon Europe Invited Lecturer – Redfern Lecture at 50th University of (Director) Anniversary of the Dept of Biochemistry, Leicester; Leicester 13,881 Speaker at meeting – “Starting from Transcription… $4,288 Honneur a Pierre Chambon”, IGBMC; Meeting re. HIRF – Erlangen, Germany ; Attend the 36th FEBS Congress, Torino, Italy
Dr Cameron McDonald Canada BioIron Conference 3,989 (Research Officer) Dr Deepak Darshan (Research Officer) Assoc Prof Nathan Subramaniam (Lab Head)
Dr Lutz Krause USA/Europe Attend the Human Micro biome Research 8,991 (Lab Head) Conference; FASEB Conference and ISMB Conference
Prof Nick Hayward Israel/UK International Melanoma Genetics Consortium 6,613 European (Lab Head) (GenoMEL) Annual Conference – Israel : Meeting of Commission grant BioGenoMEL Consortium (UK) $4,613
Ms Michelle Richards Canada Attend 2011 Annual International High Containment 3,523 (Safety Officer) Bio-safety Workshop, International Centre for Infectious Diseases
Ms Grace Chojnowski USA Attend CYTO2011 and ISAC Council Meeting 4,300 (Scientific Technical Officer)
Dr Antiopi Varelias USA 98th Annual Meeting of the American Association 2,043 (Research Officer) of Immunologists
Dr Ingrid Rowlands UK Laboratory visit – National Perinatal Epidemiology 1,106 (Research Officer) Unit, Oxford
Mr Yi Chieh Lim USA Gordon Research Conference 1,875 (PhD Student)
Dr Rachel Neale Copenhagen/ 1st International Conference on UV and Skin Cancer 3,972 $2,672 (Senior Research Fellow) Denmark Prevention
Dr Alex Combes Germany Chromatin and Epigenetics Conference 3,505 $2,505 (Research Officer)
Dr Zhen Zhen Zhao China Attend and present at Cold Harbor Springs Asia 2,500 $1,500 (Senior Research Officer) Meeting
Dr Olivier Becherel USA Keystone Symposia – Genomic Instability and 1,860 (Senior Research Officer) DNA Repair
Page 132 QIMR Annual Report 2010–2011 Scientific puBLicationS
Abdel-Aal ABM, Zaman M, Fujita Y, Batzloff MR, Oostra B, Palmer LJ, Raitakari O, Ridker PM, I, Gayther SA, Gentry-Maharaj A, Menon U, Good MF, Toth I. Design of Three-Component Rioux JD, Rissanen A, Rivolta C, Schunkert H, Chang-Claude J, Wang-Gohrke S, Anton-Culver Vaccines against Group A Streptococcal Infections: Shuldiner AR, Siscovick DS, Stumvoll M, Tonjes H, Ziogas A, Dork T, Durst M, Antonenkova Importance of Spatial Arrangement of Vaccine A, Tuomilehto J, van Ommen GJ, Viikari J, Heath N, Bogdanova N, Brown R, Flanagan JM, Components. Journal of Medicinal Chemistry. AC, Martin NG, Montgomery GW, Province MA, Kaye SB, Paul J, Butzow R, Nevanlinna H, 2010;53(22):8041-8046. Kayser M, Arnold AM, Atwood LD, Boerwinkle Campbell I, Eccles DM, Karlan BY, Gross J, E, Chanock SJ, Deloukas P, Gieger C, Gronberg Walsh C, Pharoah PDP, Song HL, Kjaer SK, Ainger SA, Wong SS, Roberts DW, Leonard JH, H, Hall P, Hattersley AT, Hengstenberg C, Hogdall E, Hogdall C, Lundvall L, Nedergaard Sturm RA. Effect of MC1R variant allele status on Hoffman W, Lathrop GM, Salomaa V, Schreiber L, Kiemeney LALM, Massuger LFAG, van MSH-ligand induction of dopachrome tautomerase S, Uda M, Waterworth D, Wright AF, Assimes Altena AM, Vermeulen SHHM, Le ND, Brooks- in melanocytes co-cultured with keratinocytes. TL, Barroso I, Hofman A, Mohlke KL, Boomsma Wilson A, Cook LS, Phelan CM, Cunningham Experimental Dermatology. 2011;20(8):681-684. DI, Caulfield MJ, Cupples LA, Erdmann J, Fox JM, Vachon CM, Vierkant RA, Iversen ES, Al-Ejeh F, Kumar R, Wiegmans A, Lakhani CS, Gudnason V, Gyllensten U, Harris TB, Berchuck A, Goode EL, Sellers TA, Kelemen LE. SR, Brown MP, Khanna KK. Harnessing the Hayes RB, Jarvelin MR, Mooser V, Munroe PB, Polymorphisms in Stromal Genes and Susceptibility complexity of DNA-damage response pathways to Ouwehand WH, Penninx BW, Pramstaller PP, to Serous Epithelial Ovarian Cancer: A Report from improve cancer treatment outcomes. Oncogene. Quertermous T, Rudan I, Samani NJ, Spector the Ovarian Cancer Association Consortium. PLoS 2010;29(46):6085-6098. TD, Volzke H, Watkins H, Wilson JF, Groop LC, ONE. 2011;6(5). Haritunians T, Hu FB, Kaplan RC, Metspalu A, Al-Ejeh F, Smart CE, Morrison BJ, Chenevix- North KE, Schlessinger D, Wareham NJ, Hunter Amante FH, Engwerda CR, Good MF. Trench G, Lopez JA, Lakhani SR, Brown MP, DJ, O’Connell JR, Strachan DP, Schadt HE, Experimental asexual blood stage malaria Khanna KK. Breast cancer stem cells: treatment Thorsteinsdottir U, Peltonen L, Uitterlinden AG, immunity. Current Protocols in Immunology. resistance and therapeutic opportunities. Visscher PM, Chatterjee N, Loos RJF, Boehnke 2011;Chapter19(Unit19.4). Carcinogenesis. 2011;32(5):650-658. M, McCarthy MI, Ingelsson E, Lindgren CM, Amante FH, Haque A, Stanley AC, Rivera FD, Abecasis GR, Stefansson K, Frayling TM, Alford JR, Hatemi PK, Hibbing JR, Martin NG, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb Hirschhorn JN. Hundreds of variants clustered in Eaves LJ. The Politics of Mate Choice. Journal of BS, de Koning-Ward TF, Lundie RJ, Good genomic loci and biological pathways affect human Politics. 2011;73(2):362–379. MF, Pinzon-Charry A, Pearson MS, Duke MG, height. Nature. 2010;467(7317):832-838. McManus DP, Loukas A, Hill GR, Engwerda Allen HL, Estrada K, Lettre G, Berndt SI, Allen KJ, Bertalli NA, Osborne NJ, Constantine CR. Immune-Mediated Mechanisms of Parasite Weedon MN, Rivadeneira F, Willer CJ, Jackson CC, Delatycki MB, Nisselle AE, Nicoll AJ, Tissue Sequestration during Experimental Cerebral AU, Vedantam S, Raychaudhuri S, Ferreira Gertig DM, McLaren CE, Giles GG, Hopper JL, Malaria. Journal of Immunology. 2010;185(6):3632- T, Wood AR, Weyant RJ, Segre AV, Speliotes Anderson GJ, Olynyk JK, Powell LW, Gurrin 3642. EK, Wheeler E, Soranzo N, Park JH, Yang J, LC. HFE Cys282Tyr Homozygotes With Serum Gudbjartsson D, Heard-Costa NL, Randall JC, Amstadter AB, Balachandar V, Bergen SE, Ferritin Concentrations Below 1000 mu g/L Are Qi L, Smith AV, Magi R, Pastinen T, Liang L, Ceulemans S, Christensen JH, Cole J, Dagdan at Low Risk of Hemochromatosis. Hepatology. Heid IM, Luan J, Thorleifsson G, Winkler TW, E, De Luca V, Ducci F, Tee SF, Hartz S, Keers R, 2010;52(3):925-933. Goddard ME, Lo KS, Palmer C, Workalemahu Medland S, Melas PA, Muhleisen TW, Ozomaro T, Aulchenko YS, Johansson A, Zillikens MC, Amankwah EK, Kelemen LE, Wang Q, Song H, U, Pidsley R, Scott AP, Sha L, Talati A, Teltsh Feitosa MF, Esko T, Johnson T, Ketkar S, Kraft Chenevix-Trench G; Australian Ovarian Cancer O, Videtic A, Wang K, Wong CCY, DeLisi LE. P, Mangino M, Prokopenko I, Absher D, Albrecht Study Group, Beesley J, Webb PM; Australian Selected summaries from the XVII World Congress E, Ernst F, Glazer NL, Hayward C, Hottenga JJ, Cancer Study (Ovarian Cancer), Pearce CL, of Psychiatric Genetics, San Diego, California, Jacobs KB, Knowles JW, Kutalik Z, Monda KL, Wu AH, Pike MC, Stram DO, Chang-Claude USA, 4-8 November 2009 (vol 20, pg 229, 2010). Polasek O, Preuss M, Rayner NW, Robertson J, Wang-Gohrke S, Ness RB, Goode EL, Psychiatric Genetics. 2011;21(1):55-55. NR, Steinthorsdottir V, Tyrer JP, Voight BF, Cunningham JM, Fridley BL, Vierkant RA, Anderson CA, Boucher G, Lees CW, Franke Wiklund F, Xu JF, Zhao JH, Nyholt DR, Pellikka Tworoger SS, Whittemore AS, McGuire V, Sieh A, D’Amato M, Taylor KD, Lee JC, Goyette N, Perola M, Perry JRB, Surakka I, Tammesoo W, Gayther SA, Gentry-Maharaj A, Menon U, P, Imielinski M, Latiano A, Lagace C, Scott ML, Altmaier EL, Amin N, Aspelund T, Bhangale Ramus SJ, Rossing MA, Doherty JA, Goodman R, Amininejad L, Bumpstead S, Baidoo L, T, Boucher G, Chasman DI, Chen C, Coin L, MT, Carney ME, Lurie G, Wilkens LR, Kjær SK, Baldassano RN, Barclay M, Bayless TM, Brand Cooper MN, Dixon AL, Gibson Q, Grundberg Høgdall E, Cramer DW, Terry KL, Garcia-Closas S, Buning C, Colombel JF, Denson LA, De E, Hao K, Junttila MJ, Kaplan LM, Kettunen J, M, Yang H, Lissowska J, Anton-Culver H, Vos M, Dubinsky M, Edwards C, Ellinghaus Konig IR, Kwan T, Lawrence RW, Levinson DF, Ziogas A, Schildkraut JM, Berchuck A, Pharoah D, Fehrmann RSN, Floyd JAB, Florin T, Lorentzon M, McKnight B, Morris AP, Muller M, PD; Ovarian Cancer Association Consortium. Franchimont D, Franke L, Georges M, Glas J, Ngwa JS, Purcell S, Rafelt S, Salem RM, Salvi Prostate cancer susceptibility polymorphism Glazer NL, Guthery SL, Haritunians T, Hayward E, Sanna S, Shi JX, Sovio U, Thompson JR, rs2660753 is not associated with invasive ovarian NK, Hugot JP, Jobin G, Laukens D, Lawrance Turchin MC, Vandenput L, Verlaan DJ, Vitart V, cancer. Cancer Epidemiology Biomarkers & I, Lemann M, Levine A, Libioulle C, Louis E, White CC, Ziegler A, Almgren P, Balmforth AJ, Prevention. 2011;20(5):1028-31. McGovern DP, Milla M, Montgomery GW, Morley Campbell H, Citterio L, De Grandi A, Dominiczak KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi A, Duan J, Elliott P, Elosua R, Eriksson JG, Amankwah EK, Kelemen LE, Wang QG, Song L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips Freimer NB, Geus EJC, Glorioso N, Haiqing S, HL, Chenevix-Trench G, Beesley J, Webb A, Prescott NJ, Proctor DD, Roberts R, Russell Hartikainen AL, Havulinna AS, Hicks AA, Hui PM, Pearce CL, Wu ANH, Pike MC, Stram R, Rutgeerts P, Sanderson J, Sans M, Schumm JN, Igl W, Illig T, Jula A, Kajantie E, Kilpelaeinen DO, Chang-Claude J, Wang-Gohrke S, Ness P, Seibold F, Sharma Y, Simms LA, Seielstad M, TO, Koiranen M, Kolcic I, Koskinen S, Kovacs P, RB, Goode EL, Cunningham JM, Fridley BL, Steinhart AH, Targan SR, van den Berg LH, Vatn Laitinen J, Liu JJ, Lokki ML, Marusic A, Maschio Vierkant RA, Tworoger SS, Whittemore AS, M, Verspaget H, Walters T, Wijmenga C, Wilson A, Meitinger T, Mulas A, Pare G, Parker AN, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen Peden JF, Petersmann A, Pichler I, Pietilainen A, Menon U, Ramus SJ, Rossing MA, Doherty CY, Andersen V, Torkvist L, Gazouli M, Anagnou KH, Pouta A, Riddertrale M, Rotter JI, Sambrook JA, Goodman MT, Carney ME, Lurie G, Wilkens NP, Karlsen TH, Kupcinskas L, Sventoraityte J, JG, Sanders AR, Schmidt CO, Sinisalo J, Smit LR, Kjaer SK, Hogdall E, Cramer DW, Terry KL, Mansfield JC, Kugathasan S, Silverberg MS, JH, Stringham HM, Walters GB, Widen E, Wild Garcia-Closas M, Yang H, Lissowska J, Anton- Halfvarson J, Rotter JI, Mathew CG, Griffiths SH, Willemsen G, Zagato L, Zgaga L, Zitting Culver H, Ziogas A, Schildkraut JM, Berchuck AM, Gearry R, Ahmad T, Brant SR, Chamaillard P, Alavere H, Farrall M, McArdle WL, Nelis M, A, Pharoah PDP. Prostate Cancer Susceptibility M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Peters MJ, Ripatti S, Meurs JBJ, Aben KK, Polymorphism rs2660753 Is Not Associated with Barrett JC, Parkes M, Annese V, Hakonarson Ardlie KG, Beckmann JS, Beilby JP, Bergman Invasive Ovarian Cancer. Cancer Epidemiology H, Radford-Smith G, Duerr RH, Vermeire S, RN, Bergmann S, Collins FS, Cusi D, den Heijer Biomarkers & Prevention. 2011;20(5):1028-1031. Weersma RK, Rioux JD. Meta-analysis identifies M, Eiriksdottir G, Gejman PV, Hall AS, Hamsten Amankwah EK, Wang QG, Schildkraut JM, Tsai 29 additional ulcerative colitis risk loci, increasing A, Huikuri HV, Iribarren C, Kahonen M, Kaprio YY, Ramus SJ, Fridley BL, Beesley J, Johnatty the number of confirmed associations to 47. Nature J, Kathiresan S, Kiemeney L, Kocher T, Launer SE, Webb PM, Chenevix-Trench G, Dale LC, Genetics. 2011;43(3):246-U94. LJ, Lehtimaki T, Melander O, Mosley TH, Musk Lambrechts D, Amant F, Despierre E, Vergote AW, Nieminen MS, O’Donnell CJ, Ohlsson C,
Page 133 Scientific publications | continued
Anthony B, Allen JT, Li YSS, McManus DP. Sunde L, Peterlongo P, Manoukian S, Bonanni In Vivo and Modulates the Anti-Tumor Response. Hepatic stellate cells and parasite-induced liver B, Viel A, Radice P, Caldes T, de la Hoya M, Journal of Immunology. 2010;185(2):998-1004. fibrosis. Parasites & Vectors. 2010;3(1):60. Singer CF, Fink-Retter A, Greene MH, Mai Asojo OA, Loukas A, Inan M, Barent R, Huang PL, Loud JT, Guidugli L, Lindor NM, Hansen Antoniou AC, Beesley J, McGuffog L, JC, Plantz B, Swanson A, Gouthro M, Meagher TVO, Nielsen FC, Blanco I, Lazaro C, Garber Sinilnikova OM, Healey S, Neuhausen SL, Ding MM, Hotez PJ. Crystallization and preliminary J, Ramus SJ, Gayther SA, Phelan C, Narod S, YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs X-ray analysis of Na-ASP-1, a multi-domain Szabo CI, Benitez J, Osorio A, Nevanlinna H, C, Ganz PA, Tomlinson G, Olopade OI, Couch pathogenesis-related-1 protein from the human Heikkinen T, Caligo MA, Beattie MS, Hamann U, FJ, Wang XS, Lindor NM, Pankratz VS, Radice hookworm parasite Necator americanus. Acta Godwin AK, Montagna M, Casella C, Neuhausen P, Manoukian S, Peissel B, Zaffaroni D, Barile Crystallographica Section F-Structural Biology and SL, Karlan BY, Tung N, Toland AE, Weitzel J, M, Viel A, Allavena A, Dall’Olio V, Peterlongo P, Crystallization Communications. 2010;66:1549- Olopade O, Simard J, Soucy P, Rubinstein WS, Szabo CI, Zikan M, Claes K, Poppe B, Foretova 1549. L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Arason A, Rennert G, Martin NG, Montgomery Aung HT, Harrison DK, Findlay I, Mattick JS, Glendon G, Ozcelik H, Andrulis IL, Thomassen GW, Chang-Claude J, Flesch-Janys D, Brauch Martin NG, Carroll BJ. Stringent Programming of M, Gerdes AM, Sunde L, Cruger D, Jensen UB, H, Severi G, Baglietto L, Cox A, Cross SS, DNA Methylation in Humans. Twin Research and Caligo M, Friedman E, Kaufman B, Laitman Y, Miron P, Gerty SM, Tapper W, Yannoukakos Human Genetics. 2010;13(5):405-411. Milgrom R, Dubrovsky M, Cohen S, Borg A, D, Fountzilas G, Fasching PA, Beckmann MW, Jernstrom H, Lindblom A, Rantala J, Stenmark- Silva IDS, Peto J, Lambrechts D, Paridaens Baade PD, Youlden DR, Valery PC, Hassall T, Askmalm M, Melin B, Nathanson K, Domchek R, Rudiger T, Forsti A, Winqvist R, Pylkaas K, Ward L, Green AC, Aitken JF. Population-based S, Jakubowska A, Lubinski J, Huzarski T, Osorio Diasio RB, Lee AM, Eckel-Passow J, Vachon C, survival estimates for childhood cancer in Australia A, Lasa A, Duran M, Tejada MI, Godino J, Blows F, Driver K, Dunning A, Pharoah PPD, offit during the period 1997-2006. British Journal of Benitez J, Hamann U, Kriege M, Hoogerbrugge K, Pankratz VS, Hakonarson H, Chenevix-Trench Cancer. 2010;103(11):1663-1670. G, Easton DF, Couch FJ. A locus on 19p13 N, van der Luijt RB, van Asperen CJ, Devilee Badrick AC, Jones CE. Reorganizing metals: modifies risk of breast cancer in BRCA1 mutation P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, the use of chelating compounds as potential carriers and is associated with hormone receptor- Hogervorst F, Rookus M, Cook M, Oliver C, therapies for metal-related neurodegenerative negative breast cancer in the general population. Frost D, Conroy D, Evans DG, Lalloo F, Pichert disease. Current Topics in Medicinal Chemistry. Nature Genetics. 2010;42(10):885. G, Davidson R, Cole T, Cook J, Paterson J, 2011;11(5):543-52. Hodgson S, Morrison PJ, Porteous ME, Walker Antonsson A, Green AC, Mallitt KA, O’Rourke Balen J, McManus DP, Li YS, Zhao ZY, Yuan LP, L, Kennedy MJ, Dorkins H, Peock S, Godwin PK, Pandeya N, Pawlita M, Waterboer T, Neale Utzinger J, Williams GM, Li Y, Ren MY, Liu ZC, AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer RE. Prevalence and stability of antibodies to 37 Zhou J, Raso G. Comparison of two approaches S, Bonadona V, Lasset C, Dreyfus H, Leroux human papillomavirus types - A population-based for measuring household wealth via an asset-based D, Hardouin A, Berthet P, Faivre L, Loustalot longitudinal study. Virology. 2010;407(1):26-32. index in rural and peri-urban settings of Hunan C, Noguchi T, Sobol H, Rouleau E, Nogues C, Antonsson A, Green AC, Mallitt KA, O’Rourke province, China. Emerging Themes in Epidemiology. Frenay M, Venat-Bouvet L, Hopper JL, Daly PK, Pawlita M, Waterboer T, Neale RE. 2010;7(1):7. MB, Terry MB, John EM, Buys SS, Yassin Y, Prevalence and stability of antibodies to the BK Miron A, Goldgar D, Singer CF, Dressler AC, Barnett AG, Tong S, Clements ACA. What and JC polyomaviruses: a long-term longitudinal Gschwantler-Kaulich D, Pfeiler G, Hansen measure of temperature is the best predictor study of Australians. Journal of General Virology. TVO, Jnson L, Agnarsson BA, Kirchhoff T, offit of mortality?. Environmental Research. 2010;91(Part 7):1849-1853. K, Devlin V, Dutra-Clarke A, Piedmonte M, 2010;110(6):604-611. Antonsson A, Nancarrow DJ, Brown IS, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Barnett AG, Tong SL, Clements ACA. Reply Green AC, Drew PA, Watson DI, Hayward NK, Schwartz PE, Blank SV, Toland AE, Montagna to commentary “Time series analysis on the Whiteman DC. High-Risk Human Papillomavirus M, Casella C, Imyanitov E, Tihomirova L, Blanco health effects of temperature: Two areas for in Esophageal Squamous Cell Carcinoma. I, Lazaro C, Ramus SJ, Sucheston L, Karlan future research” by Gasparrini and Armstrong. Cancer Epidemiology Biomarkers & Prevention. BY, Gross J, Schmutzler R, Wappenschmidt Environmental Research. 2010;110(6):639-639. B, Engel C, Meindl A, Lochmann M, Arnold N, 2010;19(8):2080-2087. Bates TC, Lind PA, Luciano M, Montgomery Heidemann S, Varon-Mateeva R, Niederacher Antonsson A, Nancarrow DJ, Brown IS, GW, Martin NG, Wright MJ. Dyslexia and D, Sutter C, Deissler H, Gadzicki D, Preisler- Green AC, Drew PA, Watson DI, Hayward NK, DYX1C1: deficits in reading and spelling associated Adams S, Kast K, Schonbuchner I, Caldes T, de Whiteman DC. High-Risk Human Papillomavirus in with a missense mutation. Molecular Psychiatry. la Hoya M, Aittomaki K, Nevanlinna H, Simard Esophageal Squamous Cell Carcinoma-Response. 2010;15(12):1190-1196. J, Spurdle AB, Holland H, Chen XQ, Platte R, Cancer Epidemiology Biomarkers & Prevention. Chenevix-Trench G, Easton DF. Common Breast 2011;20(2):409-410. Bates TC, Luciano M, Medland SE, Montgomery Cancer Susceptibility Alleles and the Risk of Breast GW, Wright MJ, Martin NG. Genetic Variance Anttila V, Stefansson H, Kallela M, Todt Cancer for BRCA1 and BRCA2 Mutation Carriers: in a Component of the Language Acquisition U, Terwindt GM, Calafato MS, Nyholt DR, Implications for Risk Prediction. Cancer Research. Device: ROBO1 Polymorphisms Associated with Dimas AS, Freilinger T, Muller-Myhsok B, 2010;70(23):9742-9754. Phonological Buffer Deficits. Behavior Genetics. Artto V, Inouye M, Alakurtti K, Kaunisto MA, 2011;41(1):50-57. Antoniou AC, Wang XS, Fredericksen ZS, Hamalainen E, de Vries B, Stam AH, Weller McGuffog L, Tarrell R, Sinilnikova OM, Healey S, CM, Heinze A, Heinze-Kuhn K, Goebel I, Borck Bates TC, Luciano M, Montgomery GW, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini G, Gobel H, Steinberg S, Wolf C, Bjornsson Wright MJ, Martin NG. Genes for a component M, Barrowdale D, Peock S, Cook M, Oliver C, A, Gudmundsson G, Kirchmann M, Hauge A, of the language acquisition mechanism: ROBO1 Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Werge T, Schoenen J, Eriksson JG, Hagen K, polymorphisms associated with phonological buffer Chu C, Douglas F, Paterson J, Stoppa-Lyonnet Stovner L, Wichmann E, Meitinger T, Alexander deficits. Behavior Genetics. 2010;40(6):785-786. D, Houdayer C, Mazoyer S, Giraud S, Lasset C, M, Moebus S, Schreiber S, Aulchenko YS, Batra J, Nagle CM, O’Mara T, Higgins M, Dong Remenieras A, Caron O, Hardouin A, Berthet P, Breteler MMB, Uitterlinden AG, Hofman A, van Y, Tan OL, Lose F, Skeie LM, Srinivasan S, Hogervorst FBL, Rookus MA, Jager A, van den Duijn CM, Tikka-Kleemola P, Vepsalainen, Lucae Bolton KL, Song H, Ramus SJ, Gayther SA, Ouweland A, Hoogerbrugge N, van der Luijt S, Tozzi F, Muglia P, Barrett J, Kaprio J, Farkkila Pharoah PDP, Kedda MA, Spurdle AB, Clements RB, Meijers-Heijboer H, Garcia EBG, Devilee M, Peltonen L, Stefansson K, Zwart JA, Ferrari JA. A Kallikrein 15 (KLK15) single nucleotide P, Vreeswijk MPG, Lubinski J, Jakubowska A, MD, Olesen J, Daly M, Wessman M, van den polymorphism located close to a novel exon shows Gronwald J, Huzarski T, Byrski T, Gorski B, Maagdenberg AMJM, Dichgans M, Kubisch C, evidence of association with poor ovarian cancer Cybulski C, Spurdle AB, Holland H, Goldgar DE, Dermitzakis ET, Frants RR, Palotie A. Genome- survival. BMC Cancer. 2011;11(Art. 119). John EM, Hopper JL, Southey M, Buys SS, Daly wide association study of migraine implicates a MB, Terry MB, Schmutzler RK, Wappenschmidt common susceptibility variant on 8q22.1. Nature Beadle G, Mengersen K, Moynihan S, Yates P. B, Engel C, Meindl A, Preisler-Adams S, Arnold Genetics. 2010;42(10):869. Perceptions of the ethical conduct of cancer trials N, Niederacher D, Sutter C, Domchek SM, by oncology nurses. European Journal of Cancer Ao A, Morrison BJ, Wang H, López JA, Reynolds Nathanson KL, Rebbeck T, Blum JL, Piedmonte Care. 2011;1365-2354. BA, Lu J. Response of estrogen receptor-positive M, Rodriguez GC, Wakeley K, Boggess JF, Basil breast cancer tumorspheres to antiestrogen Beam CR, Horn EE, Hunt SK, Emery RE, J, Blank SV, Friedman E, Kaufman B, Laitman treatments. PLoS ONE. 2011;6(4):e18810. Turkheimer E, Martin N. Revisiting the effect Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik of marital support on depressive symptoms in H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler Apte SH, Groves P, Olver S, Baz A, Doolan DL, mothers and fathers: A genetically informed study. D, Guiducci C, Loman N, Harbst K, Rantala Kelso A, Kienzle N. IFN-gamma Inhibits IL-4- Journal of Family Psychology. 2011;23(3):336–344. J, Ehrencrona H, Gerdes AM, Thomassen M, Induced Type 2 Cytokine Expression by CD8 T Cells
Page 134 QIMR Annual Report 2010–2011 Beaumont KA, Wong SS, Ainger SA, Liu YY, Campbell I, Gore ME, Lissowska J, Yang HP, susceptibility testing of cystic fibrosis and non- Patel MP, Millhauser GL, Smith JJ, Alewood Medrek K, Gronwald J, Lubinski J, Jakubowska cystic fibrosis clinical isolates of Pseudomonas PF, Leonard JH, Sturm RA. Melanocortin A, Le ND, Cook LS, Kelemen LE, Brook-Wilson aeruginosa: a comparison of three methods. British MC(1) receptor in human genetics and model A, Massuger LF, Kiemeney LA, Aben KK, van Journal of Biomedical Science. 2011;68(1):1-4. systems. European Journal of Pharmacology. Altena AM, Houlston R, Tomlinson I, Palmieri 2011;660(1):103-110. RT, Moorman PG, Schildkraut J, Iversen ES, Branstrom R, Kasparian NA, Chang YM, Affleck Phelan C, Vierkant RA, Cunningham JM, P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel Bedi S, Nelson EC, Lynskey MT, Mc Cutcheon Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker O, Battistuzzi L, Bergman W, Bruno W, Chan M, Risk for VV, Heath AC, Madden PA, Martin NG. J, Hogdall E, Hogdall C, Gross J, Karlan BY, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Suicidal Thoughts and Behavior after Childhood Ness RB, Edwards RP, Odunsi K, Moyisch KB, Figl A, Gonzalez M, Hayward NK, Hocevar M, Sexual Abuse in Women and Men. Suicide & Baker JA, Modugno F, Heikkinenen T, Butzow Kanetsky PA, Leachman SA, Heisele O, Palmer Life-Threatening Behavior. 2011. [Published online R, Nevanlinna H, Leminen A, Bogdanova N, J, Peric B, Puig S, Schadendorf D, Gruis NA, ahead of print]. Antonenkova N, Doerk T, Hillemanns P, Dürst Newton-Bishop J, Brandberg Y. Predictors of Sun Protection Behaviors and Severe Sunburn in Beesley J, Johnatty SE, Chen XQ, Spurdle AB, M, Runnebaum I, Thompson PJ, Carney ME, an International Online Study. Cancer Epidemiology Peterlongo P, Barile M, Pensotti V, Manoukian Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Biomarkers & Prevention. 2010;19(9):2199-2210. S, Radice P, Chenevix-Trench G. No evidence Chang-Claude J, Rossing MA, Cushing-Haugen for an association between the earwax-associated KL, Doherty J, Chen C, Rafnar T, Besenbacher Brant AM, Boomsma DI, Corley RP, DeFries JC, polymorphism in ABCC11 and breast cancer risk S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Haworth CMA, Hewitt JK, Martin NG, McGue M, in Caucasian women. Breast Cancer Research and Hernandez D, Cramer DW, Vergote I, Amant Petrill SA, Plomin R, Wadsworth SJ, Wright MJ. Treatment. 2011;126(1):235-239. F, Lambrechts D, Despierre E, Fasching PA, Ability and heritability: investigating the continuous Beckmann MW, Thiel FC, Ekici AB, Chen effect of IQ score on IQ etiology in multiple samples. Beesley VL, Clavarino AM, Webb PM, Wyld DK, X; Australian Ovarian Cancer Study Group; Behavior Genetics. 2010;40(6):788-788. Francesconi AB, Horwood KR, Doecke JD, Loos Australian Cancer Study (Ovarian Cancer); CA, Green AC. Ranked importance of outcomes Ovarian Cancer Association Consortium, Braskie MN, Jahanshad N, Stein JL, Barysheva of first-line versus repeated chemotherapy among Johnatty SE, Webb PM, Beesley J, Chanock S, M, McMahon KL, de Zubicaray GI, Martin ovarian cancer patients. Supportive Care in Cancer. Garcia-Closas M, Sellers T, Easton DF, Berchuck NG, Wright MJ, Ringman JM, Toga AW, 2010;18(8):943-949. A, Chenevix-Trench G, Pharoah PD, Gayther SA. Thompson PM. Common Alzheimer’s disease Common variants at 19p13 are associated with risk variant within the CLU gene affects white Beesley VL, Price MA, Butow PN, Green AC, susceptibility to ovarian cancer. Nature Genetics. matter microstructure in young adults. Journal of Olsen CM, Webb PM; Australian Ovarian Cancer 2010;42(10):880-884. Neuroscience. 2011;31(18):6764-6770 Study Group; Australian Ovarian Cancer Study Quality of Life Study Investigators. Physical Bond CE, Umapathy A, Buttenshaw RL, Leggett Breakspear M, Heitmann S, Daffertshofer activity in women with ovarian cancer and its BA, Whitehall VLJ. BRAF, MSI and CIN-molecular A. Generative models of cortical oscillations: association with decreased distress and improved determinants of outcome of the serrated pathway neurobiological implications of the Kuramoto model. quality of life. Psychooncology. 2010. [Published of colorectal cancer. Journal of Gastroenterology Frontiers in Human Neuroscience. 2010;4:190. online ahead of print]. and Hepatology. 2010;25:A12. Breakspear M, Jirsa V, Deco G. Computational Beesley VL, Price MA, Webb PM, Australian Bond CE, Umapathy A, Ramsnes I, Greco models of the brain: From structure to function. Ovarian Cancer Study Group, Australian SA, Zhao ZZ, Mallitt KA, Buttenshaw RL, Neuroimage. 2010;52(3):727-730. Ovarian Cancer Study Quality of Life Study Montgomery GW, Leggett BA, Whitehall VL. P53 Brennan PA, Hammen C, Sylvers P, Bor W, Investigators. Loss of lifestyle: health behaviour mutation is common in microsatellite stable, BRAF Najman J, Lind P, Montgomery G, Smith AK. and weight changes after becoming a caregiver of mutant colorectal cancers. International Journal of Interactions between the COMT Val108/158Met a family member diagnosed with ovarian cancer. Cancer. 2011. [Published online ahead of print]. Supportive Care In Cancer. 2010. [Published online polymorphism and maternal prenatal smoking ahead of print]. Botelho NK, Schneiders FI, Lord SJ, Freeman predict aggressive behavior outcomes. Biological AK, Tyagi S, Nancarrow DJ, Hayward NK, Psychology. 2011;87(1):99-105. Benyamin B, Montgomery GW, Martin NG, Whiteman DC, Lord RVN. Gene expression Buchanan DD, Sweet K, Drini M, Jenkins MA, Whitfield JB. Transferrin saturation and mortality. alterations in formalin-fixed, paraffin-embedded Win AK, English DR, Walsh MD, Clendenning M, Clin Chem. 2011;57(6):921-3. Barrett’s esophagus and esophageal McKeone DM, Walters RJ, Roberts A, Pearson adenocarcinoma tissues. Cancer Biology & Berchuck A, Pharoah P, Ramus S, Gayther SA, Pavluk E, Hopper JL, Gattas MR, Goldblatt Therapy. 2010;10(2):172-179. S, Palmieri R, Pearce C, Couch F, Antonio A, J, George J, Suthers GK, Phillips KD, Woodall S, Goode E, Schildkraut J, Chenevix-Trench G, Bouzigon E, Forabosco P, Koppelman GH, Arnold J, Tucker K, Muir A, Field M, Greening S, Sellers T, Risch H. Association of KRAS SNP Cookson WOCM, Dizier M-H, Duffy DL, Evans Gallinger S, Perrier R, Baron JA, Potter JD, Haile rs61764370 with risk of invasive epithelial ovarian DM, Ferreira MAR, Kere J, Laitinen T, Malerba R, Frankel W, de la Chapelle A, Macrae F, Rosty cancer: Implications for clinical testing. Gynecologic G, Meyers DA, Moffatt M, Martin NG, Ng MY, C, Walker NI, Parry S, Young JP. Risk Factors for Oncology. 2011;121(2):S2-S3. Pignatti PF, Wjst M, Kauffmann F, Demenais Colorectal Cancer in Patients with Multiple Serrated F, Lewis CM. Meta-analysis of 20 genome-wide Polyps: A Cross-Sectional Case Series from Bergen SE, Balhara YPS, Christoforou A, linkage studies evidenced new regions linked to Genetics Clinics. PLoS ONE. 2010;5(7). Cole J, Degenhardt F, Dempster E, Fatjo-Vilas asthma and atopy. European Journal of Human M, Khedr Y, Lopez LM, Lysenko L, McGrath Burdon KP, Macgregor S, Hewitt AW, Sharma Genetics. 2010;18(6):700-706. LM, Muhleisen TW, Neves FS, Nymberg C, S, Chidlow G, Mills RA, Danoy P, Casson R, Ozomaro U, Verweij KJH, Voineskos AN, Zai CC, Boyle GM, Woods SL, Bonazzi VF, Stark MS, Viswanathan AC, Liu JZ, Landers J, Henders O’Shea A, DeLisi LE. Summaries from the XVIII Hacker E, Aoude LG, Dutton-Regester K, Cook AK, Wood J, Souzeau E, Crawford A, Leo P, World Congress of Psychiatric Genetics, Athens, AL, Sturm RA, Hayward NK. Melanoma cell Wang JJ, Rochtchina E, Nyholt DR, Martin NG, Greece, 3-7 October 2010. Psychiatric Genetics. invasiveness is regulated by miR-211 suppression Montgomery GW, Mitchell P, Brown MA, Mackey 2011;21(3):136-172. of the BRN2 transcription factor. Pigment Cell & DA, Craig JE. Genome-wide association study Melanoma Research. 2011;24(3):525-537. identifies susceptibility loci for open angle glaucoma Berk M, Johansson S, Wray NR, Williams L, at TMCO1 and CDKN2B-AS1. Nature Genetics. Olsson C, Haavik J, Bjerkeset O. Glutamate Boyle GM. Therapy for metastatic melanoma: an 2011;43(6):574-U110. cysteine ligase (GCL) and self reported depression: overview and update. Expert Reviews of Anticancer An association study from the HUNT. Journal of Therapy. 2011;11(5):725-37. Burke ML, Mcmanus DP, Ramm GA, Duke M, Affective Disorders. 2011;131(1-3):207-213. Li Y, Jones MK, Gobert GN. Temporal expression Bradbury RS, Reid DW, Inglis TJ, Champion AC. of chemokines dictates the hepatic inflammatory Blokland G, McMahon K, Thompson P, Martin Decreased virulence of cystic fibrosis Pseudomonas infiltrate in a murine model of schistosomiasis. N, de Zubicaray G, Wright MJ. Heritability of FMRI aeruginosa in Dictyostelium discoideum. Journal of Gastroenterology and Hepatology. response in young adult twins. Behavior Genetics. Microbiology Immunology. 2011;55(4):224-30. 2010;25:A11-A11. 2010;40(6):787-787. Bradbury RS, Roddam LF, Merritt A, Reid DW, Burrows SR, Moss DJ, Khanna R. Understanding Bolton KL, Tyrer J, Song H, Ramus SJ, Champion AC. Virulence gene distribution in human T-cell-mediated immunoregulation through Notaridou M, Jones C, Sher T, Gentry-Maharaj clinical, nosocomial and environmental isolates herpesviruses. Immunology and Cell Biology. A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van of Pseudomonas aeruginosa. Journal of Medical 2011;89(3):352-358. Den Berg DJ, Stram DO, Pearce CL, Wu AH, Microbiology. 2010;59(pt8):881-90. Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Bradbury RS, Tristram SG, Roddam LF, Reid Flanagan J, Sieh W, McGuire V, Whittemore AS, DW, Inglis TJ, Champion AC. Antimicrobial
Page 135 Scientific publications | continued
Butterworth AS, Robertson AJ, Ho MF, Gatton Clements ACA, Kur LW, Gatpan G, Ngondi JM, Da Silva L, Simpson PT, Smart CE, Cocciardi ML, McCarthy JS, Trenholme KR. An improved Emerson PM, Lado M, Sabasio A, Kolaczinski S, Waddell N, Lane A, Morrison BJ, Vargas method for undertaking limiting dilution assays for JH. Targeting Trachoma Control through Risk AC, Healey S, Beesley J, Pakkiri P, Parry S, in vitro cloning of Plasmodium falciparum parasites. Mapping: The Example of Southern Sudan. PLoS Kurniawan N, Reid L, Keith P, Faria P, Pereira Malaria Journal. 2011;10. Neglected Tropical Diseases. 2010;4(8). E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Catts V, Catts S, Jablensky A, Chandler D, Clendenning M, Buchanan DD, Walsh MD, Khanna KK, Cummings M, Chenevix-Trench G, Weickert CS, Lavin M. Genomic stability and Nagler B, Rosty C, Thompson B, Spurdle AB, Lakhani SR. HER3 and downstream pathways DNA repair in lymphoblasts from patients with Hopper JL, Jenkins MA, Young JP. Mutation deep are involved in colonization of brain metastases schizophrenia. Australian and New Zealand Journal within an intron of MSH2 causes Lynch syndrome. from breast cancer. Breast Cancer Research. of Psychiatry. 2010;44:A33-A33. Familial Cancer. 2011;10(2):297-301. 2010;12(4):R46. Chang AB, Bell SC, Byrnes CA, Grimwood Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton Darshan D, Frazer DM, Anderson GJ. Molecular K, Holmes PW, King PT, Kolbe J, Landau ML. Artemisinin-induced parasite dormancy: a basis of iron-loading disorders. Expert Reviews in LI, Maguire GP, McDonald MI, Reid DW, plausible mechanism for treatment failure. Malaria Molecular Medicine. 2010. [Published online ahead Thien FC, Torzillo PJ. Chronic suppurative Journal. 2011;10:56. of print]. lung disease and bronchiectasis in children and Epigenetic adults in Australia and New Zealand. Med J Aust. Combes AN, Whitelaw E. Darshan D, Frazer DM, Wilkins SJ, Anderson reprogramming: Enforcer or enabler of 2010;193(6):356-65. GJ. Severe iron deficiency blunts the response developmental fate?. Development Growth & of the iron regulatory gene Hamp and pro- Chen NH, Chavchich M, Peters JM, Kyle Differentiation. 2010;52(6):483-491. inflammatory cytokines to lipopolysaccharide. DE, Gatton ML, Cheng Q. Deamplification of Haematologica-The Hematology Journal. pfmdr1-Containing Amplicon on Chromosome 5 in Conrad M, Zubacova Z, Dunn LA, Upcroft J, 2010;95(10):1660-1667. Plasmodium falciparum Is Associated with Reduced Sullivan SA, Tachezy J, Carlton JM. Microsatellite polymorphism in the sexually transmitted human Resistance to Artelinic Acid In Vitro. Antimicrobial Darshan D, Wilkins SJ, Frazer DM, Anderson pathogen Trichomonas vaginalis indicates a Agents and Chemotherapy. 2010;54(8):3395-3401. GJ. Reduced expression of ferroportin-1 mediates genetically diverse parasite. Molecular and hyporesponsiveness of suckling rats to stimuli Chiang MC, Barysheva M, Toga AW, Medland Biochemical Parasitology. 2011;175(1):30-38. that reduce iron absorption. Gastroenterology. SE, Hansel NK, James MR, McMahon KL, de 2011;141(1):300-9. Zubicaray GI, Martin NG, Wright MJ, Thompson Conway CC, Hammen C, Brennan PA, Lind Interaction of Chronic Stress PM. BDNF gene effects on brain circuitry replicated PA, Najman JM. Dasari V, Smith C, Zhong J, Scott G, Rawlinson with Serotonin Transporter and Catechol-O- in 455 twins. Neuroimage. 2011;55(2):448-454. W, Khanna R. Recombinant glycoprotein B Methyltransferase Polymorphisms In Predicting vaccine formulation with Toll-like receptor 9 Chiang MC, McMahon KL, de Zubicaray Youth Depression. Depression and Anxiety. agonist and immune-stimulating complex induces GI, Martin NG, Hickie I, Toga AW, Wright 2010;27(8):737-745. specific immunity against multiple strains of MJ, Thompson PM. Genetics of white matter cytomegalovirus. Journal of General Virology. development: A DTI study of 705 twins and Cook MB, Kamangar F, Whiteman DC, 2011;92:1021-1031. their siblings aged 12 to 29. Neuroimage. Freedman ND, Gammon MD, Bernstein L, 2011;54(3):2308-2317. Brown LM, Risch HA, Ye W, Sharp L, Pandeya Daveson AJ, Jones DM, Gaze S, McSorley N, Webb PM, Wu AH, Ward MH, Giffen C, H, Clouston A, Pascoe A, Cooke S, Speare Chuan J, Feng Z, Brindley PJ, McManus DP, Casson AG, Abnet CC, Murray LJ, Corley DA, R, Macdonald GA, Anderson R, McCarthy Han Z, Jianxin P, Hu W. Our Wormy World: Cigarette Nyren O, Vaughan TL, Chow WH. JS, Loukas A, Croese J. Effect of Hookworm Genomics, Proteomics and Transcriptomics in East Smoking and Adenocarcinomas of the Esophagus Infection on Wheat Challenge in Celiac Disease - A and Southeast Asia. Advances in Parasitology. and Esophagogastric Junction: A Pooled Analysis Randomised Double-Blinded Placebo Controlled 2010;73:327-371. From the International BEACON Consortium. Trial. PLoS ONE. 2011;6(3). Journal of the National Cancer Institute. Cichon S, Muehleisen TW, Degenhardt FA, 2010;102(17):1344-1353. Davidson MR, Larsen JE, Yang IA, Hayward NK, Mattheisen M, Miro X, Strohmaier J, Steffens Clarke BE, Duhig EE, Passmore LH, Bowman M, Meesters C, Herms S, Weingarten M, Craig AL, Holcakova J, Finlan LE, Nekulova RV, Fong KM. MicroRNA-218 Is Deleted and Priebe L, Haenisch B, Alexander M, Vollmer M, Hrstka R, Gueven N, DiRenzo J, Smith G, Downregulated in Lung Squamous Cell Carcinoma. J, Breuer R, Schmal C, Tessmann P, Moebus Hupp TR, Vojtesek B. Delta Np63 transcriptionally PLoS ONE. 2010;5(9). S, Wichmann HE, Schreiber S, Muller-Myhsok regulates ATM to control p53 Serine-15 B, Lucae S, Jamain S, Leboyer M, Bellivier F, phosphorylation. Molecular Cancer. 2010;9. Davidson SI, Liu Y, Danoy PA, Wu X, Thomas Etain B, Henry C, Kahn JP, Heath S, Hamshere GP, Jiang L, Sun LY, Wang NS, Han J, Han HX, M, O’Donovan MC, Owen MJ, Craddock N, Cronin-Fenton DP, Murray LJ, Whiteman DC, Visscher PM, Brown MA, Xu HJ. Association of Schwarz M, Vedder H, Kammerer-Ciernioch J, Cardwell C, Webb PM, Jordan SJ, Corley DA, STAT3 and TNFRSF1A with ankylosing spondylitis Reif A, Sasse J, Bauer M, Hautzinger M, Wright Sharp L, Lagergren J. Reproductive and sex in Han Chinese. Annals of the Rheumatic Diseases. A, Mitchell PB, Schofield PR, Montgomery hormonal factors and oesophageal and gastric 2011;70(2):289-292. GW, Medland SE, Gordon SD, Martin NG, junction adenocarcinoma: A pooled analysis. Gustafsson O, andreassen O, Djurovic S, European Journal of Cancer. 2010;46(11):2067- Daxinger L, Whitelaw E. Transgenerational Sigurdsson E, Steinberg S, Stefansson H, 2076. epigenetic inheritance: More questions Stefansson K, Kapur-Pojskic L, Oruc L, Rivas than answers. Genome Research. Cronin-Fenton DP, Murray LJ, Whiteman DC, 2010;20(12):1623-1628. F, Mayoral F, Chuchalin A, Babadjanova G, Cardwell C, Webb PM, Jordan SJ, Corley DA, Tiganov AS, Pantelejeva G, Abramova LI, Sharp L, Lagergren J. Reproductive and sex de Carcer DA, Cuiv PO, Wang TT, Kang SH, Grigoroiu-Serbanescu M, Diaconu CC, Czerski hormonal factors and oesophageal and gastric Worthley D, Whitehall V, Gordon I, McSweeney PM, Hauser J, Zimmer A, Lathrop M, Schulze junction adenocarcinoma: A pooled analysis. C, Leggett B, Morrison M. Numerical ecology TG, Wienker TF, Schumacher J, Maier W, European Journal of Cancer. 2010;46(11):2067- validates a biogeographical distribution and gender- Propping P, Rietschel M, Nothen MM. Genome- 2076. based effect on mucosa-associated bacteria along wide Association Study Identifies Genetic Variation the human colon. Isme Journal. 2011;5(5):801-809. in Neurocan as a Susceptibility Factor for Bipolar Cuiv PO, de Carcer DA, Jones M, Klaassens Disorder. American Journal of Human Genetics. ES, Worthley DL, Whitehall VLJ, Kang S, Deleyrolle LP, Ericksson G, Morrison BJ, Lopez 2011;88(3):396-396. McSweeney CS, Leggett BA, Morrison M. JA, Burrage K, Burrage P, Vescovi A, Rietze The Effects from DNA Extraction Methods on RL, Reynolds BA. Determination of somatic Claus SP, Ellero SL, Berger B, Krause L, Bruttin the Evaluation of Microbial Diversity Associated and cancer stem cell self-renewing symmetric A, Molina J, Paris A, Want EJ, de Waziers I, with Human Colonic Tissue. Microbial Ecology. division rate using sphere assays. PLoS ONE. Cloarec O, Richards SE, Wang Y, Dumas ME, 2011;61(2):353-362. 2011;6(1):e15844. Ross A, Rezzi S, Kochhar S, Van Bladeren P, Lindon JC, Holmes E, Nicholson JK. da Hora VP, Conceicao FR, Dellagostin OA, Colonization-induced host-gut microbial metabolic Doolan DL. Non-toxic derivatives of LT as potent interaction. mBio. 2011;2(2):e00271-10. adjuvants. Vaccine. 2011;29(8):1538-1544.
Page 136 QIMR Annual Report 2010–2011 Demenais F, Mohamdi H, Chaudru V, Goldstein Douradinha B, Augustijn KD, Moore SG, A, Segre AV, Shuldiner AR, Soranzo N, Sovio AM, Bishop JAN, Bishop DT, Kanetsky PA, Ramesar J, Mota MM, Waters AP, Janse CJ, U, Srinivasan SR, Strachan DP, Tammesoo ML, Hayward NK, Gillanders E, Elder DE, Avril Thompson J. Plasmodium Cysteine Repeat Tikkanen E, Toniolo D, Tsui K, Tryggvadottir MF, Azizi E, van Belle P, Bergman W, Bianchi- Modular Proteins 3 and 4 are essential for malaria L, Tyrer J, Uda M, van Dam RM, van Meurs Scarra G, Bressac-de Paillerets B, Calista D, parasite transmission from the mosquito to the JBJ, Vollenweider P, Waeber G, Wareham NJ, Carrera C, Hansson J, Harland M, Hogg D, host. Malaria Journal. 2011;10(71). Waterworth DM, Weedon MN, Wichmann HE, Hoiom V, Holland EA, Ingvar C, Landi MT, Lang Willemsen G, Wilson JF, Wright AF, Young L, Harnessing immune JM, Mackie RM, Mann GJ, Ming ME, Njauw Douradinha B, Doolan DL. Zhai GJ, Zhuang WV, Bierut LJ, Boomsma DI, responses against Plasmodium for rational vaccine CJ, Olsson H, Palmer J, Pastorino L, Puig S, Boyd HA, Crisponi L, Demerath EW, van Duijn design. Trends in Parasitology. 2011;27(6):274-83. Randerson-Moor J, Stark M, Tsao H, Tucker MA, CM, Econs MJ, Harris TB, Hunter DJ, Loos van der Velden P, Yang XR, Gruis N. Association Drini M, Wong NC, Scott HS, Craig JM, RJF, Metspalu A, Montgomery GW, Ridker of MC1R Variants and Host Phenotypes With Dobrovic A, Hewitt CA, Dow C, Young JP, PM, Spector TD, Streeten EA, Stefansson K, Melanoma Risk in CDKN2A Mutation Carriers: A Jenkins MA, Saffery R, Macrae FA. Investigating Thorsteinsdottir U, Uitterlinden AG, Widen E, GenoMEL Study. Journal of the National Cancer the Potential Role of Genetic and Epigenetic Murabito JM, Ong KK, Murray A. Thirty new loci Institute. 2010;102(20):1568-1583. Variation of DNA Methyltransferase Genes in for age at menarche identified by a meta-analysis of genome-wide association studies. Nature Genetics. Demirkan A, Amin N, Isaacs A, Jarvelin MR, Hyperplastic Polyposis Syndrome. PLoS ONE. 2010;42(12):1077-U73. Whitfield JB, Wichmann HE, Kyvik KO, Rudan 2011;6(2). I, Gieger C, Hicks AA, Johansson A, Hottenga Duffy DL, Antill YC, Stewart CJ, Young JR, Emmanuel C, Gava N, Kennedy C, Balleine JJ, Smith JJ, Wild SH, Pedersen NL, Willemsen Spurdle AB. Report of Endometrial Cancer in RL, Sharma R, Wain G, Brand A, Hogg R, G, Mangino M, Hayward C, Uitterlinden AG, Australian BRCA1 and BRCA2 Mutation-Positive Etemadmoghadam D, George J, Birrer MJ, Hofman A, Witteman J, Montgomery GW, Families. Twin Research and Human Genetics. Clarke CL, Chenevix-Trench G, Bowtell DDL, Pietilainen KH, Rantanen T, Kaprio J, Doring 2011;14(2):111-118. Harnett PR, Defazio A. Comparison of Expression A, Pramstaller PP, Gyllensten U, de Geus Profiles in Ovarian Epithelium In Vivo and Ovarian EJC, Penninx BW, Wilson JF, Rivadeneria F, Duffy DL, Iles MM, Glass D, Zhu G, Barrett Cancer Identifies Novel Candidate Genes Involved Magnusson PKE, Boomsma DI, Spector T, JH, Hoiom V, Zhao ZZ, Sturm RA, Soranzo in Disease Pathogenesis. PLoS ONE. 2011;6(3). Campbell H, Hoehne B, Martin NG, Oostra BA, N, Hammond C, Kvaskoff M, Whiteman DC, McCarthy M, Peltonen-Palotie L, Aulchenko Mangino M, Hansson J, Newton-Bishop JA, Engel C, Versmold B, Wappenschmidt B, Simard Y, Visscher PM, Ripatti S, Janssens ACJW, Bataille V, Hayward NK, Martin NG, Bishop DT, J, Easton DF, Peock S, Cook M, Oliver C, Frost van Duijn CM. Genetic architecture of circulating Spector TD, Montgomery GW. IRF4 Variants D, Mayes R, Evans DG, Eeles R, Paterson J, lipid levels. European Journal of Human Genetics. Have Age-Specific Effects on Nevus Count and Brewer C, McGuffog L, Antoniou AC, Stoppa- 2011;19(7):813-819. Predispose to Melanoma. American Journal of Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay Human Genetics. 2010;87(1):42522. M, Michel C, Leroux D, Dreyfus H, Toulas C, Demirkan A, Penninx BWJH, Hek K, Wray NR, Gladieff L, Uhrhammer N, Bignon YJ, Meindl Amin N, Aulchenko YS, van Dyck R, de Geus Dunn LA, Burgess AG, Krauer KG, Eckmann A, Arnold N, Varon-Mateeva R, Niederacher D, EJC, Hofman A, Uitterlinden AG, Hottenga JJ, L, Vanelle P, Crozet MD, Gillin FD, Upcroft P, Preisler-Adams S, Kast K, Deissler H, Sutter C, Nolen WA, Oostra BA, Sullivan PF, Willemsen Upcroft JA. A new-generation 5-nitroimidazole Gadzicki D, Chenevix-Trench G, Spurdle AB, G, Zitman FG, Tiemeier H, Janssens ACJW, can induce highly metronidazole-resistant Giardia Chen XQ, Beesley J, Olsson H, Kristoffersson Boomsma DI, van Duijn CM, Middeldorp CM. lamblia in vitro. International Journal of Antimicrobial U, Ehrencrona H, Liljegren A, van der Luijt RB, Genetic risk profiles for depression and anxiety in Agents. 2010;36(1):37-42. van Os TA, van Leeuwen FE, Domchek SM, adult and elderly cohorts. Molecular Psychiatry. Rebbeck TR, Nathanson KL, Osorio A, Cajal Earl ST, Masci PP, de Jersey J, Lavin MF, Dixon 2011;16(7):773-783. TRY, Konstantopoulou I, Benitez J, Friedman J. Drug development from Australian elapid snake E, Kaufman B, Laitman Y, Mai PL, Greene MH, Demotte N, Wieers G, Van der Smissen P, venoms and the Venomics pipeline of candidates Nevanlinna H, Aittomaki K, Szabo CI, Caldes Moser M, Schmidt C, Thielemans K, Squifflet for haemostasis: Textilinin-1 (Q8008), Haempatch™ T, Couch FJ, Andrulis IL, Godwin AK, Hamann JL, Weynand B, Carrasco J, Lurquin C, Courtoy (Q8009) and CoVase™ (V0801). Toxicon. 2010. U, Schmutzler RK. Association of the Variants PJ, van der Bruggen P. A Galectin-3 Ligand [Published online ahead of print]. CASP8 D302H and CASP10 V410I with Breast Corrects the Impaired Function of Human CD4 Earl STH, Robson J, Trabi M, de Jersey J, Masci and Ovarian Cancer Risk in BRCA1 and BRCA2 and CD8 Tumor-Infiltrating Lymphocytes and PP, Lavin MF. Characterisation of a mannose- Mutation Carriers. Cancer Epidemiology Biomarkers Favors Tumor Rejection in Mice. Cancer Research. binding C-type lectin from Oxyuranus scutellatus & Prevention. 2010;19(11):2859-2868. 2010;70(19):7476-7488. snake venom. Biochimie. 2011;93(3):519-527. Engwerda CR, Good MF. A novel pathway Distel MA, Willemsen G, Ligthart L, Derom CA, Elks CE, Perry JRB, Sulem P, Chasman DI, of haematopoiesis revealed after experimental Martin NG, Neale MC, Trull TJ, Boomsma DI. Franceschini N, He CY, Lunetta KL, Visser malaria infection. Immunology and Cell Biology. Genetic Covariance Structure of The Four Main JA, Byrne EM, Cousminer DL, Gudbjartsson 2010;88(7):692-694. Features of Borderline Personality Disorder. Journal DF, Esko T, Feenstra B, Hottenga JJ, Koller of Personality Disorders. 2010;24(4):427–444. Engwerda CR, Meeusen EN. Parasites and the DL, Kutalik Z, Lin P, Mangino M, Marongiu M, immune system: a perspective from down under. Dodoo D, Hollingdale MR, Anum D, Koram KA, McArdle PF, Smith AV, Stolk L, Van Wingerden Parasite Immunology. 2010;32(8):529-531. Gyan B, Akanmori BD, Ocran J, Adu-Amankwah SH, Zhao JH, Albrecht E, Corre T, Ingelsson S, Geneshan H, Abot E, Legano J, Banania E, Hayward C, Magnusson PKE, Smith EN, Eri RD, Adams RJ, Tran TV, Tong H, Das I, G, Sayo R, Brambilla D, Kumar S, Doolan DL, Ulivi S, Warrington NM, Zgaga L, Alavere H, Roche DK, Oancea I, Png CW, Jeffery PL, Rogers WO, Epstein J, Richie TL, Sedegah M. Amin N, Aspelund T, Bandinelli S, Barroso Radford-Smith GL, Cook MC, Florin TH, Measuring naturally acquired immune responses I, Berenson GS, Bergmann S, Blackburn McGuckin MA. An intestinal epithelial defect to candidate malaria vaccine antigens in Ghanaian H, Boerwinkle E, Buring JE, Busonero F, conferring ER stress results in inflammation adults. Malaria Journal. 2011;10:168. Campbell H, Chanock SJ, Chen W, Cornelis involving both innate and adaptive immunity. MC, Couper D, Coviello AD, d’Adamo P, de Mucosal Immunology. 2011;4(3):354-64. Doecke J, Simms LA, Zhao ZZ, Huang N, Faire U, de Geus EJC, Deloukas P, Doring A, Hanigan K, Croft A, Anzibdc, Hayward NK, Smith GD, Easton DF, Eiriksdottir G, Emilsson Fahy SJ, Sun C, Zhu G, Healey PR, Spector Webb PM, Whiteman DC, Roberts RL, Andrews V, Eriksson J, Ferrucci L, Folsom AR, Foroud TD, Martin NG, Mitchell P, Wong TY, Mackey J, Bampton PA, Mahy G, Barclay ML, Florin T, Garcia M, Gasparini P, Geller F, Gieger C, DA, Hammond CJ, Andrew T. The Relationship TH, Lawrance IC, Gearry RB, Montgomery Gudnason V, Hall P, Hankinson SE, Ferreli L, between Retinal Arteriolar and Venular Calibers GW, Radford-Smith GL. Genetic susceptibility Heath AC, Hernandez DG, Hofman A, Hu FB, Is Genetically Mediated, and Each Is Associated in IBD: overlap between ulcerative colitis and Illig T, Jarvelin MR, Johnson AD, Karasik D, with Risk of Cardiovascular Disease. Investigative Crohn’s disease. Journal of Gastroenterology and Khaw KT, Kiel DP, Kilpelainen TO, Kolcic I, Ophthalmology & Visual Science. 2011;52(2):975- Hepatology. 2010;25:A84. Kraft P, Launer LJ, Laven JSE, Li SX, Liu JJ, 981. Doolan DL. Plasmodium immunomics. International Levy D, Martin NG, McArdle WL, Melbye M, Fan J, Yin JJ, Ning B, Wu X, Hu Y, Ferrari M, Journal For Parasitology. 2011;41(1):43891. Mooser V, Murray JC, Murray SS, Nalls MA, Anderson GJ, Wei J, Zhao Y, Nie G. Direct Navarro P, Nelis M, Ness AR, Northstone K, evidence for catalase and peroxidase activities Douglas NC Douglas NC, Borgovan T, Carroll Oostra BA, Peacock M, Palmer LJ, Palotie A, of ferritin-platinum nanoparticles. Biomaterials. MJ, Siskind V, Wurm EMT, Smithers BM, Green Pare G, Parker AN, Pedersen NL, Peltonen L, 2011;32(6):1611-8. AC, Soyer HP. Dermoscopic naevus patterns Pennell CE, Pharoah P, Polasek O, Plump AS, by age and body site in the high risk and general Pouta A, Porcu E, Rafnar T, Rice JP, Ring SM, Queensland populations. Australasian Journal of Rivadeneira F, Rudan I, Sala C, Salomaa V, Dermatology. 2011;52:40825. Sanna S, Schlessinger D, Schork NJ, Scuteri
Page 137 Scientific publications | continued
Fearnley EJ, Marquart L, Spurdle AB, Weinstein Franić S, Middeldorp CM, Dolan CV, Ligthart L, Garvey G, Cunningham J, Valery PC, Condon P, Webb PM. Polycystic ovary syndrome increases Boomsma DI. Childhood and adolescent anxiety J, Roder D, Bailie R, Martin J, Olver I. Reducing the risk of endometrial cancer in women aged less and depression: beyond heritability. Journal of the burden of cancer for Aboriginal and Torres than 50 years: an Australian case-control study. the American Academy of Child & Adolescent Strait Islander Australians: time for a coordinated, Cancer Causes & Control. 2010;21(12):2303-2308. Psychiatry. 2010;49(8):820-9. collaborative, priority-driven, Indigenous-led research program. Medical Journal of Australia. Ferguson B, Muller HK, Handoko HY, Franke A, McGovern DPB, Barrett JC, Wang 2011;194(10):530-531. Khosrotehrani K, Beermann F, Hacker E, Soyer K, Radford-Smith GL, Ahmad T, Lees CW, HP, Bosenberg M, Walker GJ. Differential roles of Balschun T, Lee J, Roberts R, Anderson CA, Garvey G, Simmonds D, Clements V, O’Rourke the pRb and Arf/p53 pathways in murine naevus Bis JC, Bumpstead S, Ellinghaus D, Festen P, Sullivan K, Gorman D, Curnow V, Wise and melanoma genesis. Pigment Cell & Melanoma EM, Georges M, Green T, Haritunians T, S, Beattie E. Making sense of dementia: Research. 2010;23(6):771-780. Jostins L, Latiano A, Mathew CG, Montgomery understanding amongst Indigenous Australians. GW, Prescott NJ, Raychaudhuri S, Rotter JI, International Journal of Geriatric Psychiatry. Ferreira MA, McRae AF, Medland SE, Nyholt Schumm P, Sharma Y, Simms LA, Taylor KD, 2011;26(6):649-656. DR, Gordon SD, Wright MJ, Henders AK, Whiteman D, Wijmenga C, Baldassano RN, Madden PA, Visscher PM, Wray NR, Heath Barclay M, Bayless TM, Brand S, Buning C, Gatton ML, Cheng Q. Interrupting Malaria AC, Montgomery GW, Duffy DL, Martin NG. Cohen A, Colombel JF, Cottone M, Stronati L, Transmission: Quantifying the Impact of Association between ORMDL3, IL1RL1 and a Denson T, De Vos M, D’Inca R, Dubinsky M, Interventions in Regions of Low to Moderate deletion on chromosome 17q21 with asthma risk Edwards C, Florin T, Franchimont D, Gearry R, Transmission. PLoS ONE. 2010;5(12). in Australia. European Journal of Human Genetics. Glas J, Van Gossum A, Guthery SL, Halfvarson 2011;19(4):458-64. Gaudet MM, Kirchhoff T, Green T, Vijai J, J, Verspaget HW, Hugot JP, Karban A, Laukens Korn JM, Guiducci C, Segre AV, McGee K, Ferriera I, Smyth D, Ruyssers N, Maizels RM, D, Lawrance I, Lemann M, Levine A, Libioulle C, McGuffog L, Kartsonaki C, Morrison J, Healey Loukas A, McSorley HJ. Hookworm Excretory/ Louis E, Mowat C, Newman W, Panes J, Phillips S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer Secretory products induce TH2 responses and A, Proctor DD, Regueiro M, Russell R, Rutgeerts S, Gauthier-Villars M, Sobol H, Longy M, suppress pathology in a mouse model of colitis. P, Sanderson J, Sans M, Seibold F, Steinhart Frenay M, Hogervorst FBL, Rookus MA, Collee Immunology. 2010;131:57-58. AH, Stokkers PCF, Torkvist L, Kullak-Ublick G, JM, Hoogerbrugge N, van Roozendaal KEP, Wilson D, Walters T, Targan SR, Brant SR, Rioux Piedmonte M, Rubinstein W, Nerenstone S, Fletcher O, Johnson N, Silva ID, Orr N, JD, D’Amato M, Weersma RK, Kugathasan S, Van Le L, Blank SV, Caldes T, de la Hoya M, Ashworth A, Nevanlinna H, Heikkinen T, Griffiths AM, Mansfield JC, Vermeire S, Duerr Nevanlinna H, Aittomaki K, Lazaro C, Blanco Aittomaki K, Blomqvist C, Burwinkel B, Bartram RH, Silverberg MS, Satsangi J, Schreiber S, Cho I, Arason A, Johannsson OT, Barkardottir RB, CR, Meindl A, Schmutzler RK, Cox A, Brock JH, Annese V, Hakonarson H, Daly MJ, Parkes Devilee P, Olopade OI, Neuhausen SL, Wang XS, I, Elliott G, Reed MWR, Southey MC, Smith L, M. Genome-wide meta-analysis increases to 71 the Fredericksen ZS, Peterlongo P, Manoukian S, Spurdle AB, Hopper JL, Couch FJ, Olson JE, number of confirmed Crohn’s disease susceptibility Barile M, Viel A, Radice P, Phelan CM, Narod S, Wang XS, Fredericksen Z, Schurmann P, Waltes loci. Nature Genetics. 2010;42(12):1118–1125. Rennert G, Lejbkowicz F, Flugelman A, Andrulis R, Bremer M, Dork T, Devilee P, van Asperen CJ, IL, Glendon G, Ozcelik H, Toland AE, Montagna Tollenaar RAEM, Seynaeve C, Hall P, Czene K, Frazer DM, Darshan D, Anderson GJ. Intestinal M, D’andrea E, Friedman E, Laitman Y, Borg A, Humphreys K, Liu JJ, Ahmed S, Dunning AM, iron absorption during suckling in mammals. Beattie M, Ramus SJ, Domchek SM, Nathanson Maranian M, Pharoah PDP, Chenevix-Trench G, Biometals. 2011;24(3):567-574. KL, Rebbeck T, Spurdle AB, Chen XQ, Holland Beesley J, Bogdanova NV, Antonenkova NN, Frazer DM, Darshan D, Wilkins SJ, Anderson H, John EM, Hopper JL, Buys SS, Daly MB, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch GJ. Intestinal iron absorption in the neonatal rat Southey MC, Terry MB, Tung N, Hansen TVO, H, Ko YD, Hamann U, Fasching PA, Strick R, is refractory to systemic stimuli due to reduced Nielsen FC, Greene MI, Mai PL, Osorio A, Duran Ekici AB, Beckmann MW, Giles GG, Severi G, ferroportin expression. Journal of Gastroenterology M, andres R, Benitez J, Weitzel JN, Garber J, Baglietto L, English DR, Milne RL, Benitez J, and Hepatology. 2010;25:A10. Hamann U, Peock S, Cook M, Oliver C, Frost Arias JI, Pita G, Nordestgaard BG, Bojesen SE, D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa Freedman N, Murray LJ, Kamangar F, Abnet C, L, Walker L, Eason J, Barwell J, Godwin AK, A, Kataja V, Kosma VM, Garcia-Closas M, Cook MB, Nyren O, Ye W, Wu A, Bernstein L, Schmutzler RK, Wappenschmidt B, Engert S, Chanock S, Lissowska J, Brinton LA, Chang- Brown L, Ward M, Pandeya N, Green A, Casson Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Claude J, Wang-Gohrke S, Broeks A, Schmidt A, Giffen C, Risch H, Gammon M, Chow WH, Couch FJ, Chenevix-Trench G, Easton DF, Daly MK, van Leeuwen FE, Van’t Veer LJ, Margolin S, Alcohol Vaughan T, Corley D, Whiteman DC. MJ, Antoniou AC, Altshuler DM, offit K. Common Lindblom A, Humphreys MK, Morrison J, Platte intake and risk of esophageal adenocarcinoma: a Genetic Variants and Modification of Penetrance of R, Easton DF, Peto J. Missense Variants in ATM in pooled analysis from the BEACON Consortium. BRCA2-Associated Breast Cancer. PLoS Genetics. 26,101 Breast Cancer Cases and 29,842 Controls. Gut. 2011;60:1029-1037. 2010;6(10). Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2143-2151. Freyer F, Roberts JA, Becker R, Robinson PA, Gaudet MM, Yang HP, Bosquet JG, Healey CS, Biophysical Mechanisms Ritter P, Breakspear M. Ahmed S, Dunning AM, Easton DF, Spurdle AB, Fogarty GB, Muddle R, Sprung CN, Chen W, of Multistability in Resting-State Cortical Rhythms. Ferguson K, O’Mara T, Lambrechts D, Despierre Duffy D, Sturm RA, McKay MJ. Unexpectedly Journal of Neuroscience. 2011;31(17):6353-6361. E, Vergote I, Amant F, Lacey JV, Lissowska J, Severe Acute Radiotherapy Side Effects are Peplonska B, Brinton LA, Chanock S, Garcia- Associated with Single Nucleotide Polymorphisms Fros JJ, Liu WJ, Prow NA, Geertsema C, Closas M. No Association between FTO or HHEX of the Melanocortin-1 Receptor. International Ligtenberg M, Vanlandingham DL, Schnettler E, and Endometrial Cancer Risk. Cancer Epidemiology Journal of Radiation Oncology Biology Physics. Vlak JM, Suhrbier A, Khromykh AA, Pijlman GP. Biomarkers & Prevention. 2010;19(8):2106-2109. 2010;77(5):1486-1492. Chikungunya Virus Nonstructural Protein 2 Inhibits Type I/II Interferon-Stimulated JAK-STAT Signaling. Gehrman PR, Byrne E, Gillespie N, Martin NG. Foley DL, Morley KI, Madden PAF, Heath AC, Journal of Virology. 2010;84(20):10877-10887. Genetics of insomnia. Sleep Medicine Clinics. Whitfield JB, Martin NG. Major Depression and 2011;6(2):191-202. the Metabolic Syndrome. Twin Research and Gao Z, Wood-Baker R, Harle R, Muller K, “Bong lung” in cystic fibrosis: Human Genetics. 2010;13(4):347-358. Hauser J, Reid DW. Gillespie NA, Kendler KS, Neale MC. a case report. Journal of Medical Case Reports. Psychometric modeling of cannabis initiation Fong AW, Lee GA, O’Rourke P, Thomas R. 2010;4:371. and use and the symptoms of cannabis abuse, Management of neovascular glaucoma with dependence and withdrawal in a sample of male transscleral cyclophotocoagulation with diode Gardiner RA, Teng L, Buck M, Hancock J, Clarke and female twins. Drug Alcohol Depend. 2011. laser alone versus combination transscleral R, Samaratunga H, Schirra HJ, Zenzmaier [Published online ahead of print]. cyclophotocoagulation with diode laser and C, Berger P, Catto J, Yaxley J, Gianduzzo T, Multiple markers in prostate intravitreal bevacizumab. Clinical and Experimental Coughlin G, Lavin MF. Glanfield A, McManus DP, Smyth DJ, Lovas EM, cancer detection from ejaculate. British Journal of Ophthalmology. 2011;39(4):318-323. Loukas A, Gobert GN, Jones MK. A Cytochrome Urology International. 2011;107:28-28. b561 with Ferric Reductase Activity from the Francis SMS, Larsen JE, Pavey SJ, Duhig EE, Parasitic Blood Fluke, Schistosoma japonicum. Clarke BE, Bowman RV, Hayward NK, Fong KM, Gardner J, Anraku I, Le TT, Larcher T, Major L, PLoS Neglected Tropical Diseases. 2010;4(11). Yang IA. Genes and Gene Ontologies Common to Roques P, Schroder WA, Higgs S, Suhrbier A. Airflow Obstruction and Emphysema in the Lungs Chikungunya Virus Arthritis in Adult Wild-Type Mice. of Patients with COPD. PLoS ONE. 2011;6(3). Journal of Virology. 2010;84(16):8021-8032.
Page 138 QIMR Annual Report 2010–2011 Gles P, Javorniczky J, Henderson S, McLennan Gordon CA, Gray DJ, Gobert GN, McManus DP. Green AC, Williams GM. Increased Melanoma A, Roy C, Lock J, Lynga C, Melbourne A, DNA amplification approaches for the diagnosis After Regular Sunscreen Use? Reply. Journal of Gordon L. UVR Emissions from Solaria in of key parasitic helminth infections of humans. Clinical Oncology. 2011;29(18):E559. Australia and Implications for the Regulation Molecular & Cellular Probes. 2011;25(4):143-52. Process. Photochemistry and Photobiology. Green AC, Williams GM. Is Sunscreen Use for 2011;87(1):184-190. Gordon LG, Beesley VL, Scuffham PA. Evidence Melanoma Prevention Valid for All Sun Exposure on the economic value of psychosocial interventions Circumstances? Reply. Journal of Clinical Oncology. Gobert GN. Applications for profiling the to alleviate anxiety and depression among cancer 2011;29(14):E427. schistosome transcriptome. Trends In Parasitology. survivors: A systematic review. Asia-Pacific Journal 2010;26(9):434-439. of Clinical Oncology. 2011;7(2):96-105. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P, Marlton P, Griffiths LR. Gobert GN. Better understanding of anti- Gordon LG, Hirst NG, Young RP, Brown PM. Integrative Genomic Profiling Reveals Conserved schistosomal strategies through microarray Within a smoking-cessation program, what impact Genetic Mechanisms for Tumorigenesis in Common analysis. Infectious Disorders - Drug Targets. does genetic information on lung cancer need to Entities of Non-Hodgkin’s Lymphoma. Genes 2010;10(4):251-7. have to demonstrate cost-effectiveness?. Cost Chromosomes & Cancer. 2011;50(5):313-326. Effective Resource Allocation. 2010. [Published Goel S, Valiyaveettil M, Achur RN, Goyal A, online ahead of print]. Guo Z, Kozlov S, Lavin MF, Person MD, Paull Mattei D, Salanti A, Trenholme KR, Gardiner TT. ATM activation by oxidative stress. Science. DL, Gowda DC. Dual stage synthesis and crucial Gordon LG, Scuffham PA, Beesley VL, Green 2010;330(6003):517-521. role of cytoadherence-linked asexual gene 9 in the AC, DeFazio A, Wyld DK, Clavarino AM, Webb surface expression of malaria parasite var proteins. PM. Medical Costs and Outcomes for Australian Hacker E Hacker E, Boyce Z, Kimlin M, Hayward PNAS. 2010;107(38):16643-16648. Women With Ovarian Cancer A Patient-Level N, Whiteman D. The response of melanocytes Analysis Over 2.5 Years. International Journal of to sunlight. Australasian Journal of Dermatology. González LM, Ramiro R, García L, Parkhouse Gynecological Cancer. 2010;20(5):757-765. 2011;52:19. RM, McManus DP, Gárate T. Genetic variability of the 18 kDa/HP6 protective antigen in Taenia Goumidi L, Flamant F, Lendon C, Galimberti D, Haque A, Best SE, Amante FH, Ammerdorffer A, saginata and Taenia asiatica: implications for Pasquier F, Scarpini E, Hannequin D, Campion de Labastida F, Pereira T, Ramm GA, Engwerda vaccine development. Molecular and Biochemical D, Amouyel P, Lambert JC, Meirhaeghe CR. High Parasite Burdens Cause Liver Damage Parasitology. 2011;176(2):131-134. A. Study of thyroid hormone receptor alpha in Mice following Plasmodium berghei ANKA gene polymorphisms on Alzheimer’s disease. Infection Independently of CD8(+) T Cell-Mediated Good MF, Doolan DL. Malaria Vaccine Design: Neurobiology of Aging. 2011;32(4):624-630. Immune Pathology. Infection and Immunity. Immunological Considerations. Immunity. 2011;79(5):1882-1888. 2010;33(4):555-566. Gras S, Chen ZJ, Miles JJ, Liu YC, Bell MJ, Sullivan LC, Kjer-Nielsen L, Brennan RM, Haque A, Best SE, Amante FH, Mustafah S, Defying malaria: Good MF, Engwerda C. Burrows JM, Neller MA, Khanna R, Purcell AW, Desbarrieres L, de Labastida F, Sparwasser T, Arming T cells to halt malaria. Nature Medicine. Brooks AG, McCluskey J, Rossjohn J, Burrows Hill GR, Engwerda CR. CD4(+) Natural Regulatory 2011;17(1):49-51. SR. Allelic polymorphism in the T cell receptor T Cells Prevent Experimental Cerebral Malaria via CTLA-4 When Expanded In Vivo. PLoS Pathogens. Goode EL Goode EL, White KL, Vierkant RA, and its impact on immune responses. Journal of 2010;6(12). Phelan CM, Cunningham JM, Schildkraut JM, Experimental Medicine. 2010;207(7):1555-1567. Berchuck A, Larson MC, Fridley BL, Olson JE, Gratten J, Wilson AJ, Mcrae AF, Beraldi D, Haque A, Best SE, Ammerdorffer A, Desbarrieres Webb PM, Chen XQ, Beesley J, Chenevix- Visscher PM, Pemberton JM, Slate J. No L, de Oca MM, Amante FH, de Labastida Rivera Trench G, Sellers TA. Xenobiotic-Metabolizing evidence for warming climate theory of coat colour F, Hertzog P, Boyle GM, Hill GR, Engwerda CR. Gene Polymorphisms and Ovarian Cancer Risk. change in Soay sheep: a comment on Maloney et Type I Interferons suppress CD4+ T cell-dependent Molecular Carcinogenesis. 2011;50(5):397-402. al. Biology Letters. 2010;6(5):678-679. parasite control during blood-stage Plasmodium infection. European Journal of Immunology. 2011. Goode EL, Chenevix-Trench G, Song H, Ramus Gray DJ, McManus DP, Li YS, Williams [Published online ahead of print]. SJ, Notaridou M, Lawrenson K, Widschwendter GM, Bergquist R, Ross AG. Schistosomiasis M, Vierkant RA, Larson MC, Kjaer SK, Birrer elimination: lessons from the past guide the future. Haque A, Best SE, Ammerdorffer A, MJ, Berchuck A, Schildkraut J, Tomlinson I, Lancet Infectious Diseases. 2010;10(10):733-736. Desbarrieres L, de Oca MM, Amante FH, de Kiemeney LA, Cook LS, Gronwald J, Garcia- Labastida Rivera F, Hertzog P, Boyle GM, Hill Closas M, Gore ME, Campbell I, Whittemore Gray DJ, McManus DP, Li YS, Williams GM, GR, Engwerda CR. Type I interferons suppress AS, Sutphen R, Phelan C, Anton-Culver H, Bergquist R, Ross AG. Untitled reply. Lancet CD4+ T cell-dependent parasite control during Pearce CL, Lambrechts D, Rossing MA, Chang- Infectious Diseases. 2011;11(5):346-347. blood-stage plasmodium infection. European Claude J, Moysich KB, Goodman MT, Dörk T, Journal of Immunology. 2011. [Published online Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Gray DJ, Ross AG, Li YS, McManus DP. ahead of print]. Hogdall E, Fridley BL, Cunningham JM, Sieh W, Diagnosis and management of schistosomiasis. McGuire V, Godwin AK, Cramer DW, Hernandez British Medical Journal. 2011;342. Haque A, Best SE, Unosson K, Amante FH, de Labastida F, Anstey NM, Karupiah G, Smyth D, Levine D, Lu K, Iversen ES, Palmieri RT, Gray-McGuire C, Guda K, Adrianto I, Lin CP, Houlston R, van Altena AM, Aben KK, Massuger MJ, Heath WR, Engwerda CR. Granzyme B Natale L, Potter JD, Newcomb P, Poole EM, Expression by CD8(+) T Cells Is Required for the LF, Brooks-Wilson A, Kelemen LE, Le ND, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jakubowska A, Lubinski J, Medrek K, Stafford Development of Experimental Cerebral Malaria. Jenkins R, Le Marchand L, Casey G, Haile R, Journal of Immunology. 2011;186(11):6148-6156. A, Easton DF, Tyrer J, Bolton KL, Harrington P, Hopper J, Jenkins M, Young J, Buchanan D, Eccles D, Chen A, Molina AN, Davila BN, Arango Gallinger S, Adams M, Lewis S, Willis J, Elston Haque A, Engwerda CR. An Antioxidant Link H, Tsai YY, Chen Z, Risch HA, McLaughlin R, Markowitz SD, Wiesner GL. Confirmation between Sickle Cell Disease and Severe Malaria. J, Narod SA, Ziogas A, Brewster W, Gentry- of Linkage to and Localization of Familial Colon Cell. 2011;145(3):335-336. Maharaj A, Menon U, Wu AH, Stram DO, Pike Cancer Risk Haplotype on Chromosome 9q22. MC; Wellcome Trust Case-Control Consortium, Cancer Research. 2010;70(13):5409-5418. Harris I, Sharrock WW, Bain LM, Gray KA, Beesley J, Webb PM; Australian Cancer Study Bobogare A, Boaz L, Lilley K, Krause D, Vallely (Ovarian Cancer); Australian Ovarian Cancer Greco SA, Chia J, Inglis KJ, Cozzi SJ, A, Johnson ML, Gatton ML, Shanks GD, Cheng Study Group; Ovarian Cancer Association Ramsnes I, Buttenshaw RL, Spring KJ, Boyle Q. A large proportion of asymptomatic Plasmodium Consortium (OCAC), Chen X, Ekici AB, Thiel GM, Worthley DL, Leggett BA, Whitehall VL. infections with low and sub-microscopic parasite FC, Beckmann MW, Yang H, Wentzensen N, Thrombospondin-4 is a putative tumour-suppressor densities in the low transmission setting of Temotu Lissowska J, Fasching PA, Despierre E, Amant gene in colorectal cancer that exhibits age-related Province, Solomon Islands: challenges for malaria F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, methylation. BMC Cancer. 2010;10. diagnostics in an elimination setting. Malaria Lurie G, Carney ME, Thompson PJ, Runnebaum Journal. 2010;9. Green AC, Hughes MCB, McBride P, Fourtanier I, Hillemanns P, Dürst M, Antonenkova N, A. Factors Associated with Premature Skin Aging Harris JL, Khanna KK. BRCA1 A-Complex Bogdanova N, Leminen A, Butzow R, Heikkinen (Photoaging) before the Age of 55: A Population- fine tunes repair functions of BRCA1. Aging-Us. T, Stefansson K, Sulem P, Besenbacher S, Based Study. Dermatology. 2011;222(1):74-80. 2011;3(5):461-463. Sellers TA, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC). Green AC, Williams GM, Logan V, Strutton GM. Hatemi PK, Hibbing JR, Medland SE, Keller A genome-wide association study identifies Reduced Melanoma After Regular Sunscreen Use: MC, Alford JR, Smith KB, Martin NG, Eaves susceptibility loci for ovarian cancer at 2q31 and Randomized Trial Follow-Up. Journal of Clinical LJ. Not by Twins Alone: Using the Extended Twin 8q24. Nature Genetics. 2010;42(10):874-879. Oncology. 2011;29(3):257-263. Family Designed to Investigate the Genetic Basis of Political Beliefs. American Journal of Political Science. 2010;54(3):798-814.
Page 139 Scientific publications | continued
Haworth CMA, Wright MJ, Luciano M, Martin T, Tuomilehto J, Valle TT, Wareham NJ, Arnold Holter S, Pollett A, Zogopoulos G, Kim H, NG, de Geus EJC, van Beijsterveldt CEM, AM, Beckmann JS, Bergmann S, Boerwinkle Schwenter F, Asai K, Gallinger S, Clendenning Bartels M, Posthuma D, Boomsma DI, Davis E, Boomsma DI, Caulfield MJ, Collins FS, M, Steinbach G, Jacobson A, Boycott KM. OSP, Kovas Y, Corley RP, DeFries JC, Hewitt JK, Eiriksdottir G, Gudnason V, Gyllensten U, Hepatic Adenomas Caused by Somatic HNF1A Olson RK, Rhea SA, Wadsworth SJ, Iacono WG, Hamsten A, Hattersley AT, Hofman A, Hu FB, Mutations in Children With Biallelic Mismatch McGue M, Thompson LA, Hart SA, Petrill SA, Illig T, Iribarren C, Jarvelin MR, Kao WHL, Kaprio Repair Gene Mutations. Gastroenterology. Lubinski D, Plomin R. The heritability of general J, Launer LJ, Munroe PB, Oostra B, Penninx 2011;140(2):735-736. cognitive ability increases linearly from childhood BW, Pramstaller PP, Psaty BM, Quertermous T, Hong YS, Kang SK, Han MJ, Gobert GN, Jones to young adulthood. Molecular Psychiatry. Rissanen A, Rudan I, Shuldiner AR, Soranzo N, MK. High quality RNA isolation from Aedes aegypti 2010;15(11):1112-1120. Spector TD, Syvanen AC, Uda M, Uitterlinden A, midguts using laser microdissection microscopy. Volzke H, Vollenweider P, Wilson JF, Witteman Parasites & Vectors. 2011;4. Heath AC, Whitfield JB, Martin NG, Pergadia JC, Wright AF, Abecasis GR, Boehnke M, ML, Goate AM, Lind PA, McEvoy BP, Schrage Borecki IB, Deloukas P, Frayling TM, Groop Hopkins H, Oyibo W, Luchavez J, Mationg ML, AJ, Grant JD, Chou YL, Zhu R, Henders AK, LC, Haritunians T, Hunter DJ, Kaplan RC, North Asiimwe C, Albertini A, Gonzalez IJ, Gatton ML, Medland SE, Gordon SD, Nelson EC, Agrawal KE, O’Connell JR, Peltonen L, Schlessinger Bell D. Blood transfer devices for malaria rapid A, Nyholt DR, Bucholz KK, Madden PA, D, Strachan DP, Hirschhorn JN, Assimes TL, diagnostic tests: evaluation of accuracy, safety and Montgomery GW.. A Quantitative-Trait Genome- Wichmann HE, Thorsteinsdottir U, van Duijn ease of use. Malaria Journal. 2011;10. Wide Association Study of Alcoholism Risk in the CM, Stefansson K, Cupples LA, Loos RJF, Community: Findings and Implications. Biological Barroso I, McCarthy MI, Fox CS, Mohlke KL, Horn DI, Lord AR, Osoba A, Metzger CD, Psychiatry. 2011. [Published online ahead of print]. Lindgren CM. Meta-analysis identifies 13 new loci Kaufmann J, Schiltz K, Steiner J, Bogerts associated with waist-hip ratio and reveals sexual B, Walter M, Breakspear M. Cingulate Heid IM, Jackson AU, Randall JC, Winkler TW, MR Spectroscopy is Related to Abnormal Qi L, Steinthorsdottir V, Thorleifsson G, Zillikens dimorphism in the genetic basis of fat distribution. Nature Genetics. 2010;42(11):949-U160. Graph Metrics in the Salience Network of MC, Speliotes EK, Magi R, Workalemahu T, Depressive Patients. Biological Psychiatry. White CC, Bouatia-Naji N, Harris TB, Berndt SI, Helander A, Wielders JPM, Jeppsson 2011;69(9):165S-166S. Ingelsson E, Willer CJ, Weedon MN, Luan JA, JO, Weykamp C, Siebelder C, Anton Hou XY, Ellis MK, McManus DP, Wang YY, Li Vedantam S, Esko T, Kilpelainen TO, Kutalik Z, RF, Schellenberg F, Whitfield JB. Toward SD, Williams GM, Li YS. Diagnostic value of non- Li SX, Monda KL, Dixon AL, Holmes CC, Kaplan standardization of carbohydrate-deficient transferrin invasive bio-markers for stage-specific diagnosis LM, Liang LM, Min JL, Moffatt MF, Molony C, (CDT) measurements: II. Performance of a of hepatic fibrosis in patients with advanced Nicholson G, Schadt EE, Zondervan KT, Feitosa laboratory network running the HPLC candidate schistosomiasis japonica. International Journal For MF, Ferreira T, Allen HL, Weyant RJ, Wheeler reference measurement procedure and evaluation Parasitology. 2011;41(3-4):325-332. E, Wood AR, Estrada K, Goddard ME, Lettre of a candidate reference material. Clinical Chemistry G, Mangino M, Nyholt DR, Purcell S, Smith AV, and Laboratory Medicine. 2010;48(11):1585-1592. Hu W, Clements A, Williams G, Tong S. Spatial Visscher PM, Yang JA, McCarroll SA, Nemesh analysis of notified dengue fever infections. J, Voight BF, Absher D, Amin N, Aspelund T, Hill G. Cytokine Use In Transplantation. Epidemiology and Infection. 2011;139(3):391-399. Coin L, Glazer NL, Hayward C, Heard-Costa NL, Experimental Hematology. 2010;38(9):S121-S122. Hottenga JJ, Johansson A, Johnson T, Kaakinen Hu WB, Clements A, Williams G, Tone SL. M, Kapur K, Ketkar S, Knowles JW, Kraft P, Hill GR, Kuns RD, Raffelt NC, Don ALJ, Olver Socioecological Changes and Dengue Fever Kraja AT, Lamina C, Leitzmann MF, McKnight SD, Markey KA, Wilson YA, Tocker J, Alexander Transmission in Queensland, Australia: A B, Morris AP, Ong KK, Perry JRB, Peters MJ, WS, Clouston AD, Roberts AW, MacDonald Spatial Bayesian Approach. Epidemiology. Polasek O, Prokopenko I, Rayner NW, Ripatti S, KPA. SOCS3 regulates graft-versus-host disease. 2011;22(1):S138-S138. Rivadeneira F, Robertson NR, Sanna S, Sovio Blood. 2010;116(2):287-296. Hughes AM, Lucas RM, Ponsonby AL, U, Surakka I, Teumer A, van Wingerden S, Vitart Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt Chapman C, Coulthard A, Dear K, Dwyer T, V, Zhao JH, Cavalcanti-Proenca C, Chines NC, Don AL, Markey KA, Wilson YA, Smyth MJ, Kilpatrick TJ, McMichael AJ, Pender MP, Taylor PS, Fisher E, Kulzer JR, Lecoeur C, Narisu Iwakura Y, Tocker J, Clouston AD, MacDonald BV, Valery P, van der Mei IAF, Williams D. The N, Sandholt C, Scott LJ, Silander K, Stark K, KPA. Stem cell mobilization with G-CSF induces role of latitude, ultraviolet radiation exposure and Tammesoo ML, Teslovich TM, Timpson NJ, type 17 differentiation and promotes scleroderma. vitamin D in childhood asthma and hayfever: an Watanabe RM, Welch R, Chasman DI, Cooper Blood. 2010;116(5):819-828. Australian multicenter study. Pediatric Allergy and MN, Jansson JO, Kettunen J, Lawrence RW, Immunology. 2011;22(3):327-333. Pellikka N, Perola M, Vandenput L, Alavere H, Hinz M, Stilmann M, Arslan SC, Khanna KK, Almgren P, Atwood LD, Bennett AJ, Biffar R, Dittmar G, Scheidereit C. A Cytoplasmic ATM- Hugo LE, Kay BH, O’Neill SL, Ryan PA. Bonnycastle LL, Bornstein SR, Buchanan TA, TRAF6-cIAP1 Module Links Nuclear DNA Damage Investigation of Environmental Influences on Campbell H, Day INM, Dei M, Dorr M, Elliott Signaling to Ubiquitin-Mediated NF-kappa B a Transcriptional Assay for the Prediction of P, Erdos MR, Eriksson JG, Freimer NB, Fu M, Activation. Molecular Cell. 2010;40(1):63-74. Age of Aedes aegypti (Diptera: Culicidae) Gaget S, Geus EJC, Gjesing AP, Grallert H, Mosquitoes. Journal of Medical Entomology. Hirst NG, Gordon LG, Whiteman DC, Watson Grassler J, Groves CJ, Guiducci C, Hartikainen 2010;47(6):1044-1052. DI, Barendregt JJ. Is endoscopic surveillance AL, Hassanali N, Havulinna AS, Herzig KH, Hicks for non-dysplastic Barrett’s esophagus cost- Hutley LJ, Newell FS, Kim YH, Luo X, Widberg AA, Hui JN, Igl W, Jousilahti P, Jula A, Kajantie effective? Review of economic evaluations. CH, Shurety W, Prins JB, Whitehead JP. A E, Kinnunen L, Kolcic I, Koskinen S, Kovacs Journal of Gastroenterology and Hepatology. putative role for endogenous FGF-2 in FGF-1 P, Kroemer HK, Krzelj V, Kuusisto J, Kvaloy K, 2011;26(2):247-254. mediated differentiation of human preadipocytes. Laitinen J, Lantieri O, Lathrop GM, Lokki ML, Molecular Cell Endocrinology. 2011;339(1- Luben RN, Ludwig B, McArdle WL, McCarthy Hochberg Z, Feil R, Constancia M, Fraga M, 2):165-71. A, Morken MA, Nelis M, Neville MJ, Pare G, Junien C, Carel JC, Boileau P, Le Bouc Y, Deal Parker AN, Peden JF, Pichler I, Pietilainen KH, CL, Lillycrop K, Scharfmann R, Sheppard A, Hysi PG, Young TL, Mackey DA, andrew T, Platou CGP, Pouta A, Ridderstrale M, Samani Skinner M, Szyf M, Waterland RA, Waxman Fernandez-Medarde A, Solouki AM, Hewitt AW, NJ, Saramies J, Sinisalo J, Smit JH, Strawbridge DJ, Whitelaw E, Ong K, Albertsson-Wikland Macgregor S, Vingerling JR, Li YJ, Ikram MK, RJ, Stringham HM, Swift AJ, Teder-Laving K. Child Health, Developmental Plasticity, and Fai LY, Sham PC, Manyes L, Porteros A, Lopes M, Thomson B, Usala G, van Meurs JBJ, van Epigenetic Programming. Endocrine Reviews. MC, Carbonaro F, Fahy SJ, Martin NG, van Duijn Ommen GJ, Vatin V, Volpato CB, Wallaschofski 2011;32(2):159-224. CM, Spector TD, Rahi JS, Santos E, Klaver H, Walters GB, Widen E, Wild SH, Willemsen G, CCW, Hammond CJ. A genome-wide association Witte DR, Zgaga L, Zitting P, Beilby JP, James Hofmann A, Osman A, Leow CY, Driguez P, study for myopia and refractive error identifies a AL, Kahonen M, Lehtimaki T, Nieminen MS, McManus DP, Jones MK. Parasite annexins - susceptibility locus at 15q25. Nature Genetics. Ohlsson C, Palmer LJ, Raitakari O, Ridker PM, New molecules with potential for drug and vaccine 2010;42(10):902. Stumvoll M, Tonjes A, Viikari J, Balkau B, Ben- development. Bioessays. 2010;32(11):967-976. Shlomo Y, Bergman RN, Boeing H, Smith GD, Ibiebele TI, Hughes MC, Pandeya N, Zhao Holt DC, McCarthy JS, Carapetis JR. Parasitic Ebrahim S, Froguel P, Hansen T, Hengstenberg Z, Montgomery G, Hayward N, Green AC, diseases of remote Indigenous communities in C, Hveem K, Isomaa B, Jorgensen T, Karpe Whiteman DC, Webb PM. High Intake of Folate Australia. International Journal For Parasitology. F, Khaw KT, Laakso M, Lawlor DA, Marre from Food Sources Is Associated with Reduced Risk 2010;40(10):1119-1126. M, Meitinger T, Metspalu A, Midthjell K, of Esophageal Cancer in an Australian Population. Pedersen O, Salomaa V, Schwarz PEH, Tuomi Journal of Nutrition. 2011;141(2):274-283.
Page 140 QIMR Annual Report 2010–2011 Ibiebele TI, Taylor AR, Whiteman DC, van der JM, Iversen ES, Moorman PG, Phelan CM, Chang-Claude J, Chenevix-Trench G, Cramer Pols JC. Eating habits and risk of esophageal Sellers TA, Cunningham JM, Vierkant RA, DW, Cunningham JM, DiCioccio RA, Doherty cancers: a population-based case-control study. Rider DN, Goode EL, Haviv I, Chenevix-Trench JA, Easton DF, Fredericksen ZS, Fridley Cancer Causes & Control. 2010;21(9):1475-1484. G. Evaluation of Candidate Stromal Epithelial BL, Gates MA, Gayther SA, Gentry-Maharaj Cross-Talk Genes Identifies Association between A, Hogdall E, Kjaer SK, Lurie G, Menon U, Ider BE, Clements A, Adams J, Whitby M, Risk of Serous Ovarian Cancer and TERT, a Moorman PG, Moysich K, Ness RB, Palmieri Muugolog T. Organisation of hospital infection Cancer Susceptibility “Hot-Spot’’. PLoS Genetics. RT, Pearce CL, Pharoah PDP, Ramus SJ, Song control in Mongolia. Journal of Hospital Infection. 2010;6(7). HL, Stram DO, Tworoger SS, Van Den Berg D, 2010;75(3):209-213. Vierkant RA, Wang-Gohrke S, Whittemore AS, Johnson J, Healey S, Khanna KK, kConFab, Wilkens LR, Wu AH, Schildkraut JM, Sellers Ider BE, Clements A, Adams J, Whitby M, Mutation analysis of RAD51L1 Chenevix-Trench G. TA, Goode EL. Genetic Variation in TYMS in the Muugolog T. Prevalence of hospital-acquired (RAD51B/REC2) in multiple-case, non-BRCA1/2 infections and antibiotic use in two tertiary One-Carbon Transfer Pathway Is Associated with breast cancer families. Breast Cancer Research Ovarian Carcinoma Types in the Ovarian Cancer Mongolian hospitals. Journal of Hospital Infection. and Treatment. 2011;129(1):255-63. 2010;75(3):214-219. Association Consortium. Cancer Epidemiology Jones K, Nourse JP, Morrison L, Nguyen- Biomarkers & Prevention. 2010;19(7):1822-1830. Ikram MK, Xueling S, Jensen RA, Cotch MF, Van D, Moss DJ, Burrows SR, Gandhi MK. Kendall BJ, Macdonald GA, Hayward NK, Hewitt AW, Ikram MA, Wang JJ, Klein R, Klein Expansion of EBNA1-specific effector T cells in BEK, Breteler MMB, Cheung N, Liew G, Mitchell Prins JB, O’Brien S, Whiteman DC. Daytime posttransplantation lymphoproliferative disorders. sleepiness, gastro-oesophageal reflux and P, Uitterlinden AG, Rivadeneira F, Hofman A, de Blood. 2010;116(13):2245-2252. Jong PTVM, van Duijn CM, Kao L, Cheng CY, Barrett’s oesophagus: a case-control study. Smith AV, Glazer NL, Lumley T, McKnight B, Jones MK, Keiser J, McManus DP. Trematodes. Journal of Gastroenterology and Hepatology. Psaty BM, Jonasson F, Eiriksdottir G, Aspelund Manual of Clinical Microbiology 10th edition. 2010;25:A41-A41. T, Harris TB, Launer LJ, Taylor KD, Li XH, 2011;Chapter 144(2230-2242):ASM Press, Kendall BJ, Macdonald GA, Hayward NK, Iyengar SK, Xi QS, Sivakumaran TA, Mackey Washington. Prins JB, O’Brien S, Whiteman DC. Metabolic DA, MacGregor S, Martin NG, Young TL, Bis syndrome and the risk of Barrett’s oesophagus. JC, Wiggins KL, Heckbert SR, Hammond CJ, Jordan SJ, Coory MD, Webb PM. Re: Predictive Journal of Gastroenterology and Hepatology. andrew T, Fahy S, Attia J, Holliday EG, Scott RJ, Value of Symptoms for Early Detection of Ovarian 2010;25:A78. Islam FMA, Rotter JI, McAuley AK, Boerwinkle Cancer. Journal of the National Cancer Institute. 2010;102(20):1599-1601. E, Tai ES, Gudnason V, Siscovick DS, Vingerling Khanna R, Burrows SR. Human immunology: JR, Wong TY. Four Novel Loci (19q13, 6q24, Jordan SJ, Francis JE, Nelson AE, Zorbas HM, a case for the ascent of non-furry immunology. 12q24, and 5q14) Influence the Microcirculation In Luxford KA, Webb PM. Pathways to the diagnosis Immunology and Cell Biology. 2011;89(3):330-331. Vivo. PLoS Genetics. 2010;6(10). of epithelial ovarian cancer in Australia. Medical Kim TS, Kawaguchi M, Suzuki M, Jung CG, Asai Journal of Australia. 2010;193(6):326-330. Ishii T, Notohara K, Umapathy A, Mallitt KA, K, Shibamoto Y, Lavin MF, Khanna KK, Miura Chikuba H, Moritani Y, Tanaka N, Rosty C, Joshi AA, Lepore N, Joshi SH, Lee AD, Y. The ZFHX3 (ATBF1) transcription factor induces Matsubara N, Jass J, Leggett B, Whitehall V. Barysheva M, Stein JL, McMahon KL, Johnson PDGFRB, which activates ATM in the cytoplasm Tubular Adenomas With Minor Villous Changes K, de Zubicaray GI, Martin NG, Wright MJ, Toga to protect cerebellar neurons from oxidative stress. Show Molecular Features Characteristic of AW, Thompson PM. The contribution of genes Disease Models & Mechanisms. 2010;3(11- Tubulovillous Adenomas. American Journal of to cortical thickness and volume. Neuroreport. 12):752-762. Surgical Pathology. 2011;35(2):212-220. 2011;22(3):101-105. Klein O, Schmidt C, Knights A, Davis ID, Chen Jabbar A, Crawford S, Mlocicki D, Swiderski ZP, Jurado S, Smyth I, van Denderen B, Tenis N, W, Cebon J. Melanoma vaccines: developments Conn DB, Jones MK, Beveridge I, Lightowlers Hammet A, Hewitt K, Ng JL, McNees CJ, Kozlov over the past 10 years. Expert Reviews of Vaccines. MW. Ultrastructural reconstruction of Taenia ovis SV, Oka H, Kobayashi M, Conlan LA, Cole TJ, 2011;10(6):853-873. oncospheres from serial sections. International Yamamoto K, Taniguchi Y, Takeda S, Lavin Knox TB, Nguyen YT, Vu NS, Kay BH, Ryan Journal For Parasitology. 2010;40(12):1419-1431. Dual Functions of ASCIZ in the MF, Heierhorst J. PA. Quantitative Relationships Between Immature Jaenicke S, ander C, Bekel T, Bisdorf R, DNA Base Damage Response and Pulmonary and Emergent Adult Aedes aegypti (Diptera: Droge M, Gartemann KH, Junemann S, Kaiser Organogenesis. PLoS Genetics. 2010;6(10). Culicidae) Populations in Water Storage Container O, Krause L, Tille F, Zakrzewski M, Puhler Kaminen-Ahola N, Ahola A, Flatscher-Bader Habitats. Journal of Medical Entomology. A, Schluter A, Goesmann A. Comparative T, Wilkins SJ, Anderson GJ, Whitelaw E, 2010;47(5):748-758. and Joint Analysis of Two Metagenomic Postnatal Growth Restriction and Chong SY. Kochan NA, Breakspear M, Slavin MJ, Datasets from a Biogas Fermenter Obtained by Gene Expression Changes in a Mouse Model of Valenzuela M, McCraw S, Brodaty H, Sachdev 454-Pyrosequencing. PLoS ONE. 2011;6(1). Fetal Alcohol Syndrome. Birth Defects Research PS. Functional alterations in brain activation Jahanshad N, Lee AD, Barysheva M, McMahon Part A-Clinical and Molecular Teratology. and deactivation in mild cognitive impairment in KL, de Zubicaray GI, Martin NG, Wright MJ, 2010;88(10):818-826. response to a graded working memory challenge. Toga AW, Thompson PM. Genetic influences on Kane-Maguire NL, Cozzi SJ, Boyle GM, Dementia and Geriatric Cognitive Disorders. brain asymmetry: A DTI study of 374 twins and Steadman R, Thomas DW, Ogbourne SM, 2011;30(6):553–568. siblings. Neuroimage. 2010;52(2):455-469. Modulation of fibroblast phenotype Moseley R. Kochan NA, Breakspear M, Valenzuela M, Slavin and extracellular matrix composition by Janda M, Neale RE, Youl P, Whiteman DC, MJ, Brodaty H, Wen W, Trollor JN, Turner A, 3-ingeyl angelate induces improved dermal Gordon L, Baade PD. Impact of a Video-Based Crawford JD, Sachdev PS. Cortical Responses Intervention to Improve the Prevalence of Skin cosmesis. Wound Repair and Regeneration. to a Graded Working Memory Challenge Predict Self-examination in Men 50 Years or Older: The 2010;18(6):A85-A85. Functional Decline in Mild Cognitive Impairment. Randomized Skin Awareness Trial. Archives of Karagas MR, Waterboer T, Li ZZ, Nelson HH, Biological Psychiatry. 2011;70(2):123-130. Dermatology. 2011;147(7):799-806. Michael KM, Bavinck JNB, Perry AE, Spencer Kohonen-Corish MRJ, Macrae F, Genuardi M, Genus beta Jirsa VK, Sporns O, Breakspear M, Deco SK, Daling J, Green AC, Pawlita M. Aretz S, Bapat B, Bernstein IT, Burn J, Cotton human papillomaviruses and incidence of basal cell G, McIntosh AR. Towards the virtual brain: RGH, den Dunnen JT, Frebourg T, Greenblatt and squamous cell carcinomas of skin: population network modeling of the intact and the MS, Hofstra R, Holinski-Feder E, Lappalainen based case-control study. British Medical Journal. damaged brain. Archives Italiennes de Biologie. I, Lindblom A, Maglott D, Moller P, Morreau H, 2010;341. 2011;148(3):189-205. Moslein G, Sijmons R, Spurdle AB, Tavtigian S, Tops CMJ, Weber TK, de Wind N, Woods Johnatty SE, Beesley J, Chen XQ, Macgregor S, Kaufman B, Laitman Y, Ziv E, Hamann U, Torres MO. Deciphering the Colon Cancer Genes- Duffy DL, Spurdle AB, deFazio A, Gava N, Webb D, Lahad EL, Beeri R, Renbaum P, Jakubowska Report of the InSiGHT-Human Variome Project PM, Rossing MA, Doherty JA, Goodman MT, A, Lubinski J, Huzarski T, Toloczko-Grabarek A, Workshop, UNESCO, Paris 2010. Human Mutation. Lurie G, Thompson PJ, Wilkens LR, Ness RB, Jaworska K, Durda K, Sprudle AB, Chenevix- 2011;32(4):491-494. Moysich KB, Chang-Claude J, Wang-Gohrke S, Trench G, Simard J, Easton DF, Antonis A, The CYP17A1-34T > C Cramer DW, Terry KL, Hankinson SE, Tworoger Szabo C, Friedman E. Kondalsamy-Chennakesavan S, Gordon LG, polymorphism and breast cancer risk in BRCA1 SS, Garcia-Closas M, Yang H, Lissowska J, Sanday K, Bouman C, De Jong S, Nicklin J, and BRCA2 mutation carriers. Breast Cancer Chanock SJ, Pharoah PD, Song HL, Whitemore Land R, Obermair A. Hospital costs associated AS, Pearce CL, Stram DO, Wu AH, Pike MC, Research and Treatment. 2011;126(2):521-527. with adverse events in gynecological oncology. Gayther SA, Ramus SJ, Menon U, Gentry- Kelemen LE, Goodman MT, McGuire V, Rossing Gynecologic Oncology. 2011;121(1):70-75. Maharaj A, Anton-Culver H, Ziogas A, Hogdall MA, Webb PM, Kobel M, Anton-Culver H, E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut Beesley J, Berchuck A, Brar S, Carney ME,
Page 141 Scientific publications | continued
Kote-Jarai Z, Al Olama AA, Leongamornlert Le AT, Miller PW, Slutske WS, Martin NG. Are Resistance to Type I Interferon. Journal of Virology. D, Tymrakiewicz M, Saunders E, Guy M, Giles Attitudes Towards Economic Risk Heritable? 2011;85(11):5651-5663. GG, Severi G, Southey M, Hopper JL, Sit KC, Analyses Using the Australian Twin Study of Harris JM, Batra J, Spurdle AB, Clements JA, Gambling. Twin Research and Human Genetics. Ligthart L, Nyholt DR, Penninx BWJH, Hamdy F, Neal D, Donovan J, Muir K, Pharoah 2010;13(4):330-339. Boomsma DI. Shared genetic factors influencing PDP, Chanock SJ, Brown N, Benlloch S, Castro migraine and anxious depression. Behavior E, Mahmud N, O’Brien L, Hall A, Sawyer E, Lee SH, Nyholt DR, Macgregor S, Henders AK, Genetics. 2010;40(6):803-803. Zondervan KT, Montgomery GW, Visscher PM. Wilkinson R, Easton DF, Eeles RA. Identification Ligthart L, Nyholt DR, Penninx BWJH, of a novel prostate cancer susceptibility variant A Simple and Fast Two-Locus Quality Control Test to Detect False Positives Due to Batch Effects Boomsma DI. The Shared Genetics of in the KLK3 gene transcript. Human Genetics. Migraine and Anxious Depression. Headache. 2011;129(6):687-694. in Genome-Wide Association Studies. Genetic Epidemiology. 2010;34(8):854-862. 2010;50(10):1549-1560. Kovac S, Anderson GJ, Alexander WS, Shulkes Ligthart L, Penninx BWJH, Nyholt DR, Distel A, Baldwin GS. Gastrin-Deficient Mice Have Lee SH, van der Werf JHJ, Lee SH, Park EW, Oh SJ, Gibson JP, Thompson JM. Genetic MA, de Geus EJC, Willemsen G, Smit JH, Disturbed Hematopoiesis in Response to Iron Boomsma DI. Migraine symptomatology and major Deficiency. Endocrinology. 2011;152(8):3062-3073. polymorphisms of the bovine Fatty acid binding protein 4 gene are significantly associated with depressive disorder. Cephalalgia. 2010;30(9):1073- Kovac S, Anderson GJ, Baldwin GS. Gastrins, marbling and carcass weight in Hanwoo (Korean 1081. iron homeostasis and colorectal cancer. Biochimica Cattle). Animal Genetics. 2010;41(4):442-444. Lin D, Tian F, Wu H, Gao Y, Wu J, Zhang D, Ji Et Biophysica Acta-Molecular Cell Research. M, McManus DP, Driguez HP, Wu G. Multiple 2011;1813(5):889-895. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating Missing Heritability for Disease from vaccinations with UV-attenuated cercariae in pig Koyama M, Kuns R, Olver S, Wilson Y, Don A, Genome-wide Association Studies. American enhance protective immunity against Schistosoma Raffelt N, Varelias A, Robb RJ, Markey K, Hill G, Journal of Human Genetics. 2011;88(3):294-305. japonicum infection as compared to single MacDonald K. The presentation of an exogenous vaccination. Parasites & Vectors. 2011;4(103). minor HA by host but not donor APC initiates Levinson DF, Duan JB, Oh S, Wang K, Sanders AR, Shi JX, Zhang N, Mowry BJ, Olincy A, Amin Lindor NM, Rabe KG, Petersen GM, Chen H, GvHD; however, dendritic cells are redundant. Bone Bapat B, Hopper J, Young J, Jenkins M, Potter Marrow Transplantation. 2011;46:S241. F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman J, Newcomb P, Templeton A, LeMarchand L, Kozlov SV, Graham ME, Jakob B, Tobias F, R, Dudbridge F, Pe’er I, Hakonarson H, Bergen Grove J, Burgio MR, Haile R, Green J, Woods Kijas AW, Tanuji M, Chen PL, Robinson PJ, SE, Fanous AH, Holmans PA, Gejman PV. Copy MO, Seminara D, Limburg PJ, Thibodeau Taucher-Scholz G, Suzuki K, So SR, Chen Number Variants in Schizophrenia: Confirmation of SN. Parent of origin effects on age at colorectal DV, Lavin MF. Autophosphorylation and ATM Five Previous Findings and New Evidence for 3q29 cancer diagnosis. International Journal of Cancer. Activation ADDITIONAL SITES ADD TO THE Microdeletions and VIPR2 Duplications. American 2010;127(2):361-366. COMPLEXITY. Journal of Biological Chemistry. Journal of Psychiatry. 2011;168(3):302-316. Liu A, Menon S, Colson NJ, Quinlan S, Cox 2011;286(11):9107-9119. Lewindon PJ, Ramm GA. Cystic fibrosis - H, Peterson M, Tiang T, Haupt LM, Lea RA, Krishnaprasad K, andrews J, Grafton R, cirrhosis, portal hypertension and liver biopsy. Griffiths LR. Analysis of the MTHFR C677T variant Lawrance I, Florin T, Leong R, Mahy G, Cooke Hepatology. 2011;53(3):1065-1066. with migraine phenotypes. BMC Research Notes. S, Croft A, Prosser R, Leach P, Edwards 2010;28(3):213. Lewindon PJ, Ramm GA. Reply: The Utility S, Chitti L, Cock C, Bampton P, Gearry R, Liu JZ, Mcrae AF, Nyholt DR, Medland SE, Wray Doecke J, Radford-Smith G. Inter-observer of Noninvasive Imaging in Cystic Fibrosis Liver Disease. Hepatology. 2011;53(5):1780-1781. NR, Brown KM, Hayward NK, Montgomery agreement for Crohn’s disease sub-phenotypes GW, Visscher PM, Martin NG, Macgregor S. using the Montreal classification: how good are Lewindon PJ, Shepherd RW, Walsh MJ, Greer A Versatile Gene-Based Test for Genome-wide we? A multi-centre Australasian study. Journal of RM, Williamson R, Pereira TN, Frawley K, Bell Association Studies. American Journal of Human Gastroenterology and Hepatology. 2010;25:A98. SC, Smith JL, Ramm GA. Importance of liver Genetics. 2010;87(1):139-145. Kuwahata M, Wijesinghe R, Ho MF, Pelecanos fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology. 2011;53(1):193-201. Liu Y, Blackwood DH, Caesar S, de Geus EJC, A, Bobogare A, Landry L, Bugora H, Vallely A, Farmer A, Ferreira MAR, Ferrier IN, Fraser C, McCarthy J. Population screening for glucose-6- Li Y, Ross AG, Hou X, Lou Z, McManus Gordon-Smith K, Green EK, Grozeva D, Gurling phosphate dehydrogenase deficiencies in Isabel DP. Oriental schistosomiasis with neurological HM, Hamshere ML, Heutink P, Holmans PA, Province, Solomon Islands, using a modified complications. Annals of Clinical Microbiology and Hoogendijk WJ, Hottenga JJ, Jones L, Jones IR, enzyme assay on filter paper dried bloodspots. Antimicrobials. 2011;10(5):. Kirov G, Lin D, McGuffin P, Moskvina V, Nolen Malaria Journal. 2010;9. WA, Perlis RH, Posthuma D, Scolnick EM, Smit Li YS, Chen DL, Ross AG, Burke ML, Yu XL, Li AB, Smit JH, Smoller JW, St Clair D, van Dyck Lang JM, Shennan M, Njauw JCN, Luo S, Severe hepatosplenic RS, Zhou J, McManus DP. R, Verhage M, Willemsen G, Young AH, Zandbelt Bishop JN, Harland M, Hayward NK, Tucker schistosomiasis: clinicopathologic study of 102 T, Boomsma DI, Craddock N, O’Donovan MA, Goldstein AM, Landi MT, Puig S, Gruis cases undergoing splenectomy. Human Pathology. MC, Owen MJ, Penninx BWJH, Purcell S, NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, 2011;42(1):111-119. Hogg D, Tsao H. A Flexible Multiplex Bead-Based Sklar P, Sullivan PF. Meta-analysis of genome- Assay for Detecting Germline CDKN2A and CDK4 Liberton DK, Claes P, Mcevoy B, Beleza S, wide association data of bipolar disorder and Variants in Melanoma-Prone Kindreds. Journal of Barsh G, Tang H, Absher D, Shriver MD. Using major depressive disorder. Molecular Psychiatry. Investigative Dermatology. 2011;131(2):480-486. automated high density quasi-landmarks to test 2011;16(1):40635. for associations between normal facial feature Locke S, Osborne M, O’Rourke P. Persistent Langdon AJ, Boonstra TW, Breakspear M. Multi- variation, genetic ancestry and candidate gene frequency phase locking in human somatosensory fatigue in young athletes: measuring the clinical variation in Cape Verdeans. American Journal of course and identifying variables affecting clinical cortex. Progress In Biophysics & Molecular Biology. Physical Anthropology. 2011;144:198-198. 2011;105(1-2):58-66. recovery. Scandinavian Journal of Medicine & Lickliter JD, Francesconi AB, Smith G, Burge Science In Sports. 2011;21(1):90-97. Lavin MF, Clarke RA, Teng L, Fang Z, M, Coulthard A, Rose S, Griffin M, Milne R, Loehlin JC, Martin NG. The general factor of Samaratunga H, Gardiner RA. Relationship McCarron J, Yeadon T, Wilks A, Cubitt A, Wyld between the TMPRSS2-ERG gene fusion and personality: Questions and elaborations. Journal of DK, Vasey PA. Phase I trial of CYT997, a novel Research in Personality. 2011;45(1):44-49. prostate cancer metastases. BJU International. cytotoxic and vascular-disrupting agent. British 2011;107:15. Journal of Cancer. 2010;103(5):597-606. Lose F, Nagle CM, O’Mara T, Batra J, Bolton KL, Song HL, Ramus SJ, Gentry-Maharaj A, Lawrance IC, Radford-Smith GL, Bampton Lidbury BA, Rulli NE, Musso CM, Cossetto PA, andrews JM, Tan PK, Croft A, Gearry Menon U, Gayther SA, Pharoah PDP, Kedda MA, SB, Zaid A, Suhrbier A, Rothenfluh HS, Spurdle AB. Vascular endothelial growth factor RB, Florin THJ. Serious infections in patients Rolph MS, Mahalingam S. Identification and with inflammatory bowel disease receiving gene polymorphisms and ovarian cancer survival. Characterization of a Ross River Virus Variant That Gynecologic Oncology. 2010;119(3):479-483. anti-tumor-necrosis-factor-alpha therapy: Grows Persistently in Macrophages, Shows Altered An Australian and New Zealand experience. Disease Kinetics in a Mouse Model, and Exhibits Journal of Gastroenterology and Hepatology. 2010;25(11):1732-1738.
Page 142 QIMR Annual Report 2010–2011 Lucas RM, Ponsonby AL, Burrows J, Chapman the bounty). Twin Research and Human Genetics. SM, Nathanson KL, Rebbeck TR, Johannsson C, Coulthard A, Dear K, Dwyer T, Kilpatrick TJ, 2011;14(1):42-52. OT, Couch FJ, Wang X, Fredericksen Z, Cuadras McMichael AJ, Taylor BV, Valery P, van der Mei I, D, Moreno V, Pientka FK, Depping R, Caldés Williams D, Pender MP. Epstein Barr viral infection Magalhaes RJS, Clements ACA, Patil AP, T, Osorio A, Benítez J, Bueren J, Heikkinen T, The Applications and onset of central nervous system demyelination. Gething PW, Brooker S. Nevanlinna H, Hamann U, Torres D, Caligo MA, of Model-Based Geostatistics in Helminth Multiple Sclerosis. 2010;16(8):1007-1007. Godwin AK, Imyanitov EN, Janavicius R; GEMO Epidemiology and Control. Advances In Study Collaborators, Sinilnikova OM, Stoppa- Lucas RM, Ponsonby AL, Dear K, Valery PC, Parasitology, Vol 74. 2011;74:267-296. Lyonnet D, Mazoyer S, Verny-Pierre C, Castera Pender MP, Taylor BV, Kilpatrick TJ, Dwyer L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat T, Coulthard A, Chapman C, van der Mei I, Maher C, O’Rourke P. Trocar-Guided JP, Vennin P, Ferrer SF, Collonge-Rame MA, Williams D, McMichael AJ. Sun exposure and Mesh Compared With Conventional Vaginal Mortemousque I, McGuffog L, Chenevix-Trench vitamin D are independent risk factors for CNS Repair in Recurrent Prolapse: A Randomized G, Pereira-Smith OM, Antoniou AC, Cerón J, demyelination. Neurology. 2011;76(6):540-548. Controlled Trial. Obstetrics and Gynecology. 2011;117(6):1435-1436. Tominaga K, Surrallés J, Pujana MA. Exploring Luciano M, Hansell NK, Lahti J, Davies G, the link between MORF4L1 and risk of breast Medland SE, Raikkonen K, Tenesa A, Widen Maher CF, Feiner B, DeCuyper EM, Nichlos cancer. Breast Cancer Research. ;13(2):R40. E, McGhee KA, Palotie A, Liewald D, Porteous CJ, Hickey KV, O’Rourke P. Laparoscopic sacral Maslovskaya LA, Savchenko AI, Gordon VA, DJ, Starr JM, Montgomery GW, Martin NG, colpopexy versus total vaginal mesh for vaginal Reddell PW, Pierce CJ, Parsons PG, Williams Eriksson JG, Wright MJ, Deary IJ. Whole genome vault prolapse: a randomized trial. American Journal CM. Isolation and Confirmation of the Proposed association scan for genetic polymorphisms of Obstetrics and Gynecology. 2011;204(4). Cleistanthol Biogentic Link from Croton insularis. influencing information processing speed. Biological Major L, Schroder WA, Gardner J, Fish RJ, Organic Letters. 2011;13(5):1032-1035. Psychology. 2011;86(3):193-202. Suhrbier A. Human papilloma virus transformed Mason SA, Cozzi SJ, Pierce CJ, Pavey SJ, Luciano M, Montgomery GW, Martin NG, CaSki cells constitutively express high levels of Parsons PG, Boyle GM. The induction of Wright MJ, Bates TC. SNP Sets and Reading functional SerpinB2. Experimental Cell Research. senescence-like growth arrest by protein kinase Ability: Testing Confirmation of a 10-SNP Set in a 2011;317(3):338-347. C-activating diterpene esters in solid tumor cells. Population Sample. Twin Research and Human Mallitt KA, O’Rourke P, Bavinck JNB, Abeni D, Investigational New Drugs. 2010;28(5):575-586. Genetics. 2011;14(3):228-232. de Koning MNC, Feltkamp MCW, Green AC, Massicotte R, Whitelaw E, Angers B. DNA Lurie G, Gaudet MM, Spurdle AB, Carney Quint WGV, Michael KM, Pawlita M, Pfister methylation A source of random variation in natural ME, Wilkens LR, Yang HP, Weiss NS, Webb H, Weissenborn S, Waterboer T, Neale RE. populations. Epigenetics. 2011;6(4):422-428. PM, Thompson PJ, Terada K, Setiawan VW, An analysis of clustering of betapapillomavirus antibodies. Journal of General Virology. Rebbeck TR, Prescott J, Orlow I, O’Mara T, Maugeri N, Powell J, ‘t Hoen PA, de Geus 2010;91:2062-2067. Olson SH, Narod SA, Matsuno RK, Lissowska EJ, Willemsen G, Kattenberg M, Henders AK, J, Liang XL, Levine DA, Le Marchand L, Kolonel Manh BH, Clements ACA, Thieu NQ, Hung Wallace L, Penninx B, Hottenga JJ, Medland SE, LN, Henderson BE, Garcia-Closas M, Doherty NM, Hung LX, Hay SI, Hien TT, Wertheim HFL, Saviouk V, Martin NG, Visscher PM, van Ommen JA, De Vivo I, Chen C, Brinton LA, Akbari Snow RW, Horby P. Social and environmental GJ, Frazer IH, Boomsma DI, Montgomery GW, MR, Goodman MT. The Obesity-Associated determinants of malaria in space and time in Ferreira MA. LPAR1 and ITGA4 regulate peripheral Polymorphisms FTO rs9939609 and MC4R Viet Nam. International Journal For Parasitology. blood monocyte counts. Human Mutation. 2011. rs17782313 and Endometrial Cancer Risk in Non- 2011;41(1):109-116. [Published online ahead of print]. Hispanic White Women. PLoS ONE. 2011;6(2). Marfurt J, Chalfein F, Prayoga P, Wabiser F, McConechy MK, Anglesio MS, Kalloger SE, Lurie G, Wilkens LR, Thompson PJ, Shvetsov Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Yang W, Senz J, Chow C, Heravi-Moussavi YB, Matsuno RK, Carney ME, Palmieri RT, Wu Anstey NM, andrews KT, Price RN. Ex Vivo A, Morin GB, Mes-Masson AM, Carey MS, AH, Pike MC, Pearce CL, Menon U, Gentry- Activity of Histone Deacetylase Inhibitors against McAlpine JN, Kwon JS, Prentice LM, Boyd N, Maharaj A, Gayther SA, Ramus SJ, Whittemore Multidrug-Resistant Clinical Isolates of Plasmodium Shah SP, Gilks CB, Huntsman DG. Subtype- AS, McGuire V, Sieh W, Pharoah PDP, Song falciparum and P-vivax. Antimicrobial Agents and specific mutation of PPP2R1A in endometrial HL, Gronwald J, Jakubowska A, Cybulski C, Chemotherapy. 2011;55(3):961-966. and ovarian carcinomas. Journal of Pathology. Lubinski J, Schildkraut JM, Berchuck A, Kjaer 2011;223(5):567-573. SK, Hogdall E, Fasching PA, Beckmann MW, Martin NW, Benyamin B, Hansell NK, Ekici AB, Hein A, Chenevix-Trench G, Webb PM, Montgomery GW, Martin NG, Wright MJ, Bates McDonald CJ, Ostini L, Wallace DF, John AN, Beesley J, Goodman MT. Estrogen Receptor Beta TC. Cognitive Function in Adolescence: Testing Watters DJ, Subramaniam VN. Iron loading rs1271572 Polymorphism and Invasive Ovarian for Interactions Between Breast-Feeding and and oxidative stress in the Atm(-/-) mouse liver. Carcinoma Risk: Pooled Analysis within the Ovarian FADS2 Polymorphisms. Journal of The American American Journal of Physiology-Gastrointestinal Cancer Association Consortium. PLoS ONE. Academy of Child and Adolescent Psychiatry. and Liver Physiology. 2011;300(4):G554-G560. 2011;50(1):55-62. 2011;6(6). McDonald CJ, Wallace DF, Ostini L, Bell SJ, MacDonald K. Antigen Presentation in Graft- Martin NW, Medland SE, Verweij KJH, Lee SH, Demediuk B, Subramaniam VN. G80S-linked Versus-Host Disease. Experimental Hematology. Nyholt DR, Madden PA, Heath AC, Montgomery ferroportin disease: Classical ferroportin disease in 2010;38(9):S123. GW, Wright MJ, Martin NG. Educational an Asian family and reclassification of the mutant Attainment: A Genome Wide Association Study in as iron transport defective. Journal of Hepatology. MacDonald KPA, Palmer JS, Cronau S, 9538 Australians. PLoS ONE. 2011;6(6). 2011;54(3):538-544. Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Branstetter Martrat G, Maxwell CA, Tominaga E, Porta- McEvoy BP, Lind JM, Wang ET, Moyzis D, Smith J, Paxton RJ, Cerretti DP, Bonham de-la-Riva M, Bonifaci N, Gómez-Baldó L, RK, Visscher PM, Pellekaan SMV, Wilton L, Hill GR, Hume DA. An antibody against the Bogliolo M, Lázaro C, Blanco I, Brunet J, Aguilar AN. Whole-Genome Genetic Diversity in a colony-stimulating factor 1 receptor depletes the H, Fernández-Rodríguez J, Seal S, Renwick Sample of Australians with Deep Aboriginal resident subset of monocytes and tissue- and A, Rahman N, Kühl J, Neveling K, Schindler Ancestry. American Journal of Human Genetics. tumor-associated macrophages but does not inhibit D, Ramírez MJ, Castellà M, Hernández G; 2010;87(2):297-305. inflammation. Blood. 2010;116(19):3955-3963. EMBRACE, Easton DF, Peock S, Cook M, Oliver McEvoy BP, Powell JE, Goddard ME, Visscher CT, Frost D, Platte R, Evans DG, Lalloo F, Eeles Macgregor S, Hewitt AW, Hysi PG, Ruddle JB, PM. Human population dispersal “Out of Africa’’ R, Izatt L, Chu C, Davidson R, Ong KR, Cook estimated from linkage disequilibrium and Medland SE, Henders AK, Gordon SD, andrew J, Douglas F, Hodgson S, Brewer C, Morrison T, McEvoy B, Sanfilippo PG, Carbonaro F, Tah V, allele frequencies of SNPs. Genome Research. PJ, Porteous M, Peterlongo P, Manoukian S, 2011;21(6):821-829. Li YJ, Bennett SL, Craig JE, Montgomery GW, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel Tran-Viet KN, Brown NL, Spector TD, Martin NG, A, Pasini B, Ottini L, Putignano AL, Savarese McEvoy BP, Zhao ZZ, Macgregor S, Bellis C, Young TL, Hammond CJ, Mackey DA. Genome- A, Bernard L, Radice P, Healey S, Spurdle A, Lea RA, Cox H, Montgomery GW, Griffiths wide association identifies ATOH7 as a major Chen X, Beesley J; kConFab, Rookus MA, LR, Visscher PM. European and Polynesian gene determining human optic disc size. Human Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, admixture in the Norfolk Island population. Heredity. Molecular Genetics. 2010;19(13):2716-2724. Asperen CJ, Bodmer D, Ausems MG, van Os TA, 2010;105(2):229-234. Blok MJ, Meijers-Heijboer HE, Hogervorst FB; Mackey DA, Sherwin JC, Kearns LS, Ma Y, Kelly McLachlan S, Lee SM, Steele TM, Hawthorne J, Chu BS, Macmillan R, Barbour JM, Wilkinson HEBON, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR; SWE-BRCA, Harbst PL, Zapala MA, Eskin E, Schork NJ, Anderson CH, Matovinovic E, Cox HC, Bellis C, Lea RA, GJ, Vulpe CD. In silico QTL mapping of basal liver Quinlan S, Griffiths LR, Hewitt AW. The Norfolk K, Borg A, Rantala J, Barbany-Bustinza G, Ehrencrona H, Stenmark-Askmalm M, Kaufman iron levels in inbred mouse strains. Physiological Island Eye Study (NIES): rationale, methodology Genomics. 2011;43(3):136-147. and distribution of ocular biometry (biometry of B, Laitman Y, Milgrom R, Friedman E, Domchek
Page 143 Scientific publications | continued
McManus DP, Yang YR. Helminthic diseases: Davenport MP, Tan MP, Burrows SR, Wooldridge dendritic cells by mitogen-activated protein kinases. Echinococcosis. Public Health and Infectious L, Price DA, Rizkallah PJ, Sewell AK. Genetic Molecular Immunology. 2010;47(11-12):2065-2073. Disease. 2010;(340-345):Elsevier, San Diego, USA. and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus Mitchell D, Yong M, Raju J, Willemsen N, Black McManus DP. Echinococcosis with Particular Infection. PLoS Pathogens. 2010;6(11). M, Trent A, Tirrell M, Olive C. Toll-like receptor- Reference to Southeast Asia. Advances in mediated adjuvanticity and immunomodulation in Parasitology. 2010;72:267-303. Miles JJ, Douek DC, Price DA. Bias in the alpha dendritic cells: Implications for peptide vaccines. beta T-cell repertoire: implications for disease Human Vaccines. 2011;7:85-93. McManus DP. Liver worms. Textbook of Clinical pathogenesis and vaccination. Immunology and Gastroeneterology and Hepatology 2nd Edition. Cell Biology. 2011;89(3):375-387. Mitchell D, Yong M, Schroder W, Black M, Tirrell 2011;Wiley Blackwell Publishing, Wiley & Sons, M, Olive C. Dual Stimulation of MyD88-Dependent Oxford, UK. Miles JJ, Thammanichanond D, Moneer S, Toll-Like Receptors Induces Synergistically Nivarthi UK, Kjer-Nielsen L, Tracy SL, Aitken CK, Enhanced Production of Inflammatory McManus DP. Schistosomiasis work in China and Brennan RM, Zeng WG, Marquart L, Jackson Cytokines in Murine Bone Marrow-Derived developing a transmission blocking vaccine for use D, Burrows SR, Bowden DS, Torresi J, Hellard Dendritic Cells. Journal of Infectious Diseases. in water buffaloes. Proceedings of the 3rd AVA/ M, Rossjohn J, McCluskey J, Bharadwaj M. 2010;202(2):318-329. NZVA Pan Pacific Veterinary Conference, Brisbane. Antigen-Driven Patterns of TCR Bias Are Shared 2010;PF45b.5. across Diverse Outcomes of Human Hepatitis Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S, Ramos-Jimenez P, McManus DP. Vaccines for schistosomiasis. C Virus Infection. Journal of Immunology. Gotuzzo E, Kar K, Sanchez A, Garba A, Carabin McGraw Hill Yearbook of Science and Technology 2011;186(2):901-912. H, Bassili A, Chaignat CL, Meslin FX, Abushama 2010, McGraw Hill, New York. 2010;(400-403). Miles KM, Miles JJ, Madura F, Sewell AK, HM, Willingham AL, Kioy D. Zoonoses and McMillan DJ, Bessen DE, Pinho M, Ford Cole DK. Real time detection of peptide-MHC marginalised infectious diseases of poverty: where C, Hall GS, Melo-Cristino J, Ramirez M. dissociation reveals that improvement of primary do we stand?. Parasites & Vectors. 2011;4(106). Population Genetics of Streptococcus dysgalactiae MHC-binding residues can have a minimal, or Montgomery GW. Genetics of Endometriosis. Subspecies equisimilis Reveals Widely Dispersed no, effect on stability. Molecular Immunology. Australian & New Zealand Journal of Obstetrics & Clones and Extensive Recombination. PLoS ONE. 2011;48(4):728-732. Gynaecology. 2010;50:29-29. 2010;5(7). Milne RL, Gaudet MM, Spurdle AB, Fasching Montgomery GW. Genome-wide association McNally A, Hill GR, Sparwasser T, Thomas PA, Couch FJ, Benítez J, Arias Pérez JI, Zamora studies and genetic architecture of common human R, Steptoe RJ. CD4(+)CD25(+) regulatory T MP, Malats N, Dos Santos Silva I, Gibson diseases. BMC Proceedings. 2011;5(Suppl 4):S16. cells control CD8(+) T-cell effector differentiation LJ, Fletcher O, Johnson N, Anton-Culver H, by modulating IL-2 homeostasis. PNAS. Ziogas A, Figueroa J, Brinton L, Sherman ME, Moore SP, O’Rourke PK, Mallitt KA, Garvey 2011;108(18):7529-7534. Lissowska J, Hopper JL, Dite GS, Apicella C, G, Green AC, Coory MD, Valery PC. Cancer Southey MC, Sigurdson AJ, Linet MS, Schonfeld incidence and mortality in Indigenous Australians Medland SE, Verweij KJH. Examining the effects SJ, Freedman DM, Mannermaa A, Kosma VM, in Queensland, 1997-2006. Medical Journal of of common environment and non-additive effects Kataja V, Auvinen P, Andrulis IL, Glendon G, Australia. 2010;193(10):590. on family based association results. Behavior Knight JA, Weerasooriya N, Cox A, Reed MW, Genetics. 2010;40(6):804-804. Cross SS, Dunning AM, Ahmed S, Shah M, Morrison BL, Reynolds BA, Schmidt CW, Brauch H, Ko YD, Brüning T; GENICA Network, López JA. Stem Cells and Breast Cancer. Meier MH, Slutske WS, Heath AC, Martin NG. Lambrechts D, Reumers J, Smeets A, Wang- Stem cell, Regenerative Medicine and Cancer. Sex differences in the genetic and environmental Gohrke S, Hall P, Czene K, Liu J, Irwanto AK, 2011:Chapter 22. influences on childhood conduct disorder and Chenevix-Trench G, Holland H; kConFab; AOCS, adult antisocial behavior. Journal of Abnormal Morrow BJ, Keddie DJ, Gueven N, Lavin Giles GG, Baglietto L, Severi G, Bojensen Psychology. 2011;120(2):377-388. MF, Bottle SE. A novel profluorescent nitroxide SE, Nordestgaard BG, Flyger H, John EM, as a sensitive probe for the cellular redox Menon S, Cox HC, Kuwahata M, Quinlan S, West DW, Whittemore AS, Vachon C, Olson environment. Free Radical Biology and Medicine. MacMillan JC, Haupt LM, Lea RA, Griffiths JE, Fredericksen Z, Kosel M, Hein R, Vrieling 2010;49(1):67-76. LR. Association of a Notch 3 gene polymorphism A, Flesch-Janys D, Heinz J, Beckmann MW, with migraine susceptibility. Cephalalgia. Heusinger K, Ekici AB, Haeberle L, Humphreys Mosing MA, Pedersen NL, Martin NG, 2011;31(3):264-270. MK, Morrison J, Easton DF, Pharoah PD, Wright MJ. Sex Differences in the Genetic García-Closas M, Goode EL, Chang-Claude J. Architecture of Optimism and Health and Their Mesnard L Mesnard L, Prignon A, Halabi M, Assessing interactions between the associations Interrelation: A Study of Australian and Swedish Hodgson S, Handoko H, Walker G, Hollier B, of common genetic susceptibility variants, Twins. Twin Research and Human Genetics. Rondeau E, Aractingi S, Khosrotehrani K. In reproductive history and body mass index with 2010;13(4):322-329. vivo melanoma phenotype switch from invasive breast cancer risk in the breast cancer association to proliferative in the absence of the extracellular consortium: a combined case-control study. Breast Mosing MA, Verweij KJH, Medland SE, matrix protein vitronectin. Journal of Investigative Cancer Research. 2010;12(6):R110. Painter J, Gordon SD, Heath AC, Madden Dermatology. 2011;131:S126-S126. PA, Montgomery GW, Martin NG. A Mine S. Cicek, Noralane M. Lindor, Steven Genome-Wide Association Study of Self-Rated Micallef LS, Loughrey BT, Healy PC, Parsons Gallinger, Bharati Bapat, John L. Hopper, Mark Health. Twin Research and Human Genetics. PG, Williams ML. Mono- and 1,1 ‘-Disubstituted A. Jenkins, Joanne Young, Daniel Buchanan, 2010;13(4):398-403. Organoruthenium Cyclopentadiene Complexes: Michael D. Walsh, Loic Le Marchand, Terrilea Synthesis, Structural Characterization, and Burnett, Polly A. Newcomb, William M. Grady, Mosing MA, Wright MJ, Pedersen NL, Martin Antitumoral Evaluation. Organometallics. Robert W. Haile, Graham Casey, Sarah J. NG. Genetic influences on optimism and its 2011;30(6):1395-1403. Plummer, Lisa A. Krumroy, John A. Baron, and relationship to health. Behavior Genetics. Stephen N. Thibodeau. Quality Assessment 2010;40(6):806-806. Micallef LS, Loughrey BT, Healy PC, Parsons and Correlation of MSI and IHC Markers PG, Williams ML. Synthesis, Spectroscopic Moskvina V, Smith M, Ivanov D, Blackwood D, among Population- and Clinic-Based Colorectal Characterization, and Cytotoxic Evaluation Stclair D, Hultman C, Toncheva D, Gill M, Corvin Tumors. Journal of Molecular Diagnostics. of Pentasubstituted Ruthenocenyl Esters. A, O’Dushlaine C, Morris DW, Wray NR, Sullivan 2011;13(3):271-81. Organometallics. 2010;29(23):6237-6244. P, Pato C, Pato MT, Sklar P, Purcell S, Holmans Mirza H, Teo JDW, Upcroft J, Tan KSW. A Rapid, P, O’Donovan MC, Owen MJ, Kirov G. Genetic Middeldorp CM, Slof-Op ‘t Landt MCT, Medland High-Throughput Viability Assay for Blastocystis Differences between Five European Populations. SE, van Beijsterveldt CEM, Bartels M, Willemsen spp. Reveals Metronidazole Resistance and Human Hereditary. 2010;70(2):141-149. G, Hottenga JJ, de Geus EJC, Suchiman HED, Extensive Subtype-Dependent Variations in Dolan CV, Neale MC, Slagboom PE, Boomsma Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, Drug Susceptibilities. Antimicrobial Agents and DI. Anxiety and depression in children and adults: Kemp DJ, McCarthy JS, Fischer K. A Tractable Chemotherapy. 2011;55(2):637-648. influence of serotonergic and neurotrophic genes?. Experimental Model for Study of Human and Genes Brain and Behavior. 2010;9(7):808-816. Mitchell D, Olive C. Regulation of Toll-like Animal Scabies. PLoS Neglected Tropical Diseases. receptor-induced chemokine production in murine 2010;4(7). Miles JJ, Bulek AM, Cole DK, Gostick E, Schauenburg AJA, Dolton G, Venturi V,
Page 144 QIMR Annual Report 2010–2011 Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, PG, Palmieri RT, Ness RB, Moysich K, Cramer R, Osterlind A, Berwick M, Karagas MR, Kemp DJ, McCarthy JS, Fischer K. A Tractable DW, Terry KL, Vitonis AF, Pike MC, Berchuck Whiteman DC. Biologic markers of sun exposure Experimental Model for Study of Human and A, Pearce CL. Progesterone receptor gene and melanoma risk in women: pooled case- Animal Scabies. PLoS Neglected Tropical Diseases. polymorphisms and risk of endometriosis: results control analysis. International Journal of Cancer. 2010;4(7). from an international collaborative effort. Fertility 2011;129(3):713-723. and Sterility. 2011;95(1):40-45. Mudge AM, O’Rourke P, Denaro CP. Timing O’Mara TA, Fahey P, Ferguson K, Marquart L, and Risk Factors for Functional Changes Ngo TT, Mitchell PB, Martin NG, Miller SM. Lambrechts D, Despierre E, Vergote I, Amant F, Associated With Medical Hospitalization in Psychiatric and genetic studies of binocular rivalry: Hall P, Liu JJ, Czene K, Rebbeck TR, Ahmed S, Older Patients. Journals of Gerontology Series an endophenotype for bipolar disorder?. Acta Dunning AM, Gregory CS, Shah M, Webb PM, A-Biological Sciences and Medical Sciences. Neuropsychiatrica. 2011;23(1):37-42. Spurdle AB. Progesterone receptor gene variants 2010;65(8):863-869. and risk of endometrial cancer. Carcinogenesis. Nguyen LAP, Clements ACA, Jeffery JAL, 2011;32(3):331-335. Mujaj SA, Spanevello MM, Gandhi MK, Nourse Nguyen YT,Vu SN, Vaughan G, Shinkfield R, JP. Molecular mechanisms influencing NK cell Kutcher SC, Gatton ML, KAY BH, Ryan PA. Osorio A, Milne RL, Alonso R, Pita G, development: implications for NK cell malignancies. Abundance and prevalence of Aedes aegypti Peterlongo P, Teule A, Nathanson KL, Domchek American Journal of Blood Research. ;1(1):34-45. immatures and relationships with household SM, Rebbeck T, Lasa A, Konstantopoulou I, water storage in rural areas in southern Viet Nam. Hogervorst FB, Verhoef S, van Dooren MF, Nagle CM, Francis JE, Nelson AE, Zorbas H, International Health. 2011;3(2):115-125. Jager A, Ausems MGEM, Aalfs CM, van Asperen Luxford K, de Fazio A, Fereday S, Bowtell DD, CJ, Vreeswijk M, Waisfisz Q, Van Roozendaal Green AC, Webb PM. Reducing Time to Diagnosis Norgate M, Southon A, Greenough M, Cater M, CE, Ligtenberg MJ, Easton DF, Peock S, Cook Does Not Improve Outcomes for Women With Farlow A, Batterham P, Bush AI, Subramaniam M, Oliver CT, Frost D, Curzon B, Evans DG, Symptomatic Ovarian Cancer: A Report From the Syntaxin 5 Is Required VN, Burke R, Camakaris J. Lalloo F, Eeles R, Izatt L, Davidson R, Adlard Australian Ovarian Cancer Study Group. Journal of for Copper Homeostasis in Drosophila and J, Eccles D, Ong KR, Douglas F, Downing S, Clinical Oncology. 2011;29(16):2253-2258. Mammals. PLoS ONE. 2010;5(12). Brewer C, Walker L, Nevanlinna H, Aittomaki K, Nagle CM, Kolahdooz F, Ibiebele TI, Olsen Notaridou M, Quaye L, Dafou D, Jones C, Couch FJ, Fredericksen Z, Lindor NM, Godwin CM, Lahmann PH, Green AC, Webb PM. Song HL, Hogdall E, Kjaer SK, Christensen A, Isaacs C, Caligo MA, Loman N, Jernstrom H, Carbohydrate intake, glycemic load, glycemic L, Hogdall C, Blaakaer J, McGuire V, Wu AH, Barbany-Bustinza G, Liljegren A, Ehrencrona index, and risk of ovarian cancer. Annals of Van den Berg DJ, Pike MC, Gentry-Maharaj H, Stenmark-Askmalm M, Feliubadalo L, Oncology. 2011;22(6):1332-1338. A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Manoukian S, Peissel B, Zaffaroni D, Bonanni Schildkraut JM, Moorman PG, Iversen ES, B, Fortuzzi S, Johannsson OT, Chenevix-Trench Nagle CM, Kolahdooz F, Ibiebele TI, Olsen Jakubowska A, Medrek K, Lubinski J, Ness G, Chen XC, Beesley J, Spurdle AB, Sinilnikova CM, Lahmann PH, Green AC, Webb PM. RB, Moysich KB, Lurie G, Wilkens LR, Carney OM, Healey S, McGuffog L, Antoniou AC, Carbohydrate intake, glycemic load, glycemic ME, Wang-Gohrke S, Doherty JA, Rossing MA, Brunet J, Radice P, Benitez J. Evaluation of the index, and risk of ovarian cancer. Annals of Beckmann MW, Thiel FC, Ekici AB, Chen XQ, XRCC1 gene as a phenotypic modifier in BRCA1/2 Oncology. 2011;22(6):1332-1338. Beesley J, Gronwald J, Fasching PA, Chang- mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Nagle CM, Olsen CM, Bain CJ, Whiteman DC, Claude J, Goodman MT, Chenevix-Trench Journal of Cancer. 2011;104(8):1356-1361. Green AC, Webb PM. Tea consumption and G, Berchuck A, Pearce CL, Whittemore AS, risk of ovarian cancer. Cancer Causes & Control. Menon U, Pharoah PDP, Gayther SA, Ramus SJ. Painter JN, Anderson CA, Nyholt DR, Common alleles in candidate susceptibility genes 2010;21(9):1485-1491. Macgregor S, Lin JH, Lee SH, Lambert A, Zhao associated with risk and development of epithelial ZZ, Roseman F, Guo Q, Gordon SD, Wallace L, Nawaratna SSK, McManus DP, Moertel L, ovarian cancer. International Journal of Cancer. Henders AK, Visscher PM, Kraft P, Martin NG, Gobert GN, Jones MK. Gene Atlasing of Digestive 2011;128(9):2063-2074. Morris AP, Treloar SA, Kennedy SH, Missmer and Reproductive Tissues in Schistosoma mansoni. SA, Montgomery GW, Zondervan KT. Genome- PLoS Neglected Tropical Diseases. 2011;5(4). Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative wide association study identifies a locus at 7p15.2 Neale BM, Medland S, Ripke S, Anney RJL, Disorders: Pathogenetic Insights for Targeted associated with endometriosis. Nature Genetics. Asherson P, Buitelaar J, Franke B, Gill M, Kent Therapy. American Journal of Transplantation. 2011;43(1):51-U69. L, Holmans P, Middleton F, Thapar A, Lesch 2011;11(5):888-895. Painter JN, Nyholt DR, Morris A, Zhao ZZ, KP, Faraone SV, Daly M, Nguyen TT, Schafer H, Henders AK, Lambert A, Wallace L, Martin Steinhausen HC, Reif A, Renner TJ, Romanos Obermair A, Youlden DR, Young JP, Lindor NG, Kennedy SH, Treloar SA, Zondervan KT, M, Romanos J, Warnke A, Walitza S, Freitag C, NM, Baron JA, Newcomb P, Parry S, Hopper Montgomery GW. High-density fine-mapping Meyer J, Palmason H, Rothenberger A, Hawi Z, JL, Haile R, Jenkins MA. Risk of endometrial of a chromosome 10q26 linkage peak suggests Sergeant J, Roeyers H, Mick E, Biederman J. cancer for women diagnosed with HNPCC-related association between endometriosis and Case-Control Genome-Wide Association Study of colorectal carcinoma. International Journal of variants close to CYP2C19. Fertility and Sterility. Attention-Deficit/Hyperactivity Disorder. Journal of Cancer. 2010;127(11):2678-2684. 2011;95(7):2236-2240. The American Academy of Child and Adolescent Olsen CM, Carroll HJ, Whiteman DC. Psychiatry. 2010;49(9):906-920. Estimating the attributable fraction for melanoma: Pandian JD, Dalton K, Scott J, Read SJ, Henderson RD. Cardiovascular autonomic Neale BM, Medland SE, Ripke S, Asherson P, a meta-analysis of pigmentary characteristics dysfunction in acute stroke. International Journal of Franke B, Lesch KP, Faraone SV, Nguyen TT, and freckling. International Journal of Cancer. Stroke. 2011;6(2):176-178. Schafer H, Holmans P, Daly M, Steinhausen 2010;127(10):2430-45. HC, Freitag C, Reif A, Renner TJ, Romanos Olsen CM, Pandeya N, Green AC, Webb PM, Parker G, Fletcher K, Barrett M, Breakspear M, Romanos J, Walitza S, Warnke A, Meyer Whiteman DC. Population Attributable Fractions M, Rees AM. Evaluating the first 1000 patients J, Palmason H, Buitelaar J, Vasquez AA, of Adenocarcinoma of the Esophagus and referred to a specialist depression clinic: A case Lambregts-Rommelse N, Gill M, Anney RJL, Gastroesophageal Junction. American Journal for tertiary referral facilities. Journal of Affective Langely K, O’Donovan M, Williams N, Owen of Epidemiology. 2011. [Published online ahead Disorders. 2011;131(1-3):52-58. M, Thapar A, Kent L, Sergeant J, Roeyers H, of print]. Mick E, Biederman J, Doyle A, Smalley S, Loo Parker G, Fletcher K, Barrett M, Synnott S, Hakonarson H, Elia J, Todorov A, Miranda Olsen CM, Zens MS, Green AC, Stukel TA, H, Breakspear M, Rees AM, Blanch B. The A, Mulas F, Ebstein RP, Rothenberger A, Holman CDJ, Mack T, Elwood JM, Holly EA, Impact of Detecting Bipolar Disorder in Previously Banaschewski T, Oades RD, Sonuga-Barke Sacerdote C, Gallagher R, Swerdlow AJ, Diagnosed Unipolar Patients at a Specialist E, McGough J, Nisenbaum L, Middleton F, Armstrong BK, Rosso S, Kirkpatrick C, Zanetti Depression Clinic. Journal of Nervous and Mental Hu XL, Nelson S. Meta-Analysis of Genome- R, Bishop JN, Bataille V, Chang YM, Mackie Disease. 2011;199(6):419-422. Wide Association Studies of Attention-Deficit/ R, Osterlind A, Berwick M, Karagas MR, Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Hyperactivity Disorder. Journal of the American Biologic markers of sun exposure Whiteman DC. Church JM, Baron JA, Giles GG, Leggett BA, Academy of Child and Adolescent Psychiatry. and melanoma risk in women: pooled case- Winship I, Lipton L, Young GP, Young JP, Lodge 2010;49(9):884-897. control analysis. International Journal of Cancer. CJ, Southey MC, Newcomb PA, Le Marchand 2011;129(3):713-723. Near AM, Wu AH, Templeman C, Van Den L, Haile RW, Lindor NM, Gallinger S, Hopper Berg DJ, Doherty JA, Rossing MA, Goode Olsen CM, Zens MS, Green AC, Stukel TA, JL, Jenkins MA. Metachronous colorectal cancer EL, Cunningham JM, Vierkant RA, Fridley Holman CDJ, Mack T, Elwood JM, Holly EA, risk for mismatch repair gene mutation carriers: the BL, Chenevix-Trench G, Webb PM, Kjaer SK, Sacerdote C, Gallagher R, Swerdlow AJ, advantage of more extensive colon surgery. Gut. Hogdall E, Gayther SA, Ramus SJ, Menon U, Armstrong BK, Rosso S, Kirkpatrick C, Zanetti 2011;60(7):950-957. Gentry-Maharaj A, Schildkraut JM, Moorman R, Bishop JN, Bataille V, Chang YM, Mackie
Page 145 Scientific publications | continued
Pasay C, Mounsey K, Stevenson G, Davis Pergadia ML, Glowinski AL, Wray NR, Agrawal Ewing Sarcoma. Clinical Cancer Research. R, Arlian L, Morgan M, Vyszenski-Moher D, A, Saccone SF, Loukola A, Broms U, Korhonen 2011;17(3):494-504. andrews K, McCarthy J. Acaricidal activity of T, Penninx BW, Grant JD, Nelson EC, Henders eugenol based compounds against scabies mites. AK, Schrage AJ, Chou YL, Keskitalo-Vuokko Plasmeijer EI, Neale RE, O’Rourke P, Mallitt PLoS ONE. 2010;5(8):e12079. K, Zhu Q, Gordon SD, Vink JM, de Geus EJ, KA, de Koning MNC, Quint W, Buettner PG, Macgregor S, Liu JZ, Willemsen G, et al. A 3p26- Pawlita M, Waterboer T, Green AC, Feltkamp Patel J, Landers K, Mortimer RH, Richard 3p25 Genetic Linkage Finding for DSM-IV Major MCW. Lack of association between the presence K. Regulation of Hypoxia Inducible Factors Depression in Heavy Smoking Families. American and persistence of betapapillomavirus DNA (HIF) in Hypoxia and Normoxia During Placental Journal of Psychiatry. 2011. [Published online in eyebrow hairs and betapapillomavirus L1 Development. Placenta. 2010;31(11):951-957. ahead of print]. antibodies in serum. Journal of General Virology. 2010;91:2073-2079. Paulson KG, Iyer JG, Tegeder AR, Thibodeau Perry CR, Burke ML, Stenzel DJ, McManus DP, R, Schelter J, Koba S, Schrama D, Simonson Ramm GA, Gobert GN. Differential expression Ponsonby AL, Lucas RM, van der Mei I, Dear WT, Lemos BD, Byrd DR, Koelle DM, Galloway of chemokine and matrix re-modelling genes K, Taylor BV, McMichael AJ, Valery P, Dwyer T, DA, Leonard JH, Madeleine MM, Argenyi ZB, is associated with contrasting schistosome- Chapman C, Pender MP, Coulthard A, Williams Disis ML, Becker JC, Cleary MA, Nghiem induced hepatopathology in murine models. PLoS D, Kilpatrick TJ. Investigation of the role of P. Transcriptome-Wide Studies of Merkel Neglected Tropical Diseases. 2011;5(6):e1178. pregnancy and exposure to biological children in Cell Carcinoma and Validation of Intratumoral the onset of central nervous system demyelination. CD8+ Lymphocyte Invasion As an Independent Pharoah PDP, Palmieri RT, Ramus SJ, Gayther Multiple Sclerosis. 2010;16(8):1007-1008. Predictor of Survival. Journal of Clinical Oncology. SA, Andrulis IL, Anton-Culver H, Antonenkova N, 2011;29(12):1539-1546. Antoniou AC, Goldgar D, Beattie MS, Beckmann Powell JE, Visscher PM, Goddard ME. MW, Birrer MJ, Bogdanova N, Bolton KL, Reconciling the analysis of IBD and IBS in Pearce CL, Doherty JA, Van Den Berg DJ, Brewster W, Brooks-Wilson A, Brown R, Butzow complex trait studies. Nature Reviews Genetics. Moysich K, Hsu C, Cushing-Haugen KL, Conti R, Caldes T, Caligo MA, Campbell I, Chang- 2010;11(11):800-805. DV, Ramus SJ, Gentry-Maharaj A, Menon Claude J, Chen YA, Cook LS, Couch FJ, Cramer U, Gayther SA, Pharoah PD, Song H, Kjaer Powell JE, Zietsch BP. Predicting sensation DW, Cunningham JM, Despierre E, Doherty JA, seeking from dopamine genes: use and misuse SK, Hogdall E, Hogdall C, Whittemore AS, Dork T, Durst M, Eccles DM, Ekici AB, Easton McGuire V, Sieh W, Gronwald J, Medrek K, of genetic prediction. Psychological Science. D, Fasching PA, de Fazio A, Fenstermacher 2011;22(3):413-5. Jakubowska A, Lubinski J, Chenevix-Trench DA, Flanagan JM, Fridley BL, Friedman E, Gao G; AOCS/ACS Study Group, Beesley J, Webb B, Sinilnikova O, Gentry-Maharaj A, Godwin Pretorius CJ, Dimeski G, O’Rourke PK, Marquart PM, Berchuck A, Schildkraut JM, Iversen ES, AK, Goode EL, Goodman MT, Gross J, Hansen L, Tyack SA, Wilgen U, Ungerer JPJ. Outliers Moorman PG, Edlund CK, Stram DO, Pike MC, TVO, Harnett P, Rookus M, Heikkinen T, Hein R, as a Cause of False Cardiac Troponin Results: Genetic variation Ness RB, Rossing MA, Wu AH. Hogdall C, Hogdall E, Iversen ES, Jakubowska Investigating the Robustness of 4 Contemporary in insulin-like growth factor 2 may play a role in A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Assays. Clinical Chemistry. 2011;57(5):710-718. ovarian cancer risk. Human Molecular Genetics. Chenevix-Trench G, Kelemen LE, Kiemeney LA, 2011;20(11):2263-72. Price MA, Butow PN, Costa DSJ, King MT, Kjaer SK, Lambrechts D, LaPolla JP, Lazaro C, Aldridge LLJ, Fardell JE, DeFazio A, Webb Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Pearce CL, Doherty JA, Van Den Berg DJ, PM. Prevalence and predictors of anxiety and Lundvall L, Macgregor S, Marees T, Massuger Moysich K, Hsu C, Cushing-Haugen KL, Conti depression in women with invasive ovarian cancer LF, McLaughlin JR, Menon U, Montagna DV, Ramus SJ, Gentry-Maharaj A, Menon and their caregivers. Medical Journal of Australia. M, Moysich KB, Narod SA, Nathanson KL, U, Gayther SA, Pharoah PDP, Song H, Kjaer 2010;193(5):S52-S57. SK, Hogdall E, Hodgall C, Whittemore AS, Nedergaard L, Ness RB, Nevanlinna H, Nickels McGuire V, Sieh W, Gronwald J, Medrek K, S, Osorio A, Paul J, Pearce CL, Phelan CM, Ramm GA, Ruddell RG. Iron Homeostasis, Jakubowska A, Lubinski J, Chenevix-Trench Pike MC, Radice P, Rossing MA, Schildkraut Hepatocellular Injury, and Fibrogenesis in G, AOCS/ACS Study Group, Beesley J, Webb JM, Sellers TA, Singer CF, Song HL, Stram DO, Hemochromatosis: The Role of Inflammation in a PM, Berchuck A, Schildkraut JM, Iversen ES, Sutphen R, Lindblom A, Terry KL, Tsai YY, van Noninflammatory Liver Disease. Seminars in Liver Moorman PG, Edlund CK, Stram DO, Pike MC, Altena AM, Vergote I, Vierkant RA, Vitonis AF, Disease. 2010;30(3):271-287. Ness RB, Rossing MA, Wu AH. on behalf of Walsh C, Wang-Gohrke S, Wappenschmidt B, Ramsay JR, Suhrbier A, Aylward JH, Ogbourne the Ovarian Cancer Association Consortium. Wu AH, Ziogas A, Berchuck A, Risch HA. The S, Cozzi SJ, Poulsen MG, Baumann KC, Genetic Variation in Insulin-like Growth Factor 2 Role of KRAS rs61764370 in Invasive Epithelial Welburn P, Redlich GL, Parsons PG. The sap is Associated with Ovarian Cancer Risk. Human Ovarian Cancer: Implications for Clinical Testing. from Euphorbia peplus is effective against human Molecular Genetics. 2011;20(11):2263-2272. Clinical Cancer Research. 2011;17(11):3742-3750. nonmelanoma skin cancers. British Journal of Pelecanos AM, Ryan PA, Gatton ML. Outbreak Phatak P, Brissot P, Wurster M, Adams PC, Dermatology. 2011;164(3):633-636. detection algorithms for seasonal disease data: Bonkovsky HL, Gross J, Malfertheiner P, Ramus SJ, Kartsonaki C, Gayther SA, Pharoah a case study using ross river virus disease. BMC McLaren GD, Niederau C, Piperno A, Powell PDP, Sinilnikova OM, Beesley J, Chen XQ, Medical Informatics and Decision Making. 2010;10. LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A McGuffog L, Healey S, Couch FJ, Wang XS, Pelecanos AM, Ryan PA, Gatton ML. Spatial- phase 1/2, dose-escalation trial of deferasirox Fredericksen Z, Peterlongo P, Manoukian S, Temporal Epidemiological Analyses of Two for the treatment of iron overload in HFE-related Peissel B, Zaffaroni D, Roversi G, Barile M, Sympatric, Co-Endemic Alphaviral Diseases in hereditary hemochromatosis. Hepatology. Viel A, Allavena A, Ottini L, Papi L, Gismondi Queensland, Australia. Vector-Borne and Zoonotic 2010;52(5):1671-779. V, Capra F, Radice P, Greene MH, Mai PL, Diseases. 2011;11(4):375-382. Andrulis IL, Glendon G, Ozcelik H, Thomassen Pinzon-Charry A, McPhun V, Kienzle V, M, Gerdes AM, Kruse TA, Cruger D, Jensen Peng JB, Gobert GN, Hong Y, Jiang WB, Han Hirunpetcharat C, Engwerda C, McCarthy J, UB, Caligo MA, Olsson H, Kristoffersson U, HX, McManus DP, Wang XZ, Liu JM, Fu ZQ, Shi Good MF. Low doses of killed parasite in CpG Lindblom A, Arver B, Karlsson P, Askmalm MS, YJ, Lin JJ. Apoptosis Governs the Elimination of elicit vigorous CD4(+) T cell responses against Borg A, Neuhausen SL, Ding YC, Nathanson Schistosoma japonicum from the Non-Permissive blood-stage malaria in mice. Journal of Clinical KL, Domchek SM, Jakubowska A, Lubinski Host Microtus fortis. PLoS ONE. 2011;6(6). Investigation. 2010;120(8):2967-2978. J, Huzarski T, Byrski T, Gronwald J, Gorski B, Cybulski C, Debniak T, Osorio A, Duran M, Pereira TN, Lewindon PJ, Shepherd RW, Walsh Piper M, Barry G, Hawkins J, Mason S, Lindwall Tejada MI, Benitez J, Hamann U, Rookus MA, MJ, Tirnitz-Parker JE, Olynyk JK, Yeoh G, C, Little E, Sarkar A, Smith AG, Moldrich RX, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Ramm GA. The Role of Monocyte Chemotaxis Boyle GM, Tole S, Gronostajski RM, Bailey Bodmer D, Ausems MGEM, van Os TA, Asperen Protein-1 and The Ductular Reaction In Initiating TL, Richards LJ. NFIA Controls Telencephalic CJ, Blok MJ, Meijers-Heijboer HEJ, Peock S, Fibrogenesis in Pediatric Cholestatic Liver Disease. Progenitor Cell Differentiation through Repression of Cook M, Oliver C, Frost D, Dunning AM, Evans Hepatology. 2010;52(4):1266A-1267A. the Notch Effector Hes1. Journal of Neuroscience. DG, Eeles R, Pichert G, Cole T, Hodgson S, 2010;30(27):9127-9139. Pergadia ML, Agrawal A, Heath AC, Martin Brewer C, Morrison PJ, Porteous M, Kennedy NG, Bucholz KK, Madden PAF. Nicotine Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, MJ, Rogers MT, Side LE, Donaldson A, Gregory Withdrawal Symptoms in Adolescent and Adult Evdokiou A, Brown MP, Callen DF, Neilsen H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Twins. Twin Research and Human Genetics. PM. Nutlin-3a Is a Potential Therapeutic for Castera L, Mazoyer S, Barjhoux L, Bonadona 2010;13(4):359-369. V, Leroux D, Faivre L, Lidereau R, Nogues
Page 146 QIMR Annual Report 2010–2011 C, Bignon YJ, Prieur F, Collonge-Rame MA, Bayesian Geostatistical Models. American exposure of DNA to toll-like receptor-9. Immunology Venat-Bouvet L, Fert-Ferrer S, Miron A, Buys Journal of Tropical Medicine and Hygiene. and Cell Biology. 2011;89(4):517-525. SS, Hopper JL, Daly MB, John EM, Terry MB, 2010;83(4):861-867. Goldgar D, Hansen TVO, Jonson L, Ejlertsen B, Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Agnarsson BA, offit K, Kirchhoff T, Vijai J, Dutra- Richard DJ, Cubeddu L, Urquhart AJ, Bain A, Whiley DM, Nissen MD, Trenholme K, Mc Carthy Clarke AVC, Przybylo JA, Montagna M, Casella Bolderson E, Menon D, White MF, Khanna KK. JS, Sloots TP. A real-time, quantitative PCR C, Imyanitov EN, Janavicius R, Blanco I, Lazaro hSSB1 interacts directly with the MRN complex method using hydrolysis probes for the monitoring C, Moysich KB, Karlan BY, Gross J, Beattie MS, stimulating its recruitment to DNA double-strand of Plasmodium falciparum load in experimentally Schmutzler R, Wappenschmidt B, Meindl A, breaks and its endo-nuclease activity. Nucleic Acids infected human volunteers. Malaria Journal. Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler Research. 2011;39(9):3643-3651. 2011;10. H, Varon-Mateeva R, Kast K, Niederacher D, Richard DJ, Savage K, Bolderson E, Cubeddu Roque JB, O’Leary CA, Kyaw-Tanner M, Latter Gadzicki D, Caldes T, de la Hoya M, Nevanlinna L, So S, Ghita M, Chen DJ, White MF, Richard M, Mason K, Shipstone M, Vogelnest L, Duffy H, Aittomaki K, Simard J, Soucy P, Spurdle K, Prise KM, Schettino G, Khanna KK. hSSB1 D. High allergen-specific serum immunoglobulin AB, Holland H, Chenevix-Trench G, Easton rapidly binds at the sites of DNA double-strand E levels in nonatopic West Highland white terriers. DF, Antoniou AC. Genetic Variation at 9p22.2 breaks and is required for the efficient recruitment Veterinary Dermatology. 2011;22(3):257-266. and Ovarian Cancer Risk for BRCA1 and BRCA2 of the MRN complex. Nucleic Acids Research. Mutation Carriers. Journal of the National Cancer 2011;39(5):1692-1702. Rosty C, Parry S, Young JP. Serrated Institute. 2011;103(2). polyposis:an enigmatic model of colorectal cancer Richards R, St Pierre L, Trabi M, Johnson predisposition. Pathology Research International. Randall LM, Engwerda CR. TNF family members LA, de Jersey J, Masci PP, Lavin MF. 2011;2011:157073. and malaria: Old observations, new insights Cloning and characterisation of novel cystatins and future directions. Experimental Parasitology. from elapid snake venom glands. Biochimie. Royce-Tolland ME, Andersen AA, Koyfman HR, 2010;126(3):326-331. 2011;93(4):659-668. Talbot DJ, Wutz A, Tonks ID, Kay GF, Panning B. The A-repeat links ASF/SF2-dependent Xist Randall LM, Kenangalem E, Lampah DA, Richmond-Sinclair NM, Pandeya N, Williams RNA processing with random choice during X Tjitra E, Mwaikambo ED, Handojo T, Piera KA, GM, Neale RE, van der Pols JC, Green AC. inactivation. Nature Structural & Molecular Biology. Zhao ZZ, Rivera FD, Zhou YH, McSweeney Clinical signs of photodamage are associated with 2010;17(8):948-U55. KM, Le LE, Amante FH, Haque A, Stanley AC, basal cell carcinoma multiplicity and site: a 16-year Woodberry T, Salwati E, Granger DL, Hobbs longitudinal study. International Journal of Cancer. Rubenstein JH, Scheiman JM, Sadeghi MR, Price RN, Weinberg JB, Montgomery GW, 2010;127(11):2622-2629. S, Whiteman D, Inadomi JM. Esophageal Anstey NM, Engwerda CR. A study of the TNF/ Adenocarcinoma Incidence in Individuals With LTA/LTB locus and susceptibility to severe malaria Rizzi TS, Arias-Vasquez A, Rommelse N, Gastroesophageal Reflux: Synthesis and Estimates in highland papuan children and adults. Malaria Kuntsi J, Anney R, Asherson P, Buitelaar J, From Population Studies. American Journal of Journal. 2010;9. Banaschewski T, Ebstein R, Ruano D, Van der Gastroenterology. 2011;106(2):254-260. Sluis S, Markunas CA, Garrett ME, Ashley- Randall LM, Kenangalem E, Lampah DA, Tjitra Koch AE, Kollins SH, Anastopoulos AD, Hansell Rubinov M, Bassett DS. Emerging Evidence E, Mwaikambo ED, Handojo T, Piera KA, Zhao NK, Wright MJ, Montgomery GW, Martin NG, of Connectomic Abnormalities in Schizophrenia. ZZ, Rivera FD, Zhou YH, McSweeney KM, Le L, Harris SE, Davies G, Tenesa A, Porteous DJ, Journal of Neuroscience. 2011;31(17):6263-6265. Amante FH, Haque A, Stanley AC, Woodberry Starr JM, Deary IJ, St Pourcain B, Smith GD, Rubinov M, Sporns O, Thivierge JP, Breakspear T, Salwati E, Granger DL, Hobbs MR, Price Timpson NJ, Evans DM, Gill M, Miranda A, M. Neurobiologically realistic determinants of self- RN, Weinberg JB, Montgomery GW, Anstey Mulas F, Oades RD, Roeyers H, Rothenberger organized criticality in networks of spiking neurons. NM, Engwerda CR. Age-Related Susceptibility A, Sergeant J, Sonuga-Barke E, Steinhausen PLoS Computational Biology. 2011;7(6):e1002038. to Severe Malaria Associated with Galectin-2 in HC, Taylor E, Faraone SV, Franke B, Posthuma Highland Papuans. Journal of Infectious Diseases. D. The ATXN1 and TRIM31 Genes Are Related to Rubinov M, Sporns O. Complex 2010;202(1):117-124. Intelligence in an ADHD Background: Evidence network measures of brain connectivity: Uses and interpretations. Neuroimage. Rattanasena P, Anraku I, Gardner J, Le TT, From a Large Collaborative Study Totaling 2010;52(3):1059-1069. Wang XJ, Khromykh AA, Suhrbier A. Prime-boost 4,963 Subjects. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. vaccinations using recombinant flavivirus replicon Rubinov M, Sporns O. Weight-conserving 2011;156B(2):145-157. and vaccinia virus vaccines: an ELISPOT analysis. characterization of complex functional brain Immunol Cell Biol. 2011;89(3):426-36. Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver networks. Neuroimage. 2011;56(4):2068-2079. SD, Don AL, Raffelt NC, De Weerd NA, Lineburg Rawson JB, Manno M, Mrkonjic M, Daftary D, Saccone NL, Culverhouse RC, Schwantes-An KE, Varelias A, Markey KA, Koyama M, Clouston Dicks E, Buchanan DD, Younghusband HB, TH, Cannon DS, Chen XN, Cichon S, Giegling AD, Hertzog PJ, Macdonald KP, Hill GR. Type I Parfrey PS, Young JP, Pollett A, Green RC, I, Han SZ, Han YH, Keskitalo-Vuokko K, Kong interferons control GVHD and GVL responses after Gallinger S, McLaughlin JR, Knight JA, Bapat B. XY, Landi MT, Ma JZ, Short SE, Stephens SH, transplantation. Blood. 2011. Promoter methylation of Wnt antagonists DKK1 and Stevens VL, Sun LW, Wang YF, Wenzlaff AS, SFRP1 is associated with opposing tumor subtypes Robb RJ, Kuns R, Wilson Y, Olver S, Don A, Aggen SH, Breslau N, Broderick P, Chatterjee in two large populations of colorectal cancer Raffelt N, Lineburg KE, Varelias A, Markey K, N, Chen JC, Heath AC, Heliovaara M, Hoft NR, patients. Carcinogenesis. 2011;32(5):741-747. Koyama M, Hill G, MacDonald K. Identification Hunter DJ, Jensen MK, Martin NG, Montgomery GW, Niu TH, Payne TJ, Peltonen L, Pergadia Rawson JB, Mrkonjic M, Daftary D, Dicks E, of a novel CD8+FoxP3+population following ML, Rice JP, Sherva R, Spitz MR, Sun JZ, Wang Buchanan DD, Younghusband HB, Parfrey allogeneic bone marrow transplantation. Bone JC, Weiss RB, Wheeler W, Witt SH, Yang BZ, PS, Young JP, Pollett A, Green RC, Gallinger Marrow Transplantation. 2011;46:S48. Caporaso NE, Ehringer MA, Eisen T, Gapstur S, McLaughlin JR, Knight JA, Bapat B. Roberts A, Nancarrow D, Clendenning M, SM, Gelernter J, Houlston R, Kaprio J, Kendler Promoter methylation of Wnt5a is associated Buchanan DD, Jenkins MA, Duggan D, Taverna KS, Kraft P, Leppert MF, Li MD, Madden PAF, with microsatellite instability and BRAF V600E D, McKeone D, Walters R, Walsh MD, Young Nothen MM, Pillai S, Rietschel M, Rujescu mutation in two large populations of colorectal BW, Jass JR, Rosty C, Gattas M, Pelzer E, D, Schwartz A, Amos CI, Bierut LJ. Multiple cancer patients. British Journal of Cancer. Hopper JL, Goldblatt J, George J, Suthers GK, Independent Loci at Chromosome 15q25.1 2011;104(12):1906-1912. Phillips K, Parry S, Woodall S, Arnold J, Tucker Affect Smoking Quantity: a Meta-Analysis and Redmond AM, Doolan DL. The Australasian K, Muir A, Drini M, Macrae F, Newcomb P, Potter Comparison with Lung Cancer and COPD. PLoS contribution to malaria vaccine development. JD, Pavluk E, Lindblom A, Young JP. Linkage Genetics. 2010;6(8). Parasite Immunology. 2010;32(8):607-622. to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Familial Cancer. Schettino G, Ghita M, Richard DJ, Prise KM. Reed DR, Zhu G, Breslin PAS, Duke FF, Henders 2011;10(2):245-254. Spatiotemporal investigations of DNA damage AK, Campbell MJ, Montgomery GW, Medland repair using microbeams. Radiation Protection SE, Martin NG, Wright MJ. The perception of Roberts TL Roberts TL, Dunn JA, Sweet MJ, Dosimetry. 2011;143(2-4):340-343. quinine taste intensity is associated with common Hume DA, Stacey KJ. The immunostimulatory genetic variants in a bitter receptor cluster on activity of phosphorothioate CpG oligonucleotides chromosome 12. Human Molecular Genetics. is affected by distal sequence changes. Molecular 2010;19(21):4278-4285. Immunology. 2011;48(8):1027-1034.
Reid H, Haque U, Clements ACA, Tatem Roberts TL, Turner ML, Dunn JA, Lenert P, Ross AJ, Vallely A, Ahmed SM, Islam A, Haque IL, Sweet MJ, Stacey KJ. B cells do not take R. Mapping Malaria Risk in Bangladesh Using up bacterial DNA: an essential role for antigen in
Page 147 Scientific publications | continued
Schoenmakers E, Agostini M, Mitchell C, Belmonte M, Sayo R, Farooq F, Doolan DL, at Ages 0-50 Years. Twin Research and Human Schoenmakers N, Papp L, Rajanayagam O, Regis D, Tamminga C, Chuang I, Bruder JT, King Genetics. 2010;13(4):370-380. Padidela R, Ceron-Gutierrez L, Doffinger R, CR, Ockenhouse CF, Faber B, Remarque E, Prevosto C, Luan J, Montano S, Lu J, Castanet Hollingdale MR, Richie TL, Sette A. Identification Smith C, Khanna R. Herpesvirus vaccines M, Clemons N, Groeneveld M, Castets P, and localization of minimal MHC-restricted CD8+ Challenges and future prospects. Human Vaccines. Karbaschi M, Aitken S, Dixon A, Williams T cell epitopes within the Plasmodium falciparum 2010;6(12):1062-1067. J, Campi I, Blount M, Burton H, Muntoni F, AMA1 protein. Malaria Journal. 2010;9. Smith C, Martinez M, Peet J, Khanna R. O’Donovan D, Dean A, Warren A, Brierley C, Differential Outcome of IL-2/Anti-IL-2 Complex Baguley D, Guicheney P, Fitzgerald R, Coles Serewko-Auret MM, Mould AW, Loffler KA, Duncan R, Kay GF, Hayward NK. Alterations in Therapy on Effector and Memory CD8(+) T Cells A, Gaston H, Todd P, Holmgren A, Khanna KK, following Vaccination with an Adenoviral Vector Cooke M, Semple R, Halsall D, Wareham N, Gene Expression in MEN1-Associated Insulinoma Development. Pancreas. 2010;39(8):1140-1146. Encoding EBV Epitopes. Journal of Immunology. Schwabe J, Grasso L, Beck-Peccoz P, Ogunko 2011;186(10):5784-5790. A, Dattani M, Gurnell M, Chatterjee K. Mutations Simmonds DM, West L, Porter J, Davies M, in the selenocysteine insertion sequence-binding Holland C, Preston-Thomas A, O’Rourke Smith NL, Huffman JE, Strachan DP, Huang protein 2 gene lead to a multisystem selenoprotein PK, Tangey A. The role of support person for J, Dehghan A, Trompet S, Lopez LM, Shin SY, deficiency disorder in humans. Journal of Clinical Ngaanyatjarra women during pregnancy and birth. Baumert J, Vitart V, Bis JC, Wild SH, Rumley Investigation. 2010;120(12):4220-4235. Women Birth. 2011. [Published online ahead of A, Yang Q, Uitterlinden AG, Stott DJ, Davies G, print]. Carter AM, Thorand B, Polasek O, McKnight B, Schroder WA Schroder WA, Major L, Suhrbier A. Campbell H, Rudnicka AR, Chen MH, Buckley The Role of SerpinB2 in Immunity. Critical Reviews Simms LA, Doecke J, Huang N, Zhao BM, Harris SE, Peters A, Pulanic D, Lumley T, In Immunology. 2011;31(1):15-30. ZZ, Kristine FU, Roberts RL, Barclay ML, de Craen AJM, Liewald DC, Gieger C, Campbell Schroder WA, Gardner J, Le TT, Duke M, Burke Montgomery GW, Lawrance IC, Gearry RB, S, Ford I, Gow AJ, Luciano M, Porteous DJ, ML, Jones MK, McManus DP, Suhrbier A. Radford-Smith GL. Genotype markers predict Guo XQ, Sattar N, Tenesa A, Cushman M, SerpinB2 deficiency modulates Th1/Th2 responses time to first resection in Crohn’s disease patients. Slagboom PE, Visscher PM, Spector TD, Illig after schistosome infection. Parasite Immunology. Journal of Gastroenterology and Hepatology. T, Rudan I, Bovill EG, Wright AF, McArdle WL, 2010;32(11-12):764-768. 2010;25:A82-A83. Tofler G, Hofman A, Westendorp RGJ, Starr JM, Grant PJ, Karakas M, Hastie ND, Psaty Schulte L, Glanfield A, Nawaratna S, Gobert Simms LA, Doecke JD, Roberts RL, Fowler EV, BM, Wilson JF, Lowe GDO, O’Donnell CJ, GN, McManus DP, Jones MK. Molecular analysis Zhao ZZ, McGuckin MA, Huang N, Hayward Witteman JCM, Jukema JW, Deary IJ, Soranzo of zinc transporters in Schistosoma japonicum. NK, Webb PM, Whiteman DC, Cavanaugh JA, N, Koenig W, Hayward C. Genetic Predictors of Experimental Parasitology. 2011;127(4):768-776. McCallum R, Florin THJ, Barclay ML, Gearry RB, Fibrin D-Dimer Levels in Healthy Adults. Circulation. Merriman TR, Montgomery GW, Radford-Smith 2011;123(17):1864. Schultze-Kraft M, Becker R, Breakspeare GL. KCNN4 Gene Variant Is Associated With Ileal M, Ritter P. Exploiting the potential of three Crohn’s Disease in the Australian and New Zealand Smithers BM, Fahey PP, Corish T, Gotley dimensional spatial wavelet analysis to explore Population. American Journal of Gastroenterology. DC, Falk GL, Smith GS, Kiroff GK, Clouston nesting of temporal oscillations and spatial variance 2010;105(10):2209-2217. AD, Watson DI, Whiteman DC. Symptoms, in simultaneous EEG-fMRI data. Progress In investigations and management of patients with Biophysics & Molecular Biology. 2011;105(1- Simpson PT, Vargas AC, Al-Ejeh F, Khanna cancer of the oesophagus and gastro-oesophageal 2):67-79. KK, Chenevix-Trench G, Lakhani SR. junction in Australia. Medical Journal of Australia. Application of molecular findings to the diagnosis 2010;193(10):572-577. Schumann G, Coin LJ, Lourdusamy A, Charoen and management of breast disease: recent P, Berger KH, Stacey D, Desrivieres S, Aliev advances and challenges. Human Pathology. Smout MJ, Kotze AC, McCarthy JS, Loukas A. A FA, Khan AA, Amin N, Aulchenko YS, Bakalkin 2011;42(2):153-165. Novel High Throughput Assay for Anthelmintic Drug G, Bakker SJ, Balkau B, Beulens JW, Bilbao A, Screening and Resistance Diagnosis by Real-Time de Boer RA, Beury D, Bots ML, Breetvelt EJ, Singh AL, D’Onofrio BM, Slutske WS, Monitoring of Parasite Motility. PLoS Neglected Cauchi S, Cavalcanti-Proenca C, Chambers Turkheimer E, Emery RE, Harden KP, Heath AC, Tropical Diseases. 2010;4(11):. JC, Clarke TK, Dahmen N, de Geus EJ, Dick Madden PAF, Statham DJ, Martin NG. Parental D, Ducci F, Easton A, Edenberg HJ, Esk T, depression and offspring psychopathology: a Soltani A, Reid DW, Sohal SS, Wood-Baker R, Fernandez-Medarde A, Foroud T, Freimer Children of Twins study. Psychological Medicine. Weston S, Muller HK, Walters EH. Basement NB, Girault JA, Grobbee DE, Guarrera S, 2011;41(7):1385-1395. membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a Gudbjartsson DF, Hartikainen AL, Heath AC, Siskind V, Hughes MCB, Palmer JM, Symmons Hesselbrock V, Hofman A, Hottenga JJ, Isohanni cross-sectional study. Respiratory Research. JM, Aitken JF, Martin NG, Hayward NK, 2010;11:105. MK, Kaprio J, Khaw KT, Kuehnel B, Laitinen J, Whiteman DC. Nevi, Family History, and Fair Lobbens S, Luan JA, Mangino M, Maroteaux Skin Increase the Risk of Second Primary Sommerlad S, Mcrae AF, McDonald B, M, Matullo G, McCarthy MI, Mueller C, Navis Melanoma. Journal of Investigative Dermatology. Johnstone I, Cuttell L, Seddon JM, O’Leary CA. G, Numans ME, Nunez A, Nyholt DR, Onland- 2011;131(2):461-467. Congenital Sensorineural Deafness in Australian Moret CN, Oostra BA, O’Reilly PF, Palkovits M, Stumpy-Tail Cattle Dogs Is an Autosomal Recessive Penninx BW, Polidoro S, Pouta A, Prokopenko Slutske WS, Bascom EN, Meier MH, Medland Trait That Maps to CFA10. PLoS ONE. 2010;5(10). I, Ricceri F, Santos E, Smit JH, Soranzo N, Song SE, Martin NG. Sensation Seeking in Females from K, Sovio U, Stumvoll M, Surakk I, Thorgeirsson Opposite- Versus Same-Sex Twin Pairs: Hormone Spatola CAM, Scaini S, Pesenti-Gritti P, TE, Thorsteinsdottir U, Troakes C, Tyrfingsson Transfer or Sibling Imitation?. Behavior Genetics. Medland SE, Moruzzi S, Ogliari A, Tambs K, T, Tonjes A, Uiterwaal CS, Uitterlinden AG, 2011;41(4):533-542. Battaglia M. Gene-Environment Interactions in van der Harst P, van der Schouw YT, Staehlin Panic Disorder and CO(2) Sensitivity: Effects of Slutske WS, Piasecki TM, Blaszczynski A, O, Vogelzangs N, Vollenweider P, Waeber G, Events Occurring Early in Life. American Journal Martin NG. Pathological gambling recovery Wareham NJ, Waterworth DM, Whitfield JB, of Medical Genetics Part B-Neuropsychiatric in the absence of abstinence. Addiction. Wichmann EH, Willemsen G, Witteman JC, Yuan Genetics. 2011;156B(1):79-88. 2010;105(12):2169-2175. X, Zhai GJ, Zhao JH, Zhang WH, Martin NG, Speliotes EK, Willer CJ, Berndt SI, Monda KL, Metspalu A, Doering A, Scott J, Spector TD, Slutske WS, Piasecki TM, Ellingson JM, Martin Thorleifsson G, Jackson AU, Allen HL, Lindgren Loos RJ, Boomsma DI, Mooser V, Peltonen L, The Family History Method in Disordered NG. CM, Luan J, Magi R, Randall JC, Vedantam Stefansson K, van Duijn CM, Vineis P, Sommer Gambling Research: A Comparison of Reports S, Winkler TW, Qi L, Workalemahu T, Heid IM, WH, Kooner JS, Spanagel R, Heberlein UA, Obtained from Discordant Twin Pairs. Twin Steinthorsdottir V, Stringham HM, Weedon Jarvelin MR, Elliott P. Genome-wide association Research and Human Genetics. 2010;13(4):340- MN, Wheeler E, Wood AR, Ferreira T, Weyant and genetic functional studies identify autism 346. RJ, Segre AV, Estrada K, Liang LM, Nemesh J, susceptibility candidate 2 gene (AUTS2) in the Park JH, Gustafsson S, Kilpelanen TO, Yang JA, regulation of alcohol consumption. Proceedings of Smit DJA, Luciano M, Bartels M, van Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, The National Academy of Sciences of The United Beijsterveldt CEM, Wright MJ, Hansell NK, Mangino M, Raychaudhuri S, Scherag A, Smith States of America. 2011;108(17):7119-7124. Brunner HG, Estourgie-van Burk GF, de Geus EJC, Martin NG, Boomsma DI. Heritability of AV, Welch R, Zhao JH, Aben KK, Absher DM, Sedegah M, Kim Y, Peters B, McGrath S, Head Size in Dutch and Australian Twin Families Amin N, Dixon AL, Fisher E, Glazer NL, Goddard Ganeshan H, Lejano J, Abot E, Banania G, ME, Heard-Costa NL, Hoesel V, Hottenga JJ,
Page 148 QIMR Annual Report 2010–2011 Johansson A, Johnson T, Ketkar S, Lamina C, Li Barroso I, Boehnke M, Stefansson K, North KE, Endophenotypes: The Australian Twins Eye SX, Moffatt MF, Myers RH, Narisu N, Perry JRB, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos Study. American Journal of Ophthalmology. Peters MJ, Preuss M, Ripatti S, Rivadeneira RJF. Association analyses of 249,796 individuals 2010;150(6):909-916. F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, reveal 18 new loci associated with body mass van Wingerden S, Watanabe RM, White CC, index. Nature Genetics. 2010;42(11):937-U53. Sun C, Yang H, Yuan Y, Tian X, Wang L, Guo Wiklund F, Barlassina C, Chasman DI, Cooper Y, Xu L, Lei J, Gao N, Anderson GJ, Liang XJ, MN, Jansson JO, Lawrence RW, Pellikka N, Sprangers MAG, Bartels M, Veenhoven R, Baas Chen C, Zhao Y, Nie G. Controlling assembly of Prokopenko I, Shi JX, Thiering E, Alavere F, Martin NG, Mosing M, Movsas B, Ropka ME, paired gold clusters within apoferritin nanoreactor H, Alibrandi MTS, Almgren P, Arnold AM, Shinozaki G, Swaab D. Which patient will feel for in vivo kidney targeting and biomedical imaging. Aspelund T, Atwood LD, Balkau B, Balmforth down, which will be happy? The need to study the Journal of the American Chemistry Society. AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, genetic disposition of emotional states. Quality of 2011;133(22):8617-24. Life Research. 2010;19(10):1429-1437. Bergmann S, Biebermann H, Blakemore AIF, Swarbrick A, Woods SL, Shaw A, Balakrishnan Boes T, Bonnycastle LL, Bornstein SR, Brown Spurdle AB, Fahey P, Chen XQ, McGuffog L, A, Phua Y, Nguyen A, Chanthery Y, Lim L, MJ, Buchanan TA, Busonero F, Campbell H, Easton D, Peock S, Cook M, Simard J, Rebbeck Ashton LJ, Judson RL, Huskey N, Blelloch R, Cappuccio FP, Cavalcanti-Proenca C, Chen TR, Antoniou AC, Chenevix-Trench G. Pooled Haber M, Norris MD, Lengyel P, Hackett CS, YDI, Chen CM, Chines PS, Clarke R, Coin L, analysis indicates that the GSTT1 deletion, GSTM1 Preiss T, Chetcuti A, Sullivan CS, Marcusson Connell J, Day INM, den Heijer M, Duan JB, deletion, and GSTP1 Ile105Val polymorphisms EG, Weiss W, L’Etoile N, Goga A. miR-380-5p Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, do not modify breast cancer risk in BRCA1 and represses p53 to control cellular survival and Erdos MR, Eriksson JG, Facheris MF, Felix SB, BRCA2 mutation carriers. Breast Cancer Research is associated with poor outcome in MYCN- Fischer-Posovszky P, Folsom AR, Friedrich N, and Treatment. 2010;122(1):281-285. amplified neuroblastoma. Nature Medicine. Freimer NB, Fu M, Gaget S, Gejman PV, Geus 2010;16(10):1134-U113. EJC, Gieger C, Gjesing AP, Goel A, Goyette P, Spurdle AB, Marquart L, McGuffog L, Healey Grallert H, Grassler J, Greenawalt DM, Groves S, Sinilnikova O, Wan F, Chen XQ, Beesley J, Tang W, Cushman M, Schwienbacher C, Lopez CJ, Gudnason V, Guiducci C, Hartikainen AL, Singer CF, Dressler AC, Gschwantler-Kaulich D, LM, Ben Shlomo Y, Basu S, Gogele M, Davies Hassanali N, Hall AS, Havulinna AS, Hayward Blum JL, Tung N, Weitzel J, Lynch H, Garber J, G, Lowe G, Pankow JS, Tenesa A, Volpato C, Heath AC, Hengstenberg C, Hicks AA, Easton DF, Peock S, Cook M, Oliver CT, Frost C, Rumley A, Gow A, Minelli C, Yarnell JWG, Hinney A, Hofman A, Homuth G, Hui J, Igl W, D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt Porteous D, Starr JM, Boerwinkle E, Visscher Iribarren C, Isomaa B, Jacobs KB, Jarick I, L, Davidson R, Chu C, Eccles D, Selkirk CG, PM, Pramstaller PP, Deary IJ, Hicks AA, Jewell E, John U, Jorgensen T, Jousilahti P, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova Folsom AR. Genome Wide Association Study Jula A, Kaakinen M, Kajantie E, Kaplan LM, OM, Buecher B, Belotti M, Mazoyer S, Barjhoux Identifies Multiple Genetic Loci for Activated Partial Kathiresan S, Kettunen J, Kinnunen L, Knowles L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol Thromboplastin Time and Prothrombin Time. JW, Kolcic I, Konig IR, Koskinen S, Kovacs P, P, Collonge-Rame MA, Rookus MA, Verhoef S, Blood. 2010;116(21):1715-1716. Kuusisto J, Kraft P, Kvaloy K, Laitinen J, Lantieri Kriege M, Hoogerbrugge N, Ausems MGEM, Tarutta E, Chua WH, Young T, Goldschmidt O, Lanzani C, Launer LJ, Lecoeur C, Lehtimaki van Os TA, Wijnen J, Devilee P, Meijers-Heijboer E, Saw SM, Rose KA, Smith E 3rd, Mutti DO, T, Lettre G, Liu JJ, Lokki ML, Lorentzon M, HEJ, Blok MJ, Heikkinen T, Nevanlinna H, Ashby R, Stone RA, Wildsoet C, Howland HC, Luben RN, Ludwig B, Manunta P, Marek D, Jakubowska A, Lubinski J, Huzarski T, Byrski Fischer AJ, Stell WK, Reichenbach A, Frost M, Marre M, Martin NG, McArdle WL, McCarthy A, T, Durocher F, Couch FJ, Lindor NM, Wang Gentle A, Zhu X, Summers-Rada J, Barathi V, McKnight B, Meitinger T, Melander O, Meyre XS, Thomassen M, Domchek S, Nathanson K, Jiang L, McFadden S, et al. Myopia: Why Study D, Midthjell K, Montgomery GW, Morken MA, Caligo MA, Jernstrom H, Liljegren A, Ehrencrona the Mechanisms of Myopia? Novel Approaches to Morris AP, Mulic R, Ngwa JS, Nelis M, Neville H, For PK, Ganz PA, Olopade OI, Tomlinson G, Risk Factors Signalling Eye Growth- How Could MJ, Nyholt DR, O’Donnell CJ, O’Rahilly S, Ong Neuhausen S, Antoniou AC, Chenevix-Trench Basic Biology Be Translated into Clinical Insights? KK, Oostra B, Pare G, Parker AN, Perola M, G, Rebbeck TR. Common Genetic Variation at Where Are Genetic and Proteomic Approaches Pichler I, Pietilainen KH, Platou CGP, Polasek BARD1 Is Not Associated with Breast Cancer Leading? How Does Visual Function Contribute to O, Pouta A, Rafelt S, Raitakari O, Rayner NW, Risk in BRCA1 or BRCA2 Mutation Carriers. an. Optometry & Vision Science. 2011. [Published Ridderstrale M, Rief W, Ruokonen A, Robertson Cancer Epidemiology Biomarkers & Prevention. online ahead of print]. NR, Rzehak P, Salomaa V, Sanders AR, Sandhu 2011;20(5):1032-1038. MS, Sanna S, Saramies J, Savolainen MJ, Spurdle AB, Thompson DJ, Ahmed S, Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Scherag S, Schipf S, Schreiber S, Schunkert Ferguson K, Healey CS, O’Mara T, Walker Evers R, Chockley P, Nieves E, Sun YP, Lowler H, Silander K, Sinisalo J, Siscovick DS, Smit LC, Montgomery SB, Dermitzakis ET, Fahey KP, Malter C, Nishimoto N, Hill GR, Reddy JH, Soranzo N, Sovio U, Stephens J, Surakka P, Montgomery GW, Webb PM, Fasching PA, P. Interleukin-6 Modulates Graft-versus-Host I, Swift AJ, Tammesoo ML, Tardif JC, Teder- Beckmann MW, Ekici AB, Hein A, Lambrechts Responses after Experimental Allogeneic Bone Laving M, Teslovich TM, Thompson JR, D, Coenegrachts L, Vergote I, Amant F, Marrow Transplantation. Clinical Cancer Research. Thomson B, Tonjes A, Tuomi T, van Meurs JBJ, Salvesen HB, Trovik J, Njolstad TS, Helland 2011;17(1):77-88. van Ommen GJ, Vatin V, Viikari J, Visvikis- H, Scott RJ, Ashton K, Proietto T, Otton G, Siest S, Vitart V, Vogel CIG, Voight BF, Waite Terzian T, Torchia EC, Dai D, Robinson SE, Tomlinson I, Gorman M, Howarth K, Hodgson LL, Wallaschofski H, Walters GB, Widen E, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, S, Garcia-Closas M, Wentzensen N, Yang HN, Wiegand S, Wild SH, Willemsen G, Witte DR, Powell MB, Pollock PM, Lozano G, Robinson Chanock S, Hall P, Czene K, Liu JJ, Li JM, Shu Witteman JC, Xu JF, Zhang QY, Zgaga L, Ziegler WA, Roop DR, Box NF. p53 prevents progression XO, Zheng W, Long JR, Xiang YB, Shah M, A, Zitting P, Beilby JP, Farooqi IS, Hebebrand of nevi to melanoma predominantly through Morrison J, Michailidou K, Pharoah PD, Dunning J, Huikuri HV, James AL, Kahonen M, Levinson cell cycle regulation. Pigment Cell & Melanoma AM, Easton DF. Genome-wide association DF, Macciardi F, Nieminen MS, Ohlsson C, Research. 2010;23(6):781-794. study identifies a common variant associated Palmer LJ, Ridker PM, Stumvoll M, Beckmann with risk of endometrial cancer. Nature Genetics. JS, Boeing H, Boerwinkle E, Boomsma DI, 2011;43(5):451. Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Gronberg Sriram KB, Larsen JE, Francis SMS, Wright H, Gyllensten U, Hall P, Hansen T, Harris TB, CM, Mattar K, Windsor M, Clarke BE, Duhig EE, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hayward NK, Bowman RV, Yang IA, Fong KM. Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe Array-Comparative Genomic Hybridization Identifies F, Khaw KT, Kiemeney LA, Krude H, Laakso M, Novel Copy Number Alterations in Recurrent Lawlor DA, Metspalu A, Munroe PB, Ouwehand Squamous Cell Lung Cancer. Journal of Thoracic WH, Pedersen O, Penninx BW, Peters A, Oncology. 2011;6(3):S34-S34. Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PEH, Straub CP, Lau WH, Preston FM, Headlam MJ, Shuldiner AR, Spector TD, Tuomilehto J, Uda Gorman JJ, Collins PL, Spann KM. Mutation of M, Uitterlinden A, Valle TT, Wabitsch M, Waeber the elongin C binding domain of human respiratory G, Wareham NJ, Watkins H, Wilson JF, Wright syncytial virus non-structural protein 1 (NS1) results AF, Zillikens MC, Chatterjee N, McCarroll SA, in degradation of NS1 and attenuation of the virus. Purcell S, Schadt EE, Visscher PM, Assimes Virology Journal. 2011;8. TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Sun C, Ponsonby AL, Brown SA, Kearns Haritunians T, Hunter DJ, Kaplan RC, Mohlke LS, MacKinnon JR, Barbour JM, Ruddle JB, KL, O’Connell JR, Peltonen L, Schlessinger Hewitt AW, Wright MJ, Martin NG, Dwyer T, D, Strachan DP, van Duijn CM, Wichmann HE, Mackey DA. Associations of Birth Weight With Frayling TM, Thorsteinsdottir U, Abecasis GR, Ocular Biometry, Refraction, and Glaucomatous
Page 149 Scientific publications | continued
Teslovich TM, Musunuru K, Smith AV, Thomsen SF, Duffy DL, Kyvik KO, Skytthe A, the Missing Heritability of Colorectal Cancer. PLoS Edmondson AC, Stylianou IM, Koseki M, Backer V. Relationship between type 1 diabetes Genetics. 2011;7(6):e1002105. Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, and atopic diseases in a twin population. Allergy. Johansen CT, Fouchier SW, Isaacs A, Peloso 2011;66(5):645-647. Tomlinson IP, Carvajal-Carmona LG, Dobbins GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko SE, Tenesa A, Jones AM, Howarth K, Palles C, YS, Thorleifsson G, Feitosa MF, Chambers J, Thomsen SF, Duffy DL, Kyvik KO, Skytthe A, Broderick P, Jaeger EE, Farrington S, Lewis Orho-Melander M, Melander O, Johnson T, Li Backer V. Risk of asthma in adult twins with type 2 A, Prendergast JG, Pittman AM, Theodoratou X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim diabetes and increased body mass index. Allergy. E, Olver B, Walker M, Penegar S, Barclay Y, Lee J-Y, Park T, Kim K, Sim X, Twee-Hee 2011;66(4):562-568. E, Whiffin N, Martin L, Ballereau S, Lloyd A, Gorman M, Lubbe S; The COGENT Consortium; Ong R, Croteau-Chonka DC, Lange LA, Smith Thomson IG, Smithers BM, Gotley DC, JD, Song K, Hua Zhao J, Yuan X, Luan Ja, The CORGI Collaborators; The EPICOLON Martin I, Thomas JM, O’Rourke P, Barbour Consortium, Howie B, Marchini J, Ruiz-Ponte C, Lamina C, Ziegler A, Zhang W, Zee RYL, Wright Thoracoscopic-Assisted Esophagectomy AP. Fernandez-Rozadilla C, Castells A, Carracedo AF, Witteman JCM, Wilson JF, Willemsen G, for Esophageal Cancer Analysis of Patterns and A, Castellvi-Bel S, Duggan D, Conti D, Cazier Wichmann HE, Whitfield JB, Waterworth DM, Prognostic Factors for Recurrence. Annals of JB, Campbell H, Sieber O, Lipton L, Gibbs P, Wareham NJ, Waeber G, Vollenweider P, Voight Surgery. 2010;252(2):281-291. BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto Martin NG, Montgomery GW, Young J, Baird J, Thompson JR, Tanaka T, Surakka I, Stringham Thorleifsson G, Walters GB, Hewitt AW, PN, Gallinger S, Newcomb P, Hopper J, Jenkins HM, Spector TD, Soranzo N, Smit JH, Sinisalo Masson G, Helgason A, Dewan A, Sigurdsson MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah J, Silander K, Sijbrands EJG, Scuteri A, Scott J, A, Jonasdottir A, Gudjonsson SA, Magnusson P, Casey G, Houlston RS, Dunlop MG. Multiple Schlessinger D, Sanna S, Salomaa V, Saharinen KP, Stefansson H, Lam DSC, Tam POS, Common Susceptibility Variants near BMP Pathway J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Gudmundsdottir GJ, Southgate L, Burdon Loci GREM1, BMP4, and BMP2 Explain Part of Roberts R, Rieder M, Psaty BM, Pramstaller PP, KP, Gottfredsdottir MS, Aldred MA, Mitchell the Missing Heritability of Colorectal Cancer. PLoS Pichler I, Perola M, Penninx BWJH, Pedersen P, St Clair D, Collier DA, Tang N, Sveinsson Genetics. 2011;7(6):e1002105. NL, Pattaro C, Parker AN, Pare G, Oostra BA, O, Macgregor S, Martin NG, Cree AJ, Gibson Tonks ID, Mould AW, Schroder WA, Hacker E, O/’Donnell CJ, Nieminen MS, Nickerson DA, J, MacLeod A, Jacob A, Ennis S, Young TL, Bosenberg M, Hayward NK, Walker GJ, Kay GF. Montgomery GW, Meitinger T, McPherson R, Chan JCN, Karwatowski WSS, Hammond CJ, Melanocyte homeostasis in vivo tolerates Rb1 loss McCarthy MI, McArdle W, Masson D, Martin Thordarson K, Zhang M, Wadelius C, Lotery AJ, in a developmentally independent fashion. Pigment NG, Marroni F, Mangino M, Magnusson PKE, Trembath RC, Pang CP, Hoh J, Craig JE, Kong Cell & Melanoma Research. 2010;23(4):564-570. Lucas G, Luben R, Loos RJF, Lokki M-L, Lettre A, Mackey DA, Jonasson F, Thorsteinsdottir G, Langenberg C, Launer LJ, Lakatta EG, U, Stefansson K. Common variants near CAV1 Turner M, Jackson H, Harle R, Bohmer R, Reid Laaksonen R, Kyvik KO, Kronenberg F, Konig and CAV2 are associated with primary open-angle DW. Atypical presentation of acute pancreatitis IR, Khaw K-T, Kaprio J, Kaplan LM, Johansson glaucoma. Nature Genetics. 2010;42(10):906. in a man with pancreatic insufficiency and cystic A, Jarvelin M-R, Cecile J. W. Janssens A, fibrosis: a case report. Journal of Medical Case Thorne RF, Ralston KJ, de Bock CE, Mhaidat Ingelsson E, Igl W, Kees Hovingh G, Hottenga Reports. 2010;4:275. NM, Zhang XD, Boyd AW, Burns GF. J-J, Hofman A, Hicks AA, Hengstenberg C, Palmitoylation of CD36/FAT regulates the rate of its Tyagi S, Stark MS, Hayward NK, Whiteman Heid IM, Hayward C, Havulinna AS, Hastie ND, post-transcriptional processing in the endoplasmic DC, Nancarrow DJ. webFOG: A web tool to Harris TB, Haritunians T, Hall AS, Gyllensten reticulum. Biochimica Et Biophysica Acta-Molecular map genomic features onto genes. Biochemical U, Guiducci C, Groop LC, Gonzalez E, Gieger Cell Research. 2010;1803(11):1298-1307. and Biophysical Research Communications. C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, 2010;401(3):447-450. Ejebe KG, Doring A, Dominiczak AF, Demissie Thrift AP, Pandeya N, Smith KJ, Green AC, S, Deloukas P, de Geus EJC, de Faire U, Hayward NK, Webb PM, Whiteman DC. Upcroft JA, Krauer KG, Upcroft P. Chromosome Crawford G, Collins FS, Chen Y-dI, Caulfield Helicobacter pylori infection and the risks of sequence maps of the Giardia lamblia MJ, Campbell H, Burtt NP, Bonnycastle LL, Barrett’s oesophagus: A population-based case- assemblage A isolate WB. Trends in Parasitology. Boomsma DI, Boekholdt SM, Bergman RN, control study. International Journal of Cancer. 2011. 2010;26(10):484-491. Barroso I, Bandinelli S, Ballantyne CM, Assimes [Published online ahead of print]. TL, Quertermous T, Altshuler D, Seielstad M, Urquhart AJ, Gatei M, Richard DJ, Khanna Wong TY, Tai ES, Feranil AB, Kuzawa CW, Thrift AP, Pandeya N, Smith KJ, Mallitt KA, KK. ATM mediated phosphorylation of CHD4 Adair LS, Taylor Jr HA, Borecki IB, Gabriel Green AC, Webb PM, Whiteman DC. Lifetime contributes to genome maintenance. Genome SB, Wilson JG, Holm H, Thorsteinsdottir U, Alcohol Consumption and Risk of Barrett’s Integrity. 2011;2(1):1. Gudnason V, Krauss RM, Mohlke KL, Ordovas Esophagus. American Journal of Gastroenterology. van der Pols JC, Hughes MCB, Ibiebele TI, JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, 2011;106(7):1220-30. Marks GC, Green AC. Food intake and risk of Kastelein JJP, Schadt EE, Rotter JI, Boerwinkle Ting MJ, Day BW, Spanevello MD, Boyd basal cell carcinoma in an 11-year prospective E, Strachan DP, Mooser V, Stefansson K, Reilly AW. Activation of ephrin A proteins influences study of Australian adults. European Journal of MP, Samani NJ, Schunkert H, Cupples LA, hematopoietic stem cell adhesion and Clinical Nutrition. 2011;65(1):39-46. Sandhu MS, Ridker PM, Rader DJ, van Duijn trafficking patterns. Experimental Hematology. CM, Peltonen L, Abecasis GR, Boehnke M, 2010;38(11):1087-1098. van der Pols JC, Xu C, Boyle GM, Hughes Kathiresan S. Biological, clinical and population MC, Carr SJ, Parsons PG, Green AC. Serum relevance of 95 loci for blood lipids. Nature. Toh SQ, Glanfield A, Gobert GN, Jones MK. omega-3 and omega-6 fatty acids and cutaneous 2010;466(7307):707-13. Heme and blood-feeding parasites: friends or p53 expression in an Australian population. foes?. Parasites & Vectors. 2010;3. Cancer Epidemiology, Biomarkers & Prevention. Teuscher F, Gatton ML, Chen NH, Peters J, Kyle 2011;20(3):530-6. DE, Cheng Q. Artemisinin-Induced Dormancy in Tomlinson IP, Carvajal-Carmona LG, Dobbins Plasmodium falciparum: Duration, Recovery Rates, SE, Tenesa A, Jones AM, Howarth K, Palles C, van Uitregt VO, Hurst TP, Wilson RS. Reduced and Implications in Treatment Failure. Journal of Broderick P, Jaeger EE, Farrington S, Lewis size and starvation resistance in adult mosquitoes, Infectious Diseases. 2010;202(9):1362-1368. A, Prendergast JG, Pittman AM, Theodoratou Aedes notoscriptus, exposed to predation cues as E, Olver B, Walker M, Penegar S, Barclay larvae. Journal of Animal Ecology. 2011. [Published Tey SK, Goodrum F, Khanna R. CD8(+) T-cell E, Whiffin N, Martin L, Ballereau S, Lloyd A, online ahead of print]. recognition of human cytomegalovirus latency- Gorman M, Lubbe S, The COGENT Consortium, associated determinant pUL138. Journal of General The CORGI Collaborators, The EPICOLON Vanoaica L, Darshan D, Richman L, Schümann Virology. 2010;91:2040-2048. Consortium, Howie B, Marchini J, Ruiz-Ponte C, K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Thompson PM, Martin NG, Wright MJ. Fernandez-Rozadilla C, Castells A, Carracedo Metabolism. 2010;12(3):273-82. Imaging genomics. Current Opinion In Neurology. A, Castellvi-Bel S, Duggan D, Conti D, Cazier 2010;23(4):368-373. JB, Campbell H, Sieber O, Lipton L, Gibbs P, Vari V, Gandhi MK. Broad spectrum Martin NG, Montgomery GW, Young J, Baird immunosuppression by classless monocytes Thomsen SF, Duffy DL, Kyvik KO, Backer V. PN, Gallinger S, Newcomb P, Hopper J, Jenkins in Non-Hodgkin Lymphoma. Immunotherapy. Genetic influence on the age at onset of asthma: MA, Aaltonen LA, Kerr DJ, Cheadle J, Pharoah 2011;3(6):723-726. A twin study. Journal of Allergy and Clinical P, Casey G, Houlston RS, Dunlop MG:. Multiple Immunology. 2010;126(3):626-630. Common Susceptibility Variants near BMP Pathway Verhulst B, Hatemi PK, Martin NG. The nature Loci GREM1, BMP4, and BMP2 Explain Part of of the relationship between personality traits
Page 150 QIMR Annual Report 2010–2011 and political attitudes. Personality and Individual Wade TD, Zhu G, Martin NG. Undue Common variants associated with breast cancer Differences. 2010;49(4):306-316. influence of weight and shape: is it distinct in genome-wide association studies are modifiers from body dissatisfaction and concern about of breast cancer risk in BRCA1 and BRCA2 Verweij KJ, Zietsch BP, Liu JZ, Medland weight and shape?. Psychological Medicine. mutation carriers. Human Molecular Genetics. SE, Lynskey MT, Madden PA, Agrawal A, 2011;41(4):819-828. 2010;19(14):2886-2897. Montgomary GW, Heath AC, Martin NG. No association of candidate genes with cannabis Waldron M, Heath AC, Lynskey, MT, Bucholz Warrilow D, Warren K, Harrich D. Strand Transfer use in a large sample of Australian twin families. KK, Madden, PAF, Martin NG. Alcoholic Marriage: and Elongation of HIV-1 Reverse Transcription Is Addiction Biology. 2011. [Published online ahead Later Start, Sooner End. Alcoholism: Clinical and Facilitated by Cell Factors In Vitro. PLoS ONE. of print]. Experimental Research. 2011;35(4):632–642. 2010;5(10).
Verweij KJH, Zietsch BP, Lynskey MT, Nelson Walker GJ, Soyer HP, Handoko HY, Ferguson Webb A, Lind PA, Kalmijn J, Feiler HS, Smith EC, Heath AC, Martin NG. Examining the B, Kunisada T, Khosrotehrani K, Box NF, Muller TL, Schuckit MA, Wilhelmsen K. The Investigation relationship between sexual orientation and HK. Superficial Spreading-Like Melanoma in Arf(- into CYP2E1 in Relation to the Level of Response depression: overlapping genetic and early /-):: Tyr-Nras(Q61K)::K14-Kitl Mice: Keratinocyte to Alcohol Through a Combination of Linkage environmental influences. Behavior Genetics. Kit Ligand Expression Sufficient to “Translocate” and Association Analysis. Alcoholism-Clinical and 2010;40(6):816-816. Melanomas from Dermis to Epidermis. Journal of Experimental Research. 2011;35(1):43374. Investigative Dermatology. 2011;131(6):1384-1387. Verweij KJH, Zietsch BP, Medland SE, Gordon Webb PM, Ibiebele TI, Hughes MC, Beesley SD, Benyamin B, Nyholt DR, McEvoy BP, Walker LC, Fredericksen ZS, Wang X, Tarrell R, J, van der Pols JC, Chen X, Nagle CM, Bain Sullivan PF, Heath AC, Madden PAF, Henders Pankratz VS, Lindor NM, Beesley J, Healey S, CJ, Chenevix-Trench G. Folate and related AK, Montgomery GW, Martin NG, Wray NR. Chen X, kConFab, Stoppa-Lyonnet D, Tirapo micronutrients, folate-metabolising genes and risk A genome-wide association study of Cloninger’s C, Giraud S, Mazoyer S, Muller D, Fricker of ovarian cancer. European Journal of Clinical temperament scales: Implications for the JP, Delnatte C, GEMO Study Collaborators, Nutrition. 2011. [Published online ahead of print]. evolutionary genetics of personality. Biological Schmutzler RK, Wappenschmidt B, Engel. Psychology. 2010;85(2):306-317. Evidence for SMAD3 as a modifier of breast cancer Webbink D, Martin N, Visscher P. Does teenage risk in BRCA2 mutation carriers. Breast Cancer childbearing reduce investment in human Vink JM, Boomsma DI, Medland SE, de Moor Research. 2010;12(6):R102. capital?. Journal of Population Economics. MHM, Stubbe JH, Cornes BK, Martin NG, 2011;24(2):701-30. Skytthea A, Kyvik KO, Rose RJ, Kujala UM, Walker RG, Landmann JK, Hewett DG, Kaprio J, Harris JR, Pedersen NL, Cherkas L, Worthley DL, Buttenshaw RL, Knight N, Wen Y, Reid DW, Zhang D, Ward C, Wood-Baker Spector TD, de Geus EJC. Variance Components Webb PM, Whiteman DC, Whitehall VL, R, Walters EH. Assessment of airway inflammation Models for Physical Activity With Age as Modifier: A Leggett BA. Hyperplastic Polyposis Syndrome Is using sputum, BAL, and endobronchial biopsies in Comparative Twin Study in Seven Countries. Twin Associated With Cigarette Smoking, Which May current and ex-smokers with established COPD. Research and Human Genetics. 2011;14(1):25-34. Be a Modifiable Risk Factor. American Journal of International Journal of Chronic Obstructive Gastroenterology. 2010;105(7):1642-1647. Pulmonary Disease. 2010;5:327-34. Vinkhuyzen AA, Dumenil T, Ryan L, Gordon SD, Henders AK, Madden PA, Heath AC, Wallace DF, McDonald C, Subramaniam VN. Wheatley NC, andrews KT, Tran TL, Lucke Montgomery GW, Martin NG, Wray NR. Transferrin receptor 1: a ferritin receptor as well?. AJ, Reid RC, Fairlie DP. Antimalarial histone Identification of tag haplotypes for 5HTTLPR for Gastroenterology. 2010;139(3):1052-3. deacetylase inhibitors containing cinnamate or different genome-wide SNP platforms. Molecular NSAID components. Bioorganic & Medicinal Psychiatry. 2011. [Published online ahead of print]. Wallace DF, McDonald CJ, Ostini L, Chemistry Letters. 2010;20(23):7080-7084. Subramaniam VN. Blunted hepcidin response to Visscher PM, Goddard ME. Cattle gain stature. inflammation in the absence of Hfe and transferrin Whiley PJ, Guidugli L, Walker LC, Healey Nature Genetics. 2011;43(5):397-398. receptor 2. Blood. 2011;117(10):2960-2966. S, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Visscher PM, McEvoy B, Yang J. From Galton Wallingford S, Alston RD, Green AC, Birch JM. Spurdle AB. Splicing and Multifactorial Analysis to GWAS: quantitative genetics of human height. Comparison of trends in the incidence of cutaneous of Intronic BRCA1 and BRCA2 Sequence Variants Genetics Research. 2010;92(5-6):371-9. malignant melanoma. Pediatric Blood & Cancer. Identifies Clinically Significant Splicing Aberrations 2010;55(5):933-933. up to 12 Nucleotides from the Intron/Exon Visscher PM, Posthuma D. Statistical Power Boundary. Human Mutation. 2011;32(6):678-687. to Detect Genetic Loci Affecting Environmental Wallingford SC, Alston RD, Birch JM, Green Sensitivity. Behavior Genetics. 2010;40(5):728-733. AC. Increases in invasive melanoma in England, Whitelaw NC, Chong S, Morgan DK, Nestor 1979-2006, by anatomic site. British Journal C, Bruxner TJ, Ashe A, Lambley E, Meehan R, Visscher PM, Yang JA, Goddard ME. A of Dermatology. 2011. [Published online ahead Whitelaw E. Reduced levels of two modifiers of Commentary on ‘Common SNPs Explain a Large of print]. epigenetic gene silencing, Dnmt3a and Trim28, Proportion of the Heritability for Human Height’ cause increased phenotypic noise. Genome by Yang et al. (2010). Twin Research and Human Wallingford SC, Alston RD, Birch JM, Green Biology. 2010;11(11):R111. Genetics. 2010;13(6):517-524. AC. Temporal trends in the incidence of invasive cutaneous melanoma by anatomic site in UK, Whitelaw NC, Chong S, Whitelaw E. Tuning In Vu LH, Whiteman DC, van der Pols JC, Kimlin 1979-2006. British Journal of Dermatology. to Noise: Epigenetics and Intangible Variation. MG, Neale RE. Serum Vitamin D Levels in office 2011;164(4):938-938. Developmental Cell. 2010;19(5):649-650. Workers in a Subtropical Climate. Photochemistry and Photobiology. 2011;87(3):714-720. Wallingford SC, Olsen CM, Plasmeijer E, Green Whiteman DC, Parmar P, Fahey P, Moore SP, AC. Skin Cancer Arising in Scars: A Systematic Stark M, Zhao ZZ, Montgomery GW, Green Waddell N, Arnold J, Cocciardi S, da Silva L, Review. Dermatologic Surgery. 2011. [Published AC, Hayward NK, Webb PM. Association Marsh A, Riley J, Johnstone CN, Orloff M, Assie online ahead of print]. of Helicobacter pylori Infection With Reduced G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee Risk for Esophageal Cancer Is Independent P, Godwin AK, Hogervorst FBL, Couch F, Wang D Wang D, Suhrbier A, Penn-Nicholson of Environmental and Genetic Modifiers. Grimmond S, Flanagan JM, Khanna K, Simpson A, Woraratanadharm J, Gardner J, Luo M, Le Gastroenterology. 2010;139(1):73-83. PT, Lakhani SR, Chenevix-Trench G. Subtypes of TT, Anraku I, Sakalian M, Einfeld D, Dong JY. A familial breast tumours revealed by expression and complex adenovirus vaccine against chikungunya Whiteman DC, Pavan WJ, Bastian BC. The copy number profiling. Breast Cancer Research virus provides complete protection against viraemia Melanomas: A synthesis of epidemiological, clinical, and Treatment. 2010;123(3):661-677. and arthritis. Vaccine. 2011;29(15):2803-2809. histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and Waddell N, Cocciardi S, Johnson J, Healey S, Wang XS, Pankratz VS, Fredericksen Z, cells of origin. Pigment Cell Melanoma Research. Marsh A, Riley J, da Silva L, Vargas AC, Reid L, Tarrell R, Karaus M, McGuffog L, Pharaoh 2011. [Published online ahead of print]. Simpson PT, Lakhani SR, Chenevix-Trench G. PD, Ponder BA, Dunning AM, Peock S, Gene expression profiling of formalin-fixed, paraffin- Cook M, Oliver C, Frost D, Sinilnikova OM, Whiteman DC. ‘Blue Sky’ epidemiology: definition, embedded familial breast tumours using the Stoppa-Lyonnet D, Mazoyer S, Houdayer C, examples and a plea for understanding. Australian whole genome-DASL assay. Journal of Pathology. Hogervorst FBL, Hooning MJ, Ligtenberg MJ, and New Zealand Journal of Public Health. 2010;221(4):452-461. Spurdle A, Chenevix-Trench G, Schmutzler 2011;35(1):4-U6. RK, Wappenschmidt B, Engel C, Meindl A, Body mass index Wade TD, Zhu G, Martin NG. Domchek SM, Nathanson KL, Rebbeck TR, Whitfield JB. Molecular biology and genetics and breast size in women: same or different Singer CF, Gschwantler-Kaulich D, Dressler C, in clinical chemistry and laboratory medicine. genes?. Twin Research and Human Genetics. Fink A, Szabo CI, Zikan M, Foretova L, Claes Clinical Chemistry and Laboratory Medicine. 2010;13(5):450-454. K, Thomas G, Hoover RN, Hunter DJ, Chanock 2010;48(4):431–434. SJ, Easton DF, Antoniou AC, Couch FJ.
Page 151 Scientific publications | continued
Whitfield JB. The Australian Experience with CDT. and lessons learned. Molecular Psychiatry. 2010. Yang JA, Lee SH, Goddard ME, Visscher PM. Alcoholism-Clinical and Experimental Research. [Published online ahead of print]. GCTA: A Tool for Genome-wide Complex Trait 2010;34(8):58A-58A. Analysis. American Journal of Human Genetics. Wray NR, Purcell SM, Visscher PM. Synthetic 2011;88(1):76-82. Williams PF, Olsen CM, Hayward NK, Whiteman Associations Created by Rare Variants Do Not DC. Melanocortin- 1-receptor and risk of cutaneous Explain Most GWAS Results. PLoS Biology. Yang JA, Visscher PM, Wray NR. Sporadic melanoma: A meta-analysis and estimates of 2011;9(1). cases are the norm for complex disease. European population burden. International Journal of Cancer. Journal of Human Genetics. 2010;18(9):1039-1043. 2010. [Published online ahead of print]. Wright CM, Francis SMS, Sriram KB, Quinn KR, Stark MS, Hayward NK, Yang IA, Bowman RV, Yang SH, Brindley PJ, Zeng QR, Li YS, Zhou Wilson R, Diseberg A, Zivkovic S, Gordon L, Fong KM. Mapping the Lung Cancer Methylome. J, Liu Y, Liu BY, Cai LT, Zeng TB, Wei Q, Lan Tatarczuch L, Mackie E, Gorman J, Bateman Journal of Thoracic Oncology. 2011;6(3):S10-S10. LM, McManus DP. Transduction of Schistosoma J. Proteomic Profiling Of Cartilage Extracellular japonicum schistosomules with vesicular stomatitis Matrix Maturation. Osteoarthritis and Cartilage. Wright CM, Larsen JE, Hayward NK, Martins virus glycoprotein pseudotyped murine leukemia 2010;18:S225-S225. MU, Tan ME, Davidson MR, Savarimuthu retrovirus and expression of reporter human SM, McLachlan RE, Passmore LH, Windsor telomerase reverse transcriptase in the transgenic Win AK, Dowty JG, Antill YC, English DR, MN, Clarke BE, Duhig EE, Yang IA, schistosomes. Molecular and Biochemical Baron JA, Young JP, Giles GG, Southey MC, Bowman RV, Fong KM. ADAM28: A Potential Parasitology. 2010;174(2):109-116. Winship I, Lipton L, Parry S, Thibodeau SN, Oncogene Involved in Asbestos-Related Lung Haile RW, Gallinger S, Le Marchand L, Lindor Adenocarcinomas. Genes Chromosomes & Cancer. Yang XR, Chang-Claude J, Goode EL, Couch NM, Newcomb PA, Hopper JL, Jenkins 2010;49(8):688-698. FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MA. Body Mass Index in Early Adulthood and MK, Broeks A, Cox A, Fasching PA, Hein R, Endometrial Cancer Risk for Mismatch Repair Gene Wright JM, Dunn LA, Kazimierczuk Z, Burgess Spurdle AB, Blows F, Driver K, Flesch-Janys Mutation Carriers. Obstetrics and Gynecology. AG, Krauer KG, Upcroft P, Upcroft JA. D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Susceptibility in vitro of clinically metronidazole- 2011;117(4):899-905. Aittomäki K, Heikkilä P, Blomqvist C, Lissowska resistant Trichomonas vaginalis to nitazoxanide, J, Peplonska B, Chanock S, Figueroa J, Brinton Win AK, Dowty JG, English DR, Campbell PT, toyocamycin, and 2-fluoro-2’-deoxyadenosine. L, Hall P, Czene K, Humphreys K, Darabi Young JP, Winship I, Macrae FA, Lipton L, Parasitology Research. 2010;107(4):847-853. H, Liu J, Van ‘t Veer LJ, van Leeuwen FE, Parry S, Young GP, Buchanan DD, Martinez Andrulis IL, Glendon G, Knight JA, Mulligan ME, Jacobs ET, Ahnen DJ, Haile RW, Casey G, Wykes MN, Kay JG, Manderson A, Liu XQ, AM, O’Malley FP, Weerasooriya N, John EM, Baron JA, Lindor NM, Thibodeau SN, Newcomb Brown DL, Richard DJ, Wipasa J, Jiang SH, Beckmann MW, Hartmann A, Weihbrecht SB, PA, Potter JD, Le Marchand L, Gallinger S, Jones MK, Janse CJ, Waters AP, Pierce SK, Wachter DL, Jud SM, Loehberg CR, Baglietto Hopper JL, Jenkins MA. Body mass index in early Miller LH, Stow JL, Good MF. Rodent blood-stage L, English DR, Giles GG, McLean CA, Severi adulthood and colorectal cancer risk for carriers Plasmodium survive in dendritic cells that infect G, Lambrechts D, Vandorpe T, Weltens C, and non-carriers of germline mutations in DNA naive mice. PNAS. 2011;108(27):11205-10. Paridaens R, Smeets A, Neven P, Wildiers H, mismatch repair genes. British Journal of Cancer. Wynne A, Kanwar RK, Khanna R, Kanwar JR. Wang X, Olson JE, Cafourek V, Fredericksen 2011;105(1):162-169. Recent Advances on the Possible Neuroprotective Z, Kosel M, Vachon C, Cramp HE, Connley D, Winzer BM, Whiteman DC, Reeves MM, Paratz Activities of Epstein-Barr Virus Oncogene BARF1 Cross SS, Balasubramanian SP, Reed MW, JD. Physical activity and cancer prevention: a Protein in Chronic Inflammatory Disorders of Central Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, systematic review of clinical trials. Cancer Causes & Nervous System. Current Neuropharmacology. Park-Simon TW, Hillemanns P, Arias Pérez JI, Control. 2011;22(6):811-826. 2010;8(3):268-275. Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Xu HL, Balakrishnan K, Malaterre J, Beasley M, Wood MJ, Powell LW, Ramm GA, Clouston AD. Justenhoven C, Brauch H, Eccles DM, Tapper Yan YQ, Essers J, Appeldoorn E, Thomaszewski The role of the ductular reaction in the progression WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones JM, Vazquez M, Verschoor S, Lavin MF, of hepatic fibrosis in haemochromatosis. A, Kerin M, Miller N, McInerney N, Anton- Bertonchello I, Ramsay RG, Mckay MJ. Rad21- Journal of Gastroenterology and Hepatology. Culver H, Ziogas A, Shen CY, Hsiung CN, Wu Cohesin Haploinsufficiency Impedes DNA Repair 2010;25:A110-A111. PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman and Enhances Gastrointestinal Radiosensitivity in CA, Henderson BE, Le Marchand L, Kolonel Wood MJ, Vigh S, Dixon JL, Ramm GA, Powell Mice. PLoS ONE. 2010;5(8). LN, Lindblom A, Margolin S, Jakubowska A, LW. Diabetes is associated with fibrosis progression Lubiński J, Huzarski T, Byrski T, Górski B, in haemochromatosis. Journal of Gastroenterology Xu M, andrews KT, Birrell GW, Tran TL, Camp Gronwald J, Hooning MJ, Hollestelle A, van den and Hepatology. 2010;25:A110. D, Davis RA, Quinn RJ. Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine Ouweland AM, Jager A, Kriege M, Tilanus- Woods SL, Bishop JM. A new transgenic mouse sponge of the genus Pseudoceratina. Bioorganic & Linthorst MM, Collée M, Wang-Gohrke S, Pylkäs line for tetracycline inducible transgene expression Medicinal Chemistry Letters. 2011;21(2):846-848. K, Jukkola-Vuorinen A, Mononen K, Grip M, in mature melanocytes and the melanocyte stem Hirvikoski P, Winqvist R, Mannermaa A, Kosma cells using the Dopachrome tautomerase promoter. Yang J, Manolio TA, Pasquale LR, Boerwinkle VM, Kauppinen J, Kataja V, Auvinen P, Soini Transgenic Research. 2011;20(2):421-428. E, Caporaso N, Cunningham JM, de andrade Y, Sironen R, Bojesen SE, Ørsted DD, Kaur- M, Feenstra B, Feingold E, Hayes MG, Hill Knudsen D, Flyger H, Nordestgaard BG, Holland Worthley DL, Hewett DG, Spring KJ, Whitehall WG, Landi MT, Alonso A, Lettre G, Lin P, Ling H, Chenevix-Trench G, Manoukian S, Barile M, VLJ, Leggett BA. Re: Protection From H, Lowe W, Mathias RA, Melbye M, Pugh E, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Right- and Left-Sided Colorectal Neoplasms Cornelis MC, Weir BS, Goddard ME, Visscher Sangrajrang S, Brennan P, McKay J, Odefrey After Colonoscopy: Population-Based Study. PM. Genome partitioning of genetic variation F, Gaborieau V, Devilee P, Huijts PE, Tollenaar Journal of the National Cancer Institute. for complex traits using common SNPs. Nature RA, Seynaeve C, Dite GS, Apicella C, Hopper 2010;102(13):990-990. Genetics. 2011;43(6):519-U44. JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Worthley DL, Whitehall VLJ, Le Leu RK, Irahara Yang J, Weedon MN, Purcell S, Lettre G, Sherman ME, Garcia-Closas M. Associations of N, Buttenshaw RL, Mallitt KA, Greco SA, Estrada K, Willer CJ, Smith AV, Ingelsson E, breast cancer risk factors with tumor subtypes: a Ramsnes I, Winter J, Hu Y, Ogino S, Young O’Connell JR, Mangino M, Magi R, Madden PA, pooled analysis from the Breast Cancer Association GP, Leggett BA. DNA Methylation in the Rectal Heath AC, Nyholt DR, Martin NG, Montgomery Consortium studies. Journal of the National Cancer Mucosa Is Associated with Crypt Proliferation and GW, Frayling TM, Hirschhorn JN, McCarthy MI, Institute. 2011;103(3):250-63. Fecal Short-Chain Fatty Acids. Digestive Diseases Goddard ME, Visscher PM. Genomic inflation and Sciences. 2011;56(2):387-396. factors under polygenic inheritance. European Yang YR, Williams GM, Craig PS, McManus Journal of Human Genetics. 2011;19(7):807-812. Wray NR, Pergadia ML, Blackwood DH, DP. Impact of Increased Economic Burden Due to Human Echinococcosis in an Underdeveloped Penninx BW, Gordon SD, Nyholt DR, Ripke S, Yang JA, Benyamin B, McEvoy BP, Gordon S, Rural Community of the People’s Republic of China. Macintyre DJ, McGhee KA, Maclean AW, Smit Henders AK, Nyholt DR, Madden PA, Heath PLoS Neglected Tropical Diseases. 2010;4(9). JH, Hottenga JJ, Willemsen G, Middeldorp AC, Martin NG, Montgomery GW, Goddard CM, de Geus EJ, Lewis CM, McGuffin P, Hickie ME, Visscher PM. Common SNPs explain a large IB, van den Oord EJ, Liu JZ, Macgregor S, proportion of the heritability for human height. McEvoy. Genome-wide association study of major Nature Genetics. 2010;42(7):565-569. depressive disorder: new results, meta-analysis,
Page 152 QIMR Annual Report 2010–2011 Yenamandra SP, Hellman U, Kempkes B, Zamudio NM Zamudio NM, Scott HS, Wolski Zhu R, Gray DJ, Thrift AP, Williams GM, Zhang Darekar SD, Petermann S, Sculley T, Klein G, K, Lo CY, Law C, Leong D, Kinkel SA, Chong Y, Qiu DC, Zheng F, Li YS, Guo JG, Zhu HQ, Wu Kashuba E. Epstein-Barr virus encoded EBNA-3 SY, Jolley D, Smyth GK, de Kretser D, Whitelaw WP, Li RS, McManus DP. A 5-year longitudinal binds to vitamin D receptor and blocks activation E, O’Bryan MK. DNMT3L Is a Regulator of X study of schistosomiasis transmission in Shian of its target genes. Cellular and Molecular Life Chromosome Compaction and Post-Meiotic Gene village, the Anning River Valley, Sichuan Province, Sciences. 2010;67(24):4249-4256. Transcription. PLoS ONE. 2011;6(3). the Peoples’ Republic of China. Parasites & Vectors. 2011;4. Yin S, Boyle GM, Carroll AR, Kotiw M, Dearnaley Zhang L, Sriprakash KS, McMillan D, J, Quinn RJ, Davis RA. Caelestines A-D, Gowardman JR, Patel B, Rickard CM. Zietsch BP, Miller GF, Bailey JM, Martin NG. Brominated Quinolinecarboxylic Acids from the Microbiological pattern of arterial catheters in the Female Orgasm Rates are Largely Independent Australian Ascidian Aplidium caelestis. Journal of intensive care unit. BMC Microbiology. 2010;10. of Other Traits: Implications for Female Orgasmic Natural Products. 2010;73(9):1586-1589. Disorder and Evolutionary Theories of Orgasm. Zhang WB, Li J, Duke M, Jones MK, Kuang Journal of Sexual Medicine. 2011. [Published online You H, Gobert GN, Jones MK, Zhang WB, L, Zhang JF, Blair D, Li YS, McManus DP. ahead of print]. McManus DP. Signalling pathways and the host- Inconsistent Protective Efficacy and Marked parasite relationship: Putative targets for control Polymorphism Limits the Value of Schistosoma Zietsch BP, Verweij KJ, Bailey JM, Wright MJ, interventions against schistosomiasis Signalling japonicum Tetraspanin-2 as a Vaccine Target. PLoS Martin NG. Sexual orientation and psychiatric pathways and future anti-schistosome therapies. Neglected Tropical Diseases. 2011;5(5). vulnerability: a twin study of neuroticism and Bioessays. 2011;33(3):203-214. psychoticism. Archives of Sexual Behaviour. Zhang WB, Li J, Jones MK, Zhang ZZ, Zhao 2011;40(1):133-42. Youl PH, Janda M, Aitken JF, Del Mar CB, L, Blair D, McManus DP. The Echinococcus Whiteman DC, Baade PD. Body-site distribution granulosus Antigen B Gene Family Comprises at Zietsch BP, Verweij KJH, Bailey JM, Wright of skin cancer, pre-malignant and common benign Least 10 Unique Genes in Five Subclasses Which MJ, Martin NG. Psychiatric vulnerability pigmented lesions excised in general practice. Are Differentially Expressed. PLoS Neglected in nonheterosexuals. Behavior Genetics. British Journal of Dermatology. 2011;165(1):35-43. Tropical Diseases. 2010;4(8). 2010;40(6):821-821.
Young JP, Parry S. Hyperplastic polyposis Zhang X, George J, Deb S, Degoutin JL, Zietsch BP, Verweij KJH, Heath AC, Martin NG. syndrome and risk of colorectal cancer. Nature Takano EA, Fox SB, Bowtell DDL, Harvey KF. Variation in Human Mate Choice: Simultaneously Reviews Gastroenterology & Hepatology. The Hippo pathway transcriptional co-activator, Investigating Heritability, Parental Influence, Sexual 2010;7(11):594-595. YAP, is an ovarian cancer oncogene. Oncogene. Imprinting, and Assortative Mating. American 2011;30(25):2810-2822. Naturalist. 2011;177(5):605-616. Youngson N, Oey H, Whitelaw E. Paternal Effects in Mice Caused by Dicer Or Dnmt1 Zhao ZZ, Croft L, Nyholt DR, Chapman Zondervan KT, Painter JN, Anderson CA, Nyholt Haploinsufficiency are Associated with Changes in B, Treloar SA, Hull ML, Montgomery GW. DR, Macgregor S, Lee H, Visscher PM, Kraft Spermatozoal Mirna Expression Profile. Journal of Evaluation of polymorphisms in predicted target P, Martin NG, Morris AP, Treloar SA, Kennedy Andrology. 2011;94-95. sites for micro RNAs differentially expressed in SH, Missmer SA, Montgomery GW. Genome- endometriosis. Molecular Human Reproduction. Wide Association Study of Endometriosis Shows Gene Youngson NA, Chong S, Whitelaw E. 2011;17(2):92-103. Differential Etiology by Stage and Identifies a Locus silencing is an ancient means of producing multiple at 7p15.2 Associated with the Development of phenotypes from the same genotype. Bioessays. Zheng WJ, Yang JA, Zhu J. QTLNetworkR: Moderate-Severe Disease. Reproductive Sciences. 2011;33(2):95-99. an interactive R package for QTL visualization. 2011;18(3):197A. Journal of Zhejiang University-Science B. Youngson NA, Vickaryous N, van der Horst A, 2010;11(7):512-515. Zondervan KT, Painter JN, Anderson CA, Nyholt Epp T, Harten S, Fleming JS, Khanna KK, de DR, Macgregor S, Lee SH, Visscher PM, Kraft Kretser DM, Whitelaw E. A missense mutation in Zhong J, Khanna R. Delineating the role of CD4(+) P, Martin NG, Morris AP, Treloar SA, Kennedy the transcription factor Foxo3a causes teratomas T cells in the activation of human cytomegalovirus- SH, Missmer SA, Montgomery GW. Genome- and oocyte abnormalities in mice. Mammalian specific immune responses following immunization wide Association Study of Endometriosis Shows Genome. 2011;22(40636):235-248. with Ad-gBCMVpoly vaccine implications for Differential Etiology by Stage and Identifies a Locus vaccination of immunocompromised individuals. at 7p15.2 Associated with the Development of Youngson NA, Whitelaw E. The effects of acquired Journal of General Virology. 2010;91:2994-3001. paternal obesity on the next generation. Asian Moderate-severe Disease. Genetic Epidemiology. Journal of Andrology. 2011;13(2):195-196. 2010;34(8):976-977.
Page 153 compLiance cHeckLiSt
FA ACT Financial Accountability Act 2009 FPMS Financial and Performance Management Standard 2009 ARRs Annual Report Requirements for Queensland Government Agencies
Annual report Summary of requirement Basis for requirement reference Accessibility Table of contents ARRs – section 8.1 Page 1 Glossary/Acronyms Page 156 Public availability ARRs – section 8.2 Inside front cover
Interpreter service statement Queensland Government Language Services Policy Inside front cover
Copyright notice Copyright Act 1968 Inside front cover
Letter of A letter of compliance from the accountable officer or ARRs – section 9 Page 2 compliance statutory body to the relevant Minister(s) Introductory Agency role and main functions ARRs – section 10.3 Page 16 information Operating environment ARRs – section 10.3 Page 17
External scrutiny ARRs – section 10.3 Page 26
Machinery of government changes ARRs – section 10.3 Page 17
Review of proposed forward operations ARRs – section 10.3 Page 18
Non-financial Government objectives for the community ARRs – section 11.2 Page 17 performance Agency objectives and performance indicators ARRs – section 11.5 Page 18
Agency outputs and output performance measures ARRs – section 11.6 Page 18
Financial Summary of financial performance ARRs – section 12.1 Page 73 performance Disclosure of budget v actual results ARRs – section 12.2 N/A
Chief Finance Officer (CFO) statement ARRs – section 12.3 N/A
Governance – Organisational structure ARRs – section 13.1 Page 20 management and Executive management ARRs – section 13.2 Page 27 structure Related entities ARRs – section 13.3 Page 40
Schedule of statutory authorities or instrumentalities ARRs – section 13.4 N/A
Boards and committees ARRs – section 13.5 Page 25
Public Sector Ethics Act 1994 Public Sector Ethics Act 1994 Page 19 - implementation statement giving details of the action (section 23 and Schedule) taken during the reporting period Whistleblowers Protection Act 1994 Whistleblowers Protection Act 1994 Page 26 - public interest disclosures received (sections 30 – 31 and Schedule)
Page 154 QIMR Annual Report 2010–2011 Annual report Summary of requirement Basis for requirement reference Governance – risk Risk management ARRs – section 14.1 Page 25 management and Audit committee ARRs – section 14.2 Page 26 accountability Internal Audit ARRs – section 14.3 Page 26
Governance – Workforce planning, attraction and retention ARRs – section 15.1 Page 19 human resources Early retirement, redundancy and retrenchment Directive No.17/09 Early Retirement, Redundancy N/A and Retrenchment Initiatives for women ARRs – section 15.1 and 15.3 N/A
Governance – Consultancies ARRs – section 16.1 Page 73 operations Overseas travel ARRs – section 16.2 Page 132
Information systems and recordkeeping Public Records Act 2002 Page 26
Waste management Environmental Protection (Waste Management) N/A Policy 2000, Environmental Protection Act 1994 Other prescribed Indigenous matters (Queensland Government Queensland Government Reconciliation Action N/A requirements Reconciliation Action Plan 2009–2012) Plan 2009–2012 Shared services ARRs – section 17.1 N/A
Carbon emissions Premier’s Statement N/A
Optional Corrections to previous annual reports ARRs – section 18.2 N/A information that Right to Information Right to Information Act 2009 N/A may be reported Information Privacy Information Privacy Act 2009 N/A
Native title N/A N/A
Financial Annual general purpose financial statements Financial Reporting Requirements for Queensland Page 74 statements Government Agencies Certification of financial statements FA Act – section 62 Page 107 FPMS – sections 42, 43 and 50 Independent Auditors Report FA Act – section 62 Page 108 FPMS – section 50 Remuneration disclosures Financial Reporting Requirements for Queensland Page 101 Government Agencies
Page 155 ACRonymS
AC | Companion of the Order of Australia DC | Dendritic cell QIMR | Queensland Institute of Medical Research ACVD | Australian Centre for Vaccine DEEDI | Department of Employment, Development Economic Development and Innovation (Qld) QSA | Queensland Studies Authority
ACRF | Australian Cancer DNA | Deoxyribonucleic acid QUT | Queensland University of Technology Research Foundation EBV | Epstein-Barr virus RBWH | Royal Brisbane and AIBN | Australian Institute for Bioengineering Women’s Hospital and Nanotechnology EVC | Emory Vaccine Center RNA | Ribonucleic acid ALF | Australian Liver Foundation FTE | Full time equivalent ROTRF | Roche Organ Transplantation ANU | Australian National University GMP | Good manufacturing practice Research Foundation
ARC | Australian Research Council GWA | Genome-wide association SSMRC | Smart State Medical Research Centre ASI | Australasian Society of Immunology HDL | High density lipoprotein TLR | Toll-like receptor ASMR | Australian Society for HIV | Human immunodeficiency virus Medical Research UCLA | University of California, Los Angeles HR | Human resources ATM | Ataxia-telangiectasia mutated UNSW | University of New South Wales IARC | International Agency for Research ATR | Australian Twin Registry on Cancer UQ | The University of Queensland
BRCA1 | Breast cancer type 1 IUBMB | The International Union of VU | Vrije Universiteit, Amsterdam susceptibility gene Biochemistry and Molecular Biology WHO | World Health Organization CCQ | Cancer Council Queensland LDL | Low density lipoprotein
CEO | Chief Executive Officer MAG | Management Advisory Group
CF | Cystic fibrosis MIC-1 | Macrophage inhibitory cytokine 1
CMV | Cytomegalovirus NHMRC | National Health and Medical Research Council Colon CFR | Colon cancer family registry NIH | National Institutes of Health COPD | Chronic obstructive pulmonary disease OHMR | Office of Health and Medical Research CRC | Cooperative Research Centre PCFA | Prostate Cancer Foundation Australia CSIRO | Commonwealth Scientific and Industrial Research Organisation
Page 156 QIMR Annual Report 2010–2011
300 Herston Road T +61 7 3362 0222 Herston QLD 4006 Australia 1800 993 000 Locked Bag 2000 F +61 7 3362 0102 RBH QLD 4029 Australia E [email protected]
Better health through medical research | www.qimr.edu.au